PubMedID,Abstract,Mesh Headings
34339292,nonsmallcell lung cancer nsclc with epidermal growth factor receptor egfr exon 20 insertion exon20ins mutation exhibit inherent resistance to approved tyrosine kinase inhibitor amivantamab an egfrmet bispecific antibody with immune celldirecting activity bind to each receptor extracellular domain bypassing resistance at the tyrosine kinase inhibitor binding site chrysalis is a phase i openlabel doseescalation and doseexpansion study which included a population with egfr exon20ins nsclc the primary end point were doselimiting toxicity and overall response rate we report finding from the postplatinum egfr exon20ins nsclc population treated at the recommended phase ii dose of mg amivantamab mg 80 kg given once weekly for the first 4 week and then once every 2 week starting at week in the efficacy population n 81 the median age wa 62 year range year 40 patient 49 were asian and the median number of previous line of therapy wa two range the overall response rate wa 40 95 ci 29 to 51 including three complete response with a median duration of response of month 95 ci to not reached the median progressionfree survival wa month 95 ci to in the safety population n 114 the most common adverse event were rash in 98 patient 86 infusionrelated reaction in 75 66 and paronychia in 51 45 the most common grade adverse event were hypokalemia in six patient 5 and rash pulmonary embolism diarrhea and neutropenia in four 4 each treatmentrelated dose reduction and discontinuation were reported in 13 and 4 of patient respectively amivantamab via it novel mechanism of action yielded robust and durable response with tolerable safety in patient with egfr exon20ins mutation after progression on platinumbased chemotherapy,"Adult, Aged, Aged, 80 and over, Antibodies, Bispecific, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Diarrhea, Disease Progression, Drug Eruptions, ErbB Receptors, Exons, Female, Humans, Hypokalemia, Injection Site Reaction, Lung Neoplasms, Male, Middle Aged, Mutagenesis, Insertional, Neutropenia, Organoplatinum Compounds, Paronychia, Progression-Free Survival, Pulmonary Embolism, Retreatment"
34338986,mitochondrial unfolded protein response play an important role in the occurrence and development of breast cancer however the role of mitochondrial unfolded protein response uprmt in the sensitivity of breast cancer to cisplatin chemotherapy ha not yet been cleared the purpose of this study is to explore the role of mitochondrial unfolded protein response in breast cancer sensitivity to cisplatin in this study qrtpcr western blotting immunofluorescence cck colony formation transwell assay and tunel staining assay were used to confirm the role of uprmt in breast cancer cell treated with cisplatin cisplatin increased the level of uprmt including clpp hsp lonp1 in mcf7 and mdamb231 cell uprmt inducer nicotinamide ribose nr could promote the proliferation and invasion of breast cancer cell treated with cisplatin importantly sirt3 wa discovered to increase uprmt in breast cancer cell and silencing of sirt3 could inhibit the effect of nr in breast cancer uprmt regulated by sirt3 could protect breast cancer cell from cisplatin controlling sirtinduced upr may be a potential therapeutic target to increase the sensitivity of breast cancer chemotherapy,"ATP-Dependent Proteases, Antineoplastic Agents, Breast Neoplasms, Chaperonin 60, Cisplatin, Drug Resistance, Neoplasm, Endopeptidase Clp, Humans, MCF-7 Cells, Mitochondria, Mitochondrial Proteins, Sirtuin 3, Unfolded Protein Response"
34338525,despite it success against cancer photothermal therapy ptt 50 c suffers from several limitation such a triggering inflammation and facilitating immune escape and metastasis and also damage to the surrounding normal cell mildtemperature ptt ha been proposed to override these shortcoming we developed a nanosystem using hepg2 cancer cell membranecloaked zinc glutamatemodified prussian blue nanoparticles with triphenylphosphineconjugated lonidamine hmpgtl np this innovative approach achieved an efficient mildtemperature ptt effect by downregulating the production of intracellular atp this disrupts a section of heat shock protein that cushion cancer cell against heat the physicochemical property antitumor efficacy and mechanism of hmpgtl np both in vitro and in vivo were investigated moreover the nanoparticles cloaked with the hepg2 cell membrane substantially prolonged the circulation time in vivo overall the designed nanocomposites enhance the efficacy of mildtemperature ptt by disrupting the production of atp in cancer cell thus we anticipate that the mildtemperature ptt nanosystem will certainly present it enormous potential in various biomedical application,"Animals, Antineoplastic Agents, Apoptosis, Cell Membrane, Cell Proliferation, Drug Carriers, Drug Liberation, Female, Ferrocyanides, Hep G2 Cells, Humans, Indazoles, Infrared Rays, Mice, Nude, Mitochondria, Nanocomposites, Nanoparticles, Neoplasms, Photothermal Therapy, Mice"
34338127,treatment strategy for posttransplant lymphoproliferative disorder ptld consist of responseadapted riskstratified method using immunosuppression reduction immunotherapy and chemotherapy we investigated the efficacy of brentuximab vedotin given concurrently with rituximab bv r once weekly for four week followed by optional consolidation and up to one year of maintenance among 20 assessable patient bv r therapy resulted in an overall response rate of 75 95 ci 51 to p with 60 achieving a complete response median time to best response wa 28 day twoyear progressionfree survival and overall survival rate were 75 and 90 respectively most common severe grade treatmentrelated toxicity included neutropenia 40 hypertension 30 infection 25 and peripheral neuropathy 15 bv r is a novel and effective therapeutic strategy that achieved rapid and durable remission in previously untreated ptld patient however this treatment platform requires further modification due to the high rate of treatmentrelated toxicitykey pointsbrentuximab vedotin rituximab showed orr and cr rate of 75 and 60 in patient with immunosuppressionassociated lymphoid malignancieshigh rate of treatment delay were attributed to treatmentrelated toxicity further dosing optimization of this regimen is required,"Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Herpesvirus 4, Human, Humans, Immunoconjugates, Immunosuppression Therapy, Ki-1 Antigen, Lymphoma, Lymphoproliferative Disorders, Rituximab"
34337082,although firstline chemotherapy drug including fluorouracil fu remain one of the major choice for cancer treatment the clinical use is also accompanied with dosedepending toxicity such a intestinal mucositis im in cancer patient undergoing treatment iminduced gastrointestinal adverse reaction become frequent reason to postpone chemotherapy and have negative impact on therapeutic outcome and prognosis various study have evidenced the anticancer role of curcumin in many cancer except for this effect study also indicated a protective role of curcumin in intestinal disease therefore in this study we investigated the effect of curcumin on inflammation intestinal epithelial cell damage in an im model fu wa used to induce the model of im in intestinal epithelial cell and curcumin at different concentration wa administrated the result showed that curcumin efficiently attenuated fuinduced damage to iec6 cell inhibited the level of inflammatory cytokine attenuated the fuinduced inhibition on cell viability and displayed antiapoptosis effect on iec6 cell further rnasequencing analysis and experiment validation found that curcumin display it protective effect against fuinduced im in intestinal epithelial cell by the inhibition of ilstat3 signaling pathway taken together these finding suggested that curcumin may be provided a a therapeutic agent in prevention and treatment of chemotherapyinduced im,"Animals, Cell Line, Curcumin, Disease Models, Animal, Epithelial Cells, Fluorouracil, Gene Expression Regulation, Humans, Interleukin-6, Intestinal Mucosa, Mucositis, Neoplasms, RNA-Seq, Rats, STAT3 Transcription Factor, Signal Transduction"
34337041,survival of patient with portal vein tumor thrombosis pvtt is extremely poor transarterial chemoembolization tace is a treatment for patient with hcc and pvtt some study showed that hepatic arterial infusion chemotherapy haic might improve the survival of hcc with pvtt there were few research of combining tace with haic for patient with hcc and pvtt this study wa aimed at comparing overall survival o and progressionfree survival pfs following treatment with conventional transarterial chemoembolization plus hepatic arterial infusion chemotherapy ctacehaic or conventional transarterial chemoembolization ctace alone in patient with hepatocellular carcinoma hcc and portal vein tumor thrombosis pvtt from january 2011 to december 155 patient with hcc and pvtt who received ctacehaic ctacehaic group n 86 or ctace alone ctace group n 69 were retrospectively evaluated propensity score matching psm reduced the confounding bias and yielded 60 matched patient pair the tumor response were evaluated using the modified response evaluation criterion in solid tumor mrecist o and pfs of group were compared using the kaplanmeier method logrank test and cox proportional hazard regression model the median followup duration wa 93 month range month the ctacehaic group o month and pfs month were significantly longer than the ctace group o month and pfs month p and p respectively in the matched cohort multivariate analysis showed that ctacehaic wa independently associated with o hazard ratio hr p and pfs hr p the matched group did not differ regarding grade 3 or 4 adverse event ctacehaic wa superior to ctace alone regarding o and pfs in patient with hcc and pvtt treatmentassociated toxicity were generally well tolerated,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Combined Modality Therapy, Disease-Free Survival, Factor Analysis, Statistical, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Magnetic Resonance Imaging, Male, Middle Aged, Portal Vein, Propensity Score, Venous Thrombosis"
34331561,fluoropyrimidines are one of the most used drug class to treat cancer patient although they show high level of associated toxicity this study analyzed 33 polymorphism in 17 pharmacogenes involved with the pharmacogenomics of fluoropyrimidines in gastrointestinal cancer patient undergoing fluoropyrimidinebased treatment in the brazilian amazon the study population wa composed of 216 patient 92 of whom have an anatomopathological diagnosis of gastric cancer and 124 of colorectal cancer the single nucleotide polymorphism snp were genotyped by allelic discrimination using the taqman openarray genotyping technology with a panel of 32 customized assay run in a quantstudio 12k flex realtime pcr system applied biosystems life technology carlsbad usa ancestry analysis wa performed using 61 autosomal ancestry informative marker aim the study population show mean value of european amerindian and african ancestry a significant risk association for general and severe toxicity wa found in the rs4451422 of fpgs p or ci 95 and p or ci 95 respectively and the rs9524885 of abcc4 p or ci 95 and p or ic 95 respectively gene the rs760370 in the slc29a1 gene p or ci 95 and the rs1801133 in the mthfr toxicity p or ci 95 gene also demonstrated to be significant although only for severe toxicity the result found in this study did not have statistic analysis correction four polymorphism of the abcc fpgs slc29a and mthfr gene are likely to be potential predictive biomarkers for precision medicine in fluoropyrimidinebased treatment in the population of the brazilian amazon which is constituted by a unique genetic background,"Antineoplastic Combined Chemotherapy Protocols, Brazil, Camptothecin, Equilibrative Nucleoside Transporter 1, Female, Fluorouracil, Gastrointestinal Neoplasms, Humans, Leucovorin, Male, Methylenetetrahydrofolate Reductase (NADPH2), Middle Aged, Multidrug Resistance-Associated Proteins, Organoplatinum Compounds, Peptide Synthases, Pharmacogenomic Variants, Polymorphism, Single Nucleotide"
34331111,this study aimed to identify the maximumtolerated dose mtd of cyclophosphamide when combined with bortezomib and fludarabine bfc in a phase 1b trial and to as the efficacy and safety of this combination in a phase 2 trial in patient with relapsed or refractory mcl rrmcl forty patient were enrolled between april and october the mtd of cyclophosphamide wa identified to be 250 mgm2 day at a median followup of month among 32 patient in phase 10 31 had a complete response and 13 41 had a partial response the median progressionfree survival wa 21 month 95 ci and the median overall survival wa month 95 ci grade hematologic aes included neutropenia 27 and thrombocytopenia 39 the bfc regimen ha satisfactory response and manageable toxicity in rrmcl patient clinicaltrialsgov nct01322776,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Cyclophosphamide, Female, Humans, Lymphoma, Mantle-Cell, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Treatment Outcome, Vidarabine"
34330885,background the impact of therapeutic drug management tdm on reducing toxicity and improving efficacy in colorectal cancer crc patient receiving fluorouracilbased chemotherapy is still unclear material and method a total of 207 patient study group n historical group n153 with metastatic colorectal cancer were enrolled all of them received 6 administration of the fu based regimen initial fu dosing of all patient wa calculated using body surface area bsa in the study group individual exposure during each cycle wa measured using a nanoparticle immunoassay and the fu blood concentration wa calculated using the area under the curve auc we adjusted the fu infusion dose of the next cycle based on the auc data of the previous cycle to achieve the target of mghl result in the fourth cycle patient in the target concentration range auc mean mghl median 28 mghl range mghl cv accounted for of all patient which were more than the one in the first cycle p fu tdm significantly reduced the toxicity of chemotherapy and improved it efficacy the study group showed a lower percentage of severe adverse event than that in the historical group p the incidence of complete response and partial response in the study group were higher than those in the historical group p conclusion tdm in colorectal cancer can reduce toxicity improve efficacy and clinical outcome and can be routinely used in fubased chemotherapy,"Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Area Under Curve, China, Colorectal Neoplasms, Drug Dosage Calculations, Drug Monitoring, Drug-Related Side Effects and Adverse Reactions, Female, Fluorouracil, Humans, Male, Medication Therapy Management, Neoplasm Metastasis, Neoplasm Staging, Risk Adjustment, Treatment Outcome"
34330766,softtissue sarcoma sts in the extremity and trunk treated with standardofcare preoperative external beam radiation therapy ebrt followed by surgical resection are associated with local and distant relapse in preclinical study oncolytic virotherapy in sarcoma ha demonstrated antitumor effect via direct intratumoral oncolysis and cytotoxic tcellmediated immune response talimogene laherparepvec tvec is a replicationcompetent immuneenhanced oncolytic herpes simplex virus type 1 engineered for intratumoral injection it ha been approved by the fda for the treatment of locally advanced and metastatic melanoma we explored a novel combination of tvec with standardofcare ebrt administered preoperatively in patient with locally advanced sts of the extremity and trunk in a phase ibii clinical trial thirty patient with primary sts 5 cm for which ebrt wa indicated to achieve negative margin were enrolled fdaapproved tvec do were used immune correlative study in peripheral blood biopsy and resected tumor tissue were performed no doselimiting toxicity wa observed adverse event were similar to those reported in prior study with tvec one patient with myxoid liposarcoma exhibited a partial response seven of the 29 24 evaluable patient achieved 95 pathological necrosis none of the patient developed a herpes infection due to the treatment eight of the 29 27 patient developed postoperative wound complication which is consistent with previous study none of the patient developed local recurrence after surgical resection of the primary sarcoma year progressionfree and overall survival were 57 and 88 respectively caspase3 demonstrated increased expression of both in tvectreated tissue sample a compared with control sample treated with radiation alone preoperative intratumoral tvec with concurrent ebrt for locally advanced sts is safe and welltolerated this combination treatment may enhance immune response in some case but did not increase the proposed rate of pathological necrosis the caspase3 biomarker may be associated with a positive effect of tvec in sarcoma tumor tissue and should be explored in future study nct,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Biological Products, Extremities, Female, Herpesvirus 1, Human, Humans, Male, Middle Aged, Preoperative Period, Sarcoma"
34330715,we performed a ncisponsored prospective study of neoadjuvant folfirinox followed by chemoradiation with carboplatinpaclitaxel followed by surgery in patient with locally advanced gastric or gastroesophageal cancer the primary objective wa to determine completion rate of neoadjuvant folfirinox 8 followed by chemoradiation secondary endpoint were toxicity and pathologic complete response pcr rate exploratory analysis wa performed of circulating tumor dna ctdna to treatment response from october 2017 to june 25 patient were enrolled all patient started folfirinox 92 completed all eight planned cycle and 88 completed chemoradiation twenty 80 patient underwent surgical resection and 7 had a pcr 35 in resected cohort 28 intention to treat tumorspecific mutation were identified in 21 84 patient of whom 4 and 17 patient had undetectable and detectable ctdna at baseline respectively presence of detectable postchemoradiation ctdna p andor postoperative ctdna p were associated with disease recurrence here we show neoadjuvant folfirinox followed by chemoradiation for locally advanced gastroesophageal cancer is feasible and yield a high rate of pcr ctdna appears to be a promising predictor of postoperative recurrencesee related commentary by catenacci p,"Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Humans, Irinotecan, Leucovorin, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Oxaliplatin, Pancreatic Neoplasms, Pilot Projects, Prospective Studies, Treatment Outcome"
34329939,there is limited evidence for the benefit of olaparib in platinumresistant ovarian cancer proc patient with brca wildtype tumor this study investigated whether this combination of a dnadamaging chemotherapy plus olaparib is effective in proc regardless brca status patient with highgrade serous or endometrioid ovarian carcinoma and one previous proc recurrence were enrolled regardless of brca status patient with 4 previous line up to 5 in brcamut with at least one previous platinumsensitive relapse were included primary proc wa allowed only in case of brcamut patient initially received six cycle of olaparib 300 mg bid biduum intravenous pegylated liposomal doxorubicin pld 40 mgm2 pld40 every 28 day followed by maintenance with olaparib 300 mg bid until progression or toxicity the pld dose wa reduced to 30 mgm2 pld30 due to toxicity the primary endpoint wa progressionfree survival pfs at 6 month 6mpfs by recist version a proportion of 40 6mpfs or more wa considered of clinical interest from 2017 to 31 proc patient were included brca mutation were present in 16 the median of previous line wa 2 range the overall disease control rate wa 77 partial response rate of 29 and stable disease rate of 48 after a median followup of 10 month the 6mpfs and median pfs were 47 and month respectively grade 3 treatmentrelated adverse event occurred in 74 of patient with neutropeniaanemia being the most frequent with pld30 serious aes were le frequent than with pld40 21 versus 47 respectively moreover pld30 wa associated with le pld delay 32 versus 38 and reduction 16 versus 22 the pldolaparib combination ha shown significant activity in proc regardless of brca status pld at 30 mgm2 is better tolerated in the combination,"Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Doxorubicin, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Phthalazines, Piperazines, Polyethylene Glycols"
34329579,progressive multifocal leukoencephalopathy pml is a serious and usually fatal cns infection caused by the john cunningham virus cd and cd tcell lymphopenia resulting from hiv infection chemotherapy or immunosuppressive therapy are primary risk factor for pml following it introduction in the immunomodulatory anticd20 monoclonal antibody rituximab ha received regulatory approval worldwide for treatment of nonhodgkin lymphoma rheumatoid arthritis chronic lymphocytic leukaemia granulomatosis with polyangiitis microscopic polyangiitis and pemphigus vulagris rituximab lead to prolonged blymphocyte depletion potentially allowing john cunningham viral infection to occur six unexpected case of pml infection developing in rituximabtreated patient were first reported in we review 20 year of information on clinical finding pathology epidemiology proposed pathogenesis and riskmanagement issue associated with pml infection developing after rituximab treatment since the first case series report of 52 case of rituximabassociated pml among patient with nonhodgkin lymphoma or chronic lymphocytic leukaemia in updated and diligent pharmacovigilance effort have provided reassurance that this fatal toxicity is a rare clinical event with concurring causal factor international harmonisation of safety warning around rituximabassociated pml should be considered with these notification listing rituximabassociated pml under a section titled warning and precaution a is the case in most country rather than a boxed warning a is the case in the usa,"Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions, Humans, Leukoencephalopathy, Progressive Multifocal, Neoplasms, Prognosis, Rituximab"
34329577,relapsed or refractory classical hodgkin lymphoma could be treated with multiagent salvage chemotherapy followed by autologous haematopoietic stemcell transplantation the aim of this study is to establish the safety and activity of dosedense brentuximab vedotin combined with ifosfamide carboplatin and etoposide bvice chemotherapy in secondline treatment of classical hodgkin lymphoma we conducted a singlearm openlabel phase study of dosedense bvice at the seattle cancer care alliance university of washington seattle wa usa eligibility criterion were age 18 year or older diagnosis of first relapse primary refractory classical hodgkin lymphoma after one previous line of therapy measurable disease of at least 1 cm in the longest axis ct of chest abdomen and pelvis with pet within the past 28 day eastern cooperative oncology group performance status of and adequate organ function a 3 3 dose escalation study wa done for the phase 1 part of the trial to establish the maximum tolerated dose to be used for the phase 2 study brentuximab vedotin wa delivered on day 1 and 8 at either 12 mgkg dose level 1 or 15 mgkg dose level 2 intravenously capped at 150 mg with standard dosing of ice on day ifosfamide 5 gm2 plus mesna 5 gm2 intravenously over 24 h on day carboplatin area under the curve 5 on day 2 in one intravenous injection and etoposide 100 mgm2 on day in one intravenous injection per day for two day cycle the primary endpoint wa to establish the recommended phase 2 dose phase 1 part and complete response rate after two cycle with a prespecified target of 78 phase 2 part safety analysis wa done in all enrolled participant and the primary activity analysis wa done in all patient with evaluable response data this study is registered with clinicaltrialsgov nct02227199 enrolment and study treatment are complete between oct and feb we enrolled 45 patient with a median age of 31 year iqr the recommended phase 2 dose of brentuximab vedotin wa established to be 15 mgkg after a median followup of 31 year iqr 11 32 74 95 ci 585 of 43 evaluable patient had complete response after two cycle of treatment grade haematological toxic effect were common including neutropenia 33 73 anaemia six 13 and thrombocytopenia 36 80 the most common grade nonhaematological toxic effect were febrile neutropenia four 9 sepsis six 13 increased alanine aminotransferase five 11 hyperglycaemia three 7 pulmonary embolism two 4 and increased aspartate aminotransferase two 4 there wa one 2 ontreatment death due to multisystem organ failure that wa considered treatment related serious adverse event occurred in 13 29 patient our data suggest that dosedense bvice is a rapidly administered and active salvage regimen for patient with relapsed or refractory classical hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target although crosstrial comparison should be made with caution activity result seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combination delivered over much longer duration and can be considered in young 60 year transplantationeligible patient for secondline therapy seagen lymphoma research foundation national institute of healthnational cancer institute and generous philanthropic donation to the university of washington from numerous individual and family in support of lymphoma research,"Adult, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Carboplatin, Drug Resistance, Neoplasm, Etoposide, Female, Follow-Up Studies, Hodgkin Disease, Humans, Ifosfamide, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Salvage Therapy, Survival Rate"
34328715,the vascular wall is the first physiologic barrier that circulating nanoparticles np encounter which also is a key biological barrier to cancer drug delivery np can continually scavenge the endothelium for biomarkers of cancer and the chance of np extravasation into the tumor can be enhanced here we envision pselectin a a target for specific delivery of drug nanocrystals to tumor the cupric diethyldithiocarbamate nanocrystals cuet nc were first prepared by an antisolvent method and then nanocrystals were coated with fucoidan via physical interaction the fucoidancoated cuet nanocrystals cuetfuc posse high drug loading and have the ability to interact with human umbilical vein endothelial cell expressing pselectin which transiently enhances the endothelial permeability and facilitates cuetfuc extravasation from the peritumoral vascular to achieve higher tumor accumulation of drug than bare cuet nc the cuet nc show poorer anticancer efficacy than cuetfuc at the same dose of cuet upon repeated dosing of cuetfuc for 2 week no mortality wa observed in treated melanomabearing mouse while the mortality in the control group and excipienttreated group reached 23 the growth rate of melanoma in the cuetfuctreated group wa significantly lower than those in other group furthermore an acute toxicity study revealed that cuetfuc is a safe formulation for cancer treatment,"Animals, Antineoplastic Agents, Cell Line, Tumor, Copper, Ditiocarb, Female, Human Umbilical Vein Endothelial Cells, Humans, Mice, Inbred C57BL, Nanoparticles, Neoplasms, P-Selectin, Polysaccharides, Mice"
34328215,sirolimus is a mammalian target of rapamycin inhibitor mtori with antiproliferative antiangiogenic and immunosuppressive property while approved in australia a an antirejection medication for renal transplant patient there is mounting evidence regarding the utility of oral and topical sirolimus in treating a plethora of dermatological condition or condition with cutaneous manifestation our aim wa to present an overview of the evidence for current usage and breadth of the application of sirolimus in dermatology we carried out a systematic review of all the literature published up to 31 august 2019 on oral and topical sirolimus with respect to dermatological condition or condition otherwise relevant to dermatology while 3368 paper were initially produced in our search 238 paper met our inclusion criterion and were examined in our review the condition examined were categorised into genodermatoses 9 condition infection 1 condition inflammatoryautoimmune 10 condition neoplasm 3 condition and vascular 17 condition we extracted data on first author publication year journal characteristic of the study and study patient condition drug modality drug efficacy side effect blood level of mtori cointerventions and followup while there is level 1 evidence for the efficacy of sirolimus in condition such a tuberous sclerosis complex tsc and gvhd prophylaxis for many other condition the evidence is limited to level 4 evidence regarding oral systemic therapy dosing regimen varied with the most common for child mgm2 twice daily and for adult 1 mg twice daily do were often adjusted to reach a typical trough level of between 5 and 15 ngml though target often varied in the overall majority of case side effect were minimal or tolerable including mucositis cytopenia lipid abnormality and nauseavomiting and only a few case had to stop due to adverse effect regarding topical therapy concentration of formulation varied from to 1 and were compounded into cream ointment or gel and administered typically once or twice per day the most common side effect wa skin irritation there were a number of limitation to our study in particular many of the published study were case report or case series with no comparator arm leading to susceptibility of bias in conclusion drawn in particular a high likelihood of publication bias given the heterogeneity amongst study comparison or aggregation of result wa difficult there continues to be growing use of oral and topical sirolimus in dermatological condition it provides new therapeutic option to patient where previous therapy have either failed or are limited due to toxicity however further study are warranted,"Humans, Immunosuppressive Agents, Sirolimus, Skin Diseases"
34328206,neurological complication are some of the most important complication that can occur in a patient undergoing haematopoietic stem cell transplantation hsct not only because of the high mortality rate but also because of the sequela that appear in survivor the cause of such complication are manifold and very often coexist in the same patient toxicity of the conditioning regimen graftversushost disease and it treatment infection and their treatment platelet and coagulation disorder liver failure or arterial hypertension with low platelet count the aim of the present study is to provide a clinical description and to describe the risk factor for complication involving the central nervous system that may occur during the course of hsct in order to assist in the early detection of these disorder that may have a negative influence on the morbidity and mortality of these patient the following type of neurological complication are described central nervous system infection vascular complication pharmacological toxicity metabolic complication immunemediated disorder and posthsct carcinogenesis and effect of graftversushost disease and thrombotic microangiopathy on the nervous system the patient undergoing hsct is at particular risk for the development of neurological complication early diagnosis and treatment are needed to try to reduce the high morbidity and mortality in these patient complicaciones neurolgicas en pacientes sometidos a trasplante de progenitores hematopoyticos introduccin la complicaciones neurolgicas son algunas de la m importantes que se pueden presentar en un paciente sometido a un trasplante de progenitores hematopoyticos tph no slo porque conllevan una mortalidad elevada sino tambin por la secuelas que aparecen en los supervivientes la causa de dichas complicaciones son mltiples y muy frecuentemente coexisten en el mismo paciente toxicidad del rgimen de acondicionamiento enfermedad del injerto contra el hospedador y su tratamiento infecciones y su tratamiento plaquetopenia y trastornos de la coagulacin fallo heptico o hipertensin arterial con plaquetopenia objetivos el objetivo del presente estudio e el de aportar una descripcin clnica y de los factores de riesgo de la complicaciones sobre el sistema nervioso central que pueden presentarse en el curso de un tph para ayudar en la deteccin precoz de estos trastornos que pueden influir negativamente en la morbimortalidad de estos pacientes desarrollo se describen los siguientes tipos de complicaciones neurolgicas infecciones sobre el sistema nervioso central complicaciones vasculares toxicidad farmacolgica complicaciones metablicas trastornos inmunomediados y carcinogenia postph y efectos de la enfermedad del injerto contra el hospedador y de la microangiopata trombtica sobre el sistema nervioso conclusiones el paciente sometido a tph e de especial riesgo para el desarrollo de complicaciones neurolgicas se precisan un diagnstico y un tratamiento precoces para intentar disminuir la elevada morbimortalidad de estos pacientes,"Adult, Anti-Bacterial Agents, Antimetabolites, Brain Diseases, Metabolic, Brain Neoplasms, Central Nervous System Diseases, Central Nervous System Infections, Cerebrovascular Disorders, Child, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Myeloablative Agonists, Neoplasms, Radiation-Induced, Neuroimaging, Posterior Leukoencephalopathy Syndrome, Risk Factors, Thrombotic Microangiopathies, Transplantation Conditioning, Whole-Body Irradiation"
34327573,lactobacillus casei l casei is one of the probiotic strain that may influence intestinal injury and inflammation in nonspecific intestinal disease we aimed to evaluate the effect of cellfree lactobacillus casei 21l10 supernatant lc on the cell line ht29 challenged with lipopolysaccharide lp in order to modulate production of no cell proliferation and apoptosis cell line ht29 wa stimulated with lp in the presence or absence of lc our result showed that lc from l casei 21l10 did not affect the viability of unstimulated ht29 cell line ht29 cell line treatment with lc caused significant decrease of lp induced no production after 3 h and 24 h but not after 48 h proliferation activity of lp stimulated ht29 cell line analysed with mtt assay significantly decreased after 24 h and 48 h but not after 3 h the majority of lp stimulated ht29 cell line treated with lc showed annexin vpi positivity at 48 h survival which corresponded to late apoptoticnecrotic cell feature the observed difference suggest that cellfree l casei 21l10 supernatant could participate in attenuation of lpsinduced inflammation and may exhibit antiproliferative and proapoptoticnecrotic effect this study provides pilot data for the further development of l casei exoproducts a an antiinflammatory or antiproliferative agent for the treatment of inflammatory and cancer disease in gut however more data is needed before final conclusion of l casei cellfree supernatant efficacy can be drawn,"Anti-Inflammatory Agents, Antineoplastic Agents, Apoptosis, Cell Proliferation, Colon, Colonic Neoplasms, HT29 Cells, Humans, Inflammation Mediators, Inflammatory Bowel Diseases, Lacticaseibacillus casei, Lipopolysaccharides, Nitric Oxide, Time Factors"
34325494,since prenatal glucocorticoid gc excess increase the risk of metabolic dysfunction in the offspring and it effect on cell recovery capacity remains unknown we investigated these aspect in offspring from mouse treated with dexamethasone dex in the late pregnancy half of the pup were treated with streptozotocin stz on the sixth postnatal day pn functional and molecular analysis were performed in male offspring on pn25 and pn prenatal dex treatment resulted in low birth weight at pn both the stztreated offspring developed hyperglycemia and had lower cell mass in parallel with higher cell mass and glucose intolerance with no impact of prenatal dex on such parameter at pn the cell mass wa partially recovered in the stztreated mouse but they remained glucoseintolerant irrespective of being insulin sensitive prenatal exposition to dex predisposed adult offspring to sustained hyperglycemia and perturbed islet function lower insulin and higher glucagon response to glucose in parallel with exacerbated glucose intolerance cellspecific knockdown of the hnf4 in mouse from the d group resulted in exacerbated glucose intolerance we conclude that high gc exposure during the prenatal period exacerbates the metabolic dysfunction in adult life of mouse exposed to stz early in life resulting in a lesser ability to recover the islet function over time this study alert to the importance of proper management of exogenous gc during pregnancy and a healthy postnatal lifestyle since the combination of adverse factor during the prenatal and postnatal period accentuates the predisposition to metabolic disorder in adult life,"Animals, Animals, Genetically Modified, Animals, Newborn, Dexamethasone, Female, Gene Expression Regulation, Glucocorticoids, Glucose Tolerance Test, Insulin, Insulin-Secreting Cells, Mice, Neoplasms, Experimental, Pregnancy, Prenatal Exposure Delayed Effects, RNA, Messenger"
34323643,this systematic review and metaanalysis aimed to determine the effectiveness of brentuximab vedotin bv in relapsedrefractory classical hodgkin lymphoma rr chl in the clinical practice setting using most recent result a total of 32 observational study reporting on treatment pattern overall response rate orr complete response cr rate progressionfree survival pfs overall survival o and adverse event were found after four cycle a randomeffect model yielded pooled orr and cr rate of 95 confidence interval ci i2 and 95 ci i2 respectively regarding survival year year and year pfs ranged from to to and to respectively o rate were and respectively most common adverse event were hematological toxicity neutropenia 23 anemia and thrombocytopenia 6 and grade 3 peripheral neuropathy this study support the effectiveness and safety of bv in rr chl patient in the realworld setting,"Brentuximab Vedotin, Hodgkin Disease, Humans, Immunoconjugates, Neoplasm Recurrence, Local, Progression-Free Survival"
34322775,background the phosphatidylinositol3 kinase pathway is often altered in head and neck squamous cell carcinoma hnscc and is involved in the resistance to egfr inhibitor objective we investigated the doselimiting toxicity dlts maximum tolerated dose pharmacokinetics and preliminary efficacy of the combination of copanlisib an intravenous panclass i pi3k inhibitor with the antiegfr monoclonal antibody cetuximab in recurrent andor metastatic hnscc patient in a phase i doseescalation trial patient and method copanlisib wa given intravenously on day and 15 of day cycle at the dose of 45 mg and 30 mg in combination with standard do of weekly cetuximab 400 mgm2 loading dose followed by 250 mgm2 on day and and weekly thereafter result three patient received copanlisib 45 mg of whom two experienced grade 3 hyperglycemia during cycle 1 that met the dlt criterion eight patient were then treated with copanlisib at the dose of 30 mg because of the occurrence of hyperglycemia a premedication with metformine wa introduced on the day of the injection no dlts were reported at this dose level the trial wa stopped early because of the unfavourable toxicity profile of the combination among eight evaluable patient for response four patient 50 had disease stabilization according to recist a best response conclusion copanlisib combined with cetuximab demonstrated unfavorable toxicity and limited efficacy in heavily pretreated recurrent andor metastatic hnscc patientstrial registration nct date of registration june,"Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Area Under Curve, Cetuximab, Dose-Response Relationship, Drug, Female, Half-Life, Head and Neck Neoplasms, Humans, Male, Maximum Tolerated Dose, Middle Aged, Phosphoinositide-3 Kinase Inhibitors, Pyrimidines, Quinazolines, Squamous Cell Carcinoma of Head and Neck"
34321417,pembrolizumab is an immune checkpoint inhibitor used in many different cancer several immunerelated adverse event iraes have been associated with pembrolizumab including toxic epidermal necrolysis here we are presenting a patient with nonsmall cell lung cancer that developed toxic epidermal necrolysis day following initiation of pembrolizumab following highdose steroid therapy intravenous immunoglobulin 2 gkg wa initiated and resulted in complete resolution of all his iraes to our knowledge this is the first reported case of total reepithelialization and resolution of immune checkpoint inhibitorinduced toxic epidermal necrolysis following the use of intravenous immunoglobulin,"Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Humans, Immunoglobulins, Intravenous, Lung Neoplasms, Male, Patient Acuity, Stevens-Johnson Syndrome"
34321280,to evaluate the safety and tolerability in phase i firstinhuman combination therapy with pexidartinib an inhibitor of colonystimulating factor1 receptor and sirolimus an mtor inhibitor to target tumorassociated macrophage tam polarization in soft tissue sarcoma sts this multicenter phase i study used the timetoevent continual reassessment method titecrm to study the combination of sirolimus do ranging from 2 to 6 mg with pexidartinib do ranging from 600 to mg both provided continuously on a day cycle in patient with advanced sarcoma a total of 24 patient 8 malignant peripheral nerve sheath tumor 3 tenosynovial giant cell tumor tgct 5 leiomyosarcoma and 8 with other sarcoma subtypes were enrolled the median age wa 46 year 56 were male and 61 had 2 prior line of therapy the recommended phase ii dose wa 2 mg of sirolimus combined with mg of pexidartinib daily of the 18 evaluable subject 5 experienced doselimiting toxicity 2 elevated aspartate aminotransferasealanine aminotransferase 2 elevated sirolimus trough level and 1 grade 5 dehydration most common grade 2 or higher treatmentrelated adverse event included anemia fatigue neutropenia and lymphopenia clinical benefit wa observed in 12 of 18 67 evaluable subject with 3 partial response all in tgct and 9 stable disease tissue staining indicated a decreased proportion of activated m2 macrophage within tumor sample with treatment pexidartinib can be safely administered with sirolimus these finding support further investigation of this combination to determine clinical efficacy clinicaltrialsgov identifier nct,"Aminopyridines, Humans, Male, Middle Aged, Neurofibrosarcoma, Pyrroles, Sarcoma, Sirolimus, Tumor-Associated Macrophages"
34319586,in this phase i doseescalation study we sought to determine the maximum tolerated dose mtd of the anaplastic lymphoma kinasecros oncogene 1 receptor alkros1 inhibitor ceritinib in combination with gemcitabinebased chemotherapy in patient with advanced solid tumor secondary objective were characterization of the safety profile pharmacokinetics and preliminary efficacy of these combination and identification of potential biomarkers of efficacy ceritinib wa combined with gemcitabine arm 1 gemcitabinenabpaclitaxel arm 2 or gemcitabinecisplatin arm 3 drug concentration in plasma were measured by tandem mass spectrometric detection lcmsms we analyzed archival tumor tissue for alk ro hepatocyte growth factor receptor cmet and cjun nterminal kinase jnk expression by immunohistochemistry arm 2 closed early secondary to toxicity twentyone patient were evaluable for doselimiting toxicity dlt there wa one dlt in arm 1 grade 3 alt increase and three dlts in arm 3 grade 3 acute renal failure grade 3 thrombocytopenia grade 3 dyspnea the mtd of ceritinib wa determined to be 600 mg arm 1 and 450 mg orally daily arm 3 main toxicity were hematologic constitutional and gastrointestinal a expected by the chemotherapy backbone the apparent clearance for ceritinib decreased substantially after repeated dosing cisplatin did not significantly affect the pharmacokinetics of ceritinib the overall response rate wa 20 the median progressionfree survival wa month three out of five responseevaluable cholangiocarcinoma patient had clinical benefit increased expression of cmet wa associated with a lack of clinical benefit ceritinib in combination with gemcitabine and gemcitabinecisplatin ha a manageable toxicity profile further development of this strategy in tumor with alk or ros1 fusion is warranted,"Adult, Aged, Anaplastic Lymphoma Kinase, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Progression-Free Survival, Protein Kinase Inhibitors, Pyrimidines, Sulfones, Gemcitabine"
34319435,this phase ii trial aimed to as the safety and efficacy of paclitaxel in combination with cisplatin and fluorouracil tpf induction chemotherapy followed by surgery for locally advanced borderlineresectable esophageal squamous cell carcinoma brescc patient with primary tumor or bulky lymph node that might invade nearby organ were eligible treatment started with cycle of tpf induction chemotherapy followed by surgery if the tumor wa assessed resectable or by radical concurrent chemoradiotherapy if unresectable the primary endpoint wa pathologically proven complete resection r0 rate from july 2014 to february a total of 47 patient were enrolled after tpf chemotherapy 27 patient received surgery and 11 patient received radical concurrent chemoradiotherapy r0 resection wa confirmed in 25 patient 95 confidence interval ci pathologic complete response wa confirmed in four patient the median overall survival o and progressionfree survival pfs for all patient were month and month respectively the median o wa significantly more favorable in surgery group than in chemoradiotherapy and chemotherapy alone group month v month hazard ratio 95 ci p during induction chemotherapy the most common grade 3 or 4 toxicity were neutropenia leucopenia and stomatitis no serious postoperative complication were observed in patient undergoing surgery the treatment strategy of induction chemotherapy followed by surgery is promising for patient with locally advanced brescc to further improve the r0 resection rate more effective induction chemotherapy regimen need to be explored clinicaltrialsgov identifier nct,"Cisplatin, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Fluorouracil, Humans, Induction Chemotherapy, Paclitaxel, Treatment Outcome"
34319255,photodynamic therapy pdt and immunotherapy have been often adopted for ovarian cancer therapy yet their application is limited by the high recurrence rate and toxic side effect intriguingly nanoparticles contribute to enhancing the performance of pdt here we investigated the synthesis of hernanobody nbconjugated human serum albumin hsa incorporated with chlorin ce6 and catalase cat nbhcc and analyzed the synergic effect of nbhccmediated pdt and immunotherapy for skov3 tumor the ce6 and cat were incorporated into hsa to construct the hcc nanoparticles hernanobody wa the purified bacterial crude extract and conjugated with hcc to prepare nbhcc via heterodisulfide the effect of nbhcc with near infrared ray nir irradiation on moderating hypoxia and hypoxia inducible factor1hif1 expression were evaluated in the skov3 cell and tumor tissue a skov3 tumorbearing model wa developed where the synergistic effect of nbhccmediated pdt and antictla4 therapy wa investigated nbhcc with a 660 nm laser irradiation could induce massive reactive oxygen specie and trigger apoptosis in skov3 cell nbhcc and pdt promoted dangerassociated molecular pattern damp which indicated immunogenic cell death and maturation of dendritic cell in the skov3 cell irradiated by nir nbhcc alleviated the hypoxia and decreased the expression of hif1 the nbhccmediated pdt and antictla4 therapy synergically inhibited the progression of distant tumor and induced t cell infiltration biosafety test suggested that nbhcc would not cause damage to the major organ with le toxicity and side effect to conclude a combination of nbhccmediated pdt and antictla4 therapy could inhibit the progression of distant tumor to attain remarkable therapeutic outcome,"Animals, Antineoplastic Agents, Catalase, Cell Hypoxia, Cell Line, Tumor, Female, Humans, Mice, Mice, Inbred BALB C, Ovarian Neoplasms, Photochemotherapy, Porphyrins, Receptor, ErbB-2, Single-Domain Antibodies"
34319205,idelalisib is associated with increased occurrence of immunerelated adverse event iraes clinical observation suggest a correlation between immune checkpoint inhibitorinduced iraes and survival outcome in patient with solid tumor however this relationship in hematologic malignancy is not well understood in a post hoc analysis of 3 registrational trial we explored the relationship between grade 3 diarrheacolitis and alanineaspartate transaminase altast elevation incidence and efficacy endpoint in patient with indolent nonhodgkin lymphoma inhl follicular lymphoma fl and chronic lymphocytic leukemia treated with idelalisib grade 3 diarrheacolitis wa associated with higher overall response rate orr and longer progressionfree survival pfs for all subgroup grade 3 altast elevation were associated with improved duration of response and overall survival for all subgroup and improved orr and pfs for patient with fl or inhl our analysis in hematologic malignancy showed a trend correlating idelalisibinduced grade 3 iraes with improved efficacy,"Colitis, Diarrhea, Hematologic Neoplasms, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Purines, Quinazolinones"
34319023,the administration of highdose methotrexate hdmtx requires an accurate monitoring of blood mtx level to determine the regimen of leucovorin rescue and urine alkalinization to prevent toxicity however it is technically and logistically challenging to screen patient routinely in limitedresource setting this study aimed to evaluate blood mtx level at and hour from start of infusion in relation to clinical toxicity in childhood all a prospective cohort study wa conducted on 32 consecutive child with acute lymphoblastic leukemia all who had received at least one cycle of 1 gm2 hdmtx intravenous infusion a a part of consolidation treatment based on the 2013 indonesian all protocol in total 68 cycle were evaluated serum mtx concentration were measured using enzyme immunoassay mtx toxicity wa categorized using common toxicity criterion ctcae version the association between mtx level and clinical toxicity wa assessed by nonparametric analysis the hour mtx level wa median ngml moll iqr with a modest decrease in hour mtx serum level in all cycle median ngml and moll iqr p the two most common toxicity were hepatotoxicity and neutropenia nephrotoxicity and febrile neutropenia occurred in and of patient respectively with low percentage of mucositis and thrombocytopenia recorded no statistically significant association wa found between mtx level and clinical toxicity except for liver toxicity serum mtx level at hour and hour are low followed by only grade iiiiv hepatotoxicity and grade iiiiv neutropenia there is no significant association between the clinical toxicity and mtx level at the two point of measurement an attempt to increase the mtx dose andor to introduce a loading dose should be considered in subsequent all protocol a supported by further pharmacokinetic mtx study in the indonesian population,"Antimetabolites, Antineoplastic, Child, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Indonesia, Infusions, Intravenous, Male, Methotrexate, Pilot Projects, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prospective Studies"
34318389,chemoradiotherapy crt after local excision for pt1 with highrisk feature or pt2 rectal cancer is recommended a an optional treatment to achieve both curability and maintenance of quality of life the aim of this study wa to evaluate the shortterm safety of combining limited surgery with adjuvant crt for t1 or t2 lower rectal cancer this wa a multicenter singlearm prospective phase ii trial patient diagnosed with lower rectal or anal canal cancer clinical t1 or t2 with a maximum diameter of 30 mm and n0 and m0 underwent local excision or endoscopic resection patient received crt with s1 tegafurgimeraciloteracil after confirmation of well or moderately differentiated adenocarcinoma and negative margin andor depth of submucosal invasion 1000 m or muscularis propria andor positive lymphovascular invasion andor tumor budding grade of the primary endpoint wa relapsefree survival secondary endpoint included overall and local relapsefree survival safety anal sphincter preservation rate and anal function pathological diagnosis wa t1 in 36 patient and t2 in 16 patient serious complication after surgery were not reported the crt completion rate per protocol wa thirtytwo patient developed 54 event of crtrelated adverse event including only one patient with a grade 3 event stomatitis the most common crtrelated adverse event wa diarrhea n 14 no patient showed deterioration of anal function at 3 year postoperatively crt with s1 after limited surgery for t1 or t2 lower rectal cancer resulted in a low incidence of toxicity and maintenance of anal function,"Chemoradiotherapy, Adjuvant, Humans, Neoplasm Recurrence, Local, Oxonic Acid, Prospective Studies, Pyridines, Quality of Life, Rectal Neoplasms, Tegafur"
34316029,the immunerelated adverse event associated with treatment with immune checkpoint inhibitor result in significant morbidity for patient a well a considerable cost to the healthcare system and can limit the use of these beneficial drug understanding the mechanism of these side effect and how they can be separated from the antitumour effect of immune checkpoint inhibitor a well a identifying biomarkers that predict the development of immunerelated toxicity will facilitate the conduct of trial to limit their onset and improve patient outcome in this review we discus the different type of immunerelated adverse event and how their treatment and identification of possible predictive biomarkers may shed light on their mechanism and describe possible strategy and target for prophylactic and therapeutic intervention to mitigate them,"Biomarkers, Drug-Related Side Effects and Adverse Reactions, Humans, Immune Checkpoint Inhibitors, Neoplasms, Programmed Cell Death 1 Receptor"
34315439,here we evaluated the feasibility efficacy tolerability and treatmentmediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patient with erpositive hernegative breast cancer postmenopausal woman with erpositive hernegative breast cancer who had a primary tumor 2 cm or positive axillary lymph node proofed by biopsy were randomly enrolled to receive neoadjuvant everolimus plus letrozole for 18 week or fluorouracil epirubicin plus cyclophosphamide fec for 6 cycle before surgery primary outcome wa feasibility of the trial secondary outcome included ultrasound response rate pathological complete response rate breastconserving surgery rate toxicity treatmentmediated immune modulation and biomarkers forty patient were randomized completion rate wa in the neoadjuvant endocrine therapy net arm but in the neoadjuvant chemotherapy nac arm the ultrasound response rate wa in net arm and in fec arm respectively in term of the adverse event clearly favored net arm everolimus plus letrozole increased the ratio of peripheral tregs to cd t cell and tumor pdl1 expression and decreased ki67 index and tumorinfiltrating tregs and patient with a greater increase of tumorspecific ctls showed more sensitive to net this pilot trial showed that neoadjuvant everolimus plus letrozole might achieve a favorable ultrasound response rate with low toxicity in treating postmenopausal erpositive hernegative breast cancer patient everolimus plus letrozole might have positive antitumoral immunity effect further large randomized controlled trial are needed to confirm our finding a trial of neoadjuvant everolimus plus letrozole versus fec in woman with erpositive hernegative breast cancer registered on 2016 and first posted on nct02742051,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Biopsy, Breast Neoplasms, Cyclophosphamide, Epirubicin, Everolimus, Female, Fluorouracil, Humans, Letrozole, Middle Aged, Pilot Projects, Receptor, ErbB-2, Receptors, Estrogen, Treatment Outcome"
34313109,escorting therapeutic for malignancy by nanoencapsulation to ameliorate treatment effect and mitigate side effect ha been pursued in precision medicine however the majority of drug delivery system suffer from uncontrollable drug release kinetics and thus lead to unsatisfactory triggeredrelease efficiency along with severe side effect herein we developed a unique nanovesicle delivery system that show nearinfrared nir lighttriggered drug release behavior and minimal premature drug release by coencapsulation of superparamagnetic iron oxide spio nanoparticles the ultrasound contrast agent perfluorohexane pfh and cisplatin in a silicatepolyaniline vesicle we achieved the controllable release of cisplatin in a thermalresponsive manner specifically vaporization of pfh triggered by the heat generated from nir irradiation imparts high inner vesicle pressure on the nanovesicles leading to pressureinduced nanovesicle collapse and subsequent cisplatin release moreover the multimodal imaging capability can track tumor engagement of the nanovesicles and as their therapeutic effect due to it precise inherent nirtriggered drug release our system show excellent tumor eradication efficacy and biocompatibility in vivo empowering it with great prospect for future clinical translation,"A549 Cells, Aniline Compounds, Animals, Antineoplastic Agents, Cisplatin, Contrast Media, Drug Carriers, Drug Liberation, Drug Therapy, Fluorocarbons, Humans, Infrared Rays, Magnetic Iron Oxide Nanoparticles, Mice, Nude, Neoplasms, Photothermal Therapy, Silicates, Xenograft Model Antitumor Assays, Mice"
34313104,nanodrug delivery system nanoddss with an existing specific interaction to tumor cell and intelligent stimulustriggered drug delivery performance in a tumor microenvironment tme remain hotspot for effective cancer therapy herein multifunctional phh2o2 dualresponsive chiral mesoporous silica nanorods hacddoxpcmsrs were creatively constructed by first grafting phenylboronic acid pinacol ester pbap onto the aminofunctioned nanorods then incorporating doxorubicin dox into the mesoporous structure and finally coating with the cyclodextrinmodified hyaluronic acid conjugate hacd through a weak hostguest interaction under a physiological environment the gatekeeper cd could avoid the premature leakage of dox and minimize the side effect to normal cell after the uptake by the tumor cell the h2osensitive moiety of pbap were exposed and a small amount of dox wa leaked along with the shift of the supramolecular switch hacd under the acidic condition notably the selfsupplying h2o2 mediated by the released dox in turn accelerated the pbap disintegration further promoted the rapid release of dox and increased the dox accumulation in tumor region innovatively this nanodds could simultaneously achieve the tumortargeting ability via cd44 receptormediated endocytosis and phh2o2 dual responsiveness activated by the tme and hence exhibited superior antitumor efficacy furthermore ha acting a the hydrophilic shell could improve the biocompatibility of this nanodds,"Animals, Antineoplastic Agents, Boronic Acids, Cell Line, Tumor, Cyclodextrins, Doxorubicin, Drug Carriers, Drug Liberation, Female, Humans, Hyaluronan Receptors, Hyaluronic Acid, Hydrogen Peroxide, Hydrogen-Ion Concentration, Mice, Inbred BALB C, Nanotubes, Neoplasms, Porosity, Silicon Dioxide, Mice"
34312098,the combination of trastuzumab with anthracycline chemotherapy drug is associated with synergistic cardiotoxicity the aim of this study is to compare the efficacy and lateonset cardiac toxicity of neoadjuvant chemotherapy regimen trastuzumab plus paclitaxel followed by fluorouracil epirubicin and cyclophosphamide phfech versus trastuzumab plus docetaxel and carboplatin tch for human epidermal growth factor receptor positive her breast cancer bc patient with her bc who received neoadjuvant chemotherapy with phfech or tch between 2002 and 2009 at md anderson cancer center were included the primary endpoint wa progressionfree survival pfs secondary endpoint included pathological complete response pcr overall survival cardiac event breast cancerspecific survival noncardiac toxicity and chemotherapy interruption we identified 249 consecutive patient 184 who received phfech and 65 who received tch the year pfs wa higher in the phfech group than in the tch group v p 044 the pcr rate wa significantly higher in the phfech group v p 021 the rate of cardiac event wa higher in the phfech group but the difference wa not significant v p 352 more patient developed lateonset cardiotoxicity in the phfech group than in the tch group hypertension odds ratio 95 confidence interval p 047 wa an independent predictor of lateonset cardiotoxicity both neoadjuvant regimen are effective and tolerable in patient with her bc the phfech regimen offer a higher pcr rate and higher pfs but no difference in overall survival or breast cancerspecific survival higher frequency of cardiac toxicity with phfech wa noted,"Adult, Aged, Anthracyclines, Antineoplastic Agents, Immunological, Breast Neoplasms, Cardiotoxicity, Disease-Free Survival, Female, Follow-Up Studies, Humans, Middle Aged, Neoadjuvant Therapy, Receptor, ErbB-2, Trastuzumab"
34311300,there is no standard chemotherapy for esophageal squamous cell carcinoma escc refractory to firstline fluoropyrimidine and platinumbased chemotherapy we therefore performed a randomized selectiondesign phase ii trial to compare docetaxel dtx and paclitaxel ptx in this setting eligible patient were randomly assigned to receive either dtx 70 mgm2 on day 1 of each day cycle or ptx 100 mgm2 on day 29 and 36 of each day cycle the primary endpoint wa overall survival o and secondary endpoint included progressionfree survival pfs time to treatment failure ttf response rate rr and safety seventyeight eligible patient n 39 in each group were included for efficacy analysis o wa significantly longer in the ptx group than in the dtx group median versus month hazard ratio hr p a significant benefit of ptx over dtx wa also apparent in pfs median versus month hr p and ttf median versus month hr p rr versus p were higher in the ptx group than in the dtx group compared to the ptx group neutropenia 28 versus 80 and leukopenia 28 versus 76 of grade 3 a well a febrile neutropenia 0 v 46 p occurred more frequently in the dtx group ptx showed a significantly better efficacy a well a a more manageable toxicity compared with dtx umin,"Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Docetaxel, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Female, Fluorouracil, Humans, Male, Middle Aged, Paclitaxel"
34310998,imageguided chemophotothermal therapy based on nearinfrared nir theranostic agent ha found promising application in treating tumor in this multimodal treatment it is of critical importance to image realtime distribution of photothermal agent in vivo and to monitor therapeutic outcome for implementing personalized treatment in this study an optimally synthesized dextranpolylactide dexpla copolymer wa assembled with doxorubicin dox and dir a kind of nir dye to construct desirable micelle dir doxdexpla for performing imageguided chemophotothermal therapy these dir doxdexpla micelle had good physical and photothermal stability in aqueous medium and showed high photothermal efficiency in vivo based on the htumorbearing mouse model dir doxdexpla micelle were found to accumulate inside tumor sustainably and to emit strong fluorescence signal for more than three day the dir doxdexpla micelle together with nir laser irradiation were able to highly inhibit tumor growth or even eradicate tumor with one injection and two dosedesignated minute laser irradiation at the tumor site during 14 day of treatment furthermore they showed almost no impairment to the body of the treated mouse these dir doxdexpla micelle have confirmative translational potential in clinical tumor therapy on account of their persistent imageguided capacity high antitumor efficacy and good in vivo safety,"Animals, Antibiotics, Antineoplastic, Carbocyanines, Carcinoma, Hepatocellular, Dextrans, Doxorubicin, Drug Carriers, Drug Compounding, Fluorescent Dyes, Hep G2 Cells, Humans, Liver Neoplasms, Male, Mice, Inbred BALB C, Micelles, Photosensitizing Agents, Photothermal Therapy, Spectroscopy, Near-Infrared, Theranostic Nanomedicine, Time Factors, Tumor Burden, Mice"
34310350,this study evaluates the toxicity and tumor response with concurrent nabpaclitaxel chemoradiotherapy crt compared with standard fluorouracil or gemcitabine crt fifty patient with borderline resectable or unresectable pancreatic adenocarcinoma from 2014 to 2017 were divided into 2 group concurrent nabpaclitaxel 100 to 125 mgm2 weekly crt median gy fraction size and gy total or standard crt median gy fraction size gy total the primary endpoint wa toxicity and secondary endpoint were local failure and conversion to resectability comparison were made using ranksum or fisher exact test and multivariable competing risk regression for the cumulative incidence of local failure there were 28 patient in the nabpaclitaxel crt group and 22 in the standard crt group 88 had the unresectable disease the median followup wa 18 month the median duration of chemotherapy before concurrent crt wa and month in the nabpaclitaxel and standard crt group p and radiotherapy dose wa gy range to gy and gy range to gy respectively there were no statistically significant grade 2 toxicity the nabpaclitaxel crt group experienced a nonstatistically significant lower incidence of local failure hazard ratio 95 confidence interval p more patient in the nabpaclitaxel crt group proceeded to surgery compared with in the standard crt p of which 6 25 in the nabpaclitaxel crt and 2 10 in the standard crt group were initially unresectable nabpaclitaxel crt had similar toxicity compared with standard crt in the treatment of borderline resectable or unresectable pancreatic cancer it use wa associated with an arithmetically lower cumulative incidence of local failure and an arithmetically higher conversion to resectability both of which were not statistically significant,"Aged, Aged, 80 and over, Albumins, Carcinoma, Pancreatic Ductal, Chemoradiotherapy, Deoxycytidine, Female, Fluorouracil, Humans, Male, Middle Aged, Paclitaxel, Pancreatic Neoplasms, Radiation-Sensitizing Agents, Treatment Outcome, Gemcitabine"
34310349,the mammalian target of rapamycin mtor is a downstream mediator in the phosphatidylinositol kinaseakt signaling pathway and play a central role in cell proliferation growth differentiation migration and survival temsirolimus cci779 a selective inhibitor of the mtor is an ester analog of rapamycin sirolimus with improved aqueous solubility and pharmacokinetic pk property preclinical study have confirmed additive and synergistic antitumor activity in cancer cell line breast prostate cancer with combination of taxanes and mtor inhibitor we conducted a phase i openlabel doseescalation study to determine the maximal tolerated dose mtd of docetaxel in combination with temsirolimus in patient with refractory solid tumor eligible patient had a diagnosis of a refractory solid malignancy measurable disease and adequate organ function patient were sequentially enrolled in 4 dose level intravenous combination of docetaxel and temsirolimus temsirolimus wa administered weekly with docetaxel administered every 3 week laboratory data for tumor marker and radiologic imaging were conducted prestudy and then after every 2 cycle of the treatment radiologic response wa assessed by response evaluation criterion in solid tumor recist criterion blood sample for pk and pharmacodynamic analysis were planned to be drawn at mtd apart from the traditional design we also implemented bayesian optimal interval design which u isotonic regression method to select mtd we proceeded with isotonic regression analysis by using 20 doselimiting toxicity dlt rate a target twentysix patient were treated in this study in 4 cohort and dose level fourteen male and 12 female were enrolled with a median age of 50 year range of 27 to 72 y and median eastern cooperative oncology group performance score of tumor histology included pancreas 6 colon 5 rectum 3 gallbladder 2 nonsmall cell lung 2 endometrium 1 neuroendocrine 1 esophagus 1 stomach 1 pharynx 1 small intestine 1 and duodenum 1 stable disease wa observed in 50 43 40 and 60 patient in cohort and respectively dose escalation in cohort and 4 wa complicated by dlts such a grade 4 neutropenia and grade 3 diarrhea and an inability for patient to tolerate treatment during and beyond cycle 1 without dose reduction therefore we could not determine an mtd or recommended phase ii dose using the traditional study analysis blood sample for pk and pharmacodynamic analysis were not collected since mtd wa not determined by using 20 dlt rate closest to the target isotonic regression analysis showed identical estimated dlt rate in dose 1 docetaxel 50 mgm2 and temsirolimus 15 mgm2 and dose level 1 docetaxel 60mgm2 and temsirolimus 15 mgm2 dose escalation of docetaxel and temsirolimus wa limited by severe myelosuppressive toxicity in this phase i study most of the dlts occurred after cycle 1 of therapy hence we were unable to determine mtd or collect blood sample for pk and pharmacodynamic analysis our trial did not meet it objective due to significant dlts with this chemotherapy combination although our novel use of bayesian optimal interval design using isotonic regression method to select mtd showed identical estimated dlt rate in dose level 1 and clinically our patient were not able to complete 2 cycle of this regimen without dose reduction due to myelosuppressive toxicity in either of these dose level and hence escaped clinical validity this combination regimen should not be studied further at the dose level and schedule tested in our study,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Docetaxel, Drug Resistance, Neoplasm, Female, Gastrointestinal Neoplasms, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Sirolimus, Treatment Outcome"
34310275,since the first production of monoclonal antibody about 35 year ago researcher have found them useful in the treatment and diagnosis of various disease such a cancer by developing different type of monoclonal antibody such a humanized drug conjugated or bispecific one researcher have achieved remarkable success in treating several complicated and challenging disease targeting specific antigen or receptor make monoclonal antibody the right choice to inhibit signaling pathway like programmed deathligand 1 pdl1 or programmed death1 pd1 and changing cell behavior a one of the most common type of malignancy among woman breast cancer is one of the most critical condition which different type of monoclonal antibody were designed and produced to treat therefore we reviewed these antibody in breast cancer their target and their efficacy and toxicity with more focus on recent pdl1or pd1 inhibitor antibody in breast cancer and beyond,"Animals, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, B7-H1 Antigen, Breast Neoplasms, Female, Humans, Programmed Cell Death 1 Receptor"
34309925,arsenical drug have achieved hallmark success in treating patient with acute promyelocytic leukemia but expanding their clinical utility to solid tumor ha proven difficult with the contradiction between the therapeutic efficacy and the systemic toxicity here leveraging effort from material science biocompatible pegylated arsenene nanodots asndspeg with high monoelemental arsenic purity that can selectively and effectively treat solid tumor are synthesized the intrinsic selective killing effect of asndspeg is closely related to high oxidative stress in tumor cell which lead to an activated valencechange of arsenic from le toxic as0 to severely toxic oxidation state followed by decreased superoxide dismutase activity and massive reactive oxygen specie ro production these effect occur selectively within cancer cell causing mitochondrial damage cellcycle arrest and dna damage moreover asndspeg when applied in a multidrug combination strategy with elemene a plantderived anticancer drug achieves synergistic antitumor outcome and it newly discovered ondemand photothermal property facilitate the elimination of the tumor without recurrence potentially further expanding it clinical utility in line of the practicability for a largescale fabrication and negligible systemic toxicity of asndspeg even at high do and with repetitive administration a newconcept arsenical drug with high therapeutic efficacy for selective solid tumor therapy is provided,"Animals, Antineoplastic Agents, Arsenic, Cell Cycle Checkpoints, Cell Line, Tumor, Cell Survival, DNA Damage, Drug Therapy, Combination, Humans, Infrared Rays, Mice, Mice, Nude, Nanoparticles, Neoplasms, Oxidative Stress, Photothermal Therapy, Polyethylene Glycols, Reactive Oxygen Species, Sesquiterpenes, Transplantation, Heterologous"
34308772,there are several controversy in the management of head and neck cancer scchn although combined modality treatment is standard in locally advanced scchn lascchn the optimal timing of chemotherapy ha been debated toxicity concern with chemoradiation crt using high dose cisplatin have prompted use of le intensive approach weekly cisplatin and targeted therapy have been explored in randomized trial benefit of neoadjuvant chemotherapy in lascchn is debated due to lack of impact on overall survival however it remains a viable option in the indian setting where many patient are not eligible for upfront surgery or definite crt due to advanced stage and poor performance status p the complexity of data of immune check point inhibitor icpi in metastatic setting need cautious interpretation till an ideal biomarker for their benefit is identified their significant cost and promising data of oral metronomic therapy ha made the treatment landscape of metastatic scchn even more complex to address these burning issue we did a critical review of evidence of systemic therapy in scchn,"Administration, Metronomic, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Chemoradiotherapy, Adjuvant, ErbB Receptors, Head and Neck Neoplasms, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Adoptive, India, Neoplasm Staging, Receptors, Chimeric Antigen"
34308512,despite being widely used to date june 2021 the regimen of bevacizumab 10 mgkg every 2 week q2w combined with chemotherapy is not approved in japan for patient with platinumresistant recurrent ovarian cancer in this retrospective analysis we evaluated the usage pattern of bevacizumab administered for platinumresistant recurrent ovarian cancer we obtained clinical data from 155 japanese medical facility between november 2013 and december 2018 via a survey item included the number of case of platinumresistant recurrent ovarian cancer treated with bevacizumab according to dosage for regimen including bevacizumab 10 mgkg q2w additional information wa requested relating to concomitantly administered agent and the efficacy and safety of the regimen of 1739 bevacizumabcontaining regimen reported in 1633 patient with recurrent ovarian cancer 264 used 10 mgkg q2w the overall response rate orr with this regimen wa response rate varied according to regimen and were particularly favorable when bevacizumab 10 mgkg q2w wa administered with paclitaxel orr versus liposomal doxorubicin p and irinotecan p the most frequent grade 3 adverse event associated with bevacizumab 10 mgkg q2w were neutropenia and hypertension the most frequent bevacizumabassociated grade 3 adverse event with bevacizumab plus paclitaxel versus bevacizumab plus liposomal doxorubicin were hypertension versus and proteinuria versus bevacizumab 10 mgkg q2w appears efficacious for patient with recurrent ovarian cancer with a manageable toxicity profile approval of this regimen is clinically desirable for japanese patient with ovarian cancer,"Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Retrospective Studies"
34306603,with the acceleration of people life rhythm the incidence of hypopharyngeal cancer ha generally increased this study mainly explores the clinical efficacy and toxicity of lobaplatin compared with cisplatin in the treatment of locally advanced hypopharyngeal carcinoma based on intelligent ct imaging group a received lobaplatin combined with docetaxel induction chemotherapy for 2 cycle after cisplatin combined with intensitymodulated radiotherapy lobaplatin wa added to the patient then 200 ml of 5 glucose wa added and the patient wa injected intravenously for hour after 2 cycle of induction chemotherapy simultaneous lobaplatin chemotherapy wa performed every week for 5 week 10 mgweek and the efficacy wa evaluated after 4 consecutive course of treatment group b received cisplatin combined with docetaxel induction chemotherapy after 2 cycle of cisplatin combined with intensitymodulated radiotherapy group c wa the control group and wa not treated with cisplatin or docetaxel stomach protection treatment wa given in time throughout the treatment process all patient underwent normal ct ncct and enhanced ct cect examination before treatment we extracted 5 mm plain scan ctqncct and enhanced ct cect digital dicom image from the pac system for omics feature selection toxic and side effect are rated in different degree according to the evaluation criterion of the national cancer institute ncd common adverse event blood routine and liver and kidney function test were checked every week and the medication wa stopped immediately if there is a serious reaction in addition in vitro cell culture wa set up to test the inhibitory effect of cisplatin and lobaplatin on the proliferation of cancer cell the incidence of digestive tract reaction wa in the a plan group and in the b plan group the a group wa lower than the b group and the difference wa statistically significant p compared with cisplatin lobaplatin ha a milder gastrointestinal reaction and there is no common hepatic and renal toxicity of cisplatin this study is helpful to provide guidance for the clinical efficacy of locally advanced hypopharyngeal cancer treatment,"Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Cyclobutanes, Docetaxel, Humans, Hypopharyngeal Neoplasms, Neoplasm Staging, Organoplatinum Compounds, Tomography, X-Ray Computed, Treatment Outcome"
34305102,oncocardiology is an emerging field linking cancer with cardiovascular injury understanding the mechanism of cardiac injury help improve the quality of life of cancer survivor a series of study on adverse reaction to cancer or oncological treatment ha indicated that adverse cardiovascular event related to cancer treatment may occur over a longer period of survival and even year after therapy ha concluded current cancer therapy including chemotherapy radiotherapy targeted therapy and immunotherapy have been found to have latent cardiovascular toxicity these toxic effect are often progressive and irreversible and ultimately lead to cardiovascular event such a heart failure hypertension coronary heart disease arrhythmia and thromboembolism therefore more emphasis should be placed on revealing the mechanism of cancer treatmentrelated cardiovascular toxicity this would help to guide prevention diagnosis and treatment of cvds in cancer survivor,"Antineoplastic Agents, Cardiology, Cardiovascular Diseases, Humans, Immunotherapy, Neoplasms, Quality of Life"
34304283,the risk of drugdrug interaction ddi ha become a major issue in cancer patient however data in sarcoma patient are scarce we aimed to evaluate the frequency and the factor associated with ddi with antitumor treatment and to evaluate the impact of a pharmacist evaluation before anticancer treatment we performed a retrospective review of consecutive sarcoma patient starting chemotherapy ct or tyrosine kinase inhibitor tki a pharmacist performed medication reconciliation and established an early toxicity risk assessment potential ddi with antitumor drug were identified using micromedex electronic software one hundred and twentytwo softtissue and 80 bone sarcoma patient 103 male median age 50 year were included before ct 86 or tki 14 the median number of medication wa 3 34 patient 22 of patient with medication reconciliation reported complementary medicine use 37 potential ddi classified a major were identified 12 of the 243 pretherapeutic assessment in multivariate analysis tki p proton pump inhibitor p and antidepressant p were identified a risk factor of ddi p only marital status p wa associated with complementary medicine use a pharmacist performed 157 medication reconciliation and made 71 intervention among 59 patient 37 in multivariate analysis factor associated with pharmacist intervention were complementary medicine p drug number p and treatment with tki p conclusion clinical intervention on ddi are more frequently required among sarcoma patient treated with tki than ct multidisciplinary risk assessment including a medication reconciliation by a pharmacist could be crucial to prevent ddi with tki,"Adult, Antineoplastic Agents, Bone Neoplasms, Drug Interactions, Female, Humans, Male, Medication Reconciliation, Middle Aged, Pharmaceutical Services, Pharmacists, Professional Role, Protein Kinase Inhibitors, Retrospective Studies, Risk Factors, Risk Management, Sarcoma, Soft Tissue Neoplasms"
34303276,acquired resistance to tki is an important unmet need in the management of egfr mutated lung cancer recent clinical trial impower150 suggested that combination approach with vegf inhibitor check point inhibitor immunotherapy and platinumbased chemotherapy wa effective in oncogene driven lung cancer the current trial examined the efficacy of a modified regimen in an egfr mutated cohort an openlabelled single arm phase ii study wa conducted in patient with egfr mutated nsclc who had progressed on at least one egfr tki for those with t790m mutation radiological progression on osimertinib wa required for enrolment patient were treated with combination atezolizumab 1200 mg bevacizumab mgkg pemetrexed 500 mgm2 and carboplatin auc 5 given once every 3 week until progression forty patient were enrolled median age wa 62 range year more than one half had progressed on osimertinib pdl1 expression wa 1 in median followup time wa month orr wa median pfs wa month 95 ci one year o wa 95 ci treatment related grade 3 or above adverse event ae occurred in immunerelated ae occurred in patient quality of life measure of function and symptom did not change significantly throughout the course of treatment posttrial rechallenge with egfr tki containing regimen resulted in pfs of month 95 ci month combination approach of atezolizumab bevacizumab pemetrexed and carboplatin achieved promising efficacy in metastatic egfr mutated nsclc after tki failure the result were comparable with taxane based regimen of impower150 while toxicity profile wa improved,"Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carboplatin, ErbB Receptors, Humans, Lung Neoplasms, Middle Aged, Mutation, Pemetrexed, Protein Kinase Inhibitors, Quality of Life"
34302589,there are limited data on trastuzumabpertuzumab hpbased treatment beyond the firstline her metastatic breast cancer mbc setting we conducted a phase ii study of eribulin mesylate which extends survival in mbc with hp in patient with previously treated her mbc to evaluate efficacy toxicity and genomic alteration driving therapeutic response after a runin phase for eribulin dosing two cohort were enrolled cohort ano prior pertuzumab cohort bprior pertuzumab all patient received eribulin mgm2 on day 8 with standarddose hp on day 1 day cycle the primary endpoint wa objective response rate orr genomic characterization via whole exome sequencing wes wa completed on tumor dna and matched germline dna from 19 patient the sixpatient runin established a dose of eribulin mgm2 with hp cohort a and b enrolled 17 and 7 patient respectively accrual stopped early due to an evolving treatment landscape and slow enrollment the orr wa 95 confidence interval ci in cohort a and 0 in cohort b 95 ci 0 wes revealed more frequent alteration in tp53 p q in patient without clinical benefit disease control for 24 week which wa not significant after multiple hypothesis correction eribulinhp had manageable toxicity and modest clinical activity in patient without prior pertuzumab exposure this study provides a preliminary landscape of somatic alteration in this patient cohort our data add to the literature on how genomic alteration may predict for therapy responseresistance a we work to individualize choice in a quickly evolving her mbc treatment landscape nct registered 24 july,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Furans, Genomics, Humans, Ketones, Receptor, ErbB-2, Trastuzumab, Treatment Outcome"
34301752,this study report the safety tolerability mtd recommended phase ii dose rp2d pharmacokineticpharmacodynamic profile and preliminary antitumor activity of ceralasertib combined with carboplatin in patient with advanced solid tumor it also examined exploratory predictive and pharmacodynamic biomarkers eligible patient n 36 received a fixed dose of carboplatin auc5 with escalating do of ceralasertib 20 mg twice daily to 60 mg once daily in day cycle sequential and concurrent combination dosing schedule were assessed two ceralasertib mtd dose schedule 20 mg twice daily on day and 40 mg once daily on day were tolerated with carboplatin auc5 the latter wa declared the rp2d the most common treatmentemergent adverse event common terminology criterion for adverse event grade 3 were anemia 39 thrombocytopenia 36 and neutropenia 25 doselimiting toxicity of grade 4 thrombocytopenia n 2 including one grade 4 platelet count decreased and a combination of grade 4 thrombocytopenia and grade 3 neutropenia occurred in 3 patient ceralasertib wa quickly absorbed tmax 1 hour with a terminal plasma halflife of hour upregulation of prad indicative of ataxia telangiectasia mutated atm activation wa observed in tumor biopsy during ceralasertib treatment two patient with absent or low atm or slfn11 protein expression achieved confirmed recist v partial response eighteen of 34 53 responseevaluable patient had recist v stable disease the rp2d for ceralasertib plus carboplatin wa established a ceralasertib 40 mg once daily on day administered with carboplatin auc5 every 3 week with pharmacokinetic and pharmacodynamic study confirming pharmacodynamic modulation and preliminary evidence of antitumor activity observed,"Antineoplastic Combined Chemotherapy Protocols, Ataxia Telangiectasia Mutated Proteins, Carboplatin, Humans, Indoles, Maximum Tolerated Dose, Morpholines, Neoplasms, Neutropenia, Nuclear Proteins, Protein Kinase Inhibitors, Pyrimidines, Sulfonamides, Sulfoxides, Thrombocytopenia"
34301751,in egfrmutated metastatic nonsmall cell lung cancer nsclc outcome from egfr tyrosine kinase inhibitor have differed historically by mutation type present with lower benefit reported in patient with ex21l858r versus ex19del mutation we investigated if egfractivating mutation subtypes impact treatment outcome in the phase iii relay study association between egfr mutation type and preexisting cooccurring and treatmentemergent genetic alteration were also explored patient with metastatic nsclc an egfr ex19del or ex21l858r mutation and no central nervous system metastasis were randomized 11 to erlotinib 150 mgday with either ramucirumab 10 mgkg ramerl or placebo pboerl every 2 week until recist vdefined progression or unacceptable toxicity the primary endpoint wa progressionfree survival pfs secondary and exploratory endpoint included overall response rate orr duration of response dor pfs timetochemotherapy ttct safety and nextgeneration sequencing analysis patient with ex19del and ex21l858r mutation had similar clinical characteristic and comutational profile oneyear pfs rate for ex19del patient were 74 for ramerl versus 54 for pboerl for ex21l858r rate were 70 ramerl versus 47 pboerl similar treatment benefit orr dor pfs and ttct were observed in ramerltreated patient with ex19del and ex21l858r baseline tp53 comutation wa associated with superior outcome for ramerl in both ex19del and ex21l858r subgroup egfr t790m mutation rate at progression wa similar between treatment arm and by mutation type ramerl provided significant clinical benefit for both egfr ex19del and ex21l858r nsclc supporting this regimen a suitable for patient with either of these egfr mutation type,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Erlotinib Hydrochloride, Humans, Lung Neoplasms, Mutation, Protein Kinase Inhibitors, Ramucirumab"
34301750,we describe the firstinhuman doseescalation trial for alrn a stabilized cellpermeating peptide that disrupts p53 inhibition by mouse double minute 2 mdm2 and mdmx to induce cellcycle arrest or apoptosis in tpwildtype wt tumor two schedule were evaluated for safety pharmacokinetics pharmacodynamics and antitumor effect in patient with solid tumor or lymphoma in arm a patient received alrn6924 by intravenous infusion onceweekly for 3 week every 28 day arm b wa twiceweekly for 2 week every 21 day seventyone patient were enrolled 41 in arm a mgkg and 30 in arm b mgkg alrn6924 showed dosedependent pharmacokinetics and increased serum level of mic a biomarker of p53 activation the most frequent treatmentrelated adverse event were gastrointestinal side effect fatigue anemia and headache in arm a at mgkg doselimiting toxicity dlt were grade 3 g3 hypotension g3 alkaline phosphatase elevation g3 anemia and g4 neutropenia in one patient each at the mtd in arm a of mgkg g3 fatigue wa observed in one patient no dlts were observed in arm b no gg4 thrombocytopenia wa observed in any patient seven patient had infusionrelated reaction 3 discontinued treatment in 41 efficacyevaluable patient with tpwt disease across both schedule the disease control rate wa 59 two patient had confirmed complete response 2 had confirmed partial response and 20 had stable disease six patient were treated for 1 year the recommended phase 2 dose wa schedule a mgkg alrn6924 wa well tolerated and demonstrated antitumor activity,"Animals, Antineoplastic Agents, Dose-Response Relationship, Drug, Fatigue, Humans, Lymphoma, Maximum Tolerated Dose, Mice, Neoplasms, Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53"
34301412,to evaluate feasibility of chemoradiation a alternative for extensive surgery in patient with locally advanced vulvar cancer and to report on locoregional control toxicity and survival in a multicenter prospective phase ii trial patient with locally advanced vulvar cancer were treated with locoregional radiotherapy combined with sensitizing chemotherapy capecitabine treatment feasibility percentage locoregional control survival and toxicity were evaluated 52 patient with mainly tt3 disease were treated according to the study protocol in 10 center in the netherlands from 2007 to full dose radiotherapy tumor dose of gy wa delivered in 92 and full dose capecitabine in 69 of patient most prevalent acute grade 3 toxicity were regarding skinmucosa and pain 54 and 37 late grade 3 toxicity wa reported for skinmucosa 10 fibrosis 4 gi incontinence 4 and stress fracture or osteoradionecrosis 4 twelve week after treatment local clinical complete response ccr and regional control rc rate were 62 and 75 respectively after 2 year local ccr persisted in 22 patient 42 and rc wa 58 thirty patient 58 had no evidence of disease at end of followup median 35 month in 9 patient 17 extensive surgery with stoma formation wa needed progression free survival wa 58 51 and 45 and overall survival wa 76 66 52 at and 5 year definitive capecitabinebased chemoradiation a alternative for extensive surgery is feasible in locally advanced vulvar cancer and result in considerable locoregional control with acceptable survival rate with manageable acute and late toxicity,"Adult, Aged, Aged, 80 and over, Capecitabine, Carcinoma, Squamous Cell, Chemoradiotherapy, Female, Humans, Middle Aged, Prospective Studies, Salvage Therapy, Vulvar Neoplasms"
34299401,bevacizumab bcz is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor which is involved in the angiogenesis process pathologic angiogenesis is observed in several disease including ophthalmic disorder and cancer the multiple administration of bcz can cause adverse effect in this way the development of controlled release system for bcz delivery can promote the modification of drug pharmacokinetics and consequently decrease the dose toxicity and cost due to improved efficacy this review highlight bcz formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluation moreover the main advantage and limitation of the different approach are discussed despite difficulty in working with antibody those nanocarriers provided advantage in bcz protection against degradation guaranteeing bioactivity maintenance,"Animals, Antineoplastic Agents, Immunological, Bevacizumab, Drug Carriers, Drug Delivery Systems, Humans, Nanoparticles, Neoplasms"
34299130,although cisplatin is one of most effective chemotherapeutic drug that is widely used to treat various type of cancer it can cause undesirable damage in immune cell and normal tissue because of it strong cytotoxicity and nonselectivity this study wa conducted to investigate the cytoprotective effect of cudrania tricuspidata fruitderived polysaccharide ctps against cisplatininduced cytotoxicity in macrophage lung cancer cell line and a mouse model and to explore the possibility of application of ctps a a supplement for anticancer therapy both cisplatin alone and cisplatin with ctps induced a significant cytotoxicity in a549 and h460 lung cancer cell whereas cytotoxicity wa suppressed by ctps in cisplatintreated raw cell ctps significantly attenuated the apoptotic and necrotic population a well a cell penetration in cisplatintreated raw cell which ultimately inhibited the upregulation of bclassociated x protein bax cytosolic cytochrome c poly adenosine diphosphateribose polymerase parp cleavage and caspase and and the downregulation of b cell lymphoma2 bcl2 the ctpsinduced cytoprotective action wa mediated with a reduction in reactive oxygen specie production and mitochondrial transmembrane potential loss in cisplatintreated raw cell in agreement with the result obtained above ctps induced the attenuation of cell damage in cisplatintreated bone marrowderived macrophage primary cell in in vivo study ctps significantly inhibited metastatic colony and bodyweight loss a well a immunotoxicity in splenic t cell compared to the cisplatintreated group in lung metastasisinduced mouse furthermore ctps decreased the level of cre and bun in serum in summation these result suggest that ctpsinduced cytoprotective action may play a role in alleviating the side effect induced by chemotherapeutic drug,"Animals, Antineoplastic Agents, Apoptosis, Cell Proliferation, Cisplatin, Female, Fruit, Humans, Lung Neoplasms, Macrophages, Melanoma, Experimental, Membrane Potential, Mitochondrial, Mice, Mice, Inbred C57BL, Mice, Nude, Moraceae, Plant Extracts, Polysaccharides, Protective Agents, Tumor Cells, Cultured, Xenograft Model Antitumor Assays"
34299059,doxorubicin dox is a firstline treatment for triple negative breast cancer tnbc but it use may be limited by it cardiotoxicity mediated by the production of reactive oxygen specie we evaluated whether vitamin d may prevent doxinduced cardiotoxicity in a mouse tnbc model female balbc mouse received rodent chow with vitamin d3 1500 iukg vehicle or chow supplemented with additional vitamin d3 total iukg the mouse were inoculated with tnbc tumor and treated with intraperitoneal dox 6 or 10 mgkg cardiac function wa evaluated with transthoracic echocardiography the cardiac tissue wa evaluated with immunohistochemistry and immunoblot for level of hydroxynonenal nadph quinone oxidoreductase nqo1 cmyc and dynaminrelated protein 1 drp1 phosphorylation at 15 to 18 day the mean ejection fraction stroke volume and fractional shortening were similar between the mouse treated with vitamin d dox 10 mgkg v vehicle but significantly greater in mouse treated with vitamin d dox 10 mgkg v dox 10 mgkg dox 10 mgkg increased the cardiac tissue level of hydroxynonenal nqo cmyc and drp1 phosphorylation at serine but these increase were not observed with vitamin d dox 10 mgkg a decreased tumor volume wa observed with dox 10 mgkg and vitamin d dox 10 mgkg vitamin d supplementation decreased doxinduced cardiotoxicity by decreasing the reactive oxygen specie and mitochondrial damage and did not decrease the anticancer efficacy of dox against tnbc,"Animals, Antibiotics, Antineoplastic, Cardiotoxicity, Cytoprotection, Doxorubicin, Female, Mice, Mice, Inbred BALB C, Protective Agents, Triple Negative Breast Neoplasms, Vitamin D, Vitamins"
34298975,previously we showed that chemotherapy paradoxically exacerbated cancer cell colonization at the secondary site in a manner dependent on atf a stressinducible gene in the noncancer host cell here we present evidence that this phenotype is established at an early stage of colonization within day of cancer cell arrival using mouse breast cancer model we showed that in the wildtype wt lung cyclophosphamide ctx increased the ability of the lung to retain cancer cell in the vascular bed although ctx did not change the wt lung to affect cancer cell extravasation or proliferation it changed the lung macrophage to be procancer protecting cancer cell from death this combined with the initial increase in cell retention resulted in higher lung colonization in ctxtreated than controltreated mouse in the atf3 knockout ko lung ctx also increased the ability of lung to retain cancer cell however the ctxtreated ko macrophage wa highly cytotoxic to cancer cell resulting in no increase in lung colonizationdespite the initial increase in cell retention in summary the status of atf3 dictate the dichotomous activity of macrophage procancer for ctxtreated wt macrophage but anticancer for the ko counterpart this dichotomy provides a mechanistic explanation for ctx to exacerbate lung colonization in the wt but not atf3 ko lung,"Activating Transcription Factor 3, Animals, Antimicrobial Cationic Peptides, Cell Line, Tumor, Cyclophosphamide, Gene Expression Regulation, Neoplastic, Genes, Reporter, Genotype, Humans, Lung Neoplasms, Macrophage Activation, Macrophages, Mammary Neoplasms, Experimental, Mice, Mice, Inbred C57BL, Mice, Inbred Strains, Mice, Knockout, Mice, Transgenic, Neoadjuvant Therapy, Neoplasm Metastasis, Neoplasm Proteins, Neoplasm Transplantation, Neoplastic Stem Cells, Stress, Physiological, Transendothelial and Transepithelial Migration, Tumor Microenvironment, Tumor-Associated Macrophages, Cathelicidins"
34298098,the present study wa conducted to investigate the therapeutic effect of a potent polyphenol fisetin on the letrozoleinduced rat model of polycystic ovary syndrome pcos twentyfour female wistar rat 42 day old were divided into four group control group received carboxy methylcellulose cmc pcos group treated with letrozole 1 mgkg fisetin group received same dose of letrozole fisetin 10 mgkg and metformin group received same dose of letrozole metformin 300 mgkg at the end of the experiment biochemical glucose lipid profile and hormonal insulin testosterone estradiol and progesterone parameter were analyzed histological examination of ovary were also conducted by hematoxylin and eosin he staining realtime polymerase chain reaction pcr and western blotting were carried out for cytochrome p450 17a1 cyp17a1 sirtuin1 sirt1 and 5 ampactivated protein kinase ampk gene expression in the ovary furthermore enzymatic activity of antioxidant including catalase cat superoxide dismutase sod and glutathione peroxidase gpx in the ovary were analyzed by colorimetric method letrozole administration resulted in a remarkable abnormality in biochemical and hormonal parameter fisetin normalized level of glucose lipid profile homeostatic model assessment for insulin resistance homair testosterone estradiol and progesterone moreover fisetin increased expression level of sirt1 and ampk and decreased expression level of cyp17a1 in the ovary additionally fisetin showed protective effect by enhancing antioxidant activity of cat sod and gpx depleted secondary to induction of pcos fisetin effect were comparable to metformin a the standard drug used for treatment of pcos our result showed that fisetin treatment caused significant alleviating effect by restoring pcosinduced alteration in the key gene involved in energy homeostasis and antioxidant enzyme suggesting that it may have a key role in combating with pcos,"AMP-Activated Protein Kinases, Animals, Antineoplastic Agents, Phytogenic, Blood Glucose, Carboxymethylcellulose Sodium, Catalase, Disease Models, Animal, Estradiol, Female, Flavonols, Gene Expression, Glutathione Peroxidase, Humans, Insulin, Letrozole, Metformin, Ovary, Polycystic Ovary Syndrome, Progesterone, Rats, Rats, Wistar, Sirtuin 1, Steroid 17-alpha-Hydroxylase, Superoxide Dismutase, Testosterone"
34297605,major progress ha occurred in multiple myeloma mm treatment in recent year but this is not seen in low and middleincome country we retrospectively assessed the efficacy and safety of cyclophosphamide thalidomide and dexamethasone cyclophosphamide 400 mgm2 for 5 day thalidomide 100 mg once daily if tolerated and dexamethasone 40 mg once weekly in day cycle in patient with newly diagnosed mm treated at our institution between april 2008 and december survival outcome were estimated by the kaplanmeier method fiftynine patient were found to meet the selection criterion median age wa 56 year fiftynine percent n 35 were male international staging system three wa found in 24 the median number of treatment cycle wa 11 range after a median of month followup range month the overall response rate wa the complete response and very good partial response were 5 and 32 respectively median progressionfree survival pfs wa 35 month 95 ci 18 to 41 the year pfs wa 95 ci to and year pfs wa 95 ci to the median of overall survival o wa 81 month 95 ci 33 to not reached the year o wa 95 ci to and year o wa 95 ci to the most common adverse event wa neutropenia grade 3 and out of 23 patient eligible for stemcell transplantation 10 proceeded with autologous transplantation treatmentrelated death occurred in four patient cyclophosphamide thalidomide and dexamethasone achieves good response rate with tolerable toxicity especially in patient age 65 year or younger representing a feasible approach for patient with mm in lowincome health care setting,"Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Cyclophosphamide, Dexamethasone, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Retrospective Studies, Thalidomide"
34297268,preclinical study have shown that modulation of the tumor microvasculature with antiangiogenic agent decrease tumor perfusion and may increase the efficacy of radiofrequency ablation rfa in hepatocellular carcinoma hcc retrospective study suggest that sorafenib given prior to rfa promotes an increase in the ablation zone but prospective randomized data are lacking we conducted a randomized doubleblind placebocontrolled phase ii trial to evaluate the efficacy of a shortcourse of sorafenib prior to rfa for hcc tumor sized 7 cm nct00813293 treatment consisted of sorafenib 400 mg twice daily for 10 day or matching placebo followed by rfa on day the primary objective were to as if priming with sorafenib increased the volume and diameter of the rfa coagulation zone and to evaluate it impact on rfa thermal parameter secondary objective included feasibility safety and to explore the relationship between tumor blood flow on mri and rfa effectiveness twenty patient were randomized 1 priming with sorafenib did not increase the size of ablation zone achieved with rfa and did not promote significant change in thermal parameter although it significantly decreased blood perfusion to the tumor by p a analyzed by dcemri no subject discontinued treatment owing to adverse event and no grade 4 toxicity wa observed priming of sorafenib did not enhance the effect of rfa in intermediate sized hcc future study should investigate whether longer duration of treatment or a different antiangiogenic strategy in the postprocedure setting would be more effective in impairing tumor perfusion and increasing rfa efficacy,"Carcinoma, Hepatocellular, Catheter Ablation, Humans, Liver Neoplasms, Niacinamide, Phenylurea Compounds, Prospective Studies, Radiofrequency Ablation, Retrospective Studies, Sorafenib, Treatment Outcome"
34297206,acute myeloid leukemia aml with antecedent hematological disease saml and treatmentrelated aml taml predicts poor prognosis intensive treatment protocol of those highrisk patient should consider allogeneic stem cell transplantation allohsct in first complete remission cr despite allohsct relapse rate remains high induction chemotherapy with liposomal cytarabine and daunorubicin cpx351 ha been approved for patient with aml with myeloidrelated change amlmrc or taml based on improved survival and remission rate compared to standard 7 3 induction 110 patient with newly diagnosed saml or taml at a university hospital were analyzed retrospectively median age wa 62 year year a total of 65 patient with saml after md 59 and 23 patient with taml were included induction chemotherapy consisted of intermediatedosed cytarabine idarac in combination with idarubicin patient up to 60 year or mitoxantrone patient over 60 year in patient subsequently undergoing allohsct reduced conditioning regimen ric were applied prior to transplantation in 47 of 62 patient 76 induction chemotherapy with idarac resulted in an overall response rate of 83 including complete remission crcri in 69 patient 63 with a low rate of early death most relevant nonhematologic toxicity consisted of infectious complication including sepsis with need of intensive care treatment in five patient and proven or probable invasive fungal disease in eight patient relapsefree survival rf eventfree survival efs and overall survival o of the whole cohort were 19 month 10 month and 15 month respectively p a significant improvement of o wa observed in patient who underwent allohsct compared to those without subsequent allohsct 9 v 46 month p rate of transplantationrelated mortality trm in the early phase post allohsct wa low at day 30 and at day respectively ric conditioning result in o rate of 60 after 60 month post allohsct median o not reached saml and taml patient receiving induction chemotherapy with intermediatedosed cytarabine showed satisfactory response rate and consolidation therapy with allohsct after full or reducedintensity conditioning further improved survival in these patient with similar outcome a reported for cpx,"Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Hematopoietic Stem Cell Transplantation, Humans, Induction Chemotherapy, Leukemia, Myeloid, Acute, Middle Aged, Prognosis, Remission Induction, Retrospective Studies"
34296427,zuma1 nct02348216 examined the safety and efficacy of axicabtagene ciloleucel axicel an autologous cddirected chimaeric antigen receptor cart cell therapy in refractory large bcell lymphoma to reduce treatmentrelated toxicity several exploratory safety management cohort were added to zuma specifically cohort 6 investigated management of cytokine release syndrome cr and neurologic event ne with prophylactic corticosteroid and earlier corticosteroid and tocilizumab intervention cr and ne incidence and severity were primary endpoint following leukapheresis patient could receive optional bridging therapy per investigator discretion all patient received conditioning chemotherapy day 5 through 3 2 106 cart cellskg day 0 and oncedaily oral dexamethasone 10 mg day 0 before axicel through day 2 forty patient received axicel cr occurred in 80 of patient all grade 2 any grade and grade 3 or higher ne occurred in 58 and 13 of patient respectively sixtyeight per cent of patient did not experience cr or ne within 72 h of axicel with a median followup of 89 month objective and complete response rate were 95 and 80 respectively overall prophylactic corticosteroid and earlier corticosteroid andor tocilizumab intervention resulted in no grade 3 or higher cr a low rate of grade 3 or higher ne and high response rate in this study population,"Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Biological Products, Cytokine Release Syndrome, Dexamethasone, Female, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged"
34293664,the impact of maintenance therapy with parp inhibitor parpi on progressionfree survival pfs in patient with brca mutation and platinumsensitive recurrent ovarian cancer psroc varies widely individual prognostic factor do not reliably distinguish patient who progress early from those who have durable benefit we developed and validated a prognostic nomogram to predict pfs in these patient the nomogram wa developed using data from a training patient cohort with brca mutation and highgrade serous psroc on the placebo arm of two maintenance therapy trial study 19 and soloengotov we performed multivariable cox regression analysis based on pretreatment characteristic to develop a nomogram that predicts pfs we assessed the discrimination and validation of the nomogram in independent validation patient cohort treated with maintenance olaparib the nomogram includes four pfs predictor ca125 at randomisation platinumfree interval presence of measurable disease and number of prior line of platinum therapy in the training placebo cohort internal validation cindex median pfs in the modelpredicted good intermediate and poorrisk group wa 95 ci and month respectively in the validation olaparib cohort cindex median pfs in the modelpredicted good intermediate and poorrisk group wa not reached and month respectively the nomogram showed good calibration in the validation cohort calibration plot this nomogram can be used to predict pfs and counsel patient with brca mutation and psroc prior to maintenance olaparib and for stratification of patient in trial of maintenance therapy,"Adult, Aged, Aged, 80 and over, Female, Genes, BRCA1, Genes, BRCA2, Humans, Middle Aged, Mutation, Neoplasm Recurrence, Local, Nomograms, Ovarian Neoplasms, Phthalazines, Piperazines, Prognosis, Progression-Free Survival"
34293201,the use of externalbeam radiotherapy for locally advanced nonanaplastic thyroid cancer remains controversial this prospective study evaluated the efficacy and tolerability of intensitymodulated radiation therapy imrt with or without concurrent chemotherapy in patient with locally advanced thyroid cancer the author conducted a nonrandomized phase 2 trial of imrt with or without concurrent doxorubicin in patient with gross residual or unresectable nonanaplastic thyroid carcinoma clinicaltrialsgov identifier nct01882816 the primary end point wa year locoregional progressionfree survival pfs secondary end point included overall survival o safety patientreported outcome and functional outcome twentyseven patient were enrolled 12 with unresectable disease and 15 with gross residual disease the median followup wa month interquartile range month the year cumulative incidence of locoregional pfs and o were and respectively the rate of grade 3 or higher acute and late toxicity wa there were no significant functional difference 12 month after treatment assessed objectively by the modified barium swallow study patientreported quality of life in the experimental group wa initially lower but returned to the baseline after 6 month and improved thereafter in a post hoc analysis concurrent chemotherapy with intensitymodulated radiation therapy ccimrt resulted in significantly le locoregional failure at 2 year no failure v 50 p 001 with higher rate of grade 2 or higher acute dermatitis mucositis and dysphagia but no difference in longterm toxicity functionality or patientreported quality of life in light of the excellent locoregional control rate achieved with ccimrt and it acceptable toxicity profile a confirmed by functional assessment and patientreported outcome ccimrt may be preferred over imrt alone,"Chemoradiotherapy, Doxorubicin, Humans, Prospective Studies, Quality of Life, Radiotherapy, Intensity-Modulated, Thyroid Neoplasms"
34292933,there is scant data from india on efficacy and safety of palbociclib and ribociclib in routine clinical practice this retrospective observational single institution study included patient with estrogen andor progesterone receptor positive and human epidermal growth factor receptor 2 her2 negative metastatic breast cancer who received palbociclib or ribociclib with any partner endocrine therapy in any line of treatment between january 2016 and june data were analyzed for progressionfree survival pfs overall survival o and toxicity the study included 101 female patient with median age of 57 iqr year of whom 80 were postmenopausal 79 received palbociclib or ribociclib in second or laterline treatment 59 received fulvestrant and 41 received an aromatase inhibitor in firstline treatment at a median followup of month median pfs and o were 95ci not estimable month and not reached respectively in second or laterline setting at a median followup of month median pfs and o were 95ci month and 95ci not estimable month respectively grade neutropenia and febrile neutropenia were seen in 45 and 9 patient respectively while dose reduction wa required in 32 patient in multivariable cox regression analysis firstline setting hr 95ci p and ecog performance status 1 hr 95ci p were significantly associated with pfs while only ecog p 1 wa significantly associated hr 95ci p with o palbociclib and ribociclib when used in routine clinical practice in first or subsequent line of treatment resulted in efficacy and toxicity outcome in concordance with those expected from pivotal trial,"Aged, Aminopyridines, Breast Neoplasms, Databases, Factual, Disease-Free Survival, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Metastasis, Piperazines, Purines, Pyridines, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Retrospective Studies, Survival Rate"
34291912,the multifunctional combined nanoplatform ha a wide application prospect in the synergistic treatment of cancer nevertheless the traditional treatment of phototherapy is limited by the catalytic nanomaterial itself so the effect is not satisfactory here the arris of the anisotropic truncated octahedral au toh au wa coated with noble metal pt to form a spatial separation structure which enhanced the local surface plasmonic resonance and thus boosted the photocatalytic effect in this system the highly efficient photocatalysis provides a strong guarantee for oncotherapy on the one hand the structure of arris deposition adequately improves the efficiency of photothermal conversion which substantially improves the effectiveness of photothermal therapy on the other hand in situ oxygen production of pt ameliorates tumor hypoxia and through the o2 selfproduction and sale mode the growth and development of tumor were inhibited meanwhile under the enhanced photocatalysis more o2 were produced which greatly evolved the treatment effect of photodynamic therapy in the end the addition of hyaluronic acid can specifically target osteosarcoma cell while improving the retention time and biocompatibility of the material in the body thus the nanocomposite show superexcellent synergistic enhancement of photothermal conversion efficiency and photodynamic capability in vitro and in vivo which provides a potential possibility for osteosarcoma cure,"Animals, Anisotropy, Antineoplastic Agents, Catalysis, Chlorophyllides, Gold, Hyaluronic Acid, Infrared Rays, Metal Nanoparticles, Mice, Nude, Osteosarcoma, Oxygen, Photochemotherapy, Photosensitizing Agents, Photothermal Therapy, Platinum, Polyethylene Glycols, Porphyrins, Reactive Oxygen Species, Surface Plasmon Resonance, Mice"
34291369,napabucasin is an oral nadphquinone oxidoreductase 1 bioactivatable agent that generates reactive oxygen specie is hypothesised to affect multiple oncogenic cellular pathway including stat and is expected to result in cancer cell death this phase i study investigated the safety tolerability and pharmacokinetics of napabucasin coadministered with fluorouracil lleucovorin and irinotecan folfiri chemotherapy plus bevacizumab in japanese patient with metastatic colorectal cancer crc patient with histologically confirmed unresectable stage iv crc received oral napabucasin 240 mg twice daily bid intravenous folfiri and bevacizumab therapy wa initiated on day 3 at approved do unacceptable toxicity wa evaluated over the first 30 day of treatment after which treatment continued in day cycle until toxicity or disease progression endpoint included safety pharmacokinetics and tumour response based on recist v four patient received treatment three were evaluable during the unacceptable toxicity period all four patient experienced diarrhoea and decreased appetite considered napabucasinrelated in four and two patient respectively and three patient experienced neutrophil count decreased no unacceptable toxicity wa reported during the day evaluation period no grade 4 event death or serious adverse event were reported the addition of folfiri and bevacizumab to napabucasin did not significantly change the pharmacokinetic profile of napabucasin however result were variable among patient the best overall response wa stable disease in two patient napabucasin 240 mg bid in combination with folfiri and bevacizumab wa tolerated with a manageable safety profile in japanese patient with metastatic crc,"Antineoplastic Combined Chemotherapy Protocols, Benzofurans, Bevacizumab, Camptothecin, Colorectal Neoplasms, Humans, Japan, Leucovorin, Naphthoquinones"
34290380,cdtargeted chimeric antigen receptor car t cell therapy ha shown high efficacy in patient with refractory bcell malignancy such a nonhodgkin lymphoma and acute lymphoblastic leukemia despite promising result response are not durable in most patient in addition patient receiving cd19 car t cell therapy are at risk of developing severe potentially lifethreatening adverse event including cytokine release syndrome and immune effectorcell associated neurotoxicity syndrome many combinatorial approach are currently being investigated to improve car t cell in vivo function antitumor effect and mitigate toxicity in this review we discus the use of ibrutinib and immune checkpoint inhibitor in combination with car t cell therapy in patient with lymphoid bcell malignancy,"Antigens, CD19, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Adoptive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, T-Lymphocytes"
34290264,application of fluorouracil fu in cholangiocarcinoma cca is limited by adverse side effect and chemoresistance therefore the combination therapy of fu with other substance especially natural product may provide a new strategy for cca treatment the aim of this study wa to evaluate the combination effect of fu and two ethanolic extract of thai noni juice tnj product on cca cell line and nude mouse xenograft the result of antiproliferative assay showed the combination treatment of fu and each tnj ethanolic extract exerted more cytotoxicity on cca cell than either single agent treatment synergistic effect of drug combination can enable the dose reduction of fu the mechanism underlying a combination treatment wa apoptosis induction through an activation of p53 and bax protein in the nude mouse xenograft model combination treatment of fu with each tnj ethanolic extract suppressed the growth of cca cell implanted mouse more than single agent treatment with no effect on mouse body weight kidney and spleen moreover low do of tnj ethanolic extract reduced the hepatotoxicity of fu in nude mouse taken together these data suggested that the ethanolic extract of tnj product can enhance the anticca effect and reduce toxicity of fu,"Animals, Antineoplastic Agents, Phytogenic, Bile Duct Neoplasms, Cell Line, Tumor, Cholangiocarcinoma, Drug Interactions, Drug Tapering, Drug Therapy, Combination, Ethanol, Fluorouracil, Heterografts, Mice, Mice, Nude, Morinda, Neoplasm Transplantation, Plant Extracts"
34289750,squamous cell carcinoma of the vulva is a rare malignancy that affect elderly woman about onethird of vulvar cancer are diagnosed in an advanced stage requiring extensive surgery neoadjuvant chemotherapy nact ha been introduced to reduce local tumor burden in this retrospective study we analyze the efficacy and toxicity of nact followed by radical surgery patient with locally advanced vulvar cancer lavc treated at our institution with neoadjuvant platinum and paclitaxelbased chemotherapy ifosfamide followed by surgery at our institution were retrospectively identified fourteen patient 93 completed nact with tolerable toxicity gg4 toxicity 30 thirteen patient 87 underwent surgery the overall clinical response rate on vulvar disease wa 66 20 complete response 46 partial response confirmed by histopathologic analysis while on inguinal lymph node it wa 69 23 complete response 46 partial response at the pathologic examination all patient had negative surgical margin three out of 9 patient 33 with lesion infiltrating the urethral meatus and 4 patient out of 7 57 with anal involvement did not require urethral amputation or colostomy respectively after nact no severe postoperative complication were described overall survival at 5 year wa 60 and median overall survival wa 76 month nact followed by surgery in locally advanced vulvar cancer is well tolerated and allows surgical modulation,"Aged, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Female, Humans, Ifosfamide, Neoadjuvant Therapy, Neoplasm Staging, Paclitaxel, Platinum, Retrospective Studies, Uterine Cervical Neoplasms, Vulvar Neoplasms"
34289686,for the purpose of improving the quality of life and minimizing the psychological morbidity of a mastectomy breastconserving treatment bct ha become the more preferable choice in breast cancer patient meanwhile tumor hypoxia ha been increasingly recognized a a major deleterious factor in cancer therapy in the current study a novel effective and noninvasive magnetothermodynamic strategy based on an oxygenindependent freeradical burst for hypoxiaovercoming bct is proposed radical precursor aiph and iron oxide nanoparticles ionps are coincorporated within the alginate alg hydrogel which is formed in situ within the tumor tissue by leveraging the crosslinking effect induced by the local physiological ca with alg solution inductive heating is mediated by ionps under amf exposure and consequently regardless of the tumor hypoxia condition a local freeradical burst is achieved by thermal decomposition of aiph via amf responsivity the combination of magnetic hyperthermia and oxygenirrelevant freeradical production effectively enhances the in vitro cytotoxic effect and also remarkably inhibits tumor proliferation this study provides a valuable protocol for an hypoxiaovercoming strategy and also an alternative formulation candidate for noninvasive bct,"Alginates, Animals, Antineoplastic Agents, Azo Compounds, Breast Neoplasms, Cell Line, Tumor, Female, Hydrogels, Hyperthermia, Induced, Imidazoles, Magnetic Iron Oxide Nanoparticles, Magnetic Phenomena, Mice, Inbred BALB C, Reactive Oxygen Species, Mice"
34289656,diffuse large bcell lymphoma dlbcl predominantly affect older adult with suboptimal therapeutic outcome due to increased treatmentrelated mortality and toxicity in vulnerable patient clinically defined by geriatric impairment such a functional limitation multimorbidity or cognitive deficit in this prospective pilot study we evaluated a rituximabprednisone prephase treatment strategy in 33 older vulnerable patient with newly diagnosed dlbcl defined by either age 70 year or age year with karnofsky performance scale kp a single dose of rituximab 375 mgm2 between day and oral prednisone for at least 5 day prior to the first dose of chemoimmunotherapy wa administered all patient completed prephase treatment and all but one commenced anthracyclinebased chemoimmunotherapy only one early cycle death occurred toxicity event defined by either unplanned hospitalization unplanned dose reductiondelay or chemotherapy discontinuation occurred in 22 patient 67 sixteen patient 48 experienced grade 3 or higher nonhematologic toxicity andor grade 4 or higher hematologic toxicity with a median followup of year both year progressionfree survival and overall survival were at 81 95 confidence interval importantly we found that phenotypic impairment in basic and instrumental activity of daily living physical function mobility kp and cancer and aging research group chemotherapy toxicity risk score were significantly associated with senescenceassociated proinflammatory cytokine milieu which wa readily reversed with prephase treatment potentially explaining it clinical effectiveness prephase therapy with rituximabprednisone should be considered for all older vulnerable dlbcl patient prior to curative intent anthracyclinebased chemoimmunotherapy this trial wa registered a clinicaltrials gov identifier nct,"Activities of Daily Living, Aged, Aging, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Cytokines, Doxorubicin, Humans, Lymphoma, Large B-Cell, Diffuse, Middle Aged, Pilot Projects, Prednisone, Prospective Studies, Rituximab, Treatment Outcome, Vincristine"
34287772,background the study determined the safety pharmacokineticspharmacodynamics pkpd and recommended phase ii dose of bct100 for arginine auxotrophic tumour in a nonchinese population method this is a phase i 3 3 doseescalation openlabel multicentre study in two arginine auxotrophic cancersmalignant melanoma mm and castration resistant prostate cancer crpc patient were enrolled to receive weekly intravenous bct the dose cohort were respectively mgkg mgkg mgkg and mgkg result there were 14 mm and 9 crpc patient 16 male and 7 female with a median age of no doselimiting toxicity were reported among all the aes 18 were drugrelated mostly were grade 1 although there were individual variation in pks amongst the patient in each cohort the median arginine level wa maintained at m lower limit of quantification in all 4 cohort of patient after the second bct100 injection therapeutic arginine depletion wa found in the and mgkgweek cohort when antitumor activity were observed the two cohort had a similar auc and hgml respectively since the mgkgweek cohort had a more sustained arginine depletion for 2 week the mgkgweek dose is chosen a the future phase ii dose there were two complete remission 1 mm 1 crpc 1pr mm and 2 stable disease with a disease control rate cr pr sd of 22 conclusion bct100 is safe in a nonchinese population and ha antitumor activity in both mm and crpc weekly bct100 at mgkg is defined a the optimal biological dose for future clinical phase ii study,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Area Under Curve, Arginase, Arginine, Dose-Response Relationship, Drug, Female, Half-Life, Humans, Male, Melanoma, Middle Aged, Prostatic Neoplasms, Castration-Resistant, Recombinant Proteins, Skin Neoplasms"
34287771,introduction the number of cancer case among the elderly continue to increase a the worldwide population age this patient subset is underrepresented in clinical trial partly because of unresolved uncertainty about ageassociated tolerabilities and antitumor activity we reviewed phase 1 trial data to study tolerance and efficacy of novel agent used for treatment of elderly patient with cancer method data from 773 consecutive evaluable patient in 85 phase 1 clinical trial at start madridciocc were analyzed according to age with respect to objective response survival and toxicity result the mean age wa range year 260 patient were 65 y elderly group one hundred thirtyseven patient received immunotherapy drug 308 received targeted agent and 328 received chemotherapy no statistically significant difference in overall survival objective response or severe toxicity rate were found according to treatment type similar toxicity and clinical activity were found between the two age subgroup of the elderly and of the younger patient experienced severe hematological toxicity p and and respectively experienced severe nonhematological toxicity p regarding antitumor activity of the elderly and 15 of the younger patient achieved objective response p there were no significant betweengroup difference in overall survival versus month respectively p or progressionfree survival versus month respectively p conclusion this retrospective study found that elderly and younger population had comparable antitumor activity and toxicity profile these result support including elderly patient with cancer in earlyphase trial,"Age Factors, Aged, Aged, 80 and over, Aging, Antineoplastic Agents, Clinical Trials, Phase I as Topic, Humans, Neoplasms, Retrospective Studies, Sociodemographic Factors, Survival Analysis"
34286585,mitochondriatargeted synergistic therapy including photothermal ptt and photodynamic therapy pdt ha aroused wide attention due to the high sensitivity to reactive oxygen specie ro and heat shock of mitochondrion however most of the developed nanosystems for the combinatorial function require the integration of different component such a photosensitizers and mitochondriatargeted molecule consequently it indispensably requires sophisticated design and complex synthetic procedure in this work a welldesigned bi2sbased nanoneedle that localizes to mitochondrion and produce extra ro with inherent photothermal effect wa reported by doping of fe denoted a feb the engineered intrinsic characteristic certify the capacity of such oneforall nanosystems without additional molecule the lipophilicity and surface positive charge are demonstrated a crucial factor for specifical mitochondrion targeting significantly fe doping overcomes the disadvantage of the narrow band gap of bi2s3 to prevent the fast recombination of electronhole hence resulting in the generation of ro for pdt the oneforall nanoparticles integrate with mitochondriatargeting and synergistic effect of pdt and ptt thus exhibit enhanced therapeutic effect and inhibit the growth of tumor observably this strategy may open a new direction in designing the mitochondriatargeted material and broadening the property of inorganic semiconductor material for satisfactory therapeutic outcome,"Animals, Antineoplastic Agents, Bismuth, Female, HeLa Cells, Humans, Iron, Mice, Inbred BALB C, Mitochondria, Nanoparticles, Neoplasms, Photochemotherapy, Photosensitizing Agents, Photothermal Therapy, Reactive Oxygen Species, Sulfides, Mice"
34286354,pharmacist consultation is unfrequently performed in oncology clinical trial that include patient who often have many cotreatments increasing the risk of drugdrug interaction ddi the aim of this study wa to determine whether best possible medication history bpmh by hospital pharmacist at inclusion and therapeutic drug monitoring could be used for ddi risk evaluation and for current oral targeted therapy management a prospective clinical trial alcina nct04025541 wa carried out in metastatic breast cancer cohort treated by palbociclib to conduct pharmacokineticstoxicity correlation study bpmh wa prospectively performed by the hospital pharmacist at each trial inclusion followed by a contact to the patient community pharmacy to complete the collected data pharmacokinetic analysis wa performed on blood sample collected at day 15 of cycle 1 of palbociclib treatment pharmacist intervention indicated that at inclusion current medication were incomplete for 63 of the enrolled patient it allowed the realtime management of highrisk ddi detected in third of patient the palbociclib ctrough geometric median minmax wa significantly higher in cohort with potential ddi 106 ngml 113 than cohort without potential ddi ngml p this is the first prospective study evaluating the relevance of proactive bpmh by pharmacist with contact to the community pharmacy during the inclusion step of a clinical trial to ensure the efficacy and safety of the investigated drug this investigation wa thus able to highlight the statistically significant impact of these ddi on palbociclib plasma concentration variation during the clinical trial clinicaltrialsgov identifier nct,"Administration, Oral, Antineoplastic Agents, Breast Neoplasms, Drug Interactions, Drug Monitoring, Female, Humans, Molecular Targeted Therapy, Pharmacists, Pharmacy Service, Hospital, Piperazines, Professional Role, Prospective Studies, Pyridines"
34284701,relapse is the most common cause of treatment failure following allogeneic blood or marrow transplantation allobmt for aml or md posttransplant maintenance therapy may prevent relapse we conducted a phase ii trial combining azacitidine aza with gmcsf in nonrelapsed posttransplant patient with aml or md patient received escalating do of aza to a maximum of 75 mgm2 for 5 day per cycle for up to 12 cycle gmcsf wa given on day of each cycle eighteen patient were treated following nonmyeloablative 17 and myeloablative 1 allobmt for aml md or therapyrelated myeloid neoplasm the majority of patient 72 received their graft from an hlahaploidentical donor the treatment wa welltolerated with rare grade hematologic toxicity one patient suffered an exacerbation of gvhd the month relapsefree and overall survival were 47 and 57 respectively with a median of and 29 month,"Azacitidine, Bone Marrow, Granulocyte-Macrophage Colony-Stimulating Factor, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Recurrence"
34284690,late onset neutropenia lon after rituximab is a previously described complication we aimed to as and characterize lon after obinutuzumab a novel anticd20 antibody in the realworld setting and compare it to lon after rituximab therapy we retrospectively analyzed 330 consecutive patient with lymphoproliferative neoplasm rituximabtreated n 283 obinutuzumabtreated n 47 lon occurred in 23 patient with similar incidence in rituximab n 23 or obinutuzumab n 21 group p patient treated for cll and posttransplantation lymphoproliferative disease ptld were at higher risk to develop lon multivariate analysis hr for cll ci 95 hr for ptld ci 95 febrile neutropenia wa uncommon during lon and occurred in 15 patient rituximab n 14 and obinutuzumab n 1these data suggest that lon after obinutuzumab treatment is a common a with rituximab the similarity in lon after rituximab and obinutuzumab argue for a possible class effect for anticd20 monoclonal antibody,"Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Neutropenia, Retrospective Studies, Rituximab"
34281470,egfrtyrosine kinase inhibitor tkis changed the natural history of egfrmutant advanced nsclc patient but acquired resistance is inevitable new strategy are being tested to overcome or prevent the emergence of resistance mechanism to firstline tkis among which combination of tkis with antiangiogenic agent we performed a literature search for preclinical and clinical data on the interplay and dual inhibition of egfrvegf pathway particularly in egfrmutant nsclc we then focused on relay a placebocontrolled phase 3 trial evaluating ramucirumab combined to erlotinib in treatmentnave advanced egfrmutant nsclc patient this article aim to summarize efficacy and safety of the ramucirumaberlotinib combination in this setting relay confirmed the clinical relevance of combining egfr and vegfrtargeting therapy previously investigated in smaller phase trial of erlotinib and bevacizumab however the meaningful pfs benefit observed in the ramucirumab erlotinib arm is counterbalanced by the toxicity profile of ramucirumab and the need for bimonthly infusion pending o result are therefore critical to as the real benefit from this combination especially a firstline osimertinib ha improved survival in egfrmutant nsclc patient and will probably remain the pivotal egfrtki in this setting however it heterogeneous efficacy across subgroup pave the way for osimertinibbased combination which are being investigated in ongoing trial,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Erlotinib Hydrochloride, Humans, Lung Neoplasms, Mutation, Protein Kinase Inhibitors, Ramucirumab"
34280922,the prescription of carboplatin is commonly based on the calvert formula and low serum creatinine value can lead to an overestimation of the glomerular filtration rate and of the carboplatin dose limited data recommend to cap carboplatin dose at 800 mg but the risk of suboptimal carboplatin dose is concerning this study compared hematologic toxicity occurrence and survival outcome in lung cancer patient receiving carboplatin or 800 mg based on the calvert formula target area under the curve 5 mgml min our result show more severe cytopenia in patient receiving carboplatin 800 mg with significant difference for all grade of thrombocytopenia in the uncapped group 37 patient v 3 p for metastatic nonsmallcell lung cancer patient we also observed hematologic toxicity in the uncapped group with more severe anemia 30 of patient v 0 p and all grade of thrombocytopenia 39 v 0 p than the capped group concerning the secondary endpoint we obtained a trend of lower progressionfree survival and overall survival in patient receiving carboplatin 800 mg but no significant difference appears for the both survival criterion this study aim to improve the determination of carboplatin dosage to know the real impact of carboplatin capping and to find the optimum balance between excessive toxicity and substandard therapeutic outcome,"Adult, Aged, Antineoplastic Agents, Carboplatin, Dose-Response Relationship, Drug, Female, Humans, Lung Neoplasms, Male, Middle Aged, Progression-Free Survival, Survival Rate, Thrombocytopenia, Treatment Outcome"
34278695,immune checkpoint inhibitor are increasingly being utilised a an effective therapy for a variety of cancer however they have the potential to cause serious autoimmune toxicity in multiple organ system termed immunotherapyrelated adverse event endocrine toxicity are common can occur well after commencement of therapy and can result in significant morbidity and mortality if not recognised this make it important for all physician in addition to endocrinologist and oncologist to understand the nature of these reaction and the general approach to their diagnosis and management this review aim to provide an overview of the epidemiology pathophysiology clinical presentation and management of the endocrine adverse event,"Antineoplastic Agents, Immunological, Endocrine System, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms"
34275517,the development of immune checkpoint inhibitor icis ha significantly improved the prognosis of cancer patient but a large population of patient are still ineffective to icis treatment or develop aquired drug resistance in order to improve the clinical benefit a number of study on icis based combination therapy have been actively explored and have achieved satisfactory result with the application of icis based combination therapy in clinical practice increasing attention ha been paid to the safety of combination therapy and the management of treatmentrelated adverse event in this review the characteristic of adverse event related to icis based combination therapy especially programmed cell death protein protein ligand 1 pdpdl1 inhibitor are discussed in order to provide profound thought for toxicity evaluation and individualized treatment decision in future clinical practice pdpdl1 immune checkpoint inhibitor icisicisicisicis1programmed cell death protein ligand pdpdl1icisicis pdpdl1,"B7-H1 Antigen, Biomedical Research, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Humans, Immune Checkpoint Inhibitors, Lung Neoplasms, Programmed Cell Death 1 Receptor"
34275396,the firstinclass btk inhibitor ibrutinib ha substantially changed the therapeutic landscape of chronic lymphocytic leukemia cll the nextgeneration btk inhibitor acalabrutinib is more selective and may have le offtarget toxicity a compared to ibrutinib acalabrutinib ha demonstrated safety and efficacy in cll and ha been approved to treat cll current clinical trial investigated acalabrutinib monotherapy or acalabrutinibbased combination therapy in relapsedrefractory and treatmentnaive cll data on the efficacy and safety of acalabrutinib in clinical trial were summarized in this review the pharmacokinetic and pharmacodynamic data of acalabrutinib were also discussed acalabrutinib selectively inhibits btk by covalent binding and show rapid absorption and elimination acalabrutinib doe not inhibit egfr tec or itk and show fewer offtarget toxicity completed phase 3 trial have demonstrated that acalabrutinib improves the outcome of patient with relapsedrefractory cll and patient with treatmentnaive cll the phase 3 trial that evaluates acalabrutinib versus ibrutinib ha met it primary endpoint early phase study suggested the combination of acalabrutinib with a cd20 antibody and venetoclax led to high rate of undetectable minimal residual disease in the bone marrow in cll patient and might provide a fixedduration therapeutic option for patient with cll,"Adenine, Agammaglobulinaemia Tyrosine Kinase, Animals, Antineoplastic Agents, Benzamides, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, Protein Kinase Inhibitors, Pyrazines"
34274878,the expanding use of immunotherapy and the growing population of patient with cancer ha led to an increase in the reporting of immune related adverse event iraes the emergency clinician should be aware of these emerging toxicity some of which can be fatal in this review we discus the cardiotoxic side effect of immune checkpoint inhibitor icis and chimeric antigen receptor tcell car tcell therapy recognizing the possible presentation of cardiotoxic iraes is of utmost important a the diagnosis of cardiotoxicity associated with ici and car tcell can be difficult to make in the emergency department the emergency clinician will have to presume the diagnosis and treat it without final confirmation in most case for this reason if the diagnosis is suspected early involvement of the cardiologist and oncologist is important to help guide management most iraes will be treated with glucocorticoid but in the case of car tcell cardiotoxicity tocilizumab should be used a first line although cardiotoxicity is rare it is often lifethreatening treatment should be initiated a soon a the diagnosis is suspected and early involvement of the cardiologist and oncologist is imperative for optimal treatment,"Cardiotoxicity, Emergency Service, Hospital, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Adoptive, Neoplasms, Receptors, Chimeric Antigen"
34274443,aloe vera l burm f is a typical traditional chinese medicine tcm collected in the pharmacopoeia of the people republic of china version 2015 it ha been traditionally used for the treatment of constipation and it potential therapeutic activity have been widely evaluated including antitumor antiinflammatory and immune regulatory effect the wide application of aloe vera in food and therapy ha raised safety issue and there are multiple safety assessment with a diverse toxicity and adverse effect from clinic and animal this study aimed to investigate the safety of aloe vera barbadensis extract c avbec in rat and analyze it anticancer activity in cell line we administrated avbec orally in an acute toxicity study and a month chronic toxicity study to observe and confirm it safety in spraguedawley sd rat additionally we explored the cytotoxicity of avbec in cancer cell and noncancer cell we further investigated the antitumor activity of avbec and in the meantime probed the function of component from avbec no death or substancerelative toxicity were observed in the acute toxicity study or the month chronic toxicity study with do of gkg1 and gkg respectively in the chronic toxicity study avbec did not cause organ toxicity including crucial organ structure and chemical function and peripheral and central immune system damage additionally we found that avbec could induce cancer cell apoptosis with a relatively higher apoptotic ratio than in noncancer cell by decreasing adenosine triphosphate atp concentration and enhancing reactive oxygen specie ro production we also identified component in avbec using highperformance liquid chromatography with tandem mass spectrometry hplcmsms and probed the function of malic acid this demonstrated that under the same circumstance malic acid induced cell necrosis in cancer cell and noncancer cell while avbec did not these result reveal a novel mechanism of aloe gel extract in regulating cancer cell apoptosis via modulating the mitochondrial metabolism and imply a possible application of avbec for the treatment of malignant cancer with the safety evaluation from rat and anticancer investigation from cancer cell and noncancer cell,"Administration, Oral, Animals, Antineoplastic Agents, Apoptosis, Breast Neoplasms, Cell Line, Tumor, Cell Survival, Drugs, Chinese Herbal, Female, Lung Neoplasms, Male, Plant Extracts, Plant Leaves, Plant Preparations, Rats, Rats, Sprague-Dawley, Toxicity Tests"
34273448,the incidence and mortality of cancer are rapidly growing all over the world nowadays antineoplastic antimetabolite still play a key role in the chemotherapy of cancer however the interindividual variation in the efficacy and toxicity of antineoplastic antimetabolite are nonnegligible challenge to their clinical application although many study have focused on genetic variation the reason for these interindividual variation have still not been fully understood gut microbiota is reported to be associated with the efficacy and toxicity of antineoplastic antimetabolite in this review we summarize the interaction of antineoplastic antimetabolite on gut microbiota and the influence of shifted gut microbiota profile on the efficacy and toxicity of antineoplastic antimetabolite the factor affecting the efficacy and toxicity of antineoplastic antimetabolite via gut microbiota are also discussed in addition we present our viewpoint that regulating the gut microbiota may increase the efficacy and decrease the toxicity of antineoplastic antimetabolite this will help u better understand the new mechanism via gut microbiota and promote individualized use of antineoplastic antimetabolite,"Animals, Antimetabolites, Antineoplastic, Food-Drug Interactions, Gastrointestinal Microbiome, Humans, Neoplasms, Probiotics, Treatment Outcome"
34272090,to estimate the maximally tolerated dose mtd and describe toxicity associated with lenvatinib and weekly paclitaxel in patient with recurrent endometrial and platinum resistant epithelial ovarian cancer using a 3 3 design patient were given weekly paclitaxel 80 mgm2 iv day 15 and oral levantinib daily on a day cycle lenvatinib dose level were 8 mg 12 mg 16 mg 20 mg toxicity were recorded using ctcae v and response wa determined with imaging after cycle then every 3rd cycle using recist criterion 26 patient were enrolled 19 with ovarian cancer 14 high grade serous 1 low grade serous 2 clear cell 1 endometrioid and 1 carcinosarcoma and 7 with endometrial cancer 3 serous and 4 endometrioid the mtd wa established at lenvatinib 16 mg and weekly paclitaxel 80 mgm toxicity all grade occurring in 25 of patient included anemia neutropenia lymphopenia mucositis nausea diarrhea anorexia hypertension fatigue proteinuria epistaxis hoarseness twentythree patient were evaluable for response and pfs 15 65 had a partial response 7 30 stable 1 4 progressive disease with an objective response rate of 65 71 in ovarian and 50 in endometrial cancer median progression free survival pfs is month month in endometrial cancer month in ovarian cancer 54 had a pfs 6 month the median duration of response for pr patient n 15 wa month the regimen wa tolerable with manageable side effect encouraging activity wa observed in endometrial and ovarian cancer and warrant further development,"Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Ovarian Epithelial, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Endometrial Neoplasms, Fallopian Tube Neoplasms, Female, Genital Neoplasms, Female, Humans, Middle Aged, Ovarian Neoplasms, Paclitaxel, Peritoneal Neoplasms, Phenylurea Compounds, Quinolines"
34272041,guideline recommend atezolizumab plus nabpaclitaxel a np for firstline treatment of unresectable locally advanced or metastatic triplenegative breast cancer expressing programmed deathligand 1 pdl1 on tumorinfiltrating immune cell ic based on impassion we report the final overall survival o and safety of that study a per the prespecified analysis plan patient were randomized to np 100 mgm2 day and 15 of a day cycle with atezolizumab 840 mg a np or placebo p np day 1 and 15 until progression or unacceptable toxicity coprimary endpoint were progressionfree survival intentiontotreat itt and pdl1 icpositive population and o tested hierarchically in the itt population and if significant in the pdl1 icpositive population each arm comprised 451 patient 666 had died by the final o analysis cutoff median followup month interquartile range month median o in the itt population wa month 95 confidence interval ci month with a np and month 95 ci month with p np stratified hazard ratio hr 95 ci p exploratory analysis in the pdl1 icpositive population showed a median o of month 95 ci month with a np n 185 and month 95 ci month with p np n 184 stratified hr 95 ci safety outcome were consistent with previous analysis and the known toxicity profile of each agent immunemediated adverse event of special interest were reported in and of patient treated with a np and p np respectively although the o benefit in the itt population wa not statistically significant precluding formal testing clinically meaningful o benefit wa observed with a np in pdl1 icpositive patient consistent with prior interim analysis this combination remained safe and tolerable with longer followup,"Albumins, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Humans, Paclitaxel, Survival Analysis, Triple Negative Breast Neoplasms"
34271103,medulloblastoma mb is a malignant pediatric brain tumor with a poor prognosis postsurgical radiation and cisplatinbased chemotherapy have been a mainstay of treatment which often lead to substantial neurocognitive impairment and morbidity highlighting the need for a novel therapeutic target to enhance the sensitivity of mb tumor to cytotoxic therapy we performed a comprehensive study using a cohort of 71 mb patient sample and pediatric mb cell line and found that mb tumor have elevated level of nucleosome remodeling fact facilitates chromatin transcription complex and dna repair enzyme apendonuclease1 ape1 fact interacts with ape1 and facilitates recruitment and acetylation of ape1 to promote repair of radiation and cisplatininduced dna damage further level of fact and acetylated ape1 both are correlate strongly with mb patient survival targeting fact complex with cbl0137 inhibits dna repair and alters expression of a subset of gene and significantly improves the potency of cisplatin and radiation in vitro and in mb xenograft notably combination of cbl0137 and cisplatin significantly suppressed mb tumor growth in an intracranial orthotopic xenograft model we conclude that fact complex promotes chemoradiation resistance in mb and fact inhibitor cbl0137 can be used a a chemoradiation sensitizer to augment treatment efficacy and reduce therapyrelated toxicity in highrisk pediatric patient,"Adolescent, Adult, Animals, Carbazoles, Child, Child, Preschool, Cisplatin, DNA Damage, DNA Repair, DNA-(Apurinic or Apyrimidinic Site) Lyase, DNA-Binding Proteins, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, Heterografts, High Mobility Group Proteins, Histone Chaperones, Humans, Male, Medulloblastoma, Mice, Transcriptional Elongation Factors, Young Adult"
34270809,triplenegative breast cancer tnbc cell are sensitive to parp1 inhibitor in vitro the combination of olaparib and radiotherapy for tnbc is currently evaluated in the phase i radioparp trial radioparp is a monocentric prospective openlabel phase i doseescalation trial evaluating the combination of breast radiotherapy and olaparib in tnbc patient with inflammatory locoregionally advanced or metastatic disease or with residual disease after neoadjuvant chemotherapy olaparib wa orally given at increasing dose level 150 or 200 mg twice a day bid radiotherapy consisted of 50 gy to the breast or chest wall with or without lymph node irradiation twentyfour tnbc patient were enrolled between september 2017 and november olaparib wa escalated to 200 mg bid without doselimiting toxicity at year followup no treatmentrelated grade 3 toxicity wa observed one patient had persistent grade 2 adverse event breast pain fibrosis and deformity there wa no cardiac pulmonary or digestive toxicity related to treatment the year followup report of the radioparp phase i trial evaluating olaparib associated with breast radiotherapy in tnbc patient consequently demonstrated an excellent toxicity profile of this combination with few lowgrade adverse event,"Adult, Aged, Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Hyperpigmentation, Middle Aged, Pain, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Prospective Studies, Radiotherapy, Radiotherapy Dosage, Treatment Outcome, Triple Negative Breast Neoplasms"
34270794,chemotherapy administered at normal therapeutic dosage can cause significant sideeffects and may result in early treatment discontinuation interindividual variation in toxicity highlight the need for biomarkers to personalise treatment we sought to identify such biomarkers by conducting 40 genomewide association study together with gene and gene set analysis for any toxicity and 10 individual toxicity in 1800 patient with advanced colorectal cancer treated with oxaliplatin and fluoropyrimidine chemotherapy cetuximab from the mrc coin and coinb trial 385 patient received folfox 360 folfox cetuximab 707 xelox and 348 xelox cetuximab single nucleotide polymorphism snp gene and gene set that reached genomewide or suggestive significance were validated in independent patient group we found that mroh5 wa significantly associated with neutropenia in magma gene analysis in patient treated with xelox p and wa independently validated in those receiving xelox cetuximab pooled p rs13260246 at 8q wa significantly associated with vomiting in patient treated with xelox odds ratio 95 confidence interval p but wa not independently replicated snp at 139 locus had suggestive association for toxicity and lead snp at five of these were independently validated rs6030266 with diarrhoea rs1546161 with handfoot syndrome rs9601722 with neutropenia rs13413764 with lethargy and rs4600090 with nausea all with pooled p in conclusion the association of mroh5 with neutropenia and five other putative biomarkers warrant further investigation for their potential clinical utility despite our comprehensive genomewide analysis of large wellcharacterised clinical trial we found a lack of common variant with modest effect size associated with toxicity,"Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Cetuximab, Colorectal Neoplasms, Diarrhea, Drug-Related Side Effects and Adverse Reactions, Female, Fluorouracil, Genome-Wide Association Study, Genotype, Humans, Male, Middle Aged, Oxaliplatin, Polymorphism, Single Nucleotide, Randomized Controlled Trials as Topic, Ribosomal Proteins, Serine-Arginine Splicing Factors, Vomiting"
34269290,portal vein tumor thrombus pvtt remains a poor prognostic factor occurring in about 1040 of patient with hepatocellular carcinoma hcc for the optimal treatment is controversial anlotinib is an novel small molecule inhibitor that ha a broad spectrum of inhibitory activity on tumor angiogenesis and growth however so far no study have reported the use of anlotinib in the treatment of hcc patient with pvtt here we evaluated the safety and efficacy of anlotinib followed by transarterial chemoembolization tace and radiofrequency ablation rfa for the treatment of patient with hcc and pvtt a total of 145 consecutive hcc patient who underwent tace in combination with rfa were enrolled in the retrospective study twentyeight patient were diagnosed with pvtt and received anlotinib a basic treatment the adverse event aes were graded according to the national cancer institute common terminology criterion for aes version time to tumor progression ttp and overall survival o were calculated using the kaplanmeier method the most common toxicity related to anlotinib were pharyngalgia fatigue and handfoot skin reaction the median o wa 13 month range month with year o rate of the median ttp wa 7 month range month with month rate of anlotinib followed by tace and rfa is a safe and effective initial treatment modality for hcc patient with pvtt anlotinib may be a promising therapeutic option for relieving andor stabilizing hcc with pvtt,"Carcinoma, Hepatocellular, Catheter Ablation, Chemoembolization, Therapeutic, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Indoles, Kaplan-Meier Estimate, Liver Neoplasms, Male, Neoplasm Invasiveness, Portal Vein, Postoperative Complications, Quinolines, Retrospective Studies, Sorafenib, Survival Rate, Venous Thrombosis"
34268711,introduction imc001 is a fully human igg1 monoclonal antibody that bind to human pdl1 programmed deathligand 1 this study evaluated the safety pharmacokinetics and pharmacodynamics of imc001 in patient with advanced solid tumor material and method this openlabeled phase i study used a standard 3 3 doseescalation design with do ranging from 2 to 20 mgkg imc001 wa administered intravenously every 2 week until disease progression or unacceptable toxicity the doselimiting toxicity window wa defined a 21 day from the first dose result fifteen subject were included in 5 doseescalation cohort no doselimiting toxicity wa observed and the maximum tolerated dose wa not reached the most common adverse event aes were general weakness decreased appetite fever and cough no grade 4 or 5 treatment emergent aes were reported during the study one subject in the 2 mgkg cohort showed grade 2 immuneinduced thyroiditis and diabetes mellitus suspected to be related to imc over the dose range of mgkg imc the aucd auc and cmax generally increased in a doseproportional manner for each step of dose escalation of the 15 enrolled patient 1 subject with rectal cancer showed a partial response and the disease control rate wa conclusion imc001 demonstrated a favorable safety profile up to 20 mgkg administered intravenously every 2 week and showed preliminary efficacy in patient with advanced solid tumor based on pharmacokinetic and pharmacodynamic data 20 mgkg wa selected a the recommended phase ii dose clinical trial identification nct03644056 date of registration august 2018,"Adult, Aged, Female, Humans, Male, Middle Aged, Antineoplastic Agents, Area Under Curve, B7-H1 Antigen, Dose-Response Relationship, Drug, Maximum Tolerated Dose, Neoplasm Metastasis, Neoplasms, Antibodies, Monoclonal, Humanized"
34268530,acalabrutinib wa approved by the u food and drug administration fda for treatmentnaive tn and relapsedrefractory rr use for patient with chronic lymphocytic leukemia cll in november 2019 following the phase iii ascend and elevatetn registration trial acalabrutinib is a secondgeneration bruton tyrosine kinase inhibitor btki that wa developed after ibrutinib the firstinclass btki ibrutinib is usually well tolerated and provides durable remission however some patient experience toxicity from the offtarget effect that lead to treatment discontinuation a recent press release of the phase iii elevaterr trial comparing acalabrutinib to ibrutinib in relapsed highrisk cll reported noninferior progressionfree survival and statistically significantly lower rate of atrial fibrillation however publication of this data is pending there is currently 53 month of followup for patient receiving acalabrutinib compared with 8 year for those on ibrutinib acalabrutinib is approved a monotherapy in the rr or tn setting and in the tn setting can be combined with the anticd20 monoclonal antibody obinutuzumab the data for acalabrutinib development and clinical use are discussed in this review,"Benzamides, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors, Pyrazines, Pyrimidines"
34266689,to compare the outcome of patient with lowrisk gestational trophoblastic neoplasia gtn treated with day methotrexate mtx with two different regimen of folinic acid fa retrospective cohort study of lowrisk gtn followed at rio de janeiro federal university from januarydecember2019 with day mtx with fa at mgkg versus 15 mg fixed dose among 667 patient with lowrisk gtn 323 were treated with fa at mgkg and 142 with fa at 15 mg fixed dose the weightbased and fixed dose group were comparable in term of clinical profile but did differ in the hcg pretreatment level 8883 versus 5127 iul p and figo risk score versus p respectively despite this there wa no difference in the remission rate in firstline treatment versus 81 p although fa at mgkg had a significantly higher number of chemotherapy cycle to remission 5 versus p need to delay chemotherapy due to toxicity versus p and time to remission 12 versus 8 week p respectively a logistic regression analysis showed that the different fa rescue regimen appeared comparable in term of achieving remission in firstline chemotherapy for lowrisk gtn or ci95 p fa with 15 mg fixed dose a compared to mgkg of fa wa associated with similar primary remission rate relapse or death among lowrisk gtn treated with day mtx this regimen is highly practical reduces visit to health facility appears equally safe and may be preferable with the day mtx regimen in the treatment of lowrisk gtn,"Adult, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Drug Administration Schedule, Female, Gestational Trophoblastic Disease, Humans, Leucovorin, Methotrexate, Pregnancy, Retrospective Studies, Young Adult"
34265432,the optimal management for immunerelated adverse event iraes in patient who do not respond or become intolerant to steroid is unclear guideline suggest additional immunosuppressant on the basis of case report and expert opinion we evaluated patient with lung cancer at memorial sloan kettering cancer center treated with immune checkpoint blockade from 2011 to pharmacy record were queried to identify patient who received systemic steroid and an additional immunosuppressant eg tumor necrosis factor inhibitor mycophenolate mofetil patient record were manually reviewed to evaluate baseline characteristic management and outcome among 2750 patient with lung cancer treated with immune checkpoint blockade 51 2 received both steroid and an additional immunosuppressant for a severe irae tumor necrosis factor inhibitor 73 mycophenolate mofetil 20 the most common event were colitis 53 pneumonitis 20 hepatitis 12 and neuromuscular 10 at 90 day after the start of an additional immunosuppressant 57 were improved from their irae 18 were unchanged and 25 were deceased improvement wa more common in hepatitis five of six and colitis 18 of 27 but le common in neuromuscular one of five and pneumonitis 3 of 10 of the patient who died 8 of 13 were attributable directly to the irae and 4 of 13 were related to toxicity from immunosuppression three infectionrelated death one druginduced liver injury leading to acute liver failure steroidrefractory or resistant iraes event are rare although existing treatment help patient with hepatitis and colitis many patient with other iraes remain refractory or experience toxicity from immunosuppression a more precise understanding of the pathophysiology of specific iraes is needed to guide biologicallyinformed treatment for severe iraes,"Humans, Immune Checkpoint Inhibitors, Immunologic Factors, Immunosuppressive Agents, Lung Neoplasms, Steroids"
34265157,immunotherapy with immune checkpoint inhibitor icis ha transformed cancer treatment over the past decade improving survival rate in numerous advanced cancer immunerelated adverse event iraes are common and can affect any organ system with many of these toxicity being wellcharacterized with clear grading criterion and management approach there ha been le emphasis on oral manifestation of iraes this review provides an overview of oral manifestation of iraes including mucosal and salivary gland toxicity and proposes a grading system and management guideline iraes are common treatmentrelated toxicity in patient treated with icis oral iraes can range from asymptomatic white reticulation to lifethreatening mucocutaneous reaction requiring aggressive management with corticosteroid andor permanent discontinuation of icis oral healthcare provider should be prepared to identify and manage oral iraes in collaboration with oncologist and other specialist,"Humans, Immune Checkpoint Inhibitors, Immunologic Factors, Immunotherapy, Neoplasms, Survival Rate"
34264439,in lotus nct02162719 adding the oral akt inhibitor ipatasertib to firstline paclitaxel for locally advancedmetastatic triplenegative breast cancer atnbc improved progressionfree survival pfs primary endpoint with an enhanced effect in patient with pik3caaktptenaltered tumor foundationone nextgeneration sequencing ng assay we report final overall survival o result eligible patient had measurable previously untreated atnbc patient were stratified by prior neoadjuvant therapy chemotherapyfree interval and tumor immunohistochemistry pten status and were randomized 11 to paclitaxel 80 mgm2 day 15 plus ipatasertib 400 mg or placebo day every 28 day until disease progression or unacceptable toxicity o intenttotreat itt immunohistochemistry ptenlow and pi3kakt pathwayactivated ng pik3caaktptenaltered population wa a secondary endpoint median followup wa versus month in the ipatasertibpaclitaxel versus placebopaclitaxel arm respectively in the itt population n 124 median o wa numerically longer with ipatasertibpaclitaxel than placebopaclitaxel hazard ratio 95 ci median v month respectively year o 83 v 68 likewise median o favored ipatasertibpaclitaxel in the ptenlow n 48 v month hazard ratio and pik3caaktptenaltered n 42 v month hazard ratio subgroup the ipatasertibpaclitaxel safety profile wa unchanged final o result show a numerical trend favoring ipatasertibpaclitaxel and median o exceeding 2 year with ipatasertibpaclitaxel overall result are consistent with the reported pfs benefit interpretation within biomarkerdefined subgroup is complicated by small sample size and tnbc heterogeneity,"Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Disease-Free Survival, Double-Blind Method, Female, Humans, Paclitaxel, Phosphatidylinositol 3-Kinases, Piperazines, Pyrimidines, Triple Negative Breast Neoplasms"
34264412,background we report a phase 1 study of ly an antibodydrug conjugate composed of human igg1 monoclonal antibody against the human fgfr3 attached with a cleavable linker to the maytansine derivative dm4 in patient with advanced or metastatic cancer method this study wa comprised of two part a dose escalation in patient with advanced or metastatic cancer and b dose expansion in patient with urothelial carcinoma with locally determined fgfr3 alteration the dose range of ly3076226 tested wa mgkg a an intravenous infusion on day 1 of each day cycle the primary objective wa to determine a recommended phase 2 dose rp2d result twentyfive patient were enrolled part a part b 3 and received 1 dose of ly no doselimiting toxicity were reported ly3076226 wa generally well tolerated most of the toxicity were grade 1 or two patient experienced treatmentrelated grade 3 toxicity embolism and decreased platelet count four patient experienced serious adverse event not treatmentrelated all in part a doseproportional exposure wa observed with an estimated halflife of day no response were seen with ly3076226 treatment stable disease persisting for 6 month wa observed in 1 patient receiving mgkg of ly conclusion the study demonstrates acceptable safety and tolerability of ly3076226 up to the mgkg dose recruitment wa stopped due to pipeline prioritization dose escalation of ly3076226 beyond mgkg in patient with advanced tumor may be possible the trial wa registered on august 2015 under identifier nct02529553 with clinicaltrialsgov,"Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Antineoplastic Agents, Area Under Curve, Dose-Response Relationship, Drug, Half-Life, Immunoconjugates, Maximum Tolerated Dose, Maytansine, Metabolic Clearance Rate, Neoplasms, Receptor, Fibroblast Growth Factor, Type 3, Urologic Neoplasms, Antibodies, Monoclonal, Humanized"
34264316,nivolumab plus ipilimumab is superior to platinumbased chemotherapy in treatmentnaive advanced nonsmall cell lung cancer nsclc nivolumab is superior to docetaxel in advanced pretreated nsclc to determine whether the addition of ipilimumab to nivolumab improves survival in patient with advanced pretreated immunotherapynaive squamous sq nsclc the lung cancer master protocol lungmap s1400i phase openlabel randomized clinical trial wa conducted from december to april randomizing patient in a 11 ratio to nivolumab alone or combined with ipilimumab the median followup in surviving patient wa month the trial wa conducted through the national clinical trial network and included patient with advanced immunotherapynaive sqnsclc and a zubrod score of 0 asymptomatic to 1 symptomatic but completely ambulatory with disease progression after standard platinumbased chemotherapy randomization wa stratified by sex and number of prior therapy 1 v 2 or more data were analyzed from may to february nivolumab 3 mgkg intravenously every 2 week with or without ipilimumab 1 mgkg intravenously every 6 week until disease progression or intolerable toxic effect the primary end point wa overall survival o secondary end point included investigatorassessed progressionfree survival iapfs and response per response evaluation criterion in solid tumor recist guideline version of 275 enrolled patient 252 mean age year range year 169 men 67 206 white patient 82 were deemed eligible 125 randomized to nivolumabipilimumab and 127 to nivolumab the study wa closed for futility at a planned interim analysis overall survival wa not significantly different between the group hazard ratio hr 95 ci p 34 median survival wa 10 month 95 ci month in the nivolumabipilimumab group and 11 month 95 ci month in the nivolumab group the iapfs hr wa 95 ci p 09 median iapfs wa month 95 ci month in the nivolumabipilimumab group and month 95 ci month in the nivolumab alone group response rate were 18 95 ci 1225 with nivolumabipilimumab and 17 95 ci 1023 with nivolumab median response duration wa month 95 ci month to not reached with nivolumabipilimumab and month with nivolumab 95 ci month grade 3 or higher treatmentrelated adverse event occurred in 49 of 124 patient who received nivolumabipilimumab and in 41 of 123 who received nivolumab alone toxic effect led to discontinuation in 31 of 124 patient 25 on nivolumabipilimumab and in 19 of 123 15 on nivolumab in this phase 3 randomized clinical trial ipilimumab added to nivolumab did not improve outcome in patient with advanced pretreated immune checkpoint inhibitornaive sqnsclc clinicaltrialsgov identifier nct,"Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Epithelial Cells, Humans, Ipilimumab, Lung, Lung Neoplasms, Nivolumab"
34263677,the prognosis of advanced esophageal cancer ec remains poor and few effective agent are available for advanced ec patient a combination of platinum and fluoropyrimidine is recognized a the standard firstline treatment after firstline treatment taxane or irinotecan ha been used based on the keynote181 and the attraction3 trial immune checkpoint inhibitor icis such a pembrolizumab and nivolumab appear to prolong survival compared with cytotoxic agent a secondline treatment for advanced ec patient in addition icis have different safety profile than conventional cytotoxic agent herein we discus the difference in the safety profile of cytotoxic agent and icis for the treatment of advanced ec patient after firstline chemotherapyicis a a secondline treatment are tolerable in advanced ec patient although infrequent icis can cause immunerelated adverse event that are sometimes fatal therefore regular monitoring of physical and laboratory examination is needed during and after the administration of icis a the major toxicity of taxane are neutropenia and neuropathy while those of irinotecan are neutropenia and diarrhea appropriate supportive care or dose modification may be needed for individual patient icicontaining treatment have been developed not only a secondline treatment but also a firstline treatment or for use in perioperative setting thus particular attention with regard to immunerelated toxicity is needed,"Antineoplastic Combined Chemotherapy Protocols, Drug Monitoring, Esophageal Neoplasms, Humans, Immune Checkpoint Inhibitors, Prognosis, Survival Rate"
34263665,this is a summary of the article discussing the result of the destinybreast01 study originally published in the new england journal of medicine the destinybreast01 study is a clinical study in participant with a type of breast cancer called herpositive breast cancer the participant in the study received a treatment called trastuzumab deruxtecan also known a tdxd the purpose of this summary is to help you understand the result of the destinybreast01 study tdxd is currently available a a treatment for adult with herpositive breast cancer that can not be removed by surgery also called unresectable or that ha spread also called metastatic in the destinybreast01 study all the participant had herpositive breast cancer that wa metastatic or unresectable all participant were required to have had previous treatment for their herpositive breast cancer with another treatment called trastuzumab emtansine or tdm all the participant received tdxd every 3 week part 1 wa done to learn how tdxd acted in the body and to choose a dose to give to all the participant in part in part 184 participant received tdxd at mgkg and the result showed that tdxd reduced tumor growth up to of the participant had their tumor shrink or disappear with a treatment response that lasted for nearly 15 month on average the participant lived with their cancer for around 16 month before it got worse during the study 183 out of 184 participant had side effect known a adverse event the most common adverse event wa nausea there were 42 participant who had serious adverse event including lung toxicity these result suggest that tdxd could be a treatment option for people with metastatic herpositive breast cancer who have already been treated with tdm additional study will provide more information and result about tdxd clinicaltrialsgov nct number nct to read the full plain language summary of this article click on the view article button above and download the pdf link to original article here,"Adult, Breast Neoplasms, Camptothecin, Female, Humans, Immunoconjugates, Language, Receptor, ErbB-2, Trastuzumab"
34263358,chemoradiotherapy with docetaxel doc cisplatin cddp and fu tpfcrt for locally advanced external auditory canal cancer eacc ha favorable oncological and functional outcome to establish tpfcrt a a standard of care for advanced eacc we conducted this study to determine the maximum tolerated mtd and recommended dose rd of doc in tpfcrt for locally advanced eacc to determine the recommended rd and maximum tolerated dose mtd of doc in tpfcrt for eacc a phase i trial wa conducted using the standard 3 3 design for maximum dose finding doc wa administered twice every 4 week cddp at 70 mgm2 and fu at 700 mgm2 patient were also receiving radiotherapy 66 gy eight patient with t3 or t4 eacc were prospectively enrolled two patient treated with doc 50 mgm and one out of six patient treated with doc 40 mgm had doselimiting toxicity prolonged febrile neutropenia wa observed in three patient grade 3 nonhematological toxicity were observed in only three patient at study completion six patient survived five of whom were disease free the rd and mtd of doc in tpfcrt for locally advanced eacc are 40 mgm2 when do of cddp and fu are 70 mgm2 and 700 mgm respectively,"Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Chemoradiotherapy, Cisplatin, Docetaxel, Ear Canal, Fluorouracil, Head and Neck Neoplasms, Humans, Taxoids"
34262262,despite recent therapeutic advance multiple myeloma mm patient experience relapse a they become resistant to various class and combination of treatment melphalan lpam is an ageless drug however it use in the autologous stem cell transplantation asct setting and the innovative quadruplet regimen a well a daratumumab bortezomib and prednisone make this old drug current yet melflufen is a peptideconjugated alkylator belonging to a novel class of compound representing an overcoming of lpam in term of mechanism of action and effectiveness the improved melflufen cytotoxicity is related to aminopeptidase activity notably present in normal and neoplastic cell and remarkably heavily overexpressed in mm cell upon entering a cell melflufen is cleaved by aminopeptidases ultimately releasing the lpam payload and eliciting further the inflow and cleavage of the conjugated peptide this virtuous loop persists until all extracellular melflufen ha been utilized the aminopeptidasedriven accumulation result in a fold increase in lpam cell enrichment a compared with free alkylator this condition produce selective cytotoxicity increased ontarget cell potency and decreased offtarget cell toxicity ultimately overcoming resistance pathway triggered by previous treatment including alkylators due to it distinct mechanism of action melflufen plus dexamethasone a a doublet and in combination with other novel drug ha the potential to be beneficial for a broad range of patient with relapsedrefractory rr mm in third or even in secondline therapy the safety profile of melflufen ha been consistent across study and no new safety concern have been identified when melflufen wa administered in doublet and triplet combination based on growing clinical evidence melflufen could be not only a good addition in the fight against rrmm but also a drug with a very favorable tolerability profile,"Antineoplastic Agents, Alkylating, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm, Humans, Melphalan, Multiple Myeloma, Phenylalanine"
34261922,pembrolizumab is a mab against the programmed cell death protein1 pd1 it ha been approved for the treatment of advanced melanoma unresectable or metastatic in adult side effect associated with the use of antipd1 are usually considered well tolerated nevertheless there are immunerelated adverse event that may require treatment discontinuation a yearold man diagnosed with stage iv right scapular melanoma experienced unspecific symptom and alteration of the hypothalamushypophysis axis after six cycle with pembrolizumab the case wa compatible with immunerelated hypophysitis autoimmune thyroiditis and primary hypophysitis were excluded and toxicity due to pembrolizumab wa considered the cause of hypophysitis pembrolizumab wa discontinued and toxicity wa managed with corticosteroid and hormonal replacement therapy hrt after 7 month of followup symptom were controlled with hrt but thyrotropin and corticotropin hormone had not recovered it wa decided not to reintroduce immunotherapy although endocrine disorder are common with the use of antipd hypophysitis is very rare however clinical sign and symptom can be nonspecific therefore it ha probably been underdiagnosed monitoring hormone before and during the treatment is important for an early diagnosis and also to replace the alteration with hrt to control the symptom hormonal function doe not always recover but it doe not mean immunotherapy can not be restarted and it should be evaluated in every case,"Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Humans, Hypophysitis, Male, Melanoma, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms"
34261919,advanced nonclear cell renal cell carcinoma nccrcc ha a poor prognosis and clinical data on the therapeutic option currently available including immunotherapy are generally limited highlighting an unmet clinical need moreover the onset of rare adverse event raise the need of a better therapeutic management of limited treatment option we report the clinical case of a yearold man with the diagnosis of metastatic mucinous tubular and spindle cell carcinoma a rare nccrcc with sarcomatoid differentiation who developed two episode of posterior reversible encephalopathy syndrome pres to firstline sunitinib it appeared after 5 month the start of the targeted therapy and reappeared at the reintroduction of the therapy pres is a rare and unusual adverse event to antivascular endothelial growth factor receptor vegfr therapy which is characterized by acute neurological disorder along with typical change on neurological imaging especially mri moreover this rare histotype of rcc experienced a longterm response to immunotherapy which is lasting more than 2 year this clinical case is interesting for it rarity a a rare neurological adverse event developed twice in a rare type of rcc which also experienced an unusual longterm benefit to immunotherapy,"Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Posterior Leukoencephalopathy Syndrome, Receptors, Vascular Endothelial Growth Factor, Sunitinib"
34261336,this metaanalysis investigated the clinical benefit of chemoimmunotherapy in extensivestage smallcell lung cancer essclc seven randomized controlled trial with a total of 2862 patient were analyzed compared with chemotherapy alone chemoimmunotherapy provided a better progressionfree survival pfs with a hazard ratio hr of p and overall survival o with a hr of p however the incidence of treatmentrelated adverse effect traes wa significantly increased subgroup analysis showed that good performance status cisplatinbased chemotherapy without brain metastasis at baseline and nonasian population were associated with greater benefit in o from chemoimmunotherapy chemoimmunotherapy demonstrated better pfs and o compared with chemotherapy alone a first line treatment in essclc but additional traes should be closely monitored lung cancer is the leading cause of cancer death worldwide of which smallcell lung cancer sclc is an extremely lethal type because most patient present with incurable extensivestage sclc essclc the standard firstline treatment for essclc for the last 30 year ha been chemotherapy immunotherapy have recently been introduced a cancer treatment and have shown the potential to provide a higher and more durable treatment response with relatively tolerable toxicity this study systematically assessed the result of previous research and provided evidence that addon immunotherapy with standard chemotherapy a the first line treatment in essclc offered great improvement in survival but patient should be closely monitor for additional side effect,"Antineoplastic Agents, Humans, Immunotherapy, Lung Neoplasms, Small Cell Lung Carcinoma"
34260879,panchvalkala an ayurvedic traditional formulation ha reference in charak samhita and bhavaprakasha nighantu for the treatment of woman with endometriosisrelated problem leucorrhea and vaginal ailment the formulation comprises of equal ratio of the bark from ficus glomerata ficus virens ficus religiosa ficus benghalensis and thespesia populnea the present study aimed to evaluate the anticancer and immunomodulatory activity of aqueous extract of panchvalkala pvaq against cervical cancer in vitro and in vivo the effect of pvaq on disruption of mitochondrial membrane potential in cervical cancer cell line siha and hela wa studied by using jc1 dye the expression of generic caspase in the cell after treatment with pvaq wa evaluated by elisa kit the expression of prb p e6 and e7 protein were evaluated by western blotting acute oral toxicity and drf study were performed in swiss albino mouse by following oecd guideline 423 and respectively tumor retardation study wa done in c57bl6 mouse papilloma model the mouse were divided into six group no tumor control ntc tumor control tc cisplatin ci 4 mgkg bw pvaq 200 mgkg bw and combination of pvaq 200 mgkg bw and cisplatin 4 mgkg bw the mouse were orally gavaged with pvaq daily for 14 day and cisplatin wa given intravenously on every 1st 5th and 9th day hematological and biochemical parameter were studied by using hematology analyzer and kit respectively e6 and e7 gene expression in the tumor sample wa determined by qpcr th1 and th2 cytokine level were determined by elisa pvaq induced mitochondrial depolarization in siha and hela and increased the expression of generic caspase resulting into apoptosis pvaq upregulated the expression of tumor suppressor protein p53 and prb and reduced the expression of viral oncoproteins e6 and e7 acute toxicity study displayed nontoxicity of pvaq while drf study ensured it safe dose for further efficacy study pvaq reduced tumor volume and weight in mouse papilloma model and induced immunomodulation in the animal it increased serum level of il2 th1 with a concomitant decrease in il10 th2 cytokine the drug did not affect body weight food consumption and organ histopathology of the animal pvaq exhibited anticancer and immunomodulatory activity against cervical cancer cell and female mouse papilloma model,"Animals, Female, Humans, Mice, Antineoplastic Agents, Phytogenic, Apoptosis, Cisplatin, Cytokines, Dose-Response Relationship, Drug, Ficus, HeLa Cells, Immunologic Factors, Malvaceae, Medicine, Ayurvedic, Mice, Inbred C57BL, Papilloma, Plant Bark, Plant Extracts, Toxicity Tests, Acute, Uterine Cervical Neoplasms"
34260719,the feasibility of intensity modulated radiotherapy imrt with involved field radiotherapy ifrt for japanese patient with locally advanced nonsmall cell lung cancer lansclc remains unclear here we reviewed our initial experience of imrt with ifrt for japanese patient with lansclc to evaluate the feasibility of the treatment twenty lansclc patient who were treated with imrt with ifrt during november 2019 to october 2020 were retrospectively analyzed all patient received 60 gy in 30 fraction of imrt and were administered concurrent platinumbased chemotherapy the median patient age wa 71 year old and the group included 15 men and 5 woman the patient group included 2 patient with stage iib 11 patient with stage iiia 5 patient with stage iiib and 2 patient with stage iiic disease histological diagnosis wa squamous cell carcinoma in 14 patient adenocarcinoma in 5 patient and nonsmall cell lung cancer in 1 patient the median followup period wa 8 month the incidence of grade 3 or greater pneumonitis wa 5 and grade 3 or greater esophagitis wa not observed none of the patient developed regional lymph node with only recurrence reported so far these finding indicate that imrt with ifrt for japanese patient with lansclc is feasible in term of acute toxicity further study with a larger number of patient and longer followup to clarify the effect of treatment on patient prognosis is required,"Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Combined Modality Therapy, Dose-Response Relationship, Radiation, Feasibility Studies, Female, Humans, Japan, Lung Neoplasms, Male, Middle Aged, Multimodal Imaging, Neoplasm Metastasis, Organoplatinum Compounds, Organs at Risk, Paclitaxel, Radiation Pneumonitis, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Conformal, Radiotherapy, Intensity-Modulated, Retrospective Studies, User-Computer Interface"
34260067,highdose chemotherapy hdct plus peripheral blood stem cell transplantation pbsct is effective salvage therapy for relapsed metastatic germ cell tumor gcts but ha potential toxicity historically an age of 40 year ha been associated with greater toxicity and worse outcome this is a retrospective analysis of 445 consecutive patient with relapsed gct treated with hdct and pbsct with tandem cycle at indiana university from between per our institutional regimen kaplanmeier method and logrank test were used for progressionfree survival pfs and overall survival o analysis a total of 329 patient were 40 year of age whereas 116 patient were 40 year of age hdct wa used a secondline therapy in 85 and 79 respectively median followup time wa month range month grade 3 toxicity were similar between either group except for greater pulmonary p 02 and renal toxicity p 01 in the yearsofage group treatmentrelated mortality wa similar between both age group 10 patient 3 in the yearsofage group and 4 patient in yearsofage group died from complication of hdct twoyear pfs for 40 year of age versus 40 year of age wa versus p 76 and year o wa versus p 93 factor predicting worse pfs included eastern cooperative oncology group performance status platinum refractory disease nonseminoma histology and not completing 2 cycle of hdct age wa not an independent predictor of worse outcome hdct plus pbsct is effective salvage therapy in patient 40 year of age with relapsed metastatic gct patient 40 year of age experience similar rate of toxicity and treatmentrelated mortality a those 40 year of age,"Adult, Antineoplastic Combined Chemotherapy Protocols, Child, Etoposide, Humans, Male, Neoplasms, Germ Cell and Embryonal, Peripheral Blood Stem Cell Transplantation, Retrospective Studies, Salvage Therapy, Stem Cell Transplantation, Testicular Neoplasms"
34257627,this study aimed to as the suitability of hyperpolarized 129xe hpxe mri for noninvasive longitudinal evaluation of pulmonary function in preclinical lung cancer model a mouse model of lung cancer lc wa induced in 5 mouse by intraperitoneal injection of urethane while a negativecontrol nc mouse n 5 wa prepared by injection of saline solution longitudinal hpxe mri wa performed over a month period to monitor lung ventilation and gas exchange the treatment efficacy of ethyl pyruvate ep an antiinflammatory drug to the mouse lc model wa monitored using hpxe mri by commencing administration of ep pre earlyphase and month post latephase injection of urethane n 5 mouse for each group gasexchange function in lc mouse wa significantly reduced at month after urethane injection compared with nc mouse administered with saline p thereafter it remained consistently lower than that of the nc group for the full month measurement period in contrast the ventilation function of the lc model mouse wa not significantly different to that of the nc mouse histological analysis revealed alveolar epithelial hyperplasia in lc mouse alveolus at 1 month after urethane injection and adenoma wa confirmed 3 month after the injection the early and latephase ep intervention were found to improve hpxe mri metric reduced at 1 month postinjection of urethane and significantly inhibit tumor growth these result suggest that hpxe mri gasexchange metric can be used to quantitatively as change in the precancerous lesion microenvironment and to evaluate therapeutic efficacy in cancer thus hpxe mri can be utilized to noninvasively monitor pulmonary pathology during lc progression and can visualize functional change during therapy,"Animals, Carcinogens, Inflammation, Lung Neoplasms, Magnetic Resonance Imaging, Male, Mice, Pyruvates, Urethane, Xenon"
34257611,the widespread application of fludarabine cyclophosphamide and rituximab combination is limited due to it toxicity particularly the prolonged cytopenia the study aimed to compare the prolonged cytopenia depending on fitness and report reallife data on dose reduction measure and efficacy according to our database 120 and 14 patient were treated with fcr between 2011 and 2015 and between 2016 and out of the first cohort 34 patient were treated in subsequent line the complete and partial remission rate after firstline treatment wa 79 16 in the first cohort and 86 14 in the second cohort respectively and 47 35 after non firstline treatment based on today standard only of the patient were fit for fcr the frequency of persistent cytopenia wa 14 and it wa significantly associated with fitness 2 1 p for all patient the small number of fcr treated patient after 2016 show how the availability of targeted therapy mostly ibrutinib in later line changed the firstline choice recently it is recommended firstline for fit patient with mutated ighv and no tp53 aberration with this narrow indication a decrease in the frequency of persistent cytopenia is predicted,"Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Molecular Targeted Therapy, Prognosis, Retrospective Studies, Rituximab, Survival Rate, Thrombocytopenia, Vidarabine"
34256279,aurora kinase a aurka is a pleiotropic serinethreonine kinase that orchestrates mitotic progression paclitaxel stabilises microtubule and disrupts mitotic spindle assembly the combination of aurka inhibitor alisertib plus paclitaxel may be synergistic in rapidly proliferative cancer we evaluated the safety and maximum tolerated dose mtd of alisertib in combination with nabpaclitaxel and it preliminary efficacy in patient with refractory highgrade neuroendocrine tumour net this is a twopart phase 1 study in part a dose escalation a standard 3 3 design wa used to determine mtd in part b dose expansion patient with predominantly refractory highgrade net were enrolled in total 31 patient were enrolled and treated 16 in part a and 15 in part b the mtd of alisertib wa 40 mg bid on d per week and nabpaclitaxel 100mgm2 weekly 3 week 1 week off doselimiting toxicity wa neutropenia and other common sideeffects included fatigue mucositis and diarrhoea in part a a patient with smallcell lung cancer with partial response pr wa treated for more than 2 year whereas four other patient with pancreatic ductal adenocarcinoma one patient small cell lung cancer sclc two patient or highgrade net one patient achieved stable disease sd in part b 13 of 15 enrolled patient had highgrade net of these one had pr and four had sd for more than 10 month the combination of alisertib and nabpaclitaxel ha manageable sideeffect profile and showed promising preliminary efficacy in highgrade net warranting further testing clinicaltrialsgov identifier nct,"Adult, Aged, Albumins, Antineoplastic Combined Chemotherapy Protocols, Azepines, Female, Humans, Male, Middle Aged, Neuroendocrine Tumors, Paclitaxel, Pyrimidines"
34255596,favipiravir is an antiviral agent that is recently used for sarscov2 infection the drugdrug interaction of favipiravir especially with chemotherapeutic agent in a patient with malignancy are not well known the patient diagnosed with metastatic osteosarcoma wa given high dose methotrexate treatment and favipiravir wa started on the third day of the treatment with suspicion of sarscov2 infection grade 3 hepatotoxicity developed after favipiravirmanagement outcome the acute viral hepatitis panel and autoimmune liver disease panel were negative the ultrasound of the abdomen wa unremarkable for any hepatobiliary pathology the all viral and hepatobiliary possible etiological factor were ruled out the patient liver enzyme increased just after 12 hour later the initiation of favipiravir and we diagnosed toxic hepatitis caused by favipiravirmethotrexate interaction therefore methylprednisolone 1 mgkg dose wa started for a presumed diagnosis of toxic hepatitis hepatotoxicity completely regressed after favipiravir wa discontinued favipiravir may inhibit methotrexate elimination by inhibiting aldehyde oxidase and it sequential use may cause hepatotoxicity in this case the clinician should keep in mind possible drug interaction while using new antiviral agent against sarscov2 like favipiravir,"Amides, Antiviral Agents, Bone Neoplasms, COVID-19, Chemical and Drug Induced Liver Injury, Humans, Methotrexate, Osteosarcoma, Pharmaceutical Preparations, Pyrazines, RNA, Viral, SARS-CoV-2"
34255109,bartogenic acid ba a natural pentacyclic triterpenoid proved to have chemomodulatory anticancer antidiabetic antiarthritic and antiinflammatory activity based on structureactivity relationship sar approach ba ha close structural resemblance to oleanolic acid and ursolic acid these two pentacyclic triterpenoids are well accepted with respect to their therapeutic value in various ailment including anticancer activity the aim of this study is to evaluate the efficacy of ba a a possible antitumor agent along with it safety in skov3 ovarian cancer in vitro cytotoxicity of ba and paclitaxel on human ovarian cancer cell skov3 wa assessed using mtt assay antitumor potential of ba alone standard anticancer drug paclitaxel alone and ba in combination with paclitaxel were evaluated in skov3 xenografted scid mouse immunohistochemical analysis of nfb wa performed and analyzed in skov3 tumor ba alone and ba in combination with paclitaxel significantly inhibited the tumor growth ic50 of ba wa found to be m similarly paclitaxel showed significant antitumor effect with ic50 of m treatment of paclitaxel ba and combination of ba with paclitaxel were well tolerated during treatment period immunohistochemical analysis of nfb in skov3 tumor treated with ba in combination with paclitaxel revealed antitumor effect in term of inhibition of nfb our result suggested that ba exhibit promising antitumor effect in the restriction of skov3 cell and tumor with considerable safety,"Animals, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Female, Humans, Inhibitory Concentration 50, Mice, Mice, SCID, NF-kappa B, Ovarian Neoplasms, Paclitaxel, Triterpenes, Xenograft Model Antitumor Assays"
34254767,artemisinin compound have shown satisfactory safety record in antimalarial clinical practice over decade and have revealed value a inexpensive antitumor adjuvant chemotherapeutic drug however the rational design and precise preparation of nanomedicines based on the artemisinin drug are still limited due to their nonaromatic and fragile chemical structure herein a bioinspired coordinationdriven selfassembly strategy wa developed to manufacture the artemisininbased nanoprodrug with a significantly increased drug loading efficacy 70 wt and decreased preparation complexity compared to conventional nanodrugs the nanoprodrug ha suitable size distribution and robust colloidal stability for cancer targeting in vivo the nanoprodrug wa able to quickly disassemble in the tumor microenvironment with weak acidity and a high glutathione concentration which guarantee a better tumor inhibitory effect than direct administration and fewer side effect on normal tissue in vivo this work highlight a new strategy to harness a robust simplified organic solventfree and highly repeatable route for nanoprodrug manufacturing which may offer opportunity to develop costeffective safe and clinically available nanomedicines,"Animals, Antineoplastic Agents, Artesunate, Cell Line, Tumor, Drug Carriers, Hemolysis, Histidine, Humans, Mice, Inbred BALB C, Nanoparticles, Neoplasms, Prodrugs, Proof of Concept Study, Mice"
34254644,this study aim to evaluate the association between polymorphism of methotrexate pathway gene and highdose methotrexaterelated hepatotoxicity in chinese patient with primary central nervous system lymphoma sixtyfive patient in 411 treatment course were enrolled and their toxicity were evaluated the association between 30 candidate snp from 20 methotrexate pathway gene and highdose methotrexaterelated hepatotoxicity wa analysed by plink and logistic regression tyms 6 bp di ii rs151264360 or 95 ci p mthfd1 1958 ga aa rs2236225 or 95 ci p and ccnd1 870 ga gg rs9344 or 95 ci p had le risk of hepatotoxicity compared with their homozygote dd gg and aa respectively while abcc2 intron 29 ga gg rs3740065 or 95 ci p wa more prevalent in patient with hepatotoxicity than tt tyms 6 bp di ii mthfd1 1958 ga aa ccnd1 870 ga gg genotype were associated with a lower probability of hepatotoxicity in patient with primary central nervous system lymphoma on highdose methotrexate therapy and abcc2 intron 29 ga gg wa correlated with increased risk of hepatotoxicity,"Adult, Aged, Aminohydrolases, Asian People, Central Nervous System, Chemical and Drug Induced Liver Injury, Cyclin D1, Female, Formate-Tetrahydrofolate Ligase, Genotype, Humans, Introns, Liver, Lymphoma, Male, Methotrexate, Methylenetetrahydrofolate Dehydrogenase (NADP), Middle Aged, Multidrug Resistance-Associated Protein 2, Multienzyme Complexes, Odds Ratio, Polymorphism, Single Nucleotide, Thymidylate Synthase"
34253390,to determine the clinical benefit of monotherapy with pi3kaktmtor inhibitor in patient diagnosed with advanced or recurrent ovarian cancer and to investigate the predictive value of current pi3kaktmtor biomarkers on therapy response a systematic search wa conducted in pubmed embase and the cochrane library for article reporting on treatment with pi3kaktmtor inhibitor in ovarian cancer the primary endpoint wa defined a the clinical benefit rate cbr including the proportion of patient with complete cr and partial response pr and stable disease sd secondary endpoint included the overall response rate orr including cr and pr and drugrelated grade 3 and 4 adverse event we included 233 patient from 19 study and observed a pooled cbr of 32 95 ci and orr of 3 95 ci in advanced or recurrent ovarian cancer patient treated with pi3kaktmtor inhibitor subgroup analysis tended to favor the study who selected patient based on current pi3kaktmtor biomarker criterion eg genomic alteration or loss of pten protein expression but the difference in cbr wa not statistically significant from study with unselected population respectively cbr of 42 95 ci and 27 95 ci p to better reflect true patient benefit we excluded sd 6 month a a beneficial outcome which resulted in a pooled cbr of 7 95 ci the overall proportion of patient with drugrelated grade 3 and 4 adverse event wa 36 the efficacy of monotherapy with pi3kaktmtor inhibitor in advanced recurrent ovarian cancer patient is limited to a small subgroup and selection of patient with the use of current biomarkers did not improved the cbr significantly given the toxicity profile we suggest that current treatment with pi3kaktmtor inhibitor should not be initiated unless in clinical trial furthermore improved biomarkers to measure functional pi3kaktmtor pathway activity are needed to optimize patient selection,"Antineoplastic Agents, Biomarkers, Tumor, Clinical Decision-Making, Female, Humans, MTOR Inhibitors, Neoplasm Staging, Ovarian Neoplasms, Patient Selection, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Predictive Value of Tests, Proto-Oncogene Proteins c-akt, Signal Transduction, TOR Serine-Threonine Kinases, Treatment Outcome"
34253136,multiple myeloma mm is still considered incurable and the outcome of patient with tripleclass refractory remains very poor immunotherapy is considered a a standard of care for the treatment of mm among immunotherapeutic approach the pdpdl1 axis is an attractive target because pdl1 is highly expressed in most myeloma plasma cell while many type of cancer benefit from checkpoint inhibitor treatment their relevance in multiple myeloma need to be defined the author evaluate the published data regarding the mechanism of action safety profile and clinical efficacy of the immune checkpoint inhibitor ici for the treatment of multiple myeloma the use of ici monotherapy doe not offer any clinical benefit in myeloma patient in combination with immunomodulatory drug imid ici failed to demonstrate clinical benefit and were associated with increased toxicity given the toxicity of these treatment predictive marker would be useful to select patient who would benefit most clinical study are necessary to evaluate the safety and efficacy of checkpoint inhibitor in combination with other standard of care such a proteasome inhibitor and monoclonal antibody the combination of antipd1 with tcell engager tce or cart cell seems theoretically attractive and should be explored in clinical trial,"Animals, Antineoplastic Combined Chemotherapy Protocols, Drugs, Investigational, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Molecular Targeted Therapy, Multiple Myeloma, Treatment Outcome"
34251048,romidepsin histone deacetylase inhibitor lenalidomide immunomodulatory agent and carfilzomib proteasome inhibitor have efficacy and lack cumulative toxicity in relapsedrefractory lymphoma we performed two investigator initiated sequential phase i study to evaluate the maximum tolerated dose mtd of romidepsin and lenalidomide regimen a and romidepsin lenalidomide and carfilzomib regimen b in relapsedrefractory lymphoma cohort in tcell lymphoma tcl bcell lymphoma bcl were enrolled at the mtd fortynine patient were treated in study a 27 tcl 17 bcl 5 hodgkin lymphoma hl and 27 16 tcl 11 bcl in study b the mtd of regimen a wa romidepsin 14 mgm2 iv on day and 15 and lenalidomide 25 mg oral on day of a day cycle the mtd of regimen b wa romidepsin 8 mgm2 on day 1 and lenalidomide 10 mg oral on day and carfilzomib 36 mgm2 iv on day 1 and 8 of a day cycle in study a 94 had aes grade most commonly neutropenia 49 thrombocytopenia 53 and electrolyte abnormality 49 in study b 59 had aes grade including thrombocytopenia 30 and neutropenia 26 in study a the orr wa 49 50 tcl 47 bcl 50 hl in study b the orr wa 48 50 tcl 50 bcl for study a and b the median progression free survival pfs wa month and month respectively with 11 patient proceeding to allogeneic transplant the combination of romidepsin and lenalidomide and of romidepsin lenalidomide and carfilzomib showed activity in relapsedrefractory lymphoma with an acceptable safety profile,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Depsipeptides, Female, Humans, Lenalidomide, Lymphoma, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Oligopeptides, Treatment Outcome"
34250737,lenvatinib is a standard of care option in firstline therapy of advanced hepatocellular carcinoma hcc in the present study we aim to identify in patient with hcc treated with lenvatinib a possible association between occurrence and grading of adverse event aes and outcome we performed a retrospective analysis of 606 japanese and italian patient treated with lenvatinib in firstline setting and investigated the possible correlation between the onset of aes toxicity grade g and outcome measure such a overall survival o and progressionfree survival pfs the appearance of arterial hypertension g 2 independently predicted prolonged o hazard ratio hr 95 confidence interval ci p 0188 whereas decreased appetite g 2 independently predicted decreased o hr 95 ci p 0007 by multivariate analysis appearance of handfoot skin reaction independently predicted prolonged pfs hr 95 ci p 0149 whereas decreased appetite g 2 predicted decreased pfs hr 95 ci p 0277 our main finding are that the occurrence of arterial hypertension g 2 is a predictor of longer survival whereas decreased appetite g 2 predicts for a poor prognosis a careful management of aes under lenvatinib treatment for hcc is required to improve patient quality of life minimize the need for treatment discontinuation and achieve optimal outcome,"Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Phenylurea Compounds, Quality of Life, Quinolines, Retrospective Studies"
34250553,background overactivation of human epidermal growth factor receptor 3 her3 trigger multiple intracellular pathway resulting in tumor cell survival this phase 1 study assessed the safety efficacy and pharmacokinetics pk of seribantumab a fully human antiher3 monoclonal antibody method adult patient with advanced or refractory solid tumor were treated in six dose cohort of seribantumab or 20 mgkg weekly or 40 mgkg loading dose followed by 20 mgkg weekly maintenance dose mgkg using a modified 3 3 dose escalation strategy with cohort expansion primary objective were identification of a recommended phase 2 dose rp2d and determination of objective response rate secondary objective were assessment of safety doselimiting toxicity and pk result fortyfour patient 26 dose escalation 18 dose expansion were enrolled seribantumab monotherapy wa well tolerated with most adverse event being transient and mild to moderate grade 1 or 2 in severity maximum tolerated dose wa not reached the highest dose mgkg wa identified a rp2d best response wa stable disease reported in 24 and 39 of patient during the dose escalation and expansion portion of the study respectively seribantumab terminal halflife wa 100 h steady state concentration were reached after weekly do conclusion seribantumab monotherapy wa well tolerated across all dose level safety and pk data from this study support further seribantumab investigation in genomically defined populationsclinical trial registration nct august,"Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Half-Life, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Receptor, ErbB-3"
34247513,immune checkpoint inhibitor have revolutionized the management of patient with cancer the increasing use of these agent ha brought up a new set of adverse event which are widely heterogenous and potentially lifethreatening rare immunerelated adverse event associated with nervous system have not been described thoroughly but their early recognition and management may be crucial immunerelated autonomic neuropathy may be presented with a constellation of symptom ranging from gastrointestinal and urinary complaint to sweating and hypotension intestinal pseudoobstruction a consequence of immunerelated myenteric autonomic neuropathy is an underrecognized notwell described and potentially fatal adverse event we herein present a unique case of enteric plexus neuropathy induced by pdl1 blockade in a patient with smallcell lung cancer lay abstract immunotherapy with immune checkpoint inhibitor ha improved the life expectancy in many cancer patient however the stimulation of immune system to fight cancer may also affect healthy tissue bringing about the risk of adverse event these adverse event may affect almost every organ system of the body and may vary from mild to lifethreatening immunotherapyrelated damage to nervous plexus which supply the gut with nerve ha been reported only in a small number of case the symptom usually mimic those of gut inflammation including diarrhea constipation abdominal distension and vomiting upon these symptom enteric nervous system toxicity should be considered early recognition and management are crucial to stop further neurological damage we present a rare case of enteric nerve damage in a patient with smallcell lung cancer treated with immunotherapy,"Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Humans, Immunotherapy, Intestinal Pseudo-Obstruction, Lung Neoplasms, Male, Myenteric Plexus, Peripheral Nervous System Diseases, Programmed Cell Death 1 Receptor, Small Cell Lung Carcinoma"
34245737,chemotherapy drug are still one of the first treatment option used in many cancer however problem such a cytotoxic side effect on normal cell after systemic administration and resistance to treatment have reduced the use of chemotherapeutics day by day targeted delivery of these drug to the tumor site and sensitization of cancer cell to death induced by chemotherapy drug are way that can overcome the limitation of the use of these drug in this study we designed and generated a novel nanocarrier composed of chitosan lactate nanoparticles np functionalized by hiv1 derived tat peptide transactivating transcriptional activator and hyaluronate ha to deliver cd73 sirna and doxorubicin to 4t1 and ct26 cancer cell both in vivo and in vitro a a novel combinatorial treatment strategy the cd73 molecule play a key role in many cancer cell behavior such a proliferation angiogenesis metastasis imunosuppression and resistance to chemotherapy therefore we decided to reduce the side effect of dox by simultaneously transmitting cd73 sirna and dox by cltatha np increase the susceptibility of cancer cell to doxinduced cell death and stimulate antitumor immune response for the first time these result indicated that simultaneous transfer of cd73 sirna and dox to cancer cell 4 t1 and ct26 increased cell death and inhibited the prolifration and spread of cancer cell also the preferential aggregation of np in the tumor microenvironment reduced tumor growh promoted the survival of tumorbearing mouse and induced antitumor immune response these finding indicate that cltatha np are a good candidate for targeted sirnadrug delivery to cancer cell and the simultaneous transfer of cd73 sirna and dox to cancer cell using this nanocarrier can be used to treat cancer,"5'-Nucleotidase, Animals, Antibiotics, Antineoplastic, Apoptosis, Breast Neoplasms, Cell Line, Tumor, Cell Movement, Cell Proliferation, Chitosan, Colorectal Neoplasms, Doxorubicin, Drug Compounding, Female, GPI-Linked Proteins, Hyaluronic Acid, Lactates, Mice, Mice, Inbred BALB C, Nanoparticles, Nanotechnology, Neoplasm Invasiveness, Neovascularization, Pathologic, RNA, Small Interfering, RNAi Therapeutics, tat Gene Products, Human Immunodeficiency Virus"
34245663,testicular germ cell tumor tgcts represent 95 of testicular malignancy and are the most common type of malignancy in young male adult while the incidence of tgcts ha increased during the last decade the advance in treatment namely introducing cisplatin into the chemotherapy regimen have made tgcts highly curable with the year survival rate exceeding 95 however in parallel with increased cure rate survivor may experience acute and late adverse effect of treatment which increase morbidity reduce the quality of life and can be potentially lifethreatening chemotherapyrelated toxicity include cardiovascular and metabolic disease secondary cancer avascular necrosis cognitive impairment cancerrelated fatigue poor mental healthrelated quality of life nephrotoxicity hypogonadism neurotoxicity pulmonary toxicity anxiety and depression these treatmentrelated adverse effect have emerged a important survivorship dilemma in tgct cancer survivor recently regular physical exercise ha increasingly attracted research and clinical attention a an adjunct therapy for cancer patient herein we review the most common chemotherapyrelated adverse effect in tgct survivor and clinical relevance of exercise and increased cardiorespiratory fitness in modulating chemotherapyrelated toxicity and quality of life in this population exercise ha positive effect on a spectrum of physical and psychosocial outcome during and after cancer treatment and current guideline on exercise prescription in chronic disease define the recommended dose volume and intensity of regular exercise for cancer survivor highlighting regular sufficiently intensive physical activity a an essential part of patient care,"Adolescent, Adult, Aged, Antineoplastic Agents, Cancer Survivors, Cisplatin, Exercise, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Physical Fitness, Testicular Neoplasms, Young Adult"
34245224,epidemiological study show a consistent and compelling association between the risk of colorectal cancer development and obesity but it mechanism remain poorly understood evidence is mounting that colorectal cancer can be prevented by nutritional supplement such a phytochemical garcinol a polyisoprenylated benzophenone derivative is widely present in garcinia plant this study investigates the potential role of garcinol supplementation in ameliorating obesityinduced colon cancer development an animal model to investigate the effect of highfatdiet hfdinduced obesity on promoting colitisassociated colon cancer aom azoxymethanedss dextran sodium sulfateinduced is designed the result show that hfd can promote colitisassociated colon cancer a compared to an aomdss group without the intervention of obesity and supplementing with garcinol in the diet can significantly ameliorate obesitypromoted colon carcinogenesis the result also reveals that the microbiota composition of each group is significantly different and clustered the most representative genus are alistipes romboutsia and ruminococcus the rnasequencing result show that the administration of garcinol can regulate gene and improve obesitypromoting colitisassociated colon carcinogenesis the study result suggest that garcinol can prevent obesitypromoted colorectal cancer and these finding provide important niche for the future development of garcinol a functional food or adjuvant therapeutic agent,"Animals, Anticarcinogenic Agents, Azoxymethane, Biomarkers, Cell Proliferation, Colitis, Colonic Neoplasms, Cytokines, Dextran Sulfate, Diet, High-Fat, Disease Models, Animal, Dysbiosis, Gastrointestinal Microbiome, Gene Expression Regulation, Neoplastic, Lipids, Male, Mice, Inbred C57BL, Obesity, Organ Size, Proliferating Cell Nuclear Antigen, Terpenes, Mice"
34244291,genetic difference in immunity may contribute to toxicity and outcome with immune checkpoint inhibitor cpi therapy but these relationship are poorly understood we examined the genetics of thyroid immunerelated adverse event irae in patient with nonsmall cell lung cancer nsclc treated with cpi at memorial sloan kettering msk and vanderbilt university medical center vumc we evaluated thyroid iraes we typed germline dna using genomewide singlenucleotide polymorphism snp array and imputed genotype germline snp imputation wa also performed in an independent danafarber cancer institute dfci cohort we developed and validated polygenic risk score pr for hypothyroidism in noncancer patient using the uk and vumc biovu biobanks these pr were applied to thyroid iraes and cpi response in patient with nsclc at msk vumc and dfci among 744 patient at msk and vumc thyroid iraes occurred in 13 and were associated with improved outcome progressionfree survival adjusted hr pfs ahr 95 confidence interval ci the pr for hypothyroidism developed from uk biobank predicted hypothyroidism in the biovu dataset in noncancer patient or per standard deviation sd 95 ci auroc the same pr also predicted development of thyroid iraes in both independent cohort of patient treated with cpi hr per sd 95 ci auroc the result were similar in the dfci cohort however pr for hypothyroidism did not predict cpi benefit thyroid iraes were associated with response to antipd1 therapy genetic risk for hypothyroidism wa associated with risk of developing thyroid iraes additional study are needed to determine whether other iraes also have shared genetic risk with known autoimmune disorder and the association with treatment response,"Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Retrospective Studies, Risk Assessment, Thyroid Diseases, Treatment Outcome"
34244200,methotrexate is a versatile antineoplastic and immunosuppressive agent we report a case of a young adult on the cancer and leukaemia group b 10403 treatment protocol for bcell acute lymphoblastic leukaemia she ha previously completed the induction and consolidation phase with good tolerance then started on capizzi methotrexate during the interim maintenance phase few day after receiving one intermediate dose of methotrexate she developed severe multiorgan toxicity including pancytopaenia and several dermatologic toxicity the patient underwent extensive diagnostic workup with all result negative pointing eventually towards severe methotrexate toxicity this case highlight the broad spectrum of toxicity that can occur even with low do of methotrexate capizzi methotrexate therapy implies no leucovorin therapy hence putting patient at risk for multiorgan toxicity our experience reinforces the importance of close monitoring for patient receiving methotrexate regardless of dose and the prompt administration of highdose leucovorin once toxicity suspected,"Acute Disease, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Leucovorin, Methotrexate, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult"
34244116,pembrolizumab plus axitinib improved efficacy over sunitinib in treatmentnaive advanced renal cell carcinoma in the keynote426 nct02853331 study however a relatively high incidence of grade aminotransferase elevation wa observed to further characterize treatmentemergent aminotransferase elevation in patient treated with pembrolizumabaxitinib patient enrolled in keynote426 were included in this study three standardized meddra query for potential hepatic disorder were used to identify patient for the hepatic event analysis subpopulation heas alanine aminotransferase event were characterized for time to onset time to recovery corticosteroid use and rechallenge with study treatment the heas comprised 44 pembrolizumabaxitinib patient and 30 sunitinib patient grade hepatic adverse event were more common in the combination arm 22 versus 7 3 discontinued the combination due to hepatic adverse event in the pembrolizumabaxitinib arm patient 29 had alanine aminotransferase alt 3 upper limit of normal uln with median time to onset of 84 d range d among patient with alt 3 uln 96 recovered to 3 uln following study treatment interruptiondiscontinuation with a median time to recovery of 15 d d 57 received corticosteroid one hundred patient were rechallenged with one or both study treatment 45 had alt 3 uln recurrence and all 45 recovered to alt 3 uln following study treatment interruptiondiscontinuation no fatal hepatic event occurred a higher incidence of grade aminotransferase elevation occurs with pembrolizumabaxitinib these event should be carefully evaluated and managed with prompt study treatment interruption or discontinuation with or without corticosteroid treatment the decision to rechallenge with one or both drug should be based on severity of event and thorough causality assessment renal cell carcinoma patient receiving pembrolizumabaxitinib are at a higher risk of liver enzyme elevation which could be reversed with appropriate management,"Alanine Transaminase, Antibodies, Monoclonal, Humanized, Axitinib, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Sunitinib"
34243976,topoisomerase1 inhibitor are an important class of cytotoxics associated with toxicity that limit their use crlx101 is a novel cyclodextrincontaining polymer conjugate of camptothecin cpt that selfassembles into nanoparticles to deliver sustained level of active cpt into cancer cell while substantially reducing systemic exposure we conducted sequential phase ii open label single arm clinical trial to evaluate crlx101 a a single agent n 29 and with bevacizumab bev n 34 patient pt had measurable recurrent epithelial ovarian tubal or primary peritoneal cancer that could be platinum refractory resistant or sensitive cohort a single agent crlx101 allowed up to 3 prior chemotherapy regimen but no prior topo1 inhibitor pt received crlx101 15 mgm2 iv every 14 day q28 with response evaluation every 2 cycle cohort b also received bev 10 mgkg d q and included only platinum resistant disease with up to 2 prior line and more rigorous eligibility criterion crlx101 wa well tolerated other than nausea fatigue and anemia 29 pt received a median of 3 cycle with a clinical benefit rate cbr of 68 and overall response rate orr of 11 with the addition of bev in cohort b n 34 the cbr wa increased to 95 and the orr to 18 pfs wa month to month in cohort a and month to month in cohort b bev increased the incidence of hypertension and qualitatively increased bladder toxicity but without saes crlx101 meet the clinical need for an effective and tolerable topoisomerase i inhibitor and can be safely combined with bevacizumab,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Carcinoma, Ovarian Epithelial, Cyclodextrins, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Peritoneal Neoplasms"
34242948,peptide receptor radionuclide therapy prrt is used for the treatment of patient with unresectable or metastasized somatostatin receptor type 2 sstr2expressing gastroenteropancreatic neuroendocrine tumour gepnets the radiolabelled somatostatin analogue 177luludotatate delivers it radiation dose to sstroverexpressing tumour cell resulting in selective cell killing during radioactive decay while tumour control can be achieved in many patient complete remission remain rare causing the majority of patient to relapse after a certain period of time this raise the question whether the currently fixed treatment regime 4 gbq leaf room for dose escalation a a mean of improving therapy efficacy the kidney have shown to play an important role in defining a patient tolerability to prrt a a consequence of the proximal tubular reabsorption of 177luludotatate via the endocytic megalincubilin receptor complex the radionuclides are retained in the renal interstitium this result in extended retention of radioactivity in the kidney generating a risk for the development of radiation nephropathy in addition a decreased kidney function ha shown to be associated with a prolonged circulation of 177luludotatate causing increased irradiation to the bone marrow this can on it turn lead to myelosuppression and haematological toxicity owing to the marked radio sensitivity of the rapidly proliferating cell in the bone marrow in contrast to external beam radiotherapy ebrt the exact absorbed dose limit for these critical organ kidney and bone marrow in prrt with 177luludotatate are still unclear better insight into these uncertainty can help in optimizing prrt to reach it maximum therapeutic potential while avoiding severe adverse event like nephropathy and hematologic toxicity in this review we focus on the nephrotoxic effect of prrt with 177luludotatate for the treatment of gepnets if the absorbed dose to the kidney can be lowered higher activity can be administered enlarging the therapeutic window for prrt therefore we evaluated the renal protective potential of current and promising future strategy and discus the importance of renal dosimetry in prrt,"Humans, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Kidney, Receptors, Peptide, Animals, Somatostatin"
34242474,to investigate realworld haematological toxicity overall survival o and the treatment characteristic of docetaxel and cabazitaxel chemotherapy in metastatic castrationresistant prostate cancer mcrpc this retrospective claim data study followed patient with mcrpc receiving cabazitaxel or docetaxel from their first chemotherapy infusion haematological toxicity were measured using treatment code and inpatient diagnosis o wa estimated using the kaplanmeier method a multivariable cox regression analysis wa used to identify o predictor data from 539 patient administered docetaxel and 240 administered cabazitaxel were analysed regarding adverse event within 8 month of treatment initiation some kind of treatment for haematological toxicity wa documented in 31 of patient given docetaxel and in 61 of patient given cabazitaxel in the same period hospitalization associated with haematological toxicity wa documented in 11 of the patient in the docetaxel cohort and in 15 of the patient in the cabazitaxel cohort in the docetaxel cohort of patient required reverse isolation and 13 were diagnosed with sepsis during hospitalization in the cabazitaxel cohort the cumulative incidence wa and 15 respectively the median o wa reached at month in the docetaxel cohort and because of a later line of therapy at month in the cabazitaxel cohort a multivariate cox regression revealed that indicator of locally advanced and metastatic disease severe comorbidities and prior hormonalcytotoxic therapy were independent predictor of early death cabazitaxel patient face an increased risk of haematological toxicity during treatment together with their short survival time this call for a strict indication when using cabazitaxel in patient with mcrpc,"Antineoplastic Combined Chemotherapy Protocols, Docetaxel, Humans, Kaplan-Meier Estimate, Male, Prostatic Neoplasms, Castration-Resistant, Retrospective Studies, Taxoids, Treatment Outcome"
34240523,development of proteolysis targeting chimera protacs is emerging a a promising strategy for targeted protein degradation however the drug development using the heterobifunctional protac molecule is generally limited by poor membrane permeability low in vivo efficacy and indiscriminate distribution herein an aptamerprotac conjugation approach wa developed a a novel strategy to improve the tumorspecific targeting ability and in vivo antitumor potency of conventional protacs a proof of concept the first aptamerprotac conjugate apc wa designed by conjugating a bettargeting protac to the nucleic acid aptamer as1411 a via a cleavable linker compared with the unmodified bet protac the designed molecule apr showed improved tumor targeting ability in a mcf7 xenograft model leading to enhanced in vivo bet degradation and antitumor potency and decreased toxicity thus the apc strategy may pave the way for the design of tumorspecific targeting protacs and have broad application in the development of protacbased drug,"Animals, Antineoplastic Agents, Aptamers, Nucleotide, Breast Neoplasms, Cell Cycle Proteins, Cell Line, Tumor, Disulfides, Heterocyclic Compounds, 3-Ring, Humans, Mice, Oligodeoxyribonucleotides, Proof of Concept Study, Proteolysis, Pyrrolidines, Transcription Factors, Xenograft Model Antitumor Assays"
34237249,there is paucity of investigation into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer we aimed to as the efficacy of stereotactic body radiotherapy sbrt plus pembrolizumab and trametinib in these patient in this openlabel randomised controlled phase 2 study participant were recruited from changhai hospital affiliated to naval medical university shanghai china eligible patient were aged 18 year or older with histologically confirmed pancreatic ductal adenocarcinoma characterised by mutant kras and positive immunohistochemical staining of pdl eastern cooperative oncology group performance status of 0 or and documented local recurrence after surgery followed by chemotherapy mfolfirinox or fluorouracil eligible participant were randomly assigned 11 using an interactive voice or web response system without stratification to receive sbrt with do ranging from gy in five fraction intravenous pembrolizumab 200 mg once every 3 week and oral trametinib 2 mg once daily or sbrt same regimen and intravenous gemcitabine 1000 mgm2 on day 1 and 8 of a day cycle for eight cycle until disease progression death unacceptable toxicity or consent withdrawal the primary endpoint wa overall survival in the intentiontotreat population safety wa assessed in the astreated population in all participant who received at least one dose of study treatment this trial is registered with clinicaltrialsgov nct and is now complete between oct and oct 198 patient were screen of whom 170 patient were enrolled and randomly assigned to receive sbrt plus pembrolizumab and trametinib n85 or sbrt plus gemcitabine n85 a of the clinical cutoff date nov 2020 median followup wa 233 month iqr 204 median overall survival wa 249 month 235 with sbrt plus pembrolizumab and trametinib and 224 month 95 ci 216 with sbrt plus gemcitabine hazard ratio hr 060 95 ci 082 p00012 the most common grade 3 or 4 adverse effect were increased alanine aminotransferase or aspartate aminotransferase ten 12 of 85 in sbrt plus pembrolizumab and trametinib group v six 7 of 85 in sbrt plus gemcitabine group increased blood bilirubin four 5 v none neutropenia one 1 v nine 11 and thrombocytopenia one 1 v four 5 serious adverse event were reported by 19 22 participant in the sbrt plus pembrolizumab and trametinib group and 12 14 in the sbrt plus gemcitabine group no treatmentrelated death occurred the combination of sbrt plus pembrolizumab and trametinib could be a novel treatment option for patient with locally recurrent pancreatic cancer after surgery phase 3 trial are needed to confirm our finding shanghai shenkang center and changhai hospital for the chinese translation of the abstract see supplementary material section,"Aged, Antibodies, Monoclonal, Humanized, Carcinoma, Pancreatic Ductal, China, Combined Modality Therapy, Deoxycytidine, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Pyridones, Pyrimidinones, Radiosurgery, Gemcitabine"
34237154,the efficacy and safety of transarterial chemoembolization tace plus lenvatinib in patient with hepatocellular carcinoma hcc and portal vein tumor thrombus pvtt have not been evaluated in this openlabel singlecenter randomized trial clinicaltrialsgov identifier nct04127396 participant with previously untreated hcc and type iiv pvtt were randomized 11 to receive tace plus lenvatinib arm l orally once daily 12 mg for body weight 60 kg or 8 mg for body weight 60 kg or tace plus sorafenib arm s 400 mg orally twice daily in day cycle the primary end point wa timetoprogression ttp time from randomization to disease progression and secondary end point included objective response rate and toxicity prognostic factor were evaluated using a multivariable cox proportional hazard model between december 2018 and may 64 patient were randomized arm l n 32 arm s n 32 most patient had type iii pvtt and the median target tumor diameter wa cm range after a median followup of month patient in arm l had a higher median ttp v month hazard ratio hr 95 ci p 029 and objective response rate v p 039 versus arm s multivariable analysis showed that tace plus lenvatinib wa significantly associated with higher ttp versus tace plus sorafenib hr 95 ci p 021 comparable safety profile were observed in arm l and s tace plus lenvatinib wa safe well tolerated and had favorable efficacy versus tace plus sorafenib in patient with advanced hcc with pvtt and large tumor burden hepatocellular carcinoma with portal vein tumor thrombus ha a poor prognosis in addition most phase 3 trial of drug for hepatocellular carcinoma exclude patient with major portal vein invasion and treatment option for these patient are limited transarterial chemoembolization ha shown promising efficacy in these patient especially in combination with systemic treatment or radiotherapy however transarterial chemoembolization plus lenvatinib ha not been investigated in this setting this openlabel singlecenter randomized trial showed that transarterial chemoembolization plus lenvatinib is safe well tolerated and ha favorable efficacy versus transarterial chemoembolization plus sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombus,"Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Humans, Liver Neoplasms, Phenylurea Compounds, Portal Vein, Prospective Studies, Quinolines, Retrospective Studies, Sorafenib, Thrombosis, Treatment Outcome"
34236556,addition of cytarabine to highdose methotrexate hdmtx chemotherapy improves outcome of primary cns lymphoma pcnsl however the combination therapy increase toxicity sequential chemotherapy and cranial radiation may decrease toxicity without altering efficacy this wa a singlecenter retrospective cohort study of consecutive newly diagnosed immunocompetent pcnsl patient treated with hdmtx 5 cycle of 3 gm2 every 2 week followed by consolidation wholebrain radiotherapy wbrt and cytarabine 2 cycle of 3 gmd for 2 day every 3 week from january 2013 to december initial wbrt before hdmtx wa allowed in patient with significant disability or brain edema at presentation primary outcome wa progressionfree survival pfs key secondary outcome were response rate treatmentrelated toxicity and overall survival o of 41 patient 25 patient had a complete response cr and ten patient had a partial response inferring an overall response rate orr of and a cr rate of more than 90 of patient were able to tolerate and complete the hdmtx the incidence of grade 3 hematologic and nonhematologic toxicity were and respectively treatmentrelated mortality rate wa there wa no difference in toxicity between patient with age 60 and 60 year at the median followup duration of month the median pfs wa month 95 ci and median o wa month 95 ci nr highdose methotrexate followed by consolidation wholebrain radiotherapy and cytarabine ha acceptable efficacy great tolerability and low toxicity in newly diagnosed pcnsl patient,"Antineoplastic Combined Chemotherapy Protocols, Brain, Central Nervous System Neoplasms, Cohort Studies, Cytarabine, Humans, Lymphoma, Methotrexate, Middle Aged, Retrospective Studies, Treatment Outcome"
34236381,the efficacy and safety profile of sarscov2 vaccine have been acquired from phase 3 study however patient with cancer were not represented in these trial owing to the recommendation to prioritize highrisk population for vaccination further data are warranted to evaluate the use and safety of the bnt162b2 vaccine in patient undergoing treatment for cancer in january mass sarscov2 vaccination of highrisk population including patient with cancer wa initiated in israel this cohort study prospectively enrolled and followed up patient with cancer and healthy participant between january 15 and march the study wa conducted at the division of oncology of rambam health care campus the major tertiary referral medical center of northern israel participant included 232 patient with cancer who were receiving active treatment after the first and second do of the bnt162b2 vaccine and 261 healthy agematched health care worker who served a control serum sample were collected after each vaccine dose and in case of seronegativity questionnaire regarding sociodemographic characteristic and adverse reaction were administered at serum collection a regulatory agenciesapproved assay wa used to as igg at all time point patient electronic medical record were reviewed for documentation of covid19 infection and result of blood cell count liver enzyme level and imaging study seroconversion rate after the first and second do of the bnt162b2 vaccine and documented covid19 infection of the 232 patient undergoing treatment for cancer 132 were men 57 mean sd age wa 66 year after the first dose of bnt162b2 vaccine 29 n 25 patient were seropositive compared with 84 n 220 of the control p 001 after the second dose the seropositive rate reached 86 n 187 in the patient testing rate ratio per 1000 persondays after the first dose were 95 ci for the patient and 95 ci for the control patient undergoing chemotherapy showed reduced immunogenicity odds ratio 95 ci in seronegative patient the rate of documented absolute leukopenia reached 39 no covid19 case were documented throughout the study period however 2 case in the patient cohort were noted immediately after the first dose reported adverse event were similar to data in former trial comprising mostly healthy individual in this cohort study the sarscov2 bnt162b2 vaccine appeared to be safe and achieve satisfactory serologic status in patient with cancer there wa a pronounced lag in antibody production compared with the rate in noncancer control however seroconversion occurred in most patient after the second dose future realworld data are warranted to determine the longterm efficacy of the vaccine with regard to type of anticancer treatment,"Adult, Aged, Aged, 80 and over, Antibodies, Viral, Antineoplastic Agents, BNT162 Vaccine, COVID-19 Vaccines, Case-Control Studies, Humans, Immunoglobulin G, Israel, Male, Middle Aged, Neoplasms, Prospective Studies, Seroconversion, Tertiary Care Centers, Treatment Outcome"
34235555,low do of folinic acid fa rescue after highdose methotrexate hdmtx have been associated with increased toxicity whereas high do may be related to a decreased antileukemic effect the optimal dosage and duration of fa rescue remain controversial this study wa designed to investigate whether a shorter duration of fa rescue in the setting of rapid hdmtx clearance is associated with increased toxicity we reviewed the file of 44 child receiving a total of 350 hdmtx course during treatment for acute lymphoblastic leukemia according to the nopho all2000 protocol following a 5 gm2 hdmtx infusion pharmacokinetically guided fa rescue commenced at hour a per local guideline the patient received only one or two 15 mgm2 do of fa in the case of rapid mtx clearance serum mtx moll at hour 42 or hour respectively data on mtx clearance fa dosing inpatient time and toxicity were collected rapid mtx clearance wa observed in 181 course there wa no difference in the steadystate mtx concentration nephrotoxicity hepatotoxicity neutropenic fever or neurotoxicity between course followed by rapid mtx clearance and those without one or two do of fa after rapid mtx clearance resulted in a h shorter inpatient time than if a minimum of three do of fa would have been given a pharmacokinetically guided fa rescue of one or two 15 mgm2 do of fa following hdmtx course with rapid mtx clearance result in a shorter hospitalization without an increase in toxic effect,"Acute Disease, Child, Cohort Studies, Humans, Leucovorin, Methotrexate, Precursor Cell Lymphoblastic Leukemia-Lymphoma"
34233590,epithelial mesenchymal transition emt and inflammation have been identified a carcinogenic agent this study aim to investigate whether inhibition of trichloroethylene tce associated hepatocellular carcinoma hcc by curcumin is associated with inflammation and emt in the current study tce subchronic cell model wa induced in vitro and the effect of tce on cell proliferation migration invasion and expression of functional protein were verified by western blot mtt clone formation wound healing transwell the detoxification effect of curcumin on tce wa explored by a mouse tumorbearing experiment tce induces hepatocyte migration colony formation and emt in vitro in vivo study have shown that curcumin significantly reduces the mortality of mouse and control the occurrence and size of liver tumor by inhibiting the ilstat3 signaling pathway in vitro curcumin inhibits the proliferation of hepg2 cell a determined by mtt assay in addition curcumin significantly inhibited the protein expression of il6r stat snail survivin and cyclin d1 in thle2 and hepg2 cell induced by il curcumin ha antiinflammatory and antiproliferative effect and inhibits the development of hcc induced by tce by reversing ilstat3 mediated emt,"Carcinoma, Hepatocellular, Cell Line, Tumor, Cell Proliferation, Curcumin, Epithelial-Mesenchymal Transition, Humans, Liver Neoplasms, STAT3 Transcription Factor, Signal Transduction, Trichloroethylene"
34232950,those with metastatic urothelial carcinoma generally respond more poorly to chemotherapy after they have progression on a checkpoint inhibitor cpi there is interest in combining cpi with conventional cytotoxic chemotherapy a a strategy to exploit the efficacy and immunomodulatory effect of chemotherapy we conducted a single institution retrospective analysis including all patient treated between may 2018 and may 2020 with carboplatin and paclitaxel concurrently or sequential with pembrolizumab after having progression on a cpi alone clinical characteristic response by recist progressionfree survival and safetytolerance of the treatment are reported median age wa 80 year five patient 100 had visceral metastasis when starting carboplatin and paclitaxel chemotherapy wa given with concurrent pembrolizumab four patient or following pembrolizumab one patient and continued until maximum response significant toxicity or progression two patient subsequently remained on maintenance pembrolizumab there were four partial response and one patient with stable disease all patient on followup have progressed with median time to progression of 47 week two patient died from disease progression this case series suggests that the combination of carboplatin paclitaxel and pembrolizumab lead to durable freedom from progression in some with metastatic urothelial cancer who have progressed on a cpi alone larger study of chemoimmunotherapy for metastatic urothelial carcinoma are warranted,"Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Humans, Middle Aged, Neoplasm Metastasis, Paclitaxel, Retrospective Studies, Urinary Bladder Neoplasms"
34232946,in this report we aim to present a case of pulmonary toxicity in a patient that received neoadjuvant chemotherapy treatment with doxorubicin and cyclophosphamide for triplenegative breast cancer that wa followed with granulocyte colonystimulating factor gcsf for prevention neutropenia our patient presented with chest discomfort and dyspnea with radiologic evidence of radiologic investigation showed acute respiratory distress syndrome after investigation and follow up we came to the conclusion that it wa gcsf adverse effect,"Adult, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Doxorubicin, Female, Granulocyte Colony-Stimulating Factor, Humans, Neutropenia, Respiratory Distress Syndrome"
34232941,this study wa to explore the efficacy and safety of camrelizumab combined with apatinib in patient with advanced liver cancer moreover the relationship between peripheral blood parameter and tumor response rate wa also investigated patient with unresectable or recurrent primary liver cancer plc who received treatment from july 2019 to july 2020 in the first affiliated hospital of guangxi medical university were included in this singlecenter retrospective study the patient were treated with camrelizumab 200 mg intravenous q2w plus apatinib 250 mg oral qd until the occurrence of disease progression or unbearable toxicity all the patient underwent blood routine test and detection of lactate dehydrogenase and serum albumin level before treatment the primary endpoint were objective response rate orr and disease control rate dcr this study included a total of 45 patient the overall orr wa 95 confidence interval ci and the overall dcr wa 95 ci the orr and dcr were higher in the firstline treatment than those in the secondline treatment orr v dcr v median progressionfree survival in the secondline treatment wa month 95 ci p adverse event occurred in 39 patient grade adverse reaction occurred in 7 patient one patient wa terminated from treatment due to adverse event one patient died which wa potentially associated with adverse event subgroup analysis indicated that the remission rate in patient with high lymphocyte to monocyte ratio hlmr wa higher than that in patient with low lymphocyte to monocyte ratio llmr v p and the remission rate in patient with high prognostic nutritional index hpni wa higher than that in patient with low prognostic nutritional index lpni v p camrelizumab combined with apatinib in the treatment of plc showed encouraging clinical efficacy with tolerable toxicity level of pni and lmr may serve a predictor of the prognosis of advanced plc patient who receive immunotherapy combined with targeted therapy,"Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Lymphocytes, Middle Aged, Monocytes, Neoplasm Metastasis, Neoplasm Staging, Progression-Free Survival, Pyridines, Retrospective Studies"
34231124,neuroendocrine carcinoma nec are a rare subgroup of neuroendocrine neoplasm that occasionally originate from gastroenteropancreatic gep tract evidence of the effectiveness of chemotherapy is scarce platinum plus etoposide regimen are currently the standard treatment in firstline while little data are available on secondline treatment the aim of this study is to evaluate the efficacy and safety of irinotecan iribased chemotherapy in a series of extrapulmonary nec patient with nec diagnosis treated at university hospital of modena florence pisa and european institute of oncology of milan with an iribased regimen folfiri or xeliri after progression to a firstline platinumbased therapy were enrolled objective response were assessed according to recist criterion progressionfree survival pfs and overall survival o were calculated thirtyfour patient 16 male and 18 female median age of 59 year range with metastatic nec were included twentyseven patient had ki67 55 and four patient ki67 of 55 for three patient data were not available the median number of treatment cycle of the iribased regimen wa range six partial response and 9 stable disease were observed with a disease control rate of median pfs and o were and month respectively neutropenia anemia and nausea were the only gg4 toxicity reported despite the relatively small sample size iribased therapy demonstrated to be a valid option for patient with pretreated extrapulmonary nec,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Neuroendocrine, Female, Humans, Irinotecan, Italy, Male, Middle Aged, Neuroendocrine Tumors"
34229968,the management of osteosarcoma in child and adolescent is based on polychemotherapy including several nephrotoxic drug eg ifosfamide methotrexate and cisplatinum chronic renal toxicity is a frequent complication but stage 5 chronic kidney disease requiring dialysis is rare we report here a series of six pediatric patient with osteosarcoma displaying chronic kidney disease after chemotherapy we retrospectively reviewed the medical chart mainly for clinical history timing between chemotherapy and development of tubulopathy and ckd type of therapy and global evolution chronic dialysis and further renal transplantation n2 death n1 notably all patient suffered from chondroblastic osteosarcoma advanced chronic kidney disease can be a complication of osteosarcoma management that could more frequently lead to dialysis and further transplantation it would be interesting to identify specific risk factor of such renal toxicity the chondroblastic subtype may be associated with such susceptibility but this need to be confirmed,"Adolescent, Bone Neoplasms, Child, Humans, Ifosfamide, Osteosarcoma, Renal Insufficiency, Chronic, Retrospective Studies"
34229596,cancer can be considered a a genetic a well a a metabolic disorder the current cancer treatment scenario look like aggravating tumor cell metabolism causing the disease to progress even with greater intensity the cancer therapy is restricted to the limitation of poor patient compliance due to toxicity to normal tissue and multidrug resistance development there is an emerging need for cancer therapy to be more focused towards better understanding of genetic epigenetic and transcriptional change resulting in cancer progression and their relationship with treatment sensitivity the thiazolidinone nucleus posse marked anticancer potential towards different biotargets thus targeting different cancer type like breast prostate lung colorectal and colon cancer renal cell adenocarcinoma and glioma therefore conjugating the thiazolidinone scaffold with other promising moiety or directing the therapy towards targeted drug delivery system like the use of nanocarrier system can provide the gateway for optimizing the anticancer efficiency and minimizing the adverse effect and drug resistance development thus providing stimulus for personalized pharmacotherapy an exhaustive literature survey ha been done to give an insight into the anticancer potential of the thiazolidinone nucleus either alone or in conjugation with other active moiety with the mechanism involved in preventing proliferation and metastasis of cancer covering a vast range of publication of repute this review aim to summarise the work reported on anticancer activity of thiazolidinone derivative covering various cancer biomarkers and pathway involved citing the data from the year 2005 till now which may be beneficial to the researcher for future development of more efficient thiazolidinone derivative,"Antineoplastic Agents, Biomarkers, Humans, Neoplasms, Thiazolidines"
34229051,the study aimed to evaluate the efficacy and safety of concurrent chemoradiation therapy ccrt combined with nimotuzumab in patient with unresectable stage iii squamous cell lung cancer sqclc a prospective singlecenter openlabel randomized phase 2 trial wa performed in patient with unresectable stage iii sqclc patient were randomized to receive 65 gy thoracic radiation over 5 week concurrent with docetaxel and cisplatin or the same ccrt regimen combined with 200 mg of nimotuzumab nimoccrt administered weekly by intravenous infusion the primary endpoint wa overall survival the secondary endpoint were progressionfree survival objective response rate failure pattern and treatmentrelated toxicity from august 2015 to june 126 patient with sqclc were randomized four patient withdrew consent before the start of treatment and 122 patient were included for analysis including 57 in the nimoccrt group and 65 in the ccrt group the median o wa month in the nimoccrt group and month in the ccrt group p 655 the median pfs wa month in the nimoccrt group and month in the ccrt group p 968 the nimoccrt group had a significantly lower risk of brain metastasis with adjusted subdistribution hazard ratio of 95 confidence interval p 031 the incidence of grade 3 pneumonitis p 894 and esophagitis p 974 wa similar between the 2 arm there wa no grade 2 or higher skin toxicity in nimoccrt group the coincident application of nimotuzumab with ccrt wa well tolerated for locally advanced sccl the nimoccrt group had an o and pfs similar to that in the ccrt group but a lower risk of brain metastasis further investigation are warranted,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Chemoradiotherapy, Cisplatin, Epithelial Cells, Humans, Lung Neoplasms, Prospective Studies"
34228505,danafarber cancer institute acute lymphoblastic leukemia all consortium protocol assessed efficacy and toxicity of calaspargase pegol calaspargase a novel pegylated asparaginase formulation with longer halflife compared with the standard formulation pegaspargase patient age 1 to 21 year with newly diagnosed all or lymphoblastic lymphoma were randomly assigned to intravenous pegaspargase or calaspargase iumdose patient received one induction dose beginning week pegaspargase wa administered every 2 week for 15 do and calaspargase every 3 week for 10 do 30 week serum asparaginase activity saa iuml considered therapeutic wa assessed and 25 day after the induction dose and before each postinduction dose between 2012 and 239 eligible patient enrolled 230 all nine lymphoblastic lymphoma 120 were assigned to pegaspargase and 119 to calaspargase after the induction dose saa wa iuml in 95 of patient on both arm 18 day after dosing at day more patient had saa iuml with calaspargase 88 v 17 p 001 postinduction median nadir saas were similar iuml for both arm of 230 evaluable patient 99 of pegaspargase and 95 of calaspargase patient achieved complete remission p 12 with no difference in frequency of high endinduction minimal residual disease among evaluable patient with b acute lymphoblastic leukemia ball there were no difference in frequency of asparaginase allergy pancreatitis thrombosis or hyperbilirubinemia with year median followup year eventfree survival for pegaspargase wa se and se for calaspargase p 65 every week calaspargase had similar nadir saa toxicity and survival outcome compared with every week pegaspargase the high nadir saa observed for both preparation suggest dosing strategy can be further optimized,"Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Asparaginase, Child, Child, Preschool, Drug-Related Side Effects and Adverse Reactions, Female, Follow-Up Studies, Humans, Infant, Male, Polyethylene Glycols, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Survival Rate, United States, Young Adult"
34227796,it ha been found that the selfassembly of nonfluorescent peptide can generate fluorescent peptide nanoparticles fpnps to perform multiple function including drug delivery and imaging and tracking therapeutic agent both pharmacologically inactive peptide and tumortargeting peptide have been explored to construct biocompatible fpnps however the application of this technology in delivering antitumor peptide ha never been reported herein the selfassembly of an antitumor dipeptide carnosine into fluorescent carnosine nanoparticles fcar np in the presence of zinc ion is demonstrated the generated fcar np exhibit fluorescence in the visible and nearinfrared nir range for fluorescence tracing in vitro and in vivo on the other hand the fcar np minimize the contact between the dipeptide and the serum which overcomes the dipeptide instability resulted from inefficient antitumor activity in addition the preparation of fcar np doe not introduce extra carrier material so the fcar np exhibit biocompatibility to normal fibroblast cell in vitro and negligible toxicity against major organ in vivo this study provides a new peptide drug delivery strategy with nir fluorescence tracing ability,"Animals, Antineoplastic Agents, Carnosine, Cell Line, Tumor, Female, Fluorescent Dyes, Fluorometry, Humans, Infrared Rays, Metal Nanoparticles, Mice, Inbred BALB C, Neoplasms, Theranostic Nanomedicine, Zinc, Mice"
34226296,adjuvant concurrent chemoradiotherapy ccrt is the standard care for patient with resected advanced gastric cancer but it survival benefit remain undetermined in patient undergoing d2 lymph node dissection d2 dissection we evaluated safety and efficacy of adjuvant ccrt with fluorouracil fu versus chemotherapy alone in 110 gastric cancer patient with d2 dissection treated in taiwan between january 2009 and january all the 71 patient receiving adjuvant ccrt were treated with daily infusional fu and radiotherapy adjuvant ccrt wa associated with higher risk of major hematologic v p and gastrointestinal v p toxicity and death v p in patient above 70 year old but this wa not the case in those 70 year of age univariate cox proportional regression identified adjuvant ccrt a a factor for better overall survival o hazard ratio hr 95 confidence interval ci and diseasefree survival dfs hr 95 ci but it wa not a significant factor for o or dfs after adjusting for other factor in the multivariate analysis however in stratified analysis by age we found adjuvant ccrt wa an independent prognostic factor for better o hr 95 ci in patient 70 year old but not in those above 70 year of age therefore it wa concluded that age may to be a modifier of the effect of adjuvant ccrt,"Adult, Aged, Aged, 80 and over, Aging, Antimetabolites, Antineoplastic, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Female, Fluorouracil, Humans, Infusions, Intravenous, Lymph Node Excision, Male, Middle Aged, Prognosis, Stomach Neoplasms, Survival Analysis, Taiwan, Treatment Outcome"
34226162,this article review the available literature that describes the incidence diagnosis mechanism symptom and management of pulmonary toxicity induced by radiation therapy and current systemic medication used to treat breast cancer an extensive literature search wa conducted via ovid medline to identify all potentially relevant article written in english from 2010 through january additional relevant article outside the time frame were included a needed although the risk of pulmonary toxicity from various breast cancer treatment is small in most instance it can be fatal due to the high prevalence of breast cancer and the range of treatment option healthcare provider should be aware of the risk of pulmonary toxicity from those treatment and how to prevent or manage complication,"Antineoplastic Agents, Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Pulmonary Fibrosis, Radiation Injuries, Radiation Pneumonitis"
34226158,targeted agent have been increasingly used in different malignancy and are associated with improved survival outcome including gastrointestinal cancer their use in the treatment of older patient is appealing given their favorable toxicity profile in the last year this subgroup of patient ha been attracting increased interest given their representativeness and specific clinical need nonetheless the lack of data on efficacy and safety of standard treatment in older patient hinders proper evidencebased decisionmaking leaving most therapeutic recommendation to be extrapolated from registration trial with low representation of older and frail patient however even if most decision regarding the use of targeted agent in older patient with gastrointestinal cancer remain guided by subanalyses of large trial data from recent older adultspecific trial are beginning to emerge particularly in colorectal cancer this review aim to summarize the existing evidence on treatment of older patient with gastrointestinal carcinoma colon and rectum stomach esophagus liver and pancreas with targeted agent cetuximab panitumumab bevacizumab ramucirumab aflibercept regorafenib encorafenib trastuzumab sorafenib lenvatinib cabozantinib erlotinib olaparib and place the evidence in a geriatric oncology perspective,"Aged, Antineoplastic Agents, Cetuximab, Colorectal Neoplasms, Gastrointestinal Neoplasms, Humans, Panitumumab, Sorafenib"
34224826,the phase iii clinical evaluation of pertuzumab and trastuzumab cleopatra trial established the combination of pertuzumab trastuzumab and docetaxel a standard firstline therapy for human epidermal growth factor receptor 2 her2positive locally recurrentmetastatic breast cancer lrmbc the multicentre singlearm pertuzumab global safety peruse study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigatorselected taxane in this setting eligible patient with inoperable herpositive lrmbc and no prior systemic therapy for lrmbc except endocrine therapy received docetaxel paclitaxel or nabpaclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity the primary endpoint wa safety secondary endpoint included progressionfree survival pfs and overall survival o prespecified subgroup analysis included subgroup according to taxane hormone receptor hr status and prior trastuzumab exploratory univariable analysis identified potential prognostic factor those that remained significant in multivariable analysis were used to analyse pfs and o in subgroup with all some or none of these factor of 1436 treated patient 588 41 initially received paclitaxel and 918 64 had hrpositive disease the most common grade 3 adverse event were neutropenia 10 mainly with docetaxel and diarrhoea 8 at the final analysis median followup year median pfs wa 95 confidence interval ci month overall and wa similar irrespective of hr status or taxane median o wa 95 ci month overall o wa similar regardless of taxane backbone but wa more favourable in patient with hrpositive than hrnegative lrmbc in exploratory analysis trastuzumabpretreated patient with visceral disease had the shortest median pfs month and o month mature result from peruse show a safety and efficacy profile consistent with result from cleopatra and median o exceeding 5 year result suggest that paclitaxel is a valid alternative to docetaxel a backbone chemotherapy exploratory analysis suggest risk factor that could guide future trial design,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Neoplasm Recurrence, Local, Receptor, ErbB-2, Taxoids, Trastuzumab, Treatment Outcome"
34218783,efficacious treatment for breast cancer is still a challenge despite the presence of various treatment option aromatase enzyme present in the breast tissue is responsible for estrogen formation from androgen aromatase inhibitor manifest remarkably ameliorated therapeutic efficacy a compared to the current therapeutic option available and exhibit a better safety profile a compared to the other drug clinical resistance to aromatase inhibitor is perceived a a lack of growth inhibition by aromatase inhibitor treatment and cancer therapy becomes ineffective in causing a decrease in the size of the tumor naturally extracted aromatase inhibitor have a huge positive impact on vitality and living standard this review article highlight the particular of the currently approved steroidal and nonsteroidal aromatase inhibitor for clinical use adverse effect associated with their use and approach to tackling the problem various strategy to overcome aromatase inhibitor resistance information on the synthesis of various peculiar aromatase inhibitor which can prove a highly efficient and potent drug in the near future and the drug of natural and semisynthetic origin which can demonstrate to be more efficient potent and lesstoxic than conventional therapy,"Antineoplastic Agents, Aromatase, Aromatase Inhibitors, Breast Neoplasms, Female, Humans"
34218217,interleukin il2 is a pleiotropic cytokine that display opposing activity on immune system acting either in favor of or against cancer progression advancedmetastatic melanoma and renal cell carcinoma rcc are the two type of cancer that included most study implemented for assessing the role of highdose il2 therapy the use of highdose il2 therapy can however increase the rate of toxicity and interferes with the activity of endothelial cell ec and effector t cell in tumor microenvironment tme this implies the need for adjusting strategy related to the cytokine therapy such a suppressing signal that are interfering with the activity of this cytokine or the use of engineered il2 variant the focus of this review is to discus about pro and con related to the il2 therapy and propose strategy to increase the efficacy of therapy the outcome of this literature will call for application of variant of il2 engineered to represent higher halflife and efficacy and are more safe in the area of cancer immunotherapy,"Animals, Antineoplastic Agents, Carcinogenesis, Carcinoma, Renal Cell, Genetic Engineering, Humans, Immunotherapy, Interleukin-2, Melanoma, Recombinant Proteins, Skin Neoplasms, Tumor Microenvironment"
34216673,to achieve targeted treatment with fewer adverse effect against fatal cancer disease the use of nanoparticles a therapeutic agent or drug carrier ha been proved to be very extensive and remarkable today in this study chitosanmagnetitereduced graphene oxide csfe3orgo nanocomposites nc were used for the targeted delivery of curcumin cur a anticancer drug to suppress mcf7 breast cancer cell and this wa accomplished using a facile waterinoil wo emulsification procedure ftir and xrd were used for characterization the average size distribution of nanoemulsions and their surface charge zeta potential were determined by dynamic light scattering dl analyzer and zeta potential measurement respectively sem mapping showed the uniform and flat surface for the nc which wa confirmed by the edx diagram measurement of vsm exhibited that the fe3orgos have superparamagnetic property according to the mtt assay the nc ha the highest toxicity at against mcf7 cancer cell the result of flow cytometry indicated apoptosis in mcf7 cell by using the dialysis method it wa determined that curcumin wa released faster in an acidic medium it is expected that the result of this study will be effective in the development of targeted drug delivery a well a the development of c fe3orgobased drug carrier against various cancer cell during future research,"Antineoplastic Agents, Apoptosis, Breast Neoplasms, Cell Cycle, Chitosan, Curcumin, Drug Carriers, Drug Compounding, Drug Liberation, Female, Graphite, Humans, MCF-7 Cells, Magnetite Nanoparticles, Nanotechnology, Oxidation-Reduction"
34215931,the study wa designed to investigate the safety of ramucirumab administered in combination with erlotinib or osimertinib for patient with untreated egfrmutated nonsmall cell lung cancer nsclc and asymptomatic brain metastasis a patient subgroup in which these regimen have remained untested this phase 1b study relaybrain consisted of two cohort with three patient each patient with asymptomatic brain metastasis received ramucirumab every 2 week plus either daily oral erlotinib or osimertinib until disease progression or intolerable toxicity the primary objective wa to as doselimiting toxicity dlt defined a central nervous system cns hemorrhage of grade six patient were enrolled neither dlt nor serious or unexpected adverse event were observed one treatmentrelated adverse event of grade 3 hypertension of grade 3 wa apparent common adverse event were generally manageable the median number of ramucirumab administration wa range 13 to 31 and there were no detected episode of cns hemorrhage five of the six patient showed an objective systemic response although only one patient had a measurable cns lesion at baseline a confirmed intracranial partial response wa observed ramucirumab in combination with erlotinib or osimertinib showed safety for egfrmutated nsclc with brain metastasis,"Acrylamides, Aged, Aniline Compounds, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Dose-Response Relationship, Drug, ErbB Receptors, Erlotinib Hydrochloride, Female, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Ramucirumab"
34215680,immunotherapy is revolutionizing cancer treatment but is often restricted by toxicity what distinguishes adverse event from concomitant antitumor reaction is poorly understood here using anticd40 treatment in mouse a a model of thpromoting immunotherapy we showed that liver macrophage promoted local immunerelated adverse event mechanistically tissueresident kupffer cell mediated liver toxicity by sensing lymphocytederived ifn and subsequently producing il conversely dendritic cell were dispensable for toxicity but drove tumor control il12 and ifn were not toxic themselves but prompted a neutrophil response that determined the severity of tissue damage we observed activation of similar inflammatory pathway after antipd1 and antictla4 immunotherapy in mouse and human these finding implicated macrophage and neutrophil a mediator and effector of aberrant inflammation in thpromoting immunotherapy suggesting distinct mechanism of toxicity and antitumor immunity,"Animals, CD40 Antigens, CTLA-4 Antigen, Cytokines, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Kupffer Cells, Liver, Mice, Transgenic, Neoplasms, Neutrophils, Programmed Cell Death 1 Receptor"
34214730,glioblastoma gbm is a challenging cancer with poor prognosis the classical standard for treatment is safe resection followed by concurrent chemoradiotherapy with subsequent adjuvant temozolomide tmz despite several attempt at different treatment the year survival rate remains poor in recent year with the continuous progress of treatment technology tumor treating field ttfields were preferable the device could generate an intermediate frequency alternating electric field and induce apoptosis of some specific type of cancer cell with few toxic and side effect ttfields induced apoptosis through multiple activation of the pathway ttfields have been food and drug administration fdaapproved for diagnosis and recurrent gbm a additional clinical trial result are revealed this study reviewed the current status mechanism correlation with immune pathway the prospect of applying ttfields for gbm and the adverse event,"Animals, Antineoplastic Agents, Alkylating, Brain Neoplasms, Chemoradiotherapy, Combined Modality Therapy, Glioblastoma, Humans, Neoplasm Recurrence, Local, Neurosurgical Procedures, Temozolomide"
34214711,the antiangiogenic agent bevacizumab is currently the only drug used clinically for neurofibromatosis type related vestibular schwannomas nfvs though benefit have been demonstrated in several case the standardized dosage remains unclear our metaanalysis wa performed to systematically and comprehensively investigate the reliability and toxicity of bevacizumab in the treatment of nfvs with particular emphasis on the impact of dosage the literature search wa conducted for study providing data on patient treated with bevacizumab for nfvs across pubmed embase and cochrane library until december two reviewer extracted the incidence rate of result independently then we calculated and pooled unadjusted incidence rate with 95 ci for each study the subgroup analyzed were conducted fourteen citation prospective or retrospective observational cohort study were eligible based on data from a total of 247 patient with nf2 and 332 related v the pooled result showed that the radiographic response rate rrr wa 30 95 ci 2042 the hearing response rate hrr wa 32 95 ci 2145 the incidence of major complication wa hypertension 29 95 ci 2335 proteinuria 30 95 ci 1844 menstrual disorder 44 95 ci 1673 hemorrhage 14 95 ci 426 grade event 12 95 ci 422 nearly onethird of nfvs patient may benefit significantly from bevacizumab due to hearing improvement and tumor reduction menstrual disorder were the most common adverse event the highdose regimen didnt show better efficacy but result varied considerably according to age,"Adult, Age Factors, Bevacizumab, Dose-Response Relationship, Drug, Female, Hearing, Hemorrhage, Humans, Hypertension, Male, Menstruation Disturbances, Neurofibromatosis 2, Neuroma, Acoustic, Prospective Studies, Proteinuria, Retrospective Studies, Vestibulocochlear Nerve, Young Adult"
34213984,colorectal cancer crc is the second cause of cancerrelated death worldwide is one of the most prevalent type of cancer conventional treatment continues to rely on surgery chemotherapy and radiotherapy but for advanced case adjuvant chemotherapy remains the main approach for improving surgical outcome and lower the disease recurrence probability chemotherapyinduced gastrointestinal gi toxicity is the main doselimiting factor for many chemotherapeutic regimen including fu and one of the biggest oncological challenge up to 40 of the patient receiving fu get mucositis of which develop severe symptom in this context our study aimed to develop a bioinspired nanosized drug delivery system a a strategy to reduce fu associated side effect such a gi mucositis to this end sfbased nanoparticles were prepared and characterized in term of size and morphology a well a in term of in vitro antitumoral activity on a biomimetic colorectal cancer model by investigation of apoptosis dna fragmentation and release of reactive oxygen specie additionally the capacity of the sfbased nanocarriers to offer intestinal protection against fuinduced gi mucositis wa evaluated in vivo using a mouse model that mimic the chemotherapyassociated gut mucositis occurring in colorectal cancer our study show that silk fibroin nanoparticles efficiently deliver fu to tumor cell in vitro while protecting against druginduced gi mucositis in a mouse model,"Colorectal Neoplasms, Fibroins, Fluorouracil, HT29 Cells, Humans, Mucositis"
34213084,we examined the efficacy and adverse event of continuous lasparaginase administration in dog with large cell lymphoma of presumedgastrointestinal gi origin we retrospectively reviewed medical record of dog with large cell lymphoma of presumed gi origin treated with continuous lasparaginase administration from 2009 to we collected information on the signalment lesion site complete blood count serum biochemical profile diagnostic imaging finding cytological and histopathological finding immunophenotype lasparaginase administration frequency treatment response adverse event rescue protocol and patient outcome clinical outcome were assessed using medical record or by contacting the owner or referring veterinarian thirtytwo dog with large cell lymphoma of presumed gi origin received weekly lasparaginase administration the median number of lasparaginase injection wa seven range although two of the 32 dog had gi toxicity of grade 3 or higher none developed a hypersensitivity reaction the response rate based on ultrasonographic finding wa 56 and that based on clinical sign wa 94 the median overall progressionfree survival wa 50 day range day and median overall survival wa 147 day range day adverse event associated with continuous lasparaginase administration were rare clinical sign at diagnosis improved in most case based on these result continuous lasparaginase administration appears to be a reasonable treatment option for dog with large cell lymphoma of presumed gi origin,"Animals, Antineoplastic Combined Chemotherapy Protocols, Asparaginase, Dog Diseases, Dogs, Lymphoma, Lymphoma, Non-Hodgkin, Retrospective Studies"
34210681,standarddose pembrolizumab plus alternativedose ipilimumab 1 mgkg q3w for 4 do were tolerable and had robust antitumor activity in advanced melanoma in cohort b of the phase 1 keynote029 study cohort c evaluated standarddose pembrolizumab with two other alternative ipilimumab regimen patient with treatmentnaive unresectable stage iiiiv melanoma were randomly assigned 11 to pembrolizumab 200 mg q3w for 24 month plus ipilimumab 50 mg q6w for 4 do pemipi50 or the same pembrolizumab regimen plus ipilimumab 100 mg q12w for 4 do pemipi100 primary end point were incidence of grade treatmentrelated adverse event trae and objective response rate orr per recist v by independent central review per protocoldefined threshold grade trae incidence 26 indicated meaningful toxicity reduction and orr 48 indicated no decrease in efficacy versus data reported for other pd1 inhibitoripilimumab combination median followup on february wa month in pemipi50 n 51 and month in pemipi100 n 51 grade traes occurred in 12 24 patient in pemipi50 and 20 39 in pemipi one patient in pemipi50 died from treatmentrelated autoimmune myocarditis immunemediated aes or infusion reaction occurred in 21 42 patient in pemipi50 and 28 55 in pemipi orr wa 55 in pemipi50 61 in pemipi pembrolizumab 200 mg q3w plus ipilimumab 50 mg q6w or 100 mg q12w demonstrated antitumor activity above the predefined threshold pembrolizumab plus ipilimumab 50 mg q6w had lower incidence of grade traes than the predefined threshold suggesting a reduction in toxicity see related commentary by jamesonlee and luke p,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Humans, Ipilimumab, Melanoma, Skin Neoplasms, Melanoma, Cutaneous Malignant"
34201529,the emergence of immunebased treatment for cancer ha led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agent immunerelated adverse event iraes can develop a isolated event or a toxicity affecting multiple body system in particular this review detail the neurological iraes from immune checkpoint inhibitor ici and chimeric antigen receptor car t cell immunotherapy the recognition and treatment of neurological iraes ha variable success depending on the severity and nature of the neurological involvement understanding the involved mechanism predicting those at higher risk for iraes and establishing safety parameter for resuming cancer immunotherapy after iraes are all important field of ongoing research,"Biomarkers, Pharmacological, Biomarkers, Tumor, CTLA-4 Antigen, Encephalitis, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Immunotherapy, Adoptive, Meningitis, Aseptic, Neoplasms, Paraneoplastic Syndromes, Receptors, Chimeric Antigen, T-Lymphocytes"
34197599,tumor heterogeneity includes variable and fluctuating oxygen concentration which result in the accumulation of hypoxic region in most solid tumor tumor hypoxia lead to increased therapy resistance and ha been linked to genomic instability here we tested the hypothesis that exposure to level of hypoxia that cause replication stress could increase apobec activity and the accumulation of apobecmediated mutation apobecdependent mutational signature have been wellcharacterized although the physiological condition which underpin them have not been described we demonstrate that fluctuatingcyclic hypoxic condition which lead to replication catastrophe induce the expression and activity of apobec3b in contrast stablechronic hypoxic condition which induce replication stress in the absence of dna damage are not sufficient to induce apobec3b most importantly the number of apobecmediated mutation in patient tumor correlated with a hypoxia signature together our data support the conclusion that hypoxiainduced replication catastrophe drive genomic instability in tumor specifically through increasing the activity of apobec3b,"APOBEC Deaminases, Cell Hypoxia, Cell Line, Tumor, Cytidine Deaminase, DNA Replication, Deamination, Humans, Hydroxyurea, Minor Histocompatibility Antigens, Neoplasms, Stress, Physiological"
34196874,previous clinical trial have demonstrated that entinostat in combination with exemestane had good tolerability and significant clinical efficacy in patient with advanced hormone receptor positive hr and her2 negative her metastatic breast cancer mbc in the usa however no clinical trial have been conducted in chinese population to investigate the safety pharmacokinetics and pilot efficacy of entinostat with or without exemestane in chinese postmenopausal patient with locally advanced or metastatic hr her mbc nineteen patient received entinostat for 4 week doselimiting toxicity dlt observation stage at or 7 mgweek with a doseescalation design and in combination with exemestane thereafter extended treatment stage entinostat 3 or 5 mgweek exemestane 25 mgday an additional 21 patient were enrolled to as the entinostat 5 mg plus exemestane 25 mg pharmacokinetic profile and potential efficacy the peak entinostat serum concentration and area under the curve increased dose proportionally without significant interaction between entinostat and exemestane entinostat wa well tolerated at all do the most common grade adverse effect aes included neutropenia and thrombocytopenia in the dlt observation stage grade aes accounted for in the 5 mg group with one suspicious dlt g3 ventricular tachycardia and in the 7 mg group in the extended treatment stage patient achieved partial response and three patient experienced stable disease 12 week the median progressionfree survival wa month for the additional 21 patient who experienced grade aes of neutropenia 38 thrombocytopenia anemia and fatigue entinostat with exemestane showed reasonable safety tolerability and encouraging efficacy in chinese patient with hrher mbc these result support further evaluation in a randomized doubleblind phase iii study with a weekly 5 mg entinostat dose in a chinese population nct,"Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, China, Female, Histone Deacetylase Inhibitors, Humans, Pilot Projects, Postmenopause, Pyridines, Treatment Outcome"
34196165,tafasitamab mor208 an fcmodified humanized anticd19 monoclonal antibody combined with the immunomodulatory drug lenalidomide wa clinically active with a good tolerability profile in the openlabel singlearm phase ii lmind study of patient with relapsedrefractory diffuse large bcell lymphoma dlbcl ineligible for autologous stemcell transplantation to as longterm outcome we report an updated analysis with 35 month followup patient were aged 18 year had received one to three prior systemic therapy including 1 cdtargeting regimen and eastern cooperative oncology group performance status patient received day cycle of tafasitamab 12 mgkg intravenously once weekly during cycle then every 2 week during cycle lenalidomide 25 mg orally wa administered on day of cycle after cycle progressionfree patient received tafasitamab every 2 week until disease progression the primary endpoint wa best objective response rate after 35 month followup data cutoff october 2020 the objective response rate wa n including a complete response in of patient n and a partial response in of patient n the median duration of response wa month 95 confidence interval 95 ci not reached the median overall survival wa month 95 ci not reached and the median progressionfree survival wa month 95 ci there were no unexpected toxicity subgroup analysis revealed consistent longterm efficacy result across most subgroup of patient this extended followup of lmind confirms the long duration of response meaningful overall survival and welldefined safety profile of tafasitamab plus lenalidomide followed by tafasitamab monotherapy in patient with relapsedrefractory diffuse large bcell lymphoma ineligible for autologous stem cell transplantation clinicaltrialsgov identifier nct,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Lymphoma, Large B-Cell, Diffuse, Transplantation, Autologous, Treatment Outcome"
34196124,nivolumab improves disease control and survival in advanced nsclc in patient with good performance status p but there is limited data on it efficacy in patient with poor p primary objective of the study wa to evaluate the efficacy and safety of nivolumab and examine the influence of p on outcome retrospective analysis of patient treated with singleagent nivolumab for advanced nsclc at a single institution wa performed sixtysix patient treated with nivolumab were identified 33 male with a median age of year fiftysix 85 patient were current or former smoker and 17 26 had brain metastasis all patient had received prior chemotherapy 39 59 patient received one and 27 41 had 2 prior line of therapy median overall survival o wa month 95ci in the overall study population o of patient with p 2 at the start of treatment wa month 95ci a compared to month 95ci with p the overall response rate wa 7 four patient had a partial response 23 40 patient had stable disease the overall disease control rate partial response and stable disease wa 47 twentysix 40 patient had p 2 at the start of treatment and 2 8 of these patient developed a partial response 4 15 had stable disease the overall disease control rate wa 23 fourteen 58 patient with p 2 had disease progression at the time of first disease response evaluation in the overall population 20 of patient experienced grade 3 treatmentrelated adverse event traes most commonly pneumonitis hepatitis and colitis fourteen traes led to treatment discontinuation 9 23 adverse event aes in patient with p 1 and 5 19 with p fourteen 21 patient died within 30 day of the last nivolumab treatment there wa no significant difference in toxicity leading to treatment discontinuation between the poor and good p group but survival wa shorter with poorer p p appears to be an important prognostic factor and remains a relevant discriminator in the selection of treatment with immunotherapy for lung cancer,"Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Nivolumab, Retrospective Studies"
34194837,cisplatin cddp nephrotoxicity is one of the most significant complication limiting it use in cancer therapy this study investigated the pivotal role played by thrombin in cddpmediated nephrotoxicity this work also aimed to clarify the possible preventive effect of dabigatran dab a direct thrombin inhibitor on cddp nephrotoxicity animal were grouped a follow normal control group cddp nephrotoxicity group cddp dab and cddp dab 25 group four day following cddp administration blood and urine sample were collected to evaluate renal function moreover tissue sample were collected from the kidney to determine apoptosis marker oxidative stress and histopathological evaluation an immunofluorescence analysis of tissue factor tf thrombin proteaseactivated receptor2 par2 fibrin perk and p53 protein expression wa also performed thrombin perk cleaved caspase and oxidative stress marker were significantly elevated in cddptreated group however pretreatment of animal with either low or high do of dab significantly improved kidney function and decreased oxidative stress and apoptotic marker we conclude that thrombin is an important factor in the pathogenesis of cddp kidney toxicity via activation of erk p53 and caspase3 pathway which can be effectively blocked by dab,"Animals, Antithrombins, Apoptosis, Blood Urea Nitrogen, Caspase 3, Cisplatin, Dabigatran, Down-Regulation, Kidney, Kidney Diseases, MAP Kinase Signaling System, Male, Neoplasms, Oxidative Stress, Rats, Thrombin, Tumor Suppressor Protein p53"
34193755,the optimal combined chemotherapy regimen with rituximab ha yet to be established for elderly patient with advancedstage indolent bcell lymphoma bnhl a multicenter study wa performed to evaluate the efficacy and toxicity of rthpcop therapy in elderly patient aged year with newly diagnosed advancedstage indolent bnhl using the complete response rate cr a the primary endpoint patient with newly diagnosed clinical stage iiiiv indolent bnhl aged year with a performance status of were eligible for this study rthpcop consists of 375 mgm2 of rituximab 50 mgm2 of pirarubicin 750 mgm2 of cyclophosphamide mgm2 of vincristine and 100 mgday of oral prednisolone for 5 day this study wa discontinued due to poor accrual after the enrollment of 18 patient although the planned sample size wa 40 patient the number of patient with follicular lymphoma mucosaassociated lymphoid tissue lymphoma and mantle cell lymphoma were and respectively the median age wa 73 range 70 to 79 year the cr including unconfirmed cr wa 45 95 confidence interval and the overall response rate wa 72 the estimated year overall survival and progressionfree survival rate were 55 and 28 respectively the major toxicity observed wa grade 4 neutropenia 94 grade 4 nonhematological toxicity were not observed and no patient developed grade cardiac toxicity this phase ii study provides useful information regarding the efficacy and toxicity of rthpcop therapy for patient aged 70 year or older with newly diagnosed advancedstage indolent bnhl although the sample size wa small,"Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Humans, Lymphoma, B-Cell, Male, Neoplasm Grading, Neoplasm Staging, Prednisolone, Rituximab, Treatment Outcome, Vincristine"
34191515,chimeric antigen receptor t cell therapy ha demonstrated antileukemia efficacy however this therapeutic approach is hampered by severe cytokine release syndrome which is a major impediment to it widespread application in the clinic the safety of this approach can be improved by engineering a rapid and reversible off or on safety switch for cart cell cuttingedge investigation combining the advantage of genetic engineering and chemical technology have led to the invention of smallmoleculebased safety switch for cart cell small molecule such a fitc folate rimiducid rapamycin proteolysistargeting chimera protac compound and dasatinib are being investigated to design such safety switch optimized cart cell may have enhanced therapeutic efficiency with fewer adverse effect herein we summarize and classify current novel smallmoleculebased safety switch for cart cell that aim to provide pharmacological control over the activity and toxicity associated with cart cellbased cancer immunotherapy,"Antineoplastic Agents, Humans, Immunotherapy, Adoptive, Leukemia, Molecular Structure, Small Molecule Libraries"
34191128,a theoretical pharmacokinetic interaction mediated through lamino acid transporter 1 and 2 exists between gabapentin gp and pregabalin pg with melphalan peripheral neuropathy is a common toxicity of various multiple myeloma regimen commonly utilized prior to autologous hematopoietic cell transplant autohct with highdose melphalan hdmel therefore it is likely concurrent administration of either gp or pg will occur in patient receiving hdmel conditioning for autohct which could potentially increase cellular uptake and worsen the mucosal injury a retrospective chart review of adult patient from january 2012 to july 2016 who received hdmel mgm2 at west virginia university medicine wa performed to as toxicity and outcome in these patient a total of 80 patient were included in the study with 30 patient receiving gp or pg and 50 control patient there were no significant difference in grade 2 or higher mucositis admission for nauseavomitingdiarrhea intravenous opioid requirement oral topical therapy antidiarrheal medication use rescue antiemetic day of nausea or vomiting pain score neutrophil or platelet engraftment treatmentrelated mortality progressionfree survival or overall survival our data suggest that it is safe to continue gppg therapy throughout hdmel therapy with no negative transplant outcome prospective study or evaluation of larger database are necessary to better characterize the clinical effect of concomitant therapy,"Gabapentin, Hematopoietic Stem Cell Transplantation, Humans, Melphalan, Multiple Myeloma, Pregabalin, Prospective Studies, Retrospective Studies, Transplant Recipients, Transplantation Conditioning, Transplantation, Autologous"
34190370,the combination of lenvatinib plus pembrolizumab ha shown efficacy in treatment of advanced endometrial carcinoma that is not microsatellite instabilityhigh or mismatch repair deficient following prior systemic therapy in any setting in the openlabel singlearm phase ibii study keynote with the exception of hypothyroidism the safety profile of the combination wa comparable to that of each monotherapy given the medical complexity and fragility of patient with endometrial carcinoma further characterization of adverse reaction ar associated with treatment will help health care professional to optimize treatment with lenvatinib plus pembrolizumab combination therapy in study keynote patient received lenvatinib at a starting dose of 20 mg orally once daily and pembrolizumab 200 mg intravenously every 3 week selected ar hypertension fatigue nauseavomiting diarrhea decreased appetiteweight loss hypothyroidism palmarplantar erythrodysesthesia syndrome musculoskeletal pain stomatitis and proteinuria were chosen for detailed post hoc analysis median time to first onset of the selected ar in this analysis all occurred within the first 10 week of treatment of the selected ar grade 3 severity of fatigue hypertension and nausea occurred in 5 of patient overall incidence of hypothyroidism wa 51 primarily of grade 2 severity 46 most of the ar assessed were managed with a combination of study drug dose modification and concomitant medication no new safety signal were identified and the toxicity profile in this study wa manageable with supportive medication dose interruption andor lenvatinib dose reduction this analysis provides ar management guidance for patient with endometrial cancer receiving lenvatinib plus pembrolizumab combination therapy lenvatinib plus pembrolizumab ha shown efficacy in the treatment of patient with advanced endometrial carcinoma that is not microsatellite instabilityhigh or mismatch repair deficient following at least one prior systemic therapy in any setting patient may experience toxicity associated with this combination including adverse reaction of hypertension fatigue nauseavomiting diarrhea decreased appetiteweight loss hypothyroidism palmarplantar erythrodysesthesia syndrome musculoskeletal pain stomatitis and proteinuria these adverse reaction may be managed with a combination of concomitant supportive care medication and judicious lenvatinib dose modification this article provides context and guidance for the recognition and management of adverse reaction in patient receiving lenvatinib plus pembrolizumab,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Female, Humans, Phenylurea Compounds, Quinolines"
34189948,the covid19 pandemic ha lasted over 1 year and will not disappear in a short time there is no specific remedy against the virus a yet vaccination is thus far one of the most important strategy for preventing covid cancer patient with covid19 have a higher mortality because of immunosuppression immune checkpoint inhibitor icis are a novel anticancer strategy for blocking inhibitory pathway which are related to the immune response there is a question regarding whether covid19 vaccination and ici treatment impact each other in cancer patient this review explores both side of the relationship between ici treatment and covid19 vaccination and suggests good efficacy and safety of ici treatment after covid19 vaccination a well a little impact on the virus protection and toxicity associated with covid19 vaccination during ici treatment lay abstract the covid19 pandemic ha lasted over 1 year vaccination is a promising strategy for preventing covid cancer patient are prone to infection with covid and these patient have high mortality immune checkpoint inhibitor icis are a novel anticancer strategy whether covid19 vaccination and ici treatment impact each other in cancer patient remains unknown this review explores both side of the relationship between ici treatment and covid19 vaccination and suggests good efficacy and safety of ici treatment after covid19 vaccination a well a little impact on the virus protection and toxicity associated with covid19 vaccination during ici treatment,"COVID-19, COVID-19 Vaccines, Clinical Decision-Making, Contraindications, Drug, Humans, Immune Checkpoint Inhibitors, Immunogenicity, Vaccine, Neoplasms, Pandemics, Patient Selection, SARS-CoV-2, Treatment Outcome"
34189636,advanced relapsed ovarian cancer ha a poor prognosis and treatment option are limited this phase i trial investigated the dosage safety pharmacokinetics and efficacy of trabectedin plus pegylated liposomal doxorubicin pld in japanese patient with advanced relapsed ovarian fallopian tube or primary peritoneal cancer patient received trabectedin or mgm2 immediately after pld 30 mgm2 both drug were given by intravenous infusion treatment wa repeated every 21 day until disease progression or unacceptable toxicity the maximum tolerated dose mtd wa determined in an initial dose escalation phase and this wa used in a subsequent safety assessment phase safety and tumor response were monitored throughout the trial and drug concentration for pharmacokinetic analysis were measured during cycle eighteen patient were included the mtd of trabectedin wa determined a mgm gastrointestinal adverse event were experienced by all patient but were mostly grade 1 or 2 in intensity most patient had grade 3 elevation in transaminase level or grade 3 reduction in neutrophil count but these event were generally manageable through dose reduction andor supportive therapy a appropriate there were no death during the trial trabectedin exposure increased in a dosedependent manner the overall response rate wa trabectedin in combination with pld may have clinical benefit in japanese patient with relapsed advanced ovarian cancer the recommended dosage of trabectedin for further study in this population is mgm2 once every 21 day japiccti,"Antineoplastic Combined Chemotherapy Protocols, Doxorubicin, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Polyethylene Glycols, Trabectedin"
34187853,radium223 is an alphaemitting radionuclide associated with overall survival o improvement in metastatic castrationresistant prostate cancer mcrpc external beam radiotherapy ebrt to prostate extends o in men with metastatic hormonesensitive prostate cancer mhspc limited to le than 4 metastasis we hypothesized that combination radium223 pelvic ebrt could safely deliver maximal radiotherapy do to primary and metastatic prostate cancer and may improve disease control thirty patient with de novo bone metastatic mhspc who had commenced androgen deprivation therapy adt and docetaxel were recruited to this singlearm openlabel prospective clinical trial neoadjuvant androgen deprivation therapy pelvic radiotherapy and radium223 adrrad for new presentation t n m1b adenocarcinoma of prostate study treatment were adt 6 cycle of radium223 q28 day conventionally fractionated prostate radiotherapy 74 gy and simultaneous integrated boost to pelvic lymph node 60 gy no grade toxicity wa observed three patient experienced grade 3 leukopenia and 1 each experienced grade 3 neutropenia and thrombocytopenia all were asymptomatic one patient each experienced grade 3 dysuria and grade 3 urinary infection no grade 3 gastrointestinal gi toxicity wa observed on treatment completion there wa a signal of efficacy 24 80 patient had wholebody mri evidence of tumor response or stability twentyseven 90 patient showed a reduction in alkaline phosphatase alp compared with pretreatment level median progressionfree survival wa month this is the first trial of combination adt radium and ebrt to pelvis post docetaxel the combination wa safe with an efficacy signal multicenter randomized controlled trial rct are warranted,"Aged, Aged, 80 and over, Androgen Antagonists, Antineoplastic Agents, Combined Modality Therapy, Docetaxel, Humans, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Prostatic Neoplasms, Radium, Treatment Outcome"
34187825,the cancer aging research group carg toxicity score is used to as toxicity risk in geriatric patient receiving chemotherapy the primary aim wa to validate the carg score in geriatric patient treated with curative intent chemotherapy in predicting grade toxicity this wa a longitudinal prospective observational study tata memorial hospital mumbai india a tertiary cancer care referral centre patient aged 65 year with gastrointestinal breast or gynaecological stage iiii cancer being planned for curative intent chemotherapy a total of 270 patient were required for accrual in the study total risk score ranged from 0 lowest toxicity risk to 19 highest toxicity risk the primary endpoint of the study wa to evaluate whether the carg risk score predicted for grade toxicity the study cohort of 270 patient had a mean age of 69 year with the most common cancer being gastrointestinal 79 fiftytwo per cent of patient had atleast one grade toxicity the risk of toxicity wa increased with an increasing risk score 42 low risk 51 medium risk and 79 high risk p there wa no association between either eastern cooperative oncology group ecog performance status p or ageadjusted charlson comorbidity index p risk category and grade chemotherapy toxicity this study validates the carg risk score in predicting for grade toxicity in geriatric oncology patient receiving curative intent chemotherapy and can be considered a the standard of care before planning chemotherapy in every elderly patient ctri007357 result,"Aged, Aged, 80 and over, Aging, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, India, Neoplasms, Prospective Studies, Risk Assessment"
34186494,bevacizumab wa shown to be effective in the treatment of brain radiation necrosis rn attributed to the use of stereotactic radiosurgery sr data on it efficacy and safety in nonsmall cell lung cancer nsclc patient treated with immune checkpoint inhibitor ici is lacking a multicenter retrospective analysis of all consecutive patient with nsclc treated with ici who received bevacizumab for postsrs rn between april 2017 and june improvement in rnassociated symptom rn radiological improvement and decrease in corticosteroid dose following bevacizumab initiation were assessed thirteen patient were identified the median time from diagnosis of rn to initiation of bevacizumab wa 3 month range month and the median number of bevacizumab cycle before assessment wa 2 range patient continued ici during treatment with bevacizumab improvement in rnassociated symptom wa observed in 11 patient 85 in ten patient 77 the daily dose of dexamethasone wa decreased radiological improvement of rn occurred in all 11 case available for radiological assessment 100 treatment wa withheld in two patient for grade toxicity at a median follow up of month range month one patient experienced a recurrent episode of rn the estimated median survival since rn diagnosis wa month 95 ci month treatment with bevacizumab appears to be safe and effective for the treatment of srsinduced rn in patient with nsclc treated with ici this is the first series to report on the use of bevacizumab in this clinical scenario,"Bevacizumab, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Necrosis, Radiosurgery, Retrospective Studies"
34186441,in the last decade immunotherapy and target therapy have revolutionized the prognosis of patient with brafv600 mutationpositive metastatic melanoma to date three different combination of brafmek inhibitor have been approved for this population showing comparable efficacy and unique toxicity profile several immunecheckpoint inhibitor including pembrolizumab nivolumab and the combination of nivolumab plus ipilimumab are also available option for untreated metastatic melanoma patient a novel approach ha emerged by combining immunecheckpoint inhibitor and targeted agent based on preclinical hint of synergy prompting clinical result from large randomized trial specifically the triplet of atezolizumab vemurafenib and cobimetinib ha been recently approved by fda for patient with untreated brafmutant metastatic melanoma with a wide variety of available treatment option in this setting it is paramount to establish criterion to select the most effective and safe frontline tailored approach for each patient result from ongoing study are awaited to maximise the benefit in survival outcome and quality of life for patient balancing adverse event and clinical benefit the purpose of this review is to summarize the current landscape of standard and experimental treatment strategy for the first line treatment of patient with brafmutated advanced melanoma and discus the best patientcentered tailored strategy in the firstline setting,"Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase III as Topic, Humans, Immune Checkpoint Inhibitors, MAP Kinase Signaling System, Melanoma, Molecular Targeted Therapy, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Randomized Controlled Trials as Topic, Skin Neoplasms, Treatment Outcome"
34186049,colorectal cancer crc with high metastasis rate ha been known a a major cause of death worldwide lack of the specificity and insufficient concentration of traditional chemotherapeutics at tumor site and their severe adverse effect necessitate development of new treatment strategy such a designing suitable nanocarriers for delivery of drug improving their pharmacological profile and reducing adverse effect we have developed a platform based on the polyursolic acid polyua a polymeric system with potential anticancer effect following the selfassembly of polyua into the nanoparticles np they were applied for delivery of mithramycin a mitha a promising candidate for crc therapy however with some limitation such a rapid clearance and serious side effect mithaloaded polyua np with suitable physicochemical property and efficient drug entrapment released mitha in a controlled manner and provided suitable toxicity against the ct26 colorectal cancer cell increased accumulation in tumor and protection against the detrimental feature of the disease polyua np demonstrated therapeutic efficiency in vivo and in vitro by themselves the prepared np induced no remarkable alteration of body weight or damage to the major organ in animal bearing tumor indicating the safety of np the bioactive nanoformulation along with improving the pharmacological profile of mitha could provide a synergistic toxicity against the crc,"Animals, Antineoplastic Agents, Cell Line, Colorectal Neoplasms, Drug Compounding, Humans, Male, Mice, Mice, Inbred BALB C"
34184418,previous study have demonstrated the preclinical pharmacological and toxicological consistency and clinical pharmacokinetic equivalence of bevacizumab biosimilar ly01008 with reference bevacizumab avastin this randomized controlled trial aimed to compare the efficacy and safety of ly01008 with avastin in firstline treatment of chinese patient with advanced or recurrent nonsquamous nonsmall cell lung cancer nsclc stage iiibiv nsclc patient with evaluable lesion good physical status and adequate organ function from 67 center across china were randomized in a ratio of 11 to receive ly01008 or avastin 15 mgkg intravenously in combination with paclitaxelcarboplatin combined treatment for cycle followed by maintenance monotherapy with ly01008 until disease progression intolerable toxicity or death the primary endpoint wa objective response rate orr in accordance with response evaluation criterion in solid tumor recist version confirmed by independent radiological review committee irrc secondary endpoint included disease control rate dcr duration of response dor progressionfree survival pfs overall survival o and safety this study wa registered in clinicaltrialsgov nct03533127 between december 15th and may 15th a total of 649 patient were randomized to the ly01008 n 324 or avastin n 325 group a of september 25th 2019 for primary endpoint analysis 589 patient received orr evaluation with a median number of combined treatment cycle of 5 range and median duration of treatment of range month orr of responseevaluable patient in the ly01008 and avastin group were and respectively the stratified orr ratio wa 90 ci within the prespecified equivalence margin of up to may 15th with a median followup of range month no notable difference in dcr median dor median pfs median o and year o rate were observed between the ly01008 and avastin group there were no clinically meaningful difference in safety and immunogenicity across treatment group ly01008 demonstrated similarity to avastin in term of efficacy and safety in chinese patient with advanced or recurrent nonsquamous nsclc ly01008 combined with paclitaxelcarboplatin is expected to become a new treatment option for unresectable metastatic or recurrent nonsquamous nsclc patient in the firstline setting,"Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Biosimilar Pharmaceuticals, Carcinoma, Non-Small-Cell Lung, China, Humans, Lung Neoplasms, Treatment Outcome"
34183522,the standard of care for resectable gastric cancer gc includes perioperative chemotherapy ct or postoperative chemochemoradiotherapy crt strategy poor treatment compliance postsurgery suggests that intensified surgical adjuvant treatment is more likely deliverable preceding surgery and therefore the safety and efficacy of perioperative cisplatincapecitabine cx with preoperative chemoradiation preopcrt were ascertained between january 2017 and december 28 potentially resectable locally advanced gc patient were offered neoadjuvant ct2 cycle of cx at weekly interval followed by preopcrt 45 gy25 fractions5 week and concurrent capecitabine followed by surgical resection and 3 adjuvant cycle of cx neoadjuvant ct wa commenced in 28 patient 100 preopcrt in 18 patient 64 and surgery performed in 13 patient 46 at each treatment step decreasing patient number were due mainly to disease progression 12 43 or other reason including 3 11 from treatmentrelated toxicity the r0 resection rate wa 92 a median of 18 node wa obtained after d2 nodal clearance in 92 there were 2044 grade 5 toxicity the median radiotherapy doseduration wa 45 gy week adjuvant ct wa started in 11 patient 39 and the third cycle wa received by 7 patient 25 no tumor ypt0n0 wa noted in 23 of the operated patient or 11 of the intentiontotreat population the median year and year survival were 12 month 53 and 32 respectively intensified preoperative treatment is doable in relatively unselected advanced gc patient in realworld setting of a publicsector hospital from a lowmiddleincome country disease progression during preoperative therapy allows patient destined for early clinical evidence of disease dissemination to avoid futile surgery a opposed to a surgeryfirst strategy without an overt increase in surgical morbidity or mortality with encouraging r0 resection rate,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Chemoradiotherapy, Cisplatin, Female, Gastrectomy, Humans, Male, Middle Aged, Pilot Projects, Preoperative Care, Prospective Studies, Radiotherapy Dosage, Stomach Neoplasms, Treatment Outcome, Young Adult"
34182493,highdose methotrexate is a therapy for acute leukemia malignant lymphoma and osteosarcoma glycyrrhizin ha been used to treat hepatic dysfunction caused by highdose methotrexate however few study have investigated the interaction between glycyrrhizin and highdose methotrexate male wistar rat were treated with highdose methotrexate 500 or mgkg alone or with coadministration of 100 mgkg glycyrrhizin plasma concentration of methotrexate alanine aminotransferase aspartate aminotransferase and total bilirubin were measured at both methotrexate do the blood concentration of methotrexate wa significantly increased and total clearance wa significantly reduced using coadministration of glycyrrhizin compared with methotrexate alone which led to increased level of hepatic enzyme these result suggest that glycyrrhizin significantly increase the plasma level and delay the clearance of methotrexate resulting in hepatic toxicity the concomitant use of methotrexate and glycyrrhizin should be considered with caution,"Animals, Bone Neoplasms, Glycyrrhizic Acid, Male, Methotrexate, Osteosarcoma, Rats, Rats, Wistar"
34181276,pemetrexed is an important component of first line treatment in patient with nonsquamous nonsmall cell lung cancer however a limitation is the contraindication in patient with renal impairment due to hematological toxicity currently it is unknown how to safely dose pemetrexed in these patient the aim of our study wa to elucidate the relationship between pemetrexed exposure and toxicity to support the development of a safe dosing regimen in patient with renal impairment a population pharmacokineticpharmacodynamic analysis wa performed based on phase ii study result in three patient with renal dysfunction supplemented with data from 106 patient in early clinical study finding were externally validated with data of different pemetrexed dosing regimen alternative dosing regimen were evaluated using the developed model we found that pemetrexed toxicity wa driven by the time above a toxicity threshold concentration the threshold for vitaminsupplemented patient wa mgml 95 ci mgml it wa observed that in patient with renal impairment estimated glomerular filtration rate egfr 45 mlmin the approved dose of 500 mgm2 would yield a high probability of severe neutropenia in the range of to a pemetrexed dose of 20 mg for patient egfr 20 mlmin is shown to be neutropenicequivalent to the approved dose in patient with adequate renal function egfr 90 mlmin but would result in an approximately fold lower area under the concentrationtime curve the pemetrexed exposuretoxicity relationship is explained by a toxicity threshold and substantially different from previously thought without prophylaxis for toxicity it is unlikely that a therapeutic dose can be safely administered to patient with renal impairment,"Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Dietary Supplements, Dose-Response Relationship, Drug, Female, Folic Acid Antagonists, Follow-Up Studies, Humans, Kidney Failure, Chronic, Lung Neoplasms, Male, Middle Aged, Neutropenia, Pemetrexed, Prognosis, Tissue Distribution"
34180037,aim the oral mdm2 antagonist idasanutlin inhibits the pmdm2 interaction enabling p53 activation tumor growth inhibition and increased survival in xenograft model method we conducted a phase i study of idasanutlin microprecipitate bulk powder formulation to determine the maximum tolerated dose mtd safety pharmacokinetics pharmacodynamics food effect and clinical activity in patient with advanced malignancy schedule investigated were once weekly for 3 week qw 3 once daily for 3 day qd 3 or qd 5 every 28 day we also analyzed p53 activation and the antiproliferative effect of idasanutlin result the doseescalation phase included 85 patient qw n 36 qd n 15 qd n 34 daily mtd wa 3200 mg qw 3 1000 mg qd 3 and 500 mg qd 5 most common adverse event were diarrhea nauseavomiting decreased appetite and thrombocytopenia doselimiting toxicity were nauseavomiting and myelosuppression myelosuppression wa more frequent with qd dosing and associated with pharmacokinetic exposure idasanutlin exposure wa approximately dose proportional at low do but le than dose proportional at 600 mg although interpatient variability in exposure wa high with all regimen cumulative idasanutlin exposure over the whole day cycle wa greatest with a qd 5 regimen no major food effect on pharmacokinetic exposure occurred mic1 level were higher with qd dosing increasing in an exposuredependent manner best response wa stable disease in of patient prolonged 600 day in 2 patient with sarcoma conclusion idasanutlin demonstrated dose and scheduledependent p53 activation with durable disease stabilization in some patient based on these finding the qd 5 schedule wa selected for further development trial registration nct01462175 clinicaltrialsgov october,"Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Proto-Oncogene Proteins c-mdm2, Pyrrolidines, para-Aminobenzoates"
34180036,the vascular endothelial growth factor vegfvegfr and hepatocyte growth factor hgfcmet signaling pathway act synergistically to promote angiogenesis study indicate vegf inhibition lead to increased level of phosphorylated cmet bypassing vegfmediated angiogenesis and leading to chemoresistance we conducted a phase 1 clinical trial with 32 patient with refractory solid tumor to evaluate the safety pharmacokinetics and pharmacodynamics of combination of vegftargeting pazopanib and the putative cmet inhibitor arq197 tivantinib at 5 dose level dl patient either took pazopanib and tivantinib from treatment initiation escalation phase or pazopanib alone for 7 day with paired tumor sampling prior to starting combination treatment expansion phase hypertension wa the most common adverse event no more than 1 dose limiting toxicity dlt occurred at any dl so the maximum tolerated dose mtd wa not determined dl5 800 mg pazopanib daily and 360 mg tivantinib bid wa used during the expansion phase twenty of 31 evaluable patient achieved stable disease lasting up to 22 cycle circulating vegf vegfr hgf and cmet level were assessed and only vegf level increased tumor cmet level total and phosphorylated were determined in paired biopsy before and after 7 day of pazopanib treatment total intact cmet decreased in 6 of 7 biopsy pair in contrast to previously reported cmet elevation in response to vegf inhibition these result are discussed in the context of our previously reported analysis of epithelialmesenchymal transition in these tumor,"Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Area Under Curve, Dose-Response Relationship, Drug, Drug Administration Schedule, Hepatocyte Growth Factor, Humans, Indazoles, Maximum Tolerated Dose, Middle Aged, Neoplasms, Proto-Oncogene Proteins c-met, Pyrimidines, Pyrrolidinones, Quinolines, Sulfonamides, Vascular Endothelial Growth Factor A"
34176818,adrenocortical carcinoma acc is a rare malignancy with a poor prognosis while mitotane is the only agent approved for acc clinical data are scarce especially in the asian population we reviewed 10 patient with acc who received mitotane a a single agent or in combination with other agent in our institution patient characteristic clinical outcome and toxicity were analyzed mitotane wa administered to 2 patient a an adjuvant therapy and to 8 patient for systemic control in the latter 8 patient 1 patient had locally advanced disease and 1 had metastatic disease at the time of initial diagnosis whereas the other 6 patient experienced metastatic relapse at mitotane initiation the administered regimen wa mitotane alone in 7 patient and mitotane plus cytotoxic chemotherapy in 3 patient the initial daily mitotane dose wa g in 2 patient g in 7 patient and g in 1 patient the median duration of treatment wa range month in 8 systemic case the median overall survival from chemotherapy initiation wa month and only 1 patient survived over 1 year the median interval from mitotane termination to death in systemic case wa month and the cause wa progressive disease in 4 patient and toxicity hallucination mycobacteriosis or liver injury in 3 patient a a secondline regimen 2 systemic case and 1 adjuvant case were enrolled in clinical trial our analysis exhibited extremely poor prognosis under mitotanebased regimen and further treatment strategy are warranted to improve outcome,"Adrenal Cortex Neoplasms, Adrenocortical Carcinoma, Antineoplastic Agents, Hormonal, Humans, Japan, Mitotane, Neoplasm Recurrence, Local"
34176449,kavain kavalactone present in piper methysticum exhibit anticonvulsive analgesic anxiolytic antiepileptic antithrombotic antiinflammatory and antioxidant property given it importance the aim of the present study wa to as 1 the mutagenic and carcinogenicity of kavain administered alone and 2 the antimutagenic and anticarcinogenic potential when administered simultaneously with the chemotherapeutic drug doxorubicin dxr using the somatic mutation and recombination test smart and epithelial tumor test ett using drosophila melanogaster a a model system thirdstage larva from a standard st and high metabolic bioactivation hb cross were treated with different kavain concentration 64 or 128 gml alone or in conjunction with dxr mgml in st descendant kavain produced no significant mutagenic or recombinogenic effect in the hb cross mutagenic activity wa observed at kavain concentration of 64 and 128 gml in the dxr and kavain cotreatment a modulating effect of the dxrmediated mutagenic response dependent upon the concentration wa detected in both cross in ett no marked carcinogenic or anticarcinogenic activity wa noted for kavain however when kavain wa combined with dxr synergistic induction of tumor by the chemotherapeutic drug occurred indicating that kavain enhanced the carcinogenic action of dxr,"Animals, Carcinogenesis, Carcinogens, Doxorubicin, Drosophila melanogaster, Larva, Mutagenicity Tests, Mutagens, Protective Agents, Pyrones"
34176192,patient with metastatic triplenegative breast cancer have a poor prognosis sacituzumab govitecan immu132 is an antibodydrug conjugate that contains the irinotecan active metabolite sn linked to a humanized monoclonal antibody targeting trophoblast cell surface antigen which is overexpressed in many solid tumor in a basket design phase iii study sacituzumab govitecan demonstrated promising singleagent therapeutic activity in multiple cancer cohort leading to accelerated approval by the u food and drug administration of sacituzumab govitecanhziy trodelvy for the treatment of patient with metastatic triplenegative breast cancer who had received at least two prior therapy in the metastatic setting recently result of the phase iii trial ascent were confirmatory there is limited available information on the adverse event management with sacituzumab govitecan needed to maximize the dose and duration of effective therapy while maintaining patient quality of life this review summarizes the clinical development and the practical management of patient receiving sacituzumab govitecan sacituzumab govitecan ha a welldefined and manageable toxicity profile and rapid recognition and appropriate early and proactive management will allow clinician to optimize sacituzumab govitecan treatment for patient implication for practice sacituzumab govitecan trodelvy is a novel antibodydrug conjugate composed of the active metabolite of irinotecan sn38 conjugated to a monoclonal antibody targeting trophoblast cell surface antigen an epithelial cell surface antigen overexpressed in many cancer because of the rapid approval of sacituzumab govitecan there is limited available information on adverse event ae management with this agent a such this article review the clinical development of the drug the ae profile and provides recommendation regarding ae management to help optimize therapy with sacituzumab govitecan,"Antibodies, Monoclonal, Humanized, Camptothecin, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Humans, Immunoconjugates, Quality of Life, Triple Negative Breast Neoplasms"
34176021,clinical guideline recommend altering chemotherapy treatment by decreasing delaying or discontinuing dosing in patient who are experiencing chemotherapyinduced peripheral neuropathy there are few data available on the clinical use of treatment alteration including the severity of cipn at the time of treatment alteration this wa a retrospective analysis of patient receiving oxaliplatin on the ncctg n08cb trial neuropathy severity wa assessed at each cycle by clinician and patient patient were classified a 1 completed treatment without alteration 2 dose reduction or delay due to neuropathy 3 discontinuation due to neuropathy 4 discontinuation for other toxicity or 5 discontinuation for another reason 5 comparison focused primarily on patient with alteration due to neuropathy group 2 andor 3 compared with patient who completed treatment without alteration group 1 in 350 participant 135 39 completed treatment without alteration 70 20 had a dose reduction or delay due to neuropathy and 35 10 discontinued early due to neuropathy clinicianassessed neuropathy severity wa greater in patient at the time of dose reduction or delay compared with severity at the end of treatment in patient without alteration p patientreported neuropathy severity at cycle 4 wa worse in patient who eventually had a reduction or delay a compared with patient who completed treatment without alteration p treatment alteration due to neuropathy are common in patient receiving oxaliplatin for colon cancer and are associated with clinicianassessed neuropathy severity rapid increase in patientreported neuropathy severity indicate a potential need for monitoring and intervention clinicaltrialsgov identifier nct01099449 ncctg n08cb,"Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Oxaliplatin, Peripheral Nervous System Diseases, Randomized Controlled Trials as Topic, Retrospective Studies"
34176014,the aim of this study wa to prospectively compare the mifap protocol which had been shown to be effective in patient with relapsed and refractory hodgkin lymphoma hl or aggressive nonhodgkins lymphoma nhl to an established regimen like dexabeam seventythree adult patient with hl n 25 or aggressive nhl n 48 suffering from relapse or refractory disease were randomly allocated to receive two cycle of dexabeam dexamethasone carmustine etoposide cytarabine melphalan n 37 or mifap mitoxantrone fludarabine cytarabine cisplatin n 36 prior to a consolidating highdose therapy and hematopoietic cell transplantation hct primary endpoint wa the overall response rate orr complete response cr and partial response pr after two course of salvage chemotherapy the orr wa 51 cr 38 and 53 cr 36 in the dexabeam arm and in the mifap arm both not significant respectively there wa a significantly higher grade toxicity after mifap compared to dexabeam thirtyfive patient were consolidated by autologous n 29 allogeneic n 1 or sequential autologousallogeneic n 5 hct no significant difference were found in progressionfree survival pfs and overall survival o between the dexabeam and the mifap arm compared to dexabeam mifap is associated with a higher toxicity and doe not improve the outcome of patient with recurrent hl or aggressive nhl for those patient innovative treatment concept like recently developed immunotherapy are necessary eudract number 7 april retrospectively registered,"Adult, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cytarabine, Dexamethasone, Etoposide, Follow-Up Studies, Hodgkin Disease, Humans, Lymphoma, Lymphoma, Non-Hodgkin, Melphalan, Neoplasm Recurrence, Local, Prospective Studies, Salvage Therapy"
34175369,diffuse large bcell lymphoma dlbcl is the most common lymphoma representing approximately one third of all nonhodgkin lymphoma and about 40 of patient do not benefit of the standard firstline immunechemotherapeutic treatment ie rchop rituximab cyclophosphamide doxorubicin vincristine and prednisone that is administered a upfront therapy to substantially all patient independently from the stage of disease and other prognostic parameter the administration of other pharmacological treatment is in fact limited to selected patient unfitting for rchop although clinical prognostic score ie international prognostic index ipi and molecular classifier based on the cell of origin are available at present no biomarkers predictive of rchop response ha been identified and validated constitutional polymorphism of gene involved in the mechanism of action of drug included in rchop have been suggested by many author to play a role in the efficacy and in some case in the toxicity of this treatment thus it is conceivable that in the future after proper validation some polymorphism can be used a pharmacogenetic biomarkers of therapeutic outcome in this disease setting this review discus the status of the art on molecular biomarkers predictive of dlbcl prognosis and deal with the relevant issue of the variability in response to dlbcl drug treatment overall this review focus on single nucleotide polymorphism snp that based on a candidate gene approach or on a genomewide association study gwas analysis have been suggested to play a role in response to rchop in particular snp discovered by a candidate gene approach are related to gene involved in drug transport ie atpbinding cassette transporter drug metabolism drug detoxification enzyme oxidative stress apoptosis dna repair immunity and angiogenesis data from a gwas analysis performed in dlbcl patient treated with rchop identified two snp associated with clinical outcome related to gene involved in pivotal cellular process and in transcriptional regulation and cell cycle progression respectively ongoing prospective pharmacogenetic clinical trial including a gwas study we performed have also been discussed,"Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Genome-Wide Association Study, Humans, Lymphoma, Large B-Cell, Diffuse, Pharmacogenetics, Prednisone, Prognosis, Prospective Studies, Rituximab, Treatment Outcome, Vincristine"
34175226,the purpose of this study wa to as the efficacy in term of neck failure of an initial neck dissection before definitive chemoradiotherapy in n oropharyngeal squamous cell carcinoma a well a the dosimetric impact and the acute and delayed morbidity of this approach all patient consecutively treated between 2009 and 2018 with definitive chemoradiotherapy using intensitymodulated conformal radiotherapy imrt for a histologically proven n oropharyngeal squamous cell carcinoma were retrospectively included the therapeutic approach consisted of induction chemotherapy followed by cisplatinebased chemoradiotherapy preceded or not by neck dissection neck dissection wa discussed on a casebycase basis in a dedicated multidisciplinary tumour board for patient with a dissociated response to induction chemotherapy defined a a better response on the primary than on the node chemoradiotherapy without neck dissection wa systematically performed in case of a major lymph node response to induction chemotherapy decrease in size of 90 or more intensitymodulated radiotherapy using a simultaneousintegrated boost delivered 70gy in 35 fraction on macroscopic tumour volume 63gy on intermediaterisk level or extranodal extension and 54gy on prophylactic lymph node area two group were constituted 47 patient without an initial neck dissection and 28 patient with a neck dissection prior to definitive chemoradiotherapy initial patient characteristic were not statistically different between the two group the median followup wa month range 119months incidence of neck failure wa higher in patient without neck dissection p the neck failure rate at 5years wa 95 confidence interval p without neck dissection versus 0 following neck dissection all lymph node failure occurred in the planned target volume at 70gy upfront neck dissection suggested a decrease in the mean dose received by the homolateral parotid gland p mandible p and thyroid gland p acute toxicity of chemoradiotherapy after neck dissection suggested a reduction in grade3 adverse event p early discontinuation of concomitant chemotherapy p and feeding tubedependence p in univariate analysis during followup there wa no difference between the two group in term of xerostomia dysgeusia dysphagia or gastrostomy dependence in univariate analysis neck dissection prior to definitive chemoradiotherapy in n oropharyngeal squamous cell carcinoma wa associated with high neck control without additional mid and longterm morbidity,"Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Cisplatin, Combined Modality Therapy, Deglutition Disorders, Dose Fractionation, Radiation, Dysgeusia, Female, Follow-Up Studies, Humans, Induction Chemotherapy, Lymphatic Metastasis, Male, Mandible, Middle Aged, Neck Dissection, Organs at Risk, Oropharyngeal Neoplasms, Parotid Gland, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck, Thyroid Gland, Xerostomia"
34174986,the brutons tyrosine kinase inhibitor btkis ibrutinib and acalabrutinib have led to durable response for patient with both treatmentnave and relapsedrefractory chronic lymphocytic leukemia cll many patient however ultimately discontinue btkis due to toxicity or progressive cll this article review the two most common reason for ibrutinib and acalabrutinib discontinuation including adverse event a well a cll progression the data for specific clldirected therapy following btki discontinuation including venetoclax phosphatidylinositol kinase inhibitor cellular therapy and ongoing clinical trial are reviewed an evidencebased sequencing algorithm for treatment of cll following btki discontinuation is proposed,"Adenine, Agammaglobulinaemia Tyrosine Kinase, Antineoplastic Agents, Benzamides, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Phosphoinositide-3 Kinase Inhibitors, Piperidines, Protein Kinase Inhibitors, Pyrazines, Pyrazoles, Pyrimidines, Sulfonamides"
34172583,costimulation via cd137 bb enhances antitumor immunity mediated by cytotoxic t lymphocyte anticd137 agonist antibody elicit mild liver inflammation in mouse and the maximum tolerated dose of urelumab an antihuman cd137 agonist monoclonal antibody in the clinic wa defined by liver inflammationrelated side effect a proteaseactivated prodrug form of the antimouse cd137 agonist antibody 1d8 1d8 probody therapeutic pbtx wa constructed and found to be selectively activated in the tumor microenvironment this construct which encompasses a proteasecleavable linker holding in place a peptide that mask the antigen binding site exerted antitumor effect comparable to the unmodified antibody but did not result in liver inflammation moreover it efficaciously synergized with both pd1 blockade and adoptive tcell therapy surprisingly minimal active pbtx reached tumordraining lymph node and regional lymphadenectomy did not abrogate antitumor efficacy by contrast s1p receptordependent recirculation of t cell wa absolutely required for efficacy the preferential cleavage of the anticd137 pbtx by tumor protease offer multiple therapeutic opportunity including neoadjuvant therapy a shown by experiment in which the pbtx is given prior to surgery to avoid spontaneous metastasis,"Animals, Antibodies, Monoclonal, Antineoplastic Agents, Cell Line, Tumor, Humans, Immunotherapy, Inflammation, Liver, Lung Neoplasms, Lymph Nodes, Mice, Neoadjuvant Therapy, Peptide Hydrolases, Tumor Necrosis Factor Receptor Superfamily, Member 9"
34172516,immune checkpoint inhibitor icis are the standard of care for the treatment of several cancer while these immunotherapy have improved patient outcome in many clinical setting they bring accompanying risk of toxicity specifically immunerelated adverse event iraes there is a need for clear effective guideline for the management of iraes during ici treatment motivating the society for immunotherapy of cancer sitc to convene an expert panel to develop a clinical practice guideline the panel discussed the recognition and management of single and combination ici iraes and ultimately developed evidence and consensusbased recommendation to assist medical professional in clinical decisionmaking and to improve outcome for patient,"Guidelines as Topic, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms, Societies, Medical"
34171733,despite multimodality treatment for curativelytreated gastroesophageal adenocarcinoma gea prognosis remains dismal the benefit of adding trastuzumab to chemotherapy for advanced human epidermal growth factor 2 her2 positive gea ha been established in the toga trial however it remains unclear if her2 inhibition might also be beneficial in the curative setting therefore we conducted a systematic review to investigate the role of her2 inhibitor for the curative treatment of gea a systematic literature search wa performed in pubmed embase central and clinicaltrialsgov to identify clinical trial investigating her2 inhibition for the curative treatment of gea study quality wa assessed using the grade methodology from the 1825 study retrieved 17 were included seven published article three published conference abstract seven ongoing study from the published study eight study investigated singleagent her2 inhibition four study had a nonrandomized design and two were randomized controlled trial two published study were assessed a highquality the addition of singleagent her2 inhibition to chemoradiotherapy showed a pathological complete response rate pcr of range 25 and dual her2 inhibition of twoyear diseasefree survival dfs wa with singleagent and with dual her2 therapy dualagent her2 inhibition showed promising pcr rate and dfs given the limited additional toxicity of the addition of her2 targeting agent and the potential benefit of dualtargeting further investigation is required in a phase iii randomized clinical trial next step include combining checkpoint inhibitor and her2 blockade given the suggested synergism a well a investigating new antiher2 agent,"Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Esophageal Neoplasms, Humans, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, Receptor, ErbB-2, Stomach Neoplasms, Trastuzumab"
34171282,year overall survival rate have surpassed 90 for childhood acute lymphocytic leukaemia but survivor are at risk for permanent health sequela although eventfree survival appropriately represents the outcome for cancer with poor overall survival this metric is inadequate when cure rate are high but challenged by serious persistent complication accordingly a group of expert in paediatric haematologyoncology representative of 17 international acute lymphocytic leukaemia study group launched an initiative to construct a measure designated severe toxicityfree survival stfs to quantify the occurrence of physicianprioritised toxicity to be integrated with standard cancer outcome reporting five generic inclusion criterion not present before cancer diagnosis symptomatic objectifiable of unacceptable severity permanent or requiring unacceptable treatment were used to as 855 health condition which resulted in inclusion of 21 severe toxicity consensus definition were reached through a modified delphi process supplemented by two additional plenary meeting the 21 severe toxicity include severe adverse health condition that substantially affect activity of daily living and are refractory to therapy eg refractory seizure are without therapeutic option eg blindness or require substantially invasive treatment eg cardiac transplantation incorporation of stfs assessment into clinical trial ha the potential to improve and diversify treatment strategy focusing not only on traditional outcome event and overall survival but also the frequency of the most severe toxicity the two major aim of this review were to prioritise and define unacceptable longterm toxicity for patient with childhood acute lymphocytic leukaemia and define how these toxicity should be combined into a composite quantity to be integrated with other reported outcome although stfs quantifies the clinically unacceptable health tradeoff for cure using childhood acute lymphocytic leukaemia a a model disease the prioritised severe toxicity are based on generic consideration of relevance to any other cancer diagnosis and age group,"Antineoplastic Agents, Blindness, Child, Hearing Loss, Hematologic Diseases, Humans, Physicians, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Progression-Free Survival, Renal Insufficiency"
34169637,curcumin is a natural polyphenol extracted from the rhizome of curcuma that ha an important antitumour effect but it effect on adverse psychological stressinduced tumour proliferation and invasion ha not been reported to date here we found that curcumin not only inhibited the growth of xenograft in chronically stressed nude mouse but also decreased the expression of matrix metalloproteinase mmp and cd147 in tumour tissue exogenous norepinephrine ne wa used to stimulate glioma cell to simulate the stress environment in vitro and it wa found that curcumin inhibited the neinduced proliferation and invasion of glioma cell in a dosedependent manner further research found that the effect of ne on glioma cell could lead to the activation of the mitogenactivated protein kinase mapk signalling pathway through adrenergic receptor while curcumin suppressed the level of extracellular signalregulated kinase erk phosphorylation in addition blocking erk expression with u0126 resulted in the downregulated expression of cd which further led to the decreased expression of mmp2 and mmp curcumin could also inhibit the expression of cyclin dcdk and antiapoptotic protein bclbclxl induced by ne and induced cell cycle change and increased apoptosis therefore curcumin may be a potential candidate drug for preventing and treating the progression of glioma induced by adverse psychological stress,"Animals, Apoptosis, Brain Neoplasms, Cell Line, Tumor, Cell Movement, Cell Proliferation, Curcumin, Cyclin D1, Down-Regulation, Female, Glioma, Humans, MAP Kinase Signaling System, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Mice, Mice, Inbred BALB C, Mice, Nude, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Norepinephrine, Stress, Psychological"
34169393,preclinical data demonstrate stat3 a an important regulator in her tumor and disruption of the iljakstats100as100a9 signaling cascade reduces her cell viability ruxolitinib is an fda approved inhibitor of jak1 and jak we performed a phase iii trial investigating the safety and efficacy of the combination of trastuzumab and ruxolitinib in patient with trastuzumabresistant metastatic her breast cancer patient with metastatic her breast cancer progressing on at least 2 line of herdirected therapy were eligible the phase i portion determined the tolerable dose of ruxolitinib in combination with trastuzumab the primary objective of the phase ii wa to as the progression free survival pfs of the combination of ruxolitinib plus trastuzumab compared to historical control twentyeight patient were enrolled with a median number of prior therapy of ruxolitinib 25 mg twice daily wa the recommended phase ii dose with no dose limiting toxicity dlts of 26 evaluable patient in phase ii the median pfs wa week 95 ci among the 14 patient with measurable disease 1 patient had a partial response and 4 patient had stable disease most of the adverse event were hematologic while well tolerated with a strong preclinical rationale the combination of ruxolitinib and trastuzumab did not lead to an improvement in pfs compared to historical control in patient with trastuzumabresistant metastatic her breast cancer,"Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Nitriles, Pyrazoles, Pyrimidines, Receptor, ErbB-2, Trastuzumab, Treatment Outcome"
34167420,recent year have registered the advent of novel treatment option for metastatic renal cell carcinoma mrcc including combination therapy with immune checkpoint inhibitor icis and tyrosine kinase inhibitor tkis immunotki combination have been suggested to improve clinical outcome but may also result in increased toxicity including gastrointestinal gi adverse event herein we performed a metaanalysis aimed at comparing the risk of certain gi toxicity in mrcc patient treated with immunotki combination versus sunitinib monotherapy overall four phase iii trial keynote javelin renal checkmate 9er clear involving 3059 mrcc patient were available the metaanalysis suggested an increased risk of allgrade diarrhea grade diarrhea and grade decreased appetite in patient treated with immunotki combination conversely an apparently higher risk of allgrade nausea wa observed in the sunitinib group the metaanalysis suggested that immunotki combination are associated with higher risk of gi toxicity compared with sunitinib beyond the efficacy of immunotki combination in mrcc patient careful consideration should be given to treatmentrelated adverse event including gi toxicity early recognition and treatment are critical to maximize recovery,"Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Diarrhea, Gastrointestinal Diseases, Humans, Immune Checkpoint Inhibitors, Kidney Neoplasms, Nausea, Neoplasm Metastasis, Protein Kinase Inhibitors, Sunitinib"
34167407,peripheral tcell lymphoma ptcls are a group of heterogeneous tcell malignancy representing 510 of aggressive lymphoma the prognosis is poor for patient with relapsedrefractory rr disease with a median overall survival of le than 6 month and no standardized treatment we discus the role of the phosphatidylinositol kinase pi3k inhibitor duvelisib a bridge to allotransplantation in a patient with rr ptcl case report a yearold woman diagnosed with relapsed nodal ptcl with tfollicular helper phenotype received pi3k inhibitor duvelisib in the context of the phase ii primo clinical trial after two cycle at a dose of 75 mg twice daily the patient achieved complete response cr which wa subsequently consolidated with human leukocyte antigen fully matched unrelated donor allotransplantation no major toxicity were recorded during the duvelisib treatment period or during hospitalization for allotransplantation at the latest followup the patient wa alive and still in cr 10 month posttransplant duvelisib should be further explored a a bridge to allotransplantation in patient with rr ptcl given the success and low toxicity in our patient,"Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Cyclophosphamide, Disease Progression, Doxorubicin, Drug Resistance, Neoplasm, Female, Hematopoietic Stem Cell Transplantation, Humans, Isoquinolines, Lymphoma, T-Cell, Peripheral, Middle Aged, Molecular Targeted Therapy, Prednisone, Purines, Recurrence, Retreatment, T-Lymphocytes, Helper-Inducer, Transplantation, Homologous, Treatment Outcome, Vincristine"
34166980,acute myeloid leukemia aml is a group of heterogeneous hematologic malignancy correlate with poor prognosis it is important to identify biomarkers for effective treatment of aml kinase participate in many regulatory pathway and biological activity in aml previous study demonstrated that map4k a serinethreonine kinase wa associated with immune regulation and cancer progression however it role and mechanism in acute myeloid leukemia aml have not been explored rnaseq profiling wa performed for homoharringtonine hhtresistant and homoharringtonine hhtsensitive cell line bioinformatic tool were used for differential analysis cell culture and transfection cell proliferation apoptosis and cell cycle assay quantitative rtpcr and western blotting analysis were used to explore biological phenotype in vitro we found that map4k1 wa highly expressed in hhtinduced resistant aml cell line in addition overexpression of map4k1 in aml cell induced resistance of aml cell against hht not only that the finding of this study showed that overexpression of map4k1 wa an independent risk factor that predicts poor prognosis of aml further in vitro study showed that map4k1 modulated cell cycle through mapk and dna damagerepair pathway therefore map4k1 is a potential target for developing therapy for aml this study demonstrates that map4k1 not only regulates hht resistance but also independently predicts aml prognosis in addition understanding the regulatory mechanism of map4k1 reveals novel treatment strategy for resistant and refractory aml funding this work wa supported by the national natural science foundation of china nsfc grant no 82070118 and the natural science foundation of zhejiang province ly20h080008,"Animals, Antineoplastic Agents, Phytogenic, Apoptosis, Biomarkers, Tumor, Cell Line, Tumor, Cell Proliferation, DNA Damage, DNA Repair, Drug Resistance, Neoplasm, Homoharringtonine, Humans, Leukemia, Myeloid, Acute, MAP Kinase Signaling System, Mice, Protein Serine-Threonine Kinases, THP-1 Cells, Transcriptome"
34166806,to compare the efficacy and safety of hepatic arterial infusion chemotherapy haic with a modified fluorouracil leucovorin and oxaliplatin mfolfox regimen with that of transarterial chemoembolization a a locoregional treatment for patient with locally advanced hepatocellular carcinoma hcc this retrospective study included adult patient with locally advanced hcc who received firstline treatment with either haicmfolfox or conventional transarterial chemoembolization monotherapy from january 2015 to december the outcome including tumor response rate evaluated via imaging assessment using the modified response evaluation criterion in solid tumor overall survival progressionfree survival and safety were compared the propensity scorematching methodology wa used to reduce the influence of confounding factor on the outcome the study included 131 patient with locally advanced hcc who underwent transarterial chemoembolization and 101 who received haicmfolfox a initial treatment after propensity score matching n 67 in each group patient who received haicmfolfox had a higher objective response rate v p 001 longer median overall survival v month p 001 and longer median progressionfree survival v month p 001 than those who underwent transarterial chemoembolization the survival benefit with haicmfolfox wa strengthened in patient with hcc with vascular invasion hazard ratio 95 confidence interval haicmfolfox wa associated with lower incidence of severe adverse event v and liver toxicity than transarterial chemoembolization compared with transarterial chemoembolization haicmfolfox is a potentially safer and more effective locoregional therapy for patient with locally advanced hcc,"Adult, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Fluorouracil, Hepatic Artery, Humans, Leucovorin, Liver Neoplasms, Oxaliplatin, Propensity Score, Retrospective Studies, Treatment Outcome"
34166502,hematotoxicity represents a frequent chimeric antigen receptor car tcellrelated adverse event and remains poorly understood in this multicenter analysis we studied pattern of hematopoietic reconstitution and evaluated potential predictive marker in 258 patient receiving axicabtagene ciloleucel axicel or tisagenlecleucel tisacel for relapsedrefractory large bcell lymphoma we observed profound absolute neutrophil count anc 100 cell per l neutropenia in 72 of patient and prolonged 21 day or longer neutropenia in 64 of patient the median duration of severe neutropenia anc 500 cell per l wa 9 day we aimed to identify predictive biomarkers of hematotoxicity using the duration of severe neutropenia until day 60 a the primary end point in the training cohort n 58 we observed a significant correlation with baseline thrombocytopenia r p 001 and hyperferritinemia r p 0001 on univariate and multivariate analysis incidence and severity of cytokinerelease syndrome immune effector cellassociated neurotoxicity syndrome and peak cytokine level were not associated with the primary end point we created the carhematotox model which included marker associated with hematopoietic reserve eg platelet count hemoglobin and anc and baseline inflammation eg creactive protein and ferritin this model wa validated in independent cohort one from europe n 91 and one from the united state n 109 and discriminated patient with severe neutropenia 14 day to 14 day pooled validation area under the curve sensitivity 89 specificity 68 a high carhematotox score resulted in a longer duration of neutropenia 12 v day p 001 and a higher incidence of severe thrombocytopenia 87 v 34 p 001 and anemia 96 v 40 p 001 the score implicates bone marrow reserve and inflammation prior to car tcell therapy a key feature associated with delayed cytopenia and will be useful for riskadapted management of hematotoxicity,"Adult, Aged, Aged, 80 and over, Anemia, Antineoplastic Agents, Immunological, Biological Products, Cytokine Release Syndrome, Hematologic Diseases, Humans, Immunotherapy, Adoptive, Incidence, Lymphoma, Large B-Cell, Diffuse, Middle Aged, Neoplasm Recurrence, Local, Neurotoxicity Syndromes, Neutropenia, Receptors, Antigen, T-Cell, Retrospective Studies, Thrombocytopenia, Young Adult"
34166302,immunotherapy with immune checkpoint inhibitor icis ha improved the prognosis of many cancer a combination of nivolumab antiprogrammed cell death protein 1 and ipilimumab anticytotoxic tlymphocyteassociated protein 4 is approved a firstline therapy for advanced melanoma with objective response obtained in more than half of patient however this combination is associated with a high rate of immunerelated adverse event which are often severe and multiple neurological immunerelated adverse event are rare but feared because they can be lifethreatening their diagnosis and management are challenging and patient can have irreversible sequela we reported a case of a young patient treated by nivolumab and ipilimumab combination for metastatic melanoma severe dysphagia with regurgitation major weight loss uveitis and vitiligo occurred after 3 infusion of nivolumab and ipilimumab magnetic resonance imaging and positron emission tomography scan showed complete remission of melanoma the endoscopic examination did not find any digestive toxicity esophageal manometry revealed achalasia this wa associated with mydriasis pathologic deep breath test and alteration of the cutaneous sympathetic response on electromyogram which wa consistent with autonomic neuropathy this rare etiology of atypical vomiting under ici should be known by prescribers a ici prescription is widening in many new cancer,"Esophageal Achalasia, Humans, Immunotherapy, Ipilimumab, Melanoma, Nivolumab"
34165503,trastuzumab emtansine tdm1 is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy but the potential of tdm1 a monotherapy is so far unknown to as pathologic complete response pcr to standard neoadjuvant therapy of combination docetaxel trastuzumab and pertuzumab dtp v tdm1 monotherapy in patient with erbb2 formerly her2positive breast cancer this randomized phase 2 trial conducted at 9 site in sweden enrolled 202 patient between december and october participant were 18 year or older with erbbpositive tumor larger than 20 mm andor verified lymph node metastasis analysis wa performed on an intentiontotreat basis patient were randomized to receive 6 cycle of dtp standard group or tdm1 investigational group crossover wa recommended at lack of response or occurrence of intolerable toxic effect assessment with fluorine labeled fluorodeoxyglucose 18ffdg positron emission tomography combined with computed tomography petct wa performed at baseline and after 2 and 6 treatment cycle pathologic complete response defined a ypt0 or ti ypn secondary end point were clinical and radiologic objective response eventfree survival invasive diseasefree survival distant diseasefree survival and overall survival safety healthrelated quality of life hrqol functional and biological tumor characteristic and frequency of breastconserving surgery overall 202 patient were randomized 197 99 woman in the standard group median age 51 year range year and 98 woman in the investigational group median age 53 year range year were evaluable for the primary end point pathologic complete response wa achieved in 45 patient in the standard group 95 ci and 43 patient in the investigational group 95 ci the difference wa not statistically significant p 82 in a subgroup analysis the pcr rate wa higher in hormone receptornegative tumor than in hormone receptorpositive tumor in both treatment group 45 of 72 v 45 of 125 three patient in the tdm1 group experienced progression during therapy in an exploratory analysis tumorinfiltrating lymphocyte at 10 or more median estimated pcr significantly odds ratio 95 ci p 003 response evaluation with 18ffdg petct revealed a relative decrease of maximum standardized uptake value by equal to or greater than median wa associated with pcr odds ratio 95 ci p 001 in this study treatment with standard neoadjuvant combination dtp wa equal to tdm clinicaltrialsgov identifier nct02568839 eudract number,"Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Docetaxel, Female, Humans, Middle Aged, Neoadjuvant Therapy, Positron Emission Tomography Computed Tomography, Quality of Life, Receptor, ErbB-2, Trastuzumab, Treatment Outcome"
34164713,we investigated the combination of tivantinib a cmet tyrosine kinase inhibitor tki and bevacizumab an antivegfa antibody patient with advanced solid tumor received bevacizumab 10 mgkg intravenously every 2 week and escalating do of tivantinib mg orally twice daily in addition to safety and preliminary efficacy we evaluated pharmacokinetics of tivantinib and it metabolite a well a pharmacodynamic biomarkers in peripheral blood and skin eleven patient received the combination treatment which wa generally well tolerated the main doselimiting toxicity wa grade 3 hypertension which wa observed in four patient other toxicity included lymphopenia and electrolyte disturbance no exposuretoxicity relationship wa observed for tivantinib or metabolite no clinical response were observed mean level of the serum cytokine bfgf increased p after the bevacizumabonly leadin and decreased back to baseline p after addition of tivantinib tivantinib reduced level of both phosphomet patient and tubulin patient in skin the combination of tivantinib and bevacizumab produced toxicity that were largely consistent with the safety profile of the individual drug the study wa terminated prior to establishment of the recommended phase ii dose rp2d due to concern regarding the mechanism of tivantinib a well a lack of clinical efficacy seen in this and other study tivantinib reversed the upregulation of bfgf caused by bevacizumab which ha been considered a potential mechanism of resistance to therapy targeting the vegf pathway the finding from this study suggest that the mechanism of action of tivantinib in human may involve inhibition of both cmet and tubulin expression nct01749384 first posted 2012,"Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Neoplasms, Proto-Oncogene Proteins c-met, Pyrrolidinones, Quinolines, Treatment Outcome, Tubulin"
34162429,immune checkpoint inhibitor icis are monoclonal antibody that block immune inhibitory pathway administration of icis augments t cellmediated immune response against tumor resulting in improved overall survival in cancer patient it ha emerged that the intestinal microbiome can modulate response to icis via the host immune system and that the use of antibiotic can lead to reduced efficacy of icis recently report that fecal microbiota transplantation can lead to ici therapy response in patient previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ici therapy intestinal microbial metabolite may also be linked to response rate to icis in addition to response rate certain toxicity that can arise during ici therapy have also been found to be associated with the intestinal microbiome including in particular colitis a key mechanistic question is how certain microbe can enhance antitumor response or alternatively predispose to iciassociated colitis evidence ha emerged that the intestinal microbiome can modulate outcome to ici therapy via two major mechanism including those that are antigenspecific and those that are antigenindependent antigenspecific mechanism occur when epitope are shared between microbial and tumor antigen that could enhance or alternatively reduce antitumor immune response via crossreactive adaptive immune cell antigenindependent mechanism include modulation of response to icis by engaging innate andor adaptive immune cell to establish microbiomebased biomarkers of outcome and specifically modulate the intestinal microbiome to enhance efficacy of icis in cancer immunotherapy further prospective interventional study will be required,"Anti-Bacterial Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Colitis, Dysbiosis, Gastrointestinal Microbiome, Host Microbial Interactions, Humans, Immune Checkpoint Inhibitors, Metabolome, Metabolomics, Models, Biological, Neoplasms"
34162250,stevenjohnson syndrome sjs is a serious mucocutaneous reaction characterized by fever influenzalike symptom and followed by dermatological manifestation capecitabine is an oral fluoropyrimidine carbamate analogue of fluorouracil fu it is widely accepted for many malignancy because of it better safety profile and tolerability handfoot syndrome is the common dermatological toxicity associated with capecitabine and sjs is the rarest manifestationcase presentation we report a case of capecitabine induced sjs in a 70 year old male patient with metastatic carcinoma pancreas he wa treated with intravenous gemcitabine and carboplatin initially and then switched to oral therapy with capecitabine 1000 mg twice daily after ten day of treatment with capecitabine he developed vomiting mucositis hyperpigmentation itching and scrotal mucosal peeling the clinical status of the patient wa suggestive of sjs which wa confirmed by dermatologic consultation according to naranjo whoumc and hartwigs scale the reaction wa found to be probable and severe pharmacological a well a supportive care measure were provided but the condition progressively worsened and the patient wa deceased capecitabine can cause severe hypersensitivity reaction which can be dangerous and lifethreatening health care provider must be aware of all rare adverse effect including sjs clinician and clinical pharmacist should educate and counsel the patient regarding the likely adverse effect of their chemo drug because the early identification of toxic symptom is crucial to reduce further complication to the patient,"Aged, Antineoplastic Agents, Capecitabine, Fluorouracil, Humans, Male, Neoplasms, Stevens-Johnson Syndrome"
34162207,although nitric oxide no ha been emerging a a novel local anticancer agent because of it potent cytotoxic effect and lack of offtarget side effect it clinical application remain a challenge because of the short effective diffusion distance of no that limit it anticancer activity in this study we synthesized albumincoated polylacticcoglycolic acid plgaconjugated linear polyethylenimine diazeniumdiolate lpno nanoparticles albplpno np that posse tumorpenetrating and noreleasing property for an effective local treatment of melanoma sufficient noloading and prolonged noreleasing characteristic of albplpno np were acquired through plgaconjugated lpno copolymer plpno synthesis followed by nanoparticle fabrication in addition tumor penetration ability wa rendered by the electrostatic adsorption of the albumin on the surface of the nanoparticles the albplpno np showed enhanced intracellular no delivery efficiency and cytotoxicity to b16f10 murine melanoma cell in b16ftumorbearing mouse the albplpno np showed improved extracellular matrix penetration and spatial distribution in the tumor tissue after intratumoral injection resulting in enhanced antitumor activity taken together the result suggest that albplpno np represent a promising new modality for the local treatment of melanoma,"Animals, Antineoplastic Agents, Apoptosis, Azo Compounds, Cattle, Cell Line, Tumor, Drug Liberation, Melanoma, Mice, Inbred C57BL, Nanoparticles, Nitric Oxide, Nitric Oxide Donors, Polyethyleneimine, Polylactic Acid-Polyglycolic Acid Copolymer, Serum Albumin, Bovine, Mice"
34162178,effective and tolerable treatment are needed for older patient with classical hodgkin lymphoma we report result for older patient with classical hodgkin lymphoma treated in the large phase iii echelon1 study of frontline brentuximab vedotin plus doxorubicin vinblastine and dacarbazine aavd versus doxorubicin bleomycin vinblastine and dacarbazine abvd modified progressionfree survival per independent review facility for older versus younger patient aged 60 v 60 year wa a prespecified subgroup analysis a the echelon 1 study wa not powered for these analysis reported pvalues are descriptive of enrolled patient 186 14 were aged 60 year aavd n abvd n102 result below refer to this age group modified progressionfree survival per independent review facility wa similar in the two arm at 24 month aavd 95 confidence interval ci abvd 95 ci hazard ratio hr 95 ci p after a median followup of month year progressionfree survival per investigator wa with aavd versus with abvd hr 95 ci p comparing aavd versus abvd grade peripheral neuropathy occurred in 18 versus 3 anygrade febrile neutropenia in 37 versus 17 and anygrade pulmonary toxicity in 2 versus 13 respectively with three 3 pulmonary toxicityrelated death in patient receiving abvd none in those receiving aavd altogether aavd showed overall similar efficacy to abvd with survival rate in both arm comparing favorably to those of prior series in older patient with advancedstage classical hodgkin lymphoma compared to abvd aavd wa associated with higher rate of neuropathy and neutropenia but lower rate of pulmonaryrelated toxicity trial registered at clinicaltrialsgov identifier nct01712490 eudract number,"Aged, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Dacarbazine, Doxorubicin, Hodgkin Disease, Humans, Neoplasm Staging, Neutropenia, Peripheral Nervous System Diseases, Vinblastine"
34160983,renal toxicity of antineoplasic agent renal toxicity of antineoplasic agent is a common complication faced by oncologist and nephrologists whose incidence depends on therapeutic class used and patient comorbidities nephrotoxicity is variable according to mecanisms chronology and potential reversibility besides acute kidney injury andor chronic kidney disease clinical feature include several urinary abnormality mainly proteinuria the onset of renal toxicity may directly compromise vital prognosis and may lead to the interruption of medication affecting cancerspecific mortality nephrotoxicity prevention when feasible and rapid diagnosis are essential to optimize cancerpatient medical care toxicit rnale de anticancreux la toxicit rnale de anticancreux est une complication laquelle le oncologues et le nphrologues sont frquemment confronts dont lincidence est lie aux class de molcules utilises et aux comorbidits de patient cette toxicit est variable dans s mcanismes sa chronologie et son ventuelle rversibilit le atteintes cliniques incluent outre linsuffisance rnale aigu etou chronique diver trouble hydrolectrolytiques ainsi que de anomaly urinaires en premier lieu une protinurie la survenue dune toxicit rnale peut directement compromettre le pronostic vital mais galement conduire linterruption danticancreux amliorant la survie oncologique la prvention quand elle est possible et lidentification rapide de toute toxicit rnale sont donc indispensables afin doptimiser la prise en charge du patient cancreux,"Acute Kidney Injury, Antineoplastic Agents, Drug-Related Side Effects and Adverse Reactions, Humans, Neoplasms, Renal Insufficiency, Chronic"
34160752,talazoparib is a polyadpribose polymerase enzyme inhibitor this openlabel nonrandomized phase 1 study of talazoparib investigated the safety pharmacokinetics and preliminary antitumor activity in japanese patient with locally advanced or metastatic solid tumor regardless of mutation in dna damage repairrelated gene who are resistant toineligible for standard therapy patient received talazoparib dosed orally at or 1 mg once daily using a modified 3 3 doseescalation scheme primary endpoint wa doselimiting toxicity during the first cycle of talazoparib nine patient median age year were included 3 and 6 patient at the and mg oncedaily dose level respectively no doselimiting toxicity were reported the most commonly reported treatmentemergent adverse event 2 patient were anemia stomatitis maculopapular rash platelet count decreased neutrophil count decreased and alanine aminotransferase increased three patient had grade 3 treatmentemergent adverse event anemia brain metastasis 1 patient each and neutrophil and white blood cell count decreased same patient two patient temporarily discontinued treatment due to a treatmentemergent adverse event and 1 patient required a dose reduction for neutrophil count decreased all at 1 mg once daily talazoparib exposure cmax and auc after single and multiple dosing wa slightly higher proportionally with talazoparib 1 mg than talazoparib mg the overall disease control rate wa including 2 patient with stable disease the recommended phase 2 dose of talazoparib wa established a 1 mg once daily singleagent talazoparib wa well tolerated and had preliminary antitumor activity in japanese patient with advanced solid tumor clinicaltrialsgov identifier nct03343054 november 2017,"Adult, Aged, Antineoplastic Agents, Asian People, Dose-Response Relationship, Drug, Humans, Japan, Maximum Tolerated Dose, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasms, Phthalazines, Poly(ADP-ribose) Polymerase Inhibitors"
34159682,tazemetostat is a selective reversible smallmolecule inhibitor of the histone methyltransferase enzyme enhancer of zest homolog 2 ezh2 in this multicenter openlabel phase ii study we assessed the efficacy and safety of tazemetostat in japanese patient with relapsed or refractory rr bcell nonhodgkin lymphoma harboring the ezh2 mutation tazemetostat 800 mg twice daily wa given orally day cycle until disease progression or unacceptable toxicity among the 20 eligible patient 17 were enrolled in cohort 1 follicular lymphoma fl and three were enrolled in cohort 2 diffuse large bcell lymphoma at data cutoff the objective response rate in cohort 1 wa including six patient with complete response and seven patient with partial response pr all three patient in cohort 2 achieved pr in cohort median progressionfree survival pfs wa not reached at the median followup of month the estimated pfs rate at 12 and 15 month wa and respectively the most common grade 3 treatmentemergent adverse event teae wa lymphopenia n 2 grade 4 teaes included hypertriglyceridemia and pneumonia aspiration n 1 each which were not related to tazemetostat treatmentemergent adverse event leading to study drug discontinuation were reported in four of the 20 patient indicating that the safety profile of tazemetostat wa acceptable and manageable tazemetostat 800 mg twice daily showed encouraging efficacy in patient with rr ezh2 mutationpositive fl with a manageable safety profile in the overall population thus tazemetostat could be a potential treatment for rr ezh2 mutationpositive fl,"Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Biphenyl Compounds, Cohort Studies, Enhancer of Zeste Homolog 2 Protein, Female, Humans, Japan, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Morpholines, Mutation, Progression-Free Survival, Pyridones, Recurrence"
34157863,the use of immune checkpoint inhibitor in patient with metastatic melanoma generates clinical benefit including improved survival yet disease resistance and immunerelated adverse event persist a unmet need sargramostim a yeastderived recombinant human gmcsf ha shown clinical activity against diverse solid tumor including metastatic melanoma here we review the use of sargramostim for treatment of advanced melanoma potential sargramostim application in melanoma draw on the unique ability of gmcsf to link innate and adaptive immune response we review preclinical and translational data describing the mechanism of action of sargramostim and synergy with immune checkpoint inhibitor to enhance efficacy and reduce treatmentrelated toxicity lay abstract immune checkpoint inhibitor are medication that help the immune system to fight cancer side effect with these medicine may occur because the immune system may attack healthy cell sargramostim is a medication that is similar to a protein in the body gmcsf study have shown that sargramostim can fight cancer including melanoma when sargramostim is used with immune checkpoint inhibitor the body natural defense to fight cancer the immune system is boosted and some side effect are reduced this article review how gmcsf is thought to boost the immune system response against cancer in the laboratory and in animal model we also review the use of sargramostim alone and combined with ipilimumab in patient with advanced melanoma,"Animals, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Immune Checkpoint Inhibitors, Melanoma, Recombinant Proteins"
34157804,lung cancer is the most common malignant tumor and the leading cause of cancerrelated death worldwide most of the patient have distant metastasis when visiting the doctor which seriously affect the survival time and quality of life of the patient with the development of molecular targeted drug lung cancer treatment ha been transformed from traditional chemotherapy to targeted therapy and precision medicine ha been gradually applied in clinical practice which can make lung cancer patient live longer and have a better quality of life we present a case of advanced lung cancer patient who presented to department of thoracic surgery of beijing haidian hospital five year ago we chose the reasonable treatment option though the genetic test and circulating tumor dna test we summarized the adverse reaction in the whole course of treatment the comprehensive therapy we utilized including targeted therapy chemotherapy antiangiogenic agent and local radiotherapy have resulted in our patient with remaining alive for advanced nonsmall cell lung cancer with epidermal growth factor receptor egfr mutation positive individualized treatment wa conducted based on precise genotyping and dynamic monitoring which can not only control the tumor but also have mild toxic and side effect the survival time of the patient wa prolonged and the quality of life wa guaranteed 1egfr 51dnacirculating tumor dna ctdna5ivepidermal growth factor receptor egfregfr,"Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Combined Modality Therapy, ErbB Receptors, Humans, Lung Neoplasms, Protein Kinase Inhibitors, Quality of Life, Treatment Outcome"
34157782,cyclindependent kinase cdk inhibitor including palbociclib are approved to treat hormone receptor hrpositivehuman epidermal growth factor receptor 2 her2negative advanced breast cancer abc and are associated with hematologic toxicity african american woman who are underrepresented in cdk inhibitor clinical trial may experience worse neutropenia because of benign ethnic neutropenia the author specifically investigated the hematologic safety of palbociclib in african american woman with hrpositivehernegative abc palina wa a singlearm openlabel investigatorinitiated study of palbociclib 125 mg daily 21 day on and 7 day off plus endocrine therapy et in african american woman who had hrpositivehernegative abc and a baseline absolute neutrophil count mm3 clinicaltrialsgov identifier nct02692755 the primary outcome wa the proportion of patient who completed 12 month of therapy without experiencing febrile neutropenia or treatment discontinuation because of neutropenia single nucleotide polymorphism analysis wa used to as duffy polymorphism status thirtyfive patient received 1 dose of palbociclib plus et 19 had a duffy null polymorphism cytosinecytosine there were no report of febrile neutropenia or permanent study discontinuation because of neutropenia significantly more patient with the duffy null versus the wildtype variant had grade 3 and 4 neutropenia v p 029 and required a palbociclib dose reduction v p 008 patient with the duffy null versus the wildtype variant had lower overall relative dose intensity mean sd and respectively p 0026 and a lower clinical benefit rate and respectively these finding suggest that palbociclib is well tolerated in african american woman with hrpositivehernegative abc duffy null status may affect the incidence of grade 3 neutropenia dose intensity and possibly clinical benefit,"Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Neutropenia, Piperazines, Pyridines, Receptor, ErbB-2"
34156283,chronic myeloid leukemia cml is characterized by the formation of the bcrabl fusion gene the bcrabl protein lead to an increased level of reactive oxygen specie which is a major cause of endogenous dna doublestrand break dsbs cml cell are prone to rely on a highly mutagenic alternative endjoining altej pathway to cope with enhanced dsbs which aggravates chromosomal instability hence targeting dysregulated dna repair protein provides new insight into cancer treatment in this study we discovered the abnormal upregulation of flap endonuclease 1 fen1 in cml a well a fen1s participation in the errorprone altej repair pathway and it interplay with dna ligase1 and proliferating cell nuclear antigen in dsb repair knockdown of fen1 by shrna not only inhibited the proliferation and induced apoptosis but also enhanced the efficacy of imatinib im in drugresistant cml cell kg moreover excessive dsb accumulation wa detected after fen1 inhibition in summary our result demonstrated that fen1 is a promising therapeutic target in cml treatment this work extends the understanding of regulating abnormal dsb repair for cancer treatment,"Antineoplastic Agents, Apoptosis, Cell Proliferation, Cells, Cultured, DNA End-Joining Repair, DNA Ligase ATP, Drug Resistance, Neoplasm, Flap Endonucleases, HEK293 Cells, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Proliferating Cell Nuclear Antigen, THP-1 Cells"
34153830,the programmed cell death ligand1 pdl1programmed cell death1 pd1 pathway is important in metastatic renal cell carcinoma mrcc however some dissimilarity between antipd1 and antipdl1 inhibitor have emerged we aimed to as difference between antipd1 and antipdl1 combination immunotherapy a firstline treatment in mrcc patient multiple database pubmed web of science and scopus were searched for article published until march study were eligible if they compared overall survival o progressionfree survival pfs objective response rate orr complete response rate crr and adverse event five study met the eligibility criterion pd1 combination therapy wa associated with significantly better o and pfs and higher orr and crr than sunitinib hazard ratio hr 95 confidence interval ci hr 95 ci odds ratio or 95 ci and or 95 ci respectively p for all oncological outcome antipd1 agent were superior to antipdl1 agent based on hr and or o hr pfs hr orr or and crr or conversely antipdl1 agent were superior to antipd1 agent in their safety profile in network metaanalyses pembrolizumab plus lenvatinib seemed the worst tolerated antipd1 combination therapy our analysis indicates the superior oncologic benefit of firstline antipd1 combination therapy over antipdl1 combination therapy in mrcc patient this biological difference is of vital importance for clinical treatment decision making and the design of future rational combination therapy trial in mrcc,"Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Carcinoma, Renal Cell, Clinical Trials, Phase III as Topic, Humans, Immune Checkpoint Inhibitors, Kidney Neoplasms, Programmed Cell Death 1 Receptor, Randomized Controlled Trials as Topic"
34153652,the role of epidermal growth factor receptor egfrtyrosine kinase inhibitor tki induction coupled with standard concurrent chemoradiotherapy crt is unclear in unresectable stage iii egfrmutant nonsmallcell lung cancer nsclc therefore a phase ii trial wa conducted to evaluate the efficacy and safety of gefitinib induction followed by crt in this disease setting patient with unresectable egfrmutant stage iii nsclc were administered gefitinib monotherapy 250 mgday for 8 week subsequently patient without disease progression during induction therapy were administered cisplatin and docetaxel 40 mgm2 each on day and 36 with concurrent radiotherapy at a total dose of 60 gy the primary endpoint wa the year overall survival o rate which wa hypothesized to reach 85 with a threshold of the lower limit of 60 twenty patient median age 66 year malefemale histology 20 adenocarcinoma stage iiiaiiib and exon were enrolled the year o rate wa 90 90 confidence interval to indicating that this trial met the primary objective the overall response rate and and year progressionfree survival rate were and respectively grade 3 adverse event 10 included hepatic toxicity during the induction phase and neutropenia and febrile neutropenia in the crt phase radiation pneumonitis grade 3 or treatmentrelated death did not occur this is the first prospective study to demonstrate the favorable efficacy and safety of egfrtki induction followed by standard crt in egfrmutant stage iii nsclc further confirmatory study are needed,"Aged, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, ErbB Receptors, Female, Gefitinib, Humans, Lung Neoplasms, Male, Mutation, Prospective Studies"
34153388,lateonset adverse event aes of antiprogrammed cell death 1 antipd1 antibody have not been systematically described the purpose wa to evaluate lateonset aes in melanoma patient treated with antipd1 administered for at least 2 year in a reallife setting patient were screened from melbase a french multicentric biobank dedicated to the prospective follow up of unresectable stage iii or iv melanoma the study included 119 patient who received antipd1 during at least 2 year from january 2013 to november median follow up wa month range month fiftythree patient received nivolumab and 66 patient received pembrolizumab aes occurred in 99 patient 83 with a median time of month range 9 month including severe aes grade 3 or 4 in 30 patient 30 lateonset aes mostly grade 1 or occurred in 51 43 patient and led to 5 4 hospitalization of which 4 were severe factor associated with lateonset aes in multivariate analysis were earlyonset aes within the first 2 year of treatment and treatment duration p 02 and p respectively our data demonstrate the possibility of lateonset aes occurring after 2 year of antipd1 therapy lateonset aes appear frequently and were mostly mild or moderate earlyonset aes and prolonged antipd1 treatment may increase the risk of lateonset aes,"Cohort Studies, Humans, Immunotherapy, Melanoma, Nivolumab, Prospective Studies, Retrospective Studies"
34149004,there is a lack of pharmacogenetic predictor of outcome in gastric cancer patient the aim of this study wa to as previously identified candidate gene associated with fluorouracil fu cisplatin or epirubicin toxicity or response in a cohort of resected gastric cancer patient treated on calgb alliance gastric or gastroesophageal cancer patient randomized to adjuvant fuleucovorin or epirubicincisplatinfu before and after fu chemoradiation were genotyped for single nucleotide polymorphism snp in gstp1 rs1695 ercc1 rs11615 and rs3212986 xrcc1 rs25487 ugt2b7 rs7439366 and the 28 basepair tandem repeat in tyms rs34743033 logistic regression and log rank test were used to as the association between each snp and incidence of grade neutropenia and leukopenia overall o and progressionfree survival pfs respectively toxicity endpoint analysis were adjusted for the treatment arm while o and pfs were also adjusted for performance status sex age lymph node involvement and primary tumor site and size of 281 subject with successful genotyping result and available clinical toxicity and efficacy data 166 selfreported nonhispanic white patient were included in the final analysis there wa a lack of evidence of an association among any snp tested with grade neutropenia and leukopenia or o and pfs age lymph node involvement and primary tumor size were significantly associated with o and pfs this study failed to confirm result of previous gastric cancer pharmacogenetic study,"Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Epirubicin, Fluorouracil, Humans, Leucovorin, Pharmacogenomic Testing, Stomach Neoplasms, X-ray Repair Cross Complementing Protein 1"
34148876,amarogentin active component of chirata wa found to prevent cclndeainduced liver carcinogenesis at mild dysplastic stage through modulation of cell cycle apoptosis selfrenewal pathway the cell cycle regulatory gene limd p16 and rbsp3 were found to be upregulated in restricted liver lesion to understand the mechanism of upregulation during restriction of cacinogenesis the effect of amarogentin on epigenetic modification wa evaluated in this study it wa also validated in vitro hypermethylation of limd1 and p16 wa seen in mouse hepatocellular carcinoma 30th week carcinogen control mouse however hypomethylation of these gene wa seen in amarogentintreated liver in the case of rbsp no such change wa seen dnmt1 expression mrnaprotein wa significantly increased in later stage of carcinogenesis whereas it expression wa comparable to normal liver in the case of amarogentin treatment no significant change in expression mrnaprotein of hdac wa observed irrespective of treatment amarogentin treatment upregulated the expression mrnaprotein of limd p16 and rbsp3 in the hepg2 cell line here also treated cell showed limd1 and p16 hypomethylation with dnmt1 downregulation increased expression of limd p16 and rbsp3 after treating cell with demethylating agent azadeoxycytidine indicated epigenetic modulation by amarogentin treatment,"Animals, Anticarcinogenic Agents, Apoptosis, Carbon Tetrachloride, Carcinogenesis, Carcinoma, Hepatocellular, Cell Cycle, Cyclin-Dependent Kinase Inhibitor p16, DNA (Cytosine-5-)-Methyltransferase 1, Decitabine, Diethylnitrosamine, Disease Models, Animal, Epigenesis, Genetic, Female, Gene Expression Regulation, Neoplastic, Hep G2 Cells, Histone Deacetylase 1, Histone Deacetylase 2, Humans, Intracellular Signaling Peptides and Proteins, Iridoids, LIM Domain Proteins, Liver, Liver Neoplasms, Mice, Phosphoric Monoester Hydrolases, Signal Transduction"
34147524,this study wa designed to present a new quercetin encapsulated chitosan functionalized copper oxide nanoparticle cuochnpsq and assessed it antibreast cancer activity both in vitro and in vivo the cuochnpsq may act a antiproliferating agent against dmbainduced mammary carcinoma in female rat the cuonps wa functionalized with chitosan then quercetin wa conjugated with them producing cuochnpsq then characterized the in vitro antiproliferating activity of the cuochnpsq wa evaluated against three human cell line then the antibreast cancer effect of the cuochnpsq wa assessed against dmbainduction compared to both cuonps and q in female rat model the in vitro result proved the potent anticancer activity of the cuochnpsq compared to cuonps and quercetin the in vivo data showed significant reduction in breast tumor of dmbainduced rat treated with cuochnpsq compared to cuonps and q the cuochnpsq treatment had induced apoptosis via increased p53 gene arrested the cellcycle and increased both cytochrome c and caspase3 level leading to mammary carcinoma cell death also the cuochnpsq treatment had suppressed the pcna gene which decreased the proliferation of the mammary carcinoma cell in conclusion the cuochnpsq might be a promising chemotherapeutic agent for treatment of breast cancer with a minimal toxicity on vital organ,"9,10-Dimethyl-1,2-benzanthracene, Animals, Antineoplastic Agents, Breast Neoplasms, Caco-2 Cells, Cell Cycle, Cell Proliferation, Cell Survival, Chitosan, Copper, Drug Compounding, Female, Gene Expression Regulation, Neoplastic, Hep G2 Cells, Humans, MCF-7 Cells, Metal Nanoparticles, Proliferating Cell Nuclear Antigen, Quercetin, Rats, Tumor Suppressor Protein p53, Xenograft Model Antitumor Assays"
34145976,cyclindependent kinase cdk inhibitor have recently been approved for the treatment of hormone receptorpositive and hernegative metastatic breast cancer in association with endocrine therapy in postmenopausal woman data on the interaction of cdk inhibition and radiotherapy are scarce but some study show unexpected toxicity we report three case of unexpected severe or prolonged soft tissue skin and gastrointestinal toxicity in patient treated with a combination of radiotherapy and the cdk inhibitor palbociclib these case indicate a possible interaction between radiotherapy and palbociclib therefore we recommend using radiotherapy cautiously when combined with cdk inhibitor,"Bone Neoplasms, Breast Neoplasms, Disease Progression, Female, Humans, Middle Aged, Pain Management, Piperazines, Postmenopause, Protein Kinase Inhibitors, Pyridines"
34145469,osteonecrosis is a burdensome treatmentrelated toxicity that is mostly diagnosed during or soon after mercaptopurine 6mpmethotrexate mtx maintenance therapy for acute lymphoblastic leukemia all possibly indicating a pathogenic role of these drug we prospectively registered symptomatic osteonecrosis during treatment of 1234 patient aged year treated according to the nordic society of hematology and oncology nopho all2008 protocol mtx6mp metabolite were measured a part of the nopho all2008 maintenance therapy study after a median followup of year interquartile range iqr 68 patient had been diagnosed with symptomatic osteonecrosis the cumulative incidence wa 95 confidence interval ci for patient aged 10 year 95 ci for patient aged year and 95 ci for patient aged 18 year the median time from diagnosis of all to diagnosis of osteonecrosis in these age group wa year iqr year iqr and year iqr respectively p with blood sample available for mtx and 6mp metabolite analysis neither erythrocyte level of thioguanine tg nucleotide p methylated 6mp metabolite p mtx polyglutamates p nor dnatg p were significantly associated with the hazard of osteonecrosis in cox model stratified by the three age group and adjusted for sex maintenance therapy intensity determined by 6mp and mtx metabolite wa not associated with the risk of developing osteonecrosis in the nopho all2008 cohort,"Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, DNA Adducts, Erythrocytes, Female, Humans, Infant, Male, Mercaptopurine, Methotrexate, Middle Aged, Osteonecrosis, Polyglutamic Acid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prospective Studies, Thioguanine, Young Adult"
34145336,jcog1113 is a randomized phase iii trial in patient with advanced biliary tract cancer btcs umin000001685 and gemcitabine plus s1 g wa not inferior to gemcitabine plus cisplatin gc however poor renal function often result in high toxicity of s therefore we examined whether g can be recommended for patient with low creatinine clearance ccr renal function wa classified by ccr a calculated by the cockcroftgault formula high ccr ccr 80 mlmin and low ccr 80 ccr 50 mlmin of 354 patient 87 patient on gc and 91 on g were included in the low ccr group while there were 88 patient on gc and 88 patient on g in the high ccr group the hr of overall survival for g compared with gc wa 95 ci in the low ccr group although the total number of incidence of all grade nonhaematological adverse reaction wa higher v p the number of patient who discontinued treatment wa not different v p for g compared with gc in the low ccr group this study suggests that g should be selected for the treatment of advanced btc patient with reduced renal function,"Aged, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Biomarkers, Deoxycytidine, Disease Management, Female, Humans, Kaplan-Meier Estimate, Kidney Diseases, Kidney Function Tests, Male, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Treatment Outcome, Gemcitabine"
34145180,cytoreductive surgery cr coupled with hyperthermic intraperitoneal chemotherapy hipec ha become the standard of treatment for many cancer with peritoneal metastasis mitomycinc mmc the most common chemotherapy utilized with hipec is associated with neutropenia but the degree of hematologic toxicity is unclear when splenectomy is included a part of cr with mmc we present an interesting case of pancytopenia following treatment with hipec using mmc and comment on the possible role of splenectomy in exacerbating it cytotoxic effect our unique case highlight potential hematologic toxicity following mmchipec and splenectomy it suggests that spleen removal may enhance toxicity profile of chemotherapy such a mmc because mmc is the preferred agent of choice used in crshipec future study should investigate optimal mmc dosing and patient selection when splenectomy is performed to balance survival benefit with hematologic toxicity,"Aged, Antineoplastic Agents, Female, Humans, Hyperthermic Intraperitoneal Chemotherapy, Mitomycin, Pancytopenia, Peritoneal Neoplasms, Splenectomy"
34144936,apalutamide a competitive inhibitor of the androgen receptor is being increasingly used for the treatment of prostate cancer there have been few report of interstitial lung disease in clinical trial of apalutamide however two case of apalutamideinduced interstitial lung disease with respiratory failure in japanese male who were successfully treated with highdose corticosteroid are presented here these case suggest that clinician should be alert to the potentially lifethreatening risk of pulmonary toxicity associated with apalutamide treatment,"Antineoplastic Agents, Humans, Japan, Lung Diseases, Interstitial, Male, Prostatic Neoplasms, Castration-Resistant, Thiohydantoins"
34143971,china ha a high burden of hepatocellular carcinoma and hepatitis b virus hbv infection is the main causative factor patient with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need the phase orient32 study aimed to as sintilimab a pd1 inhibitor plus ibi a bevacizumab biosimilar versus sorafenib a a firstline treatment for unresectable hbvassociated hepatocellular carcinoma this randomised openlabel phase study wa done at 50 clinical site in china patient aged 18 year or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma no previous systemic treatment and a baseline eastern cooperative oncology group ecog performance status of 0 or 1 were eligible for inclusion in the phase 2 part of the study patient received intravenous sintilimab 200 mg every 3 week plus intravenous ibi305 15 mgkg every 3 week in the phase 3 part patient were randomly assigned 21 to receive either sintilimab plus ibi305 sintilimabbevacizumab biosimilar group or sorafenib 400 mg orally twice daily sorafenib group until disease progression or unacceptable toxicity randomisation wa done using permuted block randomisation with a block size of six via an interactive web response system and stratified by macrovascular invasion or extrahepatic metastasis baseline fetoprotein and ecog performance status the primary endpoint of the phase 2 part of the study wa safety assessed in all patient who received at least one dose of study drug the coprimary endpoint of the phase 3 part of the study were overall survival and independent radiological review committee irrcassessed progressionfree survival according to response evaluation criterion in solid tumor recist version in the intentiontotreat population the study is registered with clinicaltrialsgov nct the study is closed to new participant and followup is ongoing for longterm outcome between feb 2019 and jan we enrolled 595 patient 24 were enrolled directly into the phase 2 safety runin and 571 were randomly assigned to sintilimabbevacizumab biosimilar n380 or sorafenib n191 in the phase 2 part of the trial 24 patient received at least one dose of the study drug with an objective response rate of 250 95 ci 97 based on the preliminary safety and activity data of the phase 2 part in which grade 3 or worse treatmentrelated adverse event occurred in seven 29 of 24 patient the randomised phase 3 part wa started at data cutoff aug 2020 the median followup wa 100 month iqr 87 in the sintilimabbevacizumab biosimilar group and 100 month 87 in the sorafenib group patient in the sintilimabbevacizumab biosimilar group had a significantly longer irrcassessed median progressionfree survival 46 month 95 ci 47 than did patient in the sorafenib group 28 month 22 stratified hazard ratio hr 0 95 ci 070 p00001 in the first interim analysis of overall survival sintilimabbevacizumab biosimilar showed a significantly longer overall survival than did sorafenib median not reached 95 ci not reachednot reached v 104 month 8not reached hr 0 95 ci 075 p00001 the most common grade treatmentemergent adverse event were hypertension 55 14 of 380 patient in the sintilimabbevacizumab biosimilar group v 11 6 of 185 patient in the sorafenib group and palmarplantar erythrodysaesthesia syndrome none v 22 12 123 32 patient in the sintilimabbevacizumab biosimilar group and 36 19 patient in the sorafenib group had serious adverse event treatmentrelated adverse event that led to death occurred in six 2 patient in the sintilimabbevacizumab biosimilar group one patient with abnormal liver function one patient with both hepatic failure and gastrointestinal haemorrhage one patient with interstitial lung disease one patient with both hepatic faliure and hyperkalemia one patient with upper gastrointestinal haemorrhage and one patient with intestinal volvulus and two 1 patient in the sorafenib group one patient with gastrointestinal haemorrhage and one patient with death of unknown cause sintilimab plus ibi305 showed a significant overall survival and progressionfree survival benefit versus sorafenib in the firstline setting for chinese patient with unresectable hbvassociated hepatocellular carcinoma with an acceptable safety profile this combination regimen could provide a novel treatment option for such patient innovent biologics for the chinese translation of the abstract see supplementary material section,"Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Biosimilar Pharmaceuticals, Carcinoma, Hepatocellular, China, Disease Progression, Female, Hepatitis B, Humans, Liver Neoplasms, Male, Middle Aged, Progression-Free Survival, Sorafenib, Time Factors, Young Adult"
34143969,despite advance in the firstline treatment of metastatic renal cell carcinoma rcc there is an unmet need for option to address disease progression during or after treatment with immune checkpoint inhibitor icis pembrolizumab and lenvatinib are active a monotherapies in rcc thus we aimed to evaluate the combination of lenvatinib plus pembrolizumab in these patient we report result of the metastatic rcc cohort from an openlabel phase 1b2 study of lenvatinib plus pembrolizumab in patient aged at least 18 year with selected solid tumour and an eastern cooperative oncology group performance status of oral lenvatinib at 20 mg wa given once daily along with intravenous pembrolizumab at 200 mg once every 3 week patient remained on study drug treatment until disease progression development of unacceptable toxicity or withdrawal of consent efficacy wa analysed in patient with clear cell metastatic rcc receiving study drug by previous therapy grouping treatment naive previously treated ici naive previously treated with at least one line of therapy but not with an antipd1 or antipdl1 ici and ici pretreated ie antipd1 or antipdl1 patient safety wa analysed in all enrolled and treated patient the primary endpoint wa the objective response rate at week 24 per immunerelated response evaluation criterion in solid tumor irrecist by investigator assessment this trial is registered with clinicaltrialsgov nct02501096 and with the eu clinical trial register eudract26 and is closed to new participant between july and oct 145 patient were enrolled in the study two patient had nonclear cell rcc and were excluded from the efficacy analysis one in the treatmentnaive group and one in the icipretreated group thus the population evaluated for efficacy comprised 143 patient n22 in the treatmentnaive group n17 in the previously treated icinaive group and n104 in the icipretreated group all 145 enrolled patient were included in the safety analysis the median followup wa 198 month iqr 144 the number of patient with an objective response at week 24 by irrecist wa 16 727 95 ci 493 of 22 treatmentnaive patient seven 412 181 of 17 previously treated icinaive patient and 58 558 455 of 104 icipretreated patient of 145 patient 82 57 had grade 3 treatmentrelated adverse event and ten 7 had grade 4 treatmentrelated adverse event the most common grade 3 treatmentrelated adverse event wa hypertension 30 21 of 145 patient treatmentrelated serious adverse event occurred in 36 25 patient and there were three treatmentrelated death upper gastrointestinal haemorrhage sudden death and pneumonia lenvatinib plus pembrolizumab showed encouraging antitumour activity and a manageable safety profile and might be an option for postici treatment of metastatic rcc eisai and merck sharp dohme,"Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Europe, Female, Humans, Immune Checkpoint Inhibitors, Kidney Neoplasms, Male, Middle Aged, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines, Time Factors, Treatment Outcome, United States"
34140482,despite the clinical success of the thirdgeneration egfr inhibitor osimertinib a a firstline treatment of egfrmutant nonsmall cell lung cancer nsclc resistance arises due to the acquisition of egfr secondsite mutation and other mechanism which necessitates alternative therapy dacomitinib a panher inhibitor is approved for firstline treatment and result in different acquired egfr mutation than osimertinib that mediate ontarget resistance a combination of osimertinib and dacomitinib could therefore induce more durable response by preventing the emergence of resistance here we present an integrated computational modeling and experimental approach to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy we developed a predictive model that encompasses tumor heterogeneity and intersubject pharmacokinetic variability to predict tumor evolution under different dosing schedule parameterized using in vitro doseresponse data this model wa validated using cell line data and used to identify an optimal combination dosing schedule our schedule wa subsequently confirmed tolerable in an ongoing doseescalation phase i clinical trial nct03810807 with some dose modification demonstrating that our rational modeling approach can be used to identify appropriate dosing for combination therapy in the clinical setting,"Acrylamides, Aniline Compounds, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Cell Survival, Cohort Studies, Computer Simulation, Drug Resistance, Neoplasm, ErbB Receptors, Humans, Lung Neoplasms, Models, Statistical, Models, Theoretical, Mutation, Quinazolinones"
34140248,onalespib is a novel heat shock protein 90 inhibitor hsp90i previous preclinical and clinical study with hsp90i have demonstrated activity in egfrmutant nonsmall cell lung cancer nsclc this study sought to determine the safety and tolerability of onalespib plus erlotinib in egfrmutant nsclc and to evaluate the preliminary efficacy of the combination in epidermal growth factor receptor exon 20 insertion egfrex20ins nsclc standard dose escalation wa followed by a phase ii expansion in egfrex20ins the phase ii component targeted a response rate of 25 versus a background rate of 5 prospective nextgeneration sequencing ng of 70 cancerrelated gene including egfr via plasma circulating tumor dna ctdna wa performed toxicity wa graded by common terminology criterion for adverse event ctcae version and response wa determined by response evaluation criterion in solid tumour recist eleven patient were treated nine dose escalation two dose expansion two doselimiting toxicity dlts occurred in dose level dl 0 and zero in dl 1 minus in 10 egfrex20ins patient no response were observed median progressionfree survival wa month 95 confidence interval and the disease control rate dcr wa 40 median month egfrex20ins wa detected in nine of 10 ctdna sample at baseline ontreatment ctdna clearance wa not observed grade 3 diarrhea wa the predominant toxicity in 45 of patient the recommended phase ii dose is dl 1 minus erlotinib 150 mg orally every morning and onalespib 120 mgm2 intravenously on day and 15 every 28 day overlapping toxicity of erlotinib and onalespib mainly diarrhea limited the tolerability of this combination and limited clinical activity wa observed so the trial wa closed early plasma egfrex20ins ctdna wa detected in the majority of patient failure to clear ctdna wa consistent with lack of tumor response nct02535338,"Aged, Benzamides, California, ErbB Receptors, Erlotinib Hydrochloride, Female, Humans, Isoindoles, Lactates, Lung Neoplasms, Male, Middle Aged, Mutation, Prospective Studies"
34139272,this international randomized doubleblind phase iii study onotasuki52 evaluated nivolumab with bevacizumab and cytotoxic chemotherapy a firstline treatment for nonsquamous nonsmallcell lung cancer nsclc between june 2017 and july this study enrolled treatmentnave patient with stage iiibiv or recurrent nonsquamous nsclc without sensitizing egfr alk or ros1 alteration they were randomly assigned in a 1 1 ratio to receive nivolumab or placebo in combination with carboplatin paclitaxel and bevacizumab every 3 week for up to six cycle followed by nivolumabplacebo with bevacizumab until progressive disease or unacceptable toxicity the primary endpoint wa progressionfree survival pfs assessed by an independent radiology review committee irrc overall 550 patient from japan korea and taiwan were randomized of these patient 273 and 275 received the nivolumab and placebo combination respectively in the present preplanned interim analysis with a median follow up of month the irrcassessed median pfs wa significantly longer in the nivolumab arm than in the placebo arm versus month hazard ratio confidence interval p the pfs benefit wa observed across all patient with any programmed deathligand 1 pdl1 expression level including pdlnegative patient the irrcassessed objective response rate were and in the nivolumab and placebo arm respectively the incidence of treatmentrelated adverse event of grade 3 or 4 wa comparable between the two arm treatmentrelated adverse event leading to death were observed in five and four patient in the nivolumab and placebo arm respectively the tasuki52 regimen should be considered a viable new treatment strategy for treatmentnave patient with advanced nonsquamous nsclc,"Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carboplatin, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, Nivolumab, Paclitaxel, Protein-Tyrosine Kinases, Proto-Oncogene Proteins"
34137282,sotorasib is a firstinclass krasg12c covalent inhibitor in clinical development for the treatment of tumor with the kras pg12c mutation a comprehensive nonclinical safety assessment package including secondarysafety pharmacology and toxicology study wa conducted to support the marketing application for sotorasib sotorasib wa negative in a battery of genotoxicity assay and negative in an in vitro phototoxicity assay based on in vitro assay sotorasib had no offtarget effect against various receptor enzyme including numerous kinase ion channel or transporter consistent with the tumorspecific target distribution ie krasg12c there were no primary pharmacologyrelated ontarget effect identified the kidney wa identified a a target organ in the rat but not the dog renal toxicity in the rat wa characterized by tubular degeneration and necrosis restricted to a specific region suggesting that the toxicity wa attributed to the local formation of a putative toxic reactive metabolite in the month dog study adaptive change of hepatocellular hypertrophy due to drug metabolizing enzyme induction were observed in the liver that wa associated with secondary effect in the pituitary and thyroid gland sotorasib wa not teratogenic and had no direct effect on embryofetal development in the rat or rabbit human dog and rat circulating metabolite m m and m raised no clinically relevant safety concern based on the general toxicology study primarysecondary pharmacology screening an in vitro human ethergogorelated gene assay or mutagenicity assessment overall the result of the nonclinical safety program support a high benefitrisk ratio of sotorasib for the treatment of patient with kras pg12cmutated tumor,"Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Humans, Mutation, Neoplasms, Piperazines, Proto-Oncogene Proteins p21(ras), Pyridines, Pyrimidines"
34136985,blocker having specific affinity to adrenergic receptor are routinely used to treat cardiovascular problem additionally it ha been demonstrated that these drug can be effective in treating apoptosisrelated disease the current study wa conducted to investigate the cytotoxic and apoptotic effect of 1 selective esmolol 2 selective ici and nonselective nadolol blocker on the cancerous and healthy lung cell mtt test wa used to evaluate cytotoxicity apoptotic action were examined by using annexin vfitcpi assay jc1 staining ro test and the determination of the caspase4 and bcl bax baxbcl and jnk level although the mrc5 showed greater resistance than a549 cell the blocker at m exhibited different level of cytotoxic effect on both lung cell line esmolol wa found to be the most ineffective blocker and the increase in bcl2 protein level were appeared to be effective in resistance to this drug the increase in reactive oxygen specie ro together with the increase in caspase4 and bax protein level have been shown to play a role in ici induced lung cell death nadolol wa the most effective blocker increasing the total apoptotic cell population in both lung cell which wa based on both mitochondrial and endoplasmic reticulum stress when the selectivity of the blocker are considered it seems that 2 specific antagonism predominantly mediated the death of lung cell and the overwhelming factor causing apoptosis mainly varied depending on the selectivity of the blocker,"A549 Cells, Adrenergic beta-Antagonists, Antineoplastic Agents, Apoptosis, Cell Differentiation, Cell Line, Tumor, Cell Proliferation, Endoplasmic Reticulum Stress, Humans, Lung, Lung Neoplasms, Membrane Potential, Mitochondrial, Mitochondria, Reactive Oxygen Species"
34134554,arsenic trioxide ato and alltrans retinoic acid atra combination therapy yield high complete remission and diseasefree survival rate in acute promyelocytic leukemia apl ato is dosed on actual body weight and high ato do in overweight patient may contribute to increased toxicity we performed a retrospective twocenter study comparing toxicity in patient who received the lococo et al atraato regimen with capped ato 10 mgdose and noncapped ato 10 mgdose a total of 44 patient were included 15 received do 10 mg and 29 received 10 mg during induction there wa no difference in the incidence of grade 3 hepatotoxicity grade 3 qtc prolongation neurotoxicity and cardiac toxicity between group in consolidation patient receiving 10 mgdose experienced a greater incidence of neurotoxicity v p capping do saved patient and reduced waste of partiallyused vial at a median followup of 27 month no disease relapse occurred in either group this represents an opportunity to improve the safety profile of this highly effective regimen,"Antineoplastic Combined Chemotherapy Protocols, Arsenic Trioxide, Arsenicals, Humans, Leukemia, Promyelocytic, Acute, Oxides, Retrospective Studies, Treatment Outcome, Tretinoin"
34134553,polyadenosine diphosphate ribose polymerase inhibitor parpi have become a cornerstone of therapy in the management ovarian cancer and other cancer parpi are associated with significant toxicity and management strategy are primarily founded on clinical trial experience this study aimed to provide an evaluation of patient receiving parpi therapy within an academic healthsystem a retrospective observational study of adult patient with gynecologic malignancy wa conducted at the university of pennsylvania health system data wa collected on patient prescribed a parpi between december 2014 and october the primary endpoint wa the status of parpi therapy at the end of the study period key secondary endpoint included toxicity management strategy time to discontinuation due to toxicity progression free survival pfs and overall survival o of the 85 patient included 45 53 received olaparib 24 28 niraparib and 16 19 rucaparib twentynine patient 34 continued on therapy 15 18 discontinued due to toxicity and 41 48 discontinued due to progression fiftyone percent of patient required a dose reduction due to toxicity the median time to discontinuation due to toxicity wa 69 day median pfs wa 181 day and median o wa 338 day parpi therapy is associated with numerous toxicity that are best managed through a multimodal approach importantly about half the patient in the current study required a dose reduction overall this observational study outline the incidence of parpi toxicity and review potential management strategy further guiding practitioner in an area with limited realworld experience,"Adult, Humans, Female, Poly(ADP-ribose) Polymerase Inhibitors, Retrospective Studies, Antineoplastic Agents, Ovarian Neoplasms, Endometrial Neoplasms"
34134548,malignant central airway obstruction is a lifethreatening condition that often cause respiratory failure in many case treatment of tumor in rigid bronchoscopy must be performed urgently soothing respiratory symptom and improving patient quality of life in many case reducing time to and allowing application of oncologic therapy immunooncologic therapy target the immune system selectively and are therefore much le toxic than standard chemotherapy sometimes leading to outstanding result in advanced cancer for which there were no effective treatment until a few year ago this report show the effect of the joint application of rigid bronchoscopy and targeted immunotherapy in an emergency scenario resulting in an unexpected extraordinary therapeutic success,"Adenocarcinoma of Lung, Airway Obstruction, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Bronchoscopy, Disease Management, Emergency Medical Services, Female, Humans, Immunotherapy, Middle Aged, Molecular Targeted Therapy, Symptom Assessment, Tomography, X-Ray Computed, Treatment Outcome"
34134525,with the advent of novel cancer therapeutic and improved screening more patient are surviving a cancer diagnosis or living longer with advanced disease many of these treatment have associated cardiovascular toxicity that can manifest in both an acute and a delayed fashion arrhythmia are an increasingly identified complication with unique management challenge in the cancer population the purpose of this scientific statement is to summarize the current state of knowledge regarding arrhythmia identification and treatment in patient with cancer atrial tachyarrhythmias particularly atrial fibrillation are most common but ventricular arrhythmia including those related to treatmentinduced qt prolongation and bradyarrhythmias can also occur despite increased recognition dedicated prospective study evaluating true incidence are lacking moreover few study have addressed appropriate prevention and treatment strategy a such this scientific statement serf to mobilize the cardiooncology electrophysiology and oncology community to develop clinical and scientific collaboration that will improve the care of patient with cancer who have arrhythmia,"Algorithms, Antineoplastic Combined Chemotherapy Protocols, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Biomarkers, Blood Coagulation, Cardiotoxicity, Clinical Decision-Making, Diagnosis, Differential, Disease Management, Disease Susceptibility, Electrocardiography, Humans, Immunotherapy, Neoplasms, Severity of Illness Index, Signal Transduction, Thrombosis"
34127515,the advent of checkpoint blockadebased immunotherapy is rapidly changing the management of lung cancer whereas past anticancer drug primary toxicity wa hematologic the newer agent have primarily autoimmune toxicity thus it is no longer enough for oncology practitioner to be skilled only in hematology they must also understand management of autoimmune condition leveraging the skill of the rheumatologist endocrinologist and gastroenterologist in the process herein we describe the mechanism of action and toxicity associated with immune checkpoint blockade in patient with lung cancer and provide a framework for management of adverse event,"Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Lung Neoplasms"
34127228,multifunctional theranostic nanoplatforms integrated of imaging function multimodality therapy stimuliresponsiveness and targeted delivery are of highly desirable attribute in achieving precise medicine however preparation of multifunctional nanoplatforms often involves laborious multiple step and inevitably utilizes lowbiocompatible or nonfunctional component herein we report a facile onestep selfassembly strategy to fabricate hyaluronic acid habased multifunctional tumor theranostic nanoplatform by employing magnetic resonance imaging mri agent mn a a reversible crosslink agent for histidinegrafted ha along with simultaneously loading chemotherapeutic agent doxorubicin hydrochloride dox and photodynamic therapy agent chlorin e to realize mriguided targeted chemophotodynamic cancer therapy the targeted delivery and stimuliresponsive payload release were demonstrated in vitro and in vivo furthermore the combined chemophotodynamic therapy of the nanoassembly dramatically improved the cancer therapeutic outcome in comparison with that of free dox and nanoplatform solely loaded dox in a melanoma bearing mouse our one step assemble strategy is of great potential in clinic transformation,"Animals, Antineoplastic Agents, Cell Line, Tumor, Chlorophyllides, Doxorubicin, Drug Carriers, Histidine, Hyaluronic Acid, Light, Manganese, Mice, Inbred C57BL, Nanogels, Neoplasms, Photochemotherapy, Photosensitizing Agents, Porphyrins, Precision Medicine, Singlet Oxygen, Mice"
34127219,the application of traditional chemotherapy drug for lung cancer ha obvious limitation such a toxic side effect uncontrolled drugrelease poor bioavailability and drugresistance thus to address the limitation of free drug and improve treatment effect we developed novel t7 peptidemodified nanoparticles tcmcsbape cbt based on carboxymethyl chitosan cmcs which is capable of targeted binding to the transferrin receptor tfr expressed on lung cancer cell and precisely regulating drugrelease according to the ph value and reactive oxygen specie ro level the result showed that the drugloading content of docetaxel dtx and curcumin cur wa approximately and respectively good biosafety wa obtained even when the concentration wa a high a 500 gml more importantly the tcmcsbapedtxcur cbtdc complex exhibited better in vitro and in vivo antitumor effect than dtx monotherapy and other nanocarriers loaded with dtx and cur alone furthermore we determined that cbtdc can ameliorate the immunosuppressive microenvironment to promote the inhibition of tumor growth collectively the current finding help lay the foundation for combinatorial lung cancer treatment,"Animals, Antineoplastic Agents, Cell Line, Tumor, Chitosan, Curcumin, Docetaxel, Drug Carriers, Drug Liberation, Humans, Hydrogen-Ion Concentration, Lung, Lung Neoplasms, Lymphocytes, Tumor-Infiltrating, Macrophages, Mice, Myeloid-Derived Suppressor Cells, Nanoparticles, Reactive Oxygen Species, T-Lymphocytes, Tumor Microenvironment, Xenograft Model Antitumor Assays"
34126703,no standard salvage regimen is available for relapsed or refractory sarcoma we investigated the efficacy and toxicity of the vincristine irinotecan and temozolomide combination vit for relapsed or refractory sarcoma of variable histology in child and young adult we retrospectively reviewed data from the relapsed or refractory sarcoma patient who were treated with vit the vit protocol wa given every 3 week a follows vincristine mgm2 intravenously on day irinotecan 50 mgmday intravenously on day and temozolomide 100 mgmday orally on day a total of 26 patient 12 male with various sarcoma histology were included in the study most common diagnosis wa rhabdomyosarcoma n8 followed by osteosarcoma n7 median age at the start of vit wa year range to vit wa delivered a 2nd to 7th line of treatment with 4th line most common median number of vit course given wa 3 range 1 to 18 of the 25 evaluable patient there wa two partial response pr and 11 stable disease sd with an overall control rate complete remissionprsd of 52 pr wa seen in one 50 of the two evaluable patient with ewing sarcoma and one of the seven patient with osteosarcoma overall survival and progressionfree survival rate were and at 1 year and and at 2 year respectively there wa no treatmentrelated mortality the vit regimen wa effective and relatively safe in our cohort of sarcoma patient,"Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Female, Humans, Irinotecan, Male, Neoplasm Recurrence, Local, Osteosarcoma, Retrospective Studies, Sarcoma, Ewing, Temozolomide, Vincristine, Young Adult"
34126112,who suggests that colon cancer incidence are rising steadily propelling researcher to search for novel chemotherapeutic option metalbased chemotherapy is a potential forte to explore rutheniumbased complex exhibiting the capability to influence a variety of cellular target we discovered the chemotherapeutic effect of rutheniumrifampicin complex on ht29 and hct116 human colorectal cell line and on a chemically developed murine colorectal cancer model complex wa synthesized and characterized by analytical technique and evaluation of antioxidant potential along with dna binding capability the complex minimizes cellular propagation and initiate apoptotic event in the colon cancer cell line of ht29 and hct the result of the in vivo study suggest that the complex ha been successful in minimizing the wide spectrum of aberrant crypt focus and hyperplastic lesion a well a encouraging elevated amount of cat sod and glutathione along with that p53 could be modulated by the rutheniumrifampicin complex to interfere with apoptosis in colon carcinoma initiated by the intrinsic apoptotic trail facilitated through bcl2 and bax thus controlling the aktmtorvegf pathway coupled through the wntcatenin trail rutheniumrifampicin chemotherapy could interrupt retract or interrupt the progression of colorectal cancer through modifying intrinsic apoptosis including the antiangiogenic pathway thereby achieving the function of a potential contender in chemotherapy in the near future,"Adenocarcinoma, Animals, Antineoplastic Agents, Apoptosis, Cell Cycle, Colon, Colonic Neoplasms, Drug Combinations, Female, HCT116 Cells, HT29 Cells, Humans, Male, Mice, Inbred BALB C, Proto-Oncogene Proteins c-akt, Rats, Wistar, Rifampin, Ruthenium Compounds, Signal Transduction, TOR Serine-Threonine Kinases, Tumor Microenvironment, Tumor Suppressor Protein p53, Vascular Endothelial Growth Factor A, Mice, Rats"
34125951,it remains unclear whether people with nonmuscle invasive bladder cancer nmibc benefit from intravesical gemcitabine compared to other agent in the primary or recurrent setting following transurethral resection of a bladder tumor this is an update of a cochrane review first published in since that time several randomized controlled trial rcts have been reported making this update relevant objective to as the comparative effectiveness and toxicity of intravesical gemcitabine instillation for nmibc we performed a comprehensive literature search of the cochrane library medline embase four other database trial registry and conference proceeding to 11 september with no restriction on the language or status of publication we included rcts in which participant received intravesical gemcitabine for primary or recurrent nmibc two review author independently assessed the included study and extracted data for the primary outcome time to recurrence time to progression grade iii to v adverse event determined by the common terminology criterion for adverse event version ctcae v and the secondary outcome time to death from bladder cancer time to death from any cause grade i or ii adverse event determined by the ctcae v and diseasespecific quality of life we performed statistical analysis using a randomeffects model and rated the certainty of the evidence using grade we included seven study with 1222 participant with nmibc across five comparison this abstract focus on the primary outcome of the three most clinically relevant comparison gemcitabine versus saline based on two year to four year followup gemcitabine may reduce the risk of recurrence over time compared to saline 39 versus 47 recurrence rate hazard ratio hr 95 confidence interval ci to study participant 734 i2 49 lowcertainty evidence but the ci included the possibility of no effect gemcitabine may result in little to no difference in the risk of progression over time compared to saline versus progression rate hr 95 ci to study participant 654 i2 53 lowcertainty evidence gemcitabine may result in little to no difference in the ctcae grade iii to v adverse event compared to saline versus adverse event rate risk ratio rr 95 ci to study participant 668 i2 24 lowcertainty evidence gemcitabine versus mitomycin based on three year followup study participant 109 gemcitabine may reduce the risk of recurrence over time compared to mitomycin 17 versus 40 recurrence rate hr 95 ci to lowcertainty evidence gemcitabine may reduce the risk of progression over time compared to mitomycin 11 versus 18 progression rate hr 95 ci to lowcertainty evidence but the ci included the possibility of no effect we are very uncertain about the effect of gemcitabine on the ctcae grade iii to v adverse event compared to mitomycin rr 95 ci to very lowcertainty evidence the analysis wa only based on recurrent nmibc gemcitabine versus bacillus calmettegurin bcg for recurrent onecourse bcg failure highrisk nmibc based on 6 month to 22 month followup study participant 80 gemcitabine may reduce the risk of recurrence compared to bcg 41 versus 97 recurrence rate hr 95 ci to lowcertainty evidence and progression over time 16 versus 33 progression rate hr 95 ci to lowcertainty evidence we are very uncertain about the effect of gemcitabine on the ctcae grade iii to v adverse event compared to bcg rr 95 ci to very lowcertainty evidence in addition the review provides information on the comparison of gemcitabine versus bcg and gemcitabine versus onethird dose bcg author conclusion based on finding of this review gemcitabine may have a more favorable impact on recurrence and progressionfree survival than mitomycin but we are very uncertain a to how major adverse event compare the same is true when comparing gemcitabine to bcg in individual with high risk disease who have previously failed bcg the underlying low to very lowcertainty evidence indicates that our confidence in these result is limited the true effect may be substantially different from these finding therefore better quality study are needed,"Adjuvants, Immunologic, Administration, Intravesical, Antibiotics, Antineoplastic, Antimetabolites, Antineoplastic, BCG Vaccine, Bias, Cause of Death, Confidence Intervals, Deoxycytidine, Disease Progression, Drug Administration Schedule, Humans, Mitomycin, Neoplasm Recurrence, Local, Randomized Controlled Trials as Topic, Saline Solution, Urinary Bladder Neoplasms, Gemcitabine"
34125338,gemcitabine plus nabpaclitaxel gnp is the firstline chemotherapeutic regimen for metastatic pancreatic cancer mpc however there are concern regarding it safety in patient undergoing biliary stent placement this study aimed to examine the tolerability and efficacy of gnp in mpc patient who underwent biliary stent placement a total of 105 mpc patient who had received gnp treatment between 2015 and 2020 were included and investigated the patient were divided into two group those undergoing biliary stent placement for symptomatic biliary obstruction bo withbo group and those without biliary stent placement withoutbo group the best tumor response overall survival o and adverse event in each group were compared the partial response stable disease and progressive disease rate were 22 61 and in the withbo group and and in the withoutbo group respectively with no significant difference the median o wa month and month in the withbo and withoutbo group respectively p grade 3 or higher biliary tractrelated event were significantly more common in the withbo group than in the withoutbo group p but all event were managed successfully by urgent intervention the rate of any treatmentrelated toxicity including febrile neutropenia were not significantly different and there were no chemotherapyrelated death in either group gnp can be a tolerable and effective in mpc patient with biliary stent a in those without biliary stent however careful management and appropriate reintervention to treat biliary tractrelated adverse event are required,"Albumins, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract, Deoxycytidine, Humans, Paclitaxel, Pancreatic Neoplasms, Stents, Treatment Outcome, Gemcitabine"
34121690,bleomycin etoposide and cisplatin bep regimen is the standard treatment for germcell tumor gcts bleomycininduced pulmonary toxicity bpt is fatal and doselimiting toxicity associated with this regimen in this study we aimed to identify the frequency and risk factor of bpt in south indian gct patient receiving bep regimen the study wa carried out in the department of medical oncology regional cancer centre at a tertiary care hospital in south india all the patient with gct testicular and ovarian who were receiving bep regimen from december 2014 to may 2018 were included in the study bpt wa defined a the presence of radiological feature andor clinical symptom during or posttreatment bpt wa observed in 11 27 patient of 41 analyzed patient five 12 patient developed bpt during treatment whereas six 15 patient developed bpt posttreatment cumulative bleomycin dose 240 mg relative risk confidence interval p wa found to increase the risk of bpt threeyear overall survival in patient with and without toxicity wa 82 and 93 respectively the frequency of bpt in the study population is 27 and cumulative bleomycin dose 240 mg ha been found to be associated with increased risk of developing bpt bpt doe not negatively impact survival outcome in gct patient receiving bep regimen,"Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Cisplatin, Etoposide, Female, Follow-Up Studies, Humans, Incidence, India, Lung, Lung Diseases, Male, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Risk Factors, Survival Analysis, Testicular Neoplasms, Tomography, X-Ray Computed, Treatment Outcome, Young Adult"
34121365,a low skeletal muscle mass smm ha been associated with increased toxicity and shorter survival in cancer patient treated with capecitabine an oral prodrug of fluorouracil fu capecitabine and it metabolite are highly watersoluble and therefore more likely to distribute to lean tissue the pharmacokinetics pk in patient with a low smm could be changed for example by reaching higher maximum plasma concentration in this study we aimed to examine whether the association between a low smm and increased toxicity and shorter survival could be explained by altered pk of capecitabine and it metabolite previously a population pk model of capecitabine and metabolite in patient with solid tumor wa developed in our analysis we included patient from this previous analysis for which evaluable abdominal computed tomography ctscans were available smm wa measured on ctscans by single slice evaluation at the third lumbar vertebra using the sliceomatic software the previously developed population pk model wa extended with smm a a covariate to as the association between smm and capecitabine and metabolite pk pk and smm data were available from 151 cancer patient with solid tumor from the included patient 55 had a low smm no relevant relationship were found between smm and the pk parameter of capecitabine and the active and toxic metabolite fu smm only correlated with the pk of the most hydrophilic but inactive and nontoxic metabolite fluoroalanine fbal patient with a low smm had a smaller apparent volume of distribution and lower apparent clearance of fbal no alteration in pk of capecitabine and the active and toxic metabolite fu were observed in patient with a low smm therefore the previously identified increased toxicity and shorter survival in patient with a low smm could not be explained by change in pharmacokinetic characteristic of capecitabine and metabolite,"Adult, Aged, Antimetabolites, Antineoplastic, Capecitabine, Female, Fluorouracil, Humans, Male, Middle Aged, Muscle, Skeletal, Neoplasms, Prodrugs, Sex Factors, Tomography, X-Ray Computed, Treatment Outcome, beta-Alanine"
34121352,recent study highlight the regulatory role of arachidonate lipoxygenase5 alox5 and it metabolite hydroxyeicosatetraenoic acid hete in cancer tumorigenesis and progression in this study we analyzed the expression biological function and the downstream signaling of alox5 in gastric cancer alox5 protein level were measured using ihc and elisa growth migration and survival assay were performed phosphorylation of molecule involved in growth and survival signaling were analyzed by wb analysis of variance and ttest were used for statistic analysis alox5 and hete level were upregulated in gastric cancer patient alox5 overexpression or hete addition activates gastric cancer cell and reduces chemotherapy efficacy in contrast alox5 inhibition via genetic and pharmacological approach suppresses gastric cancer cell and enhances chemotherapy efficacy in addition alox5 inhibition led to suppression of erkmediated signaling pathway whereas aloxhete activates erkmediated signaling in gastric cancer cell our work demonstrates the critical role of aloxhete in gastric cancer and provides preclinical evidence to initialize clinical trial using zileuton in combination with chemotherapy for treating gastric cancer,"Analysis of Variance, Antineoplastic Agents, Arachidonate 5-Lipoxygenase, Cell Proliferation, Cell Survival, Disease Progression, Humans, Hydroxyeicosatetraenoic Acids, Hydroxyurea, Lipoxygenase Inhibitors, MAP Kinase Signaling System, Phosphorylation, Stomach Neoplasms, Up-Regulation"
34121184,idelalisib idl is an oral firstinclass phosphatidylinositol kinase delta pi3k inhibitor approved for chronic lymphocytic leukaemia cll alongside rituximab r since however little data exist on routine practice the retroidel wa a protocolled retrospective study of 110 patient n 27 frontline 1l who received idlr the primary endpoint wa clinical overall response rate orr the median range followup of the whole cohort wa 302 09 month the median range age wa 72 year tumour protein pdisruption wa common 100 1l 325 relapsedrefractory rr the best orr intentiontotreat wa 882 1l 963 rr 855 overall the median eventfree survival mefs wa 203 month and timetonext treatment wa 292 month the mefs for 1l patient wa 187 month and rr patient wa 217 month the year overall survival wa 561 95 confidence interval 453 idl wa discontinued in 873 n 96 more patient discontinued due to adverse event in the frontline setting 1l 630 v rr 446 and due to progressive disease in rr patient 205 v 37 in 1l lower respiratory tract infectionpneumonia were reported in 345 grade 191 diarrhoea in 309 grade 64 and colitis in 91 grade 55 overall these data describe clear efficacy for idlr in routine practice no new safety signal were identified although careful management of known toxicity is required,"Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Gastrointestinal Diseases, Hematologic Diseases, Humans, Ireland, Kaplan-Meier Estimate, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Phosphoinositide-3 Kinase Inhibitors, Progression-Free Survival, Purines, Quinazolinones, Respiratory Tract Diseases, Retrospective Studies, Rituximab, Salvage Therapy, Treatment Outcome, United Kingdom"
34120223,chemotherapyrelated amenorrhea cra is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause here we compare cra rate with paclitaxel ttrastuzumab h to that with adotrastuzumab emtansine tdm1 patient with t1n0 her2 earlystage breast cancer ebc enrolled on the atempt trial and were randomized 31 to tdm1 mgkg iv every q 3 week w 17 v t 80 mgm2 with h iv qw 12 4 mgkg load 2 mgkg followed by h 6 mgkg iv q3w 13 enrollee who selfreported a premenopausal were asked to complete menstrual survey at baseline and every month for 60 month month cra no period reported during prior 6 month on month survey wa the primary endpoint of this analysis of 512 atempt enrollee 123 who began protocol therapy and answered baseline and at least one followup menstrual survey were premenopausal at enrollment 76 had menstrual data available at 18 month without having received a gonadotropinreleasing hormone agonist or undergone hysterectomy andor oophorectomy median age wa 45 range among 18 who had received th and 46 range among 58 who had received tdm the month rate of cra wa 50 after th and 24 after tdm1 p amenorrhea at 18 month wa le likely in recipient of adjuvant tdm1 than th future study are needed to understand how tdm1 impact risk of infertility and permanent menopause and to as amenorrhea rate when tdm1 is administered after standard herdirected chemotherapy regimen,"Ado-Trastuzumab Emtansine, Adult, Amenorrhea, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Maytansine, Middle Aged, Paclitaxel, Receptor, ErbB-2, Trastuzumab, Young Adult"
34119547,breast cancer ha been one of the top chronic and lifethreatening disease worldwide nanodrug therapeutic system have proved their efficacy a a selective treatment compared to the traditional one that are associated with serious adverse effect here biodegradable chitosan nanoparticles csnps were synthesized to provide selective and sustained release of doxorubicin dox within the breast tumor microenvironment csnps surface wa modified using polyethylene glycol peg to enhance their blood circulation timing to provide high drug selectivity csnps functionalized with two different type of breast cancerspecific monoclonal antibody mab antihuman mammaglobin antihmam and antihuman epidermal growth factor antiher2 antihmam pegylated dox loaded csnps and antiher2 pegylated dox loaded csnps nanoformulations were the most cytotoxic against mcf7 cancer cell than l929 normal cell compared to free dox finally we believe that dosedependent system toxicity of freely ingested dox can be managed with such targeted nanoformulated drug delivery platform,"Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cell Line, Cell Proliferation, Cell Survival, Chitosan, Delayed-Action Preparations, Dose-Response Relationship, Drug, Doxorubicin, Female, Gene Expression Regulation, Neoplastic, Humans, Hydrogen-Ion Concentration, MCF-7 Cells, Mammaglobin A, Mice, Nanoparticles, Polyethylene Glycols, Receptor, ErbB-2, Tumor Microenvironment"
34119189,current challenge of using cytokine is it poor distribution and systemic side effect to avoid this issue we prepared the tumortargeted and microenvironmentresponsive nanocarriers trn which were consisted of tocopheryl succinate tos loaded mesoporous silica nanoparticles a core and surfacemodified by thioketallinkage electrostatically coated with carboxymethyl chitin and further anchored glucoseregulated protein binding peptide a shell for encapsulating il trn showed a size of 260 nm after encapsulated il12 and tos with loading content of and respectively and exhibited good biocompatibility to 4 t1 cell and macrophage moreover iltos loaded trn displayed obvious antitumor efficacy on balbc nude mouse bearing 4 t1 tumor which wa derived from promoted targeting to tumor tissue endocytosed by macrophage and locally release il12 to subsequently repolarize tumorassociated macrophage into tumoricidal m1 phenotype with reduced side effect the nanosystem exhibited a a promising strategy with functional conversion of macrophage in tumor microenvironment for antitumor therapy,"Animals, Antineoplastic Agents, Cell Line, Tumor, Cell Polarity, Chitin, Drug Carriers, Immunotherapy, Interleukin-12, Mice, Mice, Inbred BALB C, Mice, Nude, Nanoparticles, Neoplasms, RAW 264.7 Cells, Silicon Dioxide, Tumor-Associated Macrophages, alpha-Tocopherol"
34119144,the fruit of lycium ruthenicum murr is used a traditional medicine and functional food previously we reported that one rgi pectin from this fruit might inhibit pancreatic cancer cell growth we further hypothesized that there might be other type of polysaccharide in this fruit also have antitumor effect here we showed novel structure of a homogeneous polysaccharide named lrps2 from this fruit and it antipancreatic cancer effect structure analysis suggested that lrps2 wa a novel arabinogalactan with the molecular weight mw of kda bioactivity test showed that lrps2 might attenuate the proliferation of pancreatic cancer cell in vitro and in vivo without significant cytotoxicity to normal pancreatic hpdec7 cell and lo2 liver cell mechanism study indicated that it might induce apoptosis of bxpc3 by inactivating p38 mapknfb and gsk3catenin signaling pathway these result suggested that lrps2 could be a potential antitumor leading compound for functional food and new drug development chemical compound arabinogalactan pectin galactan arabinan rn hh lrps lrps,"Animals, Antineoplastic Agents, Apoptosis, Carbohydrate Sequence, Cell Line, Cell Proliferation, Fruit, Galactans, Humans, Lycium, Mice, Inbred BALB C, Mice, Nude, Pancreatic Neoplasms, Signal Transduction, Xenograft Model Antitumor Assays, Mice"
34118341,tabebuia pallida lindl miers t pallida is a wellknown native caribbean medicinal plant the leaf and bark of t pallida are used a traditional medicine in the form of herbal or medicinal tea to manage cancer fever and pain moreover extract from the leaf of t pallida showed anticancer activity however the chemical profile and mechanism of anticancer activity of t pallida leaf tpl stem bark tpsb root bark tprb and flower tpf remain unexplored the present study wa designed to explore the regulation of apoptosis by t pallida using ehrlich ascites carcinoma eac cultured cell and an eac mouse model lcesimsms wa used for compositional analysis of t pallida extract dried and powdered tpl tpsb tprb and tpf were extracted with 80 methanol using cultured eac cell and eacbearing mouse with and without these extract anticancer activity were studied by assessing cytotoxicity and tumor cell growth inhibition change in life span of mouse and hematological and biochemical parameter apoptosis wa analyzed by microscopy and expression of selected apoptosisrelated gene bcl bclxl nfb parp p bax caspase3 and 8 using rtpcr lcesims analysis wa performed to identify the major compound from active extract computer aided analysis wa undertaken to sort out the bestfit phytoconstituent of total ten isolated compound of this plant for antioxidant and anticancer activity in eac mouse compared with untreated control the tpl extract exhibited the highest cancer cell toxicity with significant tumor cell growth inhibition p reduced ascites by body weight p increased the life span p normalized blood parameter rbcwbc count and increased the level of superoxide dismutase and catalase tpltreated eac cell showed increased apoptotic characteristic of membrane blebbing chromatin condensation and nuclear fragmentation and caspase3 activation compared with untreated eac cell moreover annexin vfitc and propidium iodide signal were greatly enhanced in response to tpl treatment indicating apoptosis induction pro and antiapoptotic signaling after tpl treatment demonstrated upregulated p bax and parp and downregulated nfb bcl2 and bclxl expression suggesting that tpl shift the balance of pro and antiapoptotic gene towards cell death lcesims data of tpl showed a mixture of glycoside lapachol and quercetin antioxidant and it derivative that were significantly linked to cancer cell target the compound pelargonidinoglucoside wa found to be most effective in computer aided model in conclusion the tpl extract of t pallida posse significant anticancer activity the tumor suppressive mechanism is due to apoptosis induced by activation of antioxidant enzyme and caspase and mediated by a change in the balance of pro and antiapoptotic gene that promotes cell death,"Animals, Antineoplastic Agents, Apoptosis, Carcinoma, Caspase 3, Caspase 8, Cell Line, Tumor, Cell Survival, Dose-Response Relationship, Drug, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Neoplasms, Experimental, Phytotherapy, Plant Extracts, Plant Leaves"
34117724,adriamycin adm is currently one of the most effective chemotherapeutic agent in breast cancer treatment however growing resistance to adm could lead to treatment failure and poor outcome plac8 wa reported a a novel highly conserved protein and functioned a an oncogene or tumour suppressor in various tumour here we found higher plac8 expression wa correlated with worse outcome and aggressive phenotype in breast cancer breast cancer patient with higher plac8 expression showed potential adm resistance in vitro experiment further confirmed that plac8 inhibited by sirna or enforced overexpression by infecting pcdnacplac8 plasmid correspondingly decreased or increased adm resistance subsequently we demonstrated that ectopic plac8 expression in mcfadmr cell blocked the accumulation of the autophagyassociated protein lc3 and resulted in cellular accumulation of p rapamycintriggered autophagy significantly increased cell response to adm while the autophagy inhibitor ma enhanced adm resistance ma and plac8 could synergistically cause adm resistance via blocking the autophagy process additionally the downregulation of p62 by sirna attenuated the activation of autophagy and plac8 expression in breast cancer cell thus our finding suggest that plac through the participation of p inhibits autophagy and consequently result in adm resistance in breast cancer placp62 pathway may act a novel therapeutic target in breast cancer treatment and ha potential clinical application in overcoming adm resistance,"Animals, Antibiotics, Antineoplastic, Autophagy, Doxorubicin, Drug Resistance, Neoplasm, Female, Humans, MCF-7 Cells, Mammary Neoplasms, Experimental, Mice, Mice, Nude, Proteins"
34115855,in a phase i study afatinib 30 mgbody daily plus bevacizumab 15 mgkg every 3 week wa well tolerated and showed favourable outcome in patient with epidermal growth factor receptor egfrmutant advanced nonsmallcell lung cancer herein we report the year progressionfree survival overall survival and safety profile of these patient chemonave patient with egfrmutant advanced nonsmallcell lung cancer were enrolled one group of patient received 40 mg afatinib daily and 15 mgkg bevacizumab every 3 week level 0 until disease progression or severe toxicity another group of patient received 30 mg afatinib daily and the same dose of bevacizumab level 1 doselimiting toxicity wa the primary endpoint whereas longterm progressionfree survival overall survival and tolerability were secondary endpoint survival rate were estimated using the kaplanmeier method the study included 19 patient level 0 5 level 1 14 until the data cutoff date seven patient continued the treatment whereas 12 discontinued due to disease progression n 5 or toxicity n 7 the median pfs wa month while the median overall survival wa not reached all patient developed adverse effect diarrhoea and skin rash were frequently observed a severe adverse event grade 3 a secondary egfr mutation t790m wa detected in two patient after progression prolonged followup revealed that combination therapy with afatinib and bevacizumab might improve survival outcome in egfrmutant advanced nonsmallcell lung cancer patient and seems to be promising umin,"Afatinib, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Humans, Lung Neoplasms, Mutation, Progression-Free Survival, Protein Kinase Inhibitors, Survival Rate, Treatment Outcome"
34112795,breast tumor generally consist of a diverse population of cell with varying gene expression profile breast tumor heterogeneity is a major factor contributing to drug resistance recurrence and metastasis after chemotherapy antibodydrug conjugate adcs are emerging chemotherapeutic agent with striking clinical success including tdm1 for herpositive breast cancer however these adcs often suffer from issue associated with intratumor heterogeneity here we show that homogeneous adcs containing two distinct payload are a promising drug class for addressing this clinical challenge our conjugate show herspecific cell killing potency desirable pharmacokinetic profile minimal inflammatory response and marginal toxicity at therapeutic do notably a dualdrug adc exerts greater treatment effect and survival benefit than doe coadministration of two singledrug variant in xenograft mouse model representing intratumor her2 heterogeneity and elevated drug resistance our finding highlight the therapeutic potential of the dualdrug adc format for treating refractory breast cancer and perhaps other cancer,"Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Line, Tumor, Female, Humans, Immunoconjugates, Immunohistochemistry, Inflammation, Mice, Oligopeptides, Receptor, ErbB-2, Trastuzumab, Xenograft Model Antitumor Assays"
34111539,chickpea wa used in both greek and indian traditional medicine for hormonal related condition a menstrual induction acceleration of parturation treatment of retained placenta and stimulation of lactation chickpea cicer arietinum sprout isoflavone isolates exhibited reasonable estrogenic activity isoflavones a subtype of phytoestrogens are plant derivative with moderate estrogenic activity that tend to have protective effect on hormonal and metabolic abnormality of woman with polycystic ovary syndrome pcos in this study we investigated the effect of uplcesims characterized cicer arietinum l seed ethanol extract cse on ovarian hormone oxidative response and ovarian histological change on induced pcos rat model thirtyfive rat were divided into five group including negative control pcos and treatment group pcos wa induced using letrozole 1 mgkg daily orally for 21 day each treatment group wa treated with one of the following for 28 day after induction of pcos clomiphene citrate 1 mgkg and cse at 250 and 500 mgkg ovary and uterus were excised weighed and their section were used for quantitative realtime reverse transcriptase polymerase chain reaction antioxidant assay and histomorphometric study of the ovary the antioxidant assay histopathological examination hormonal and metabolic profile and cyp11a1steroidogenic enzyme mrna expression were measured in all treatment group ovarian weight wa significantly decreased despite having no significant effect on uterine weight histomorphometric study in the treatment group revealed a significant decrease in the number and diameter of cystic follicle a significant increase in granulosa cell thickness while thickness of theca cell wa significantly decreased when compared to pcos hormone level metabolic profile and antioxidant status were improved in the treatment group moreover cyp11a1 mrna expression wa significantly downregulated in the treatment group compared to pcos in the current study cse enhanced the reproductive and metabolic disorder which were associated with pcos induction for the first time we have highlighted the effect of cse in treating pcos and it associated manifestation,"Animals, Aromatase Inhibitors, Cholesterol Side-Chain Cleavage Enzyme, Cicer, Clomiphene, Dose-Response Relationship, Drug, Estrogen Antagonists, Female, Gene Expression Regulation, Enzymologic, Letrozole, Organ Size, Ovary, Phytotherapy, Plant Extracts, Polycystic Ovary Syndrome, Random Allocation, Rats"
34111492,neuroblastoma a neoplasm of the sympathetic nervous system is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy paclitaxel taxol a diterpenoid pseudoalkaloid isolated from the shell of taxus brevifolia is the first taxane derivative used in the clinic for cancer treatment poly lacticcoglycolic acid plga is one of the most successfully used biodegradable polymer for drug delivery which ha a minimum systemic toxicity this study aimed to evaluate the cytotoxicity and genotoxicity of paclitaxel nanoencapsulated with plga cytotoxic effect were determined by dimethylthiazolyldiphenyltetrazolium bromide mtt method and genotoxic effect were determined by single cell gel electrophoresis comet method in human neuroblastoma cell shsy5y according to our result the viability of cell treated with concentration higher than 10 nm of free paclitaxel and paclitaxel loaded plga nanoparticles for 48 and 72 h wa found lower than 50 additionally dna damage increased with the increase of nanoparticle dose when the cell exposed to paclitaxel loaded plga nanoparticles for 48 and 72 h it can be concluded that plga nanoparticles can be considered a a biocompatible carrier system for drug delivery and might be promising agent against neuroblastoma,"Antineoplastic Agents, Phytogenic, Cell Line, Tumor, Comet Assay, Humans, Nanoparticles, Neuroblastoma, Paclitaxel, Polylactic Acid-Polyglycolic Acid Copolymer"
34110773,1tphase transitionmetal dichalcogenides tmds nanomaterials are one type of emerging and promising nearinfrared ii nirii photothermal agent ptas derived from their distinct metallic electronic structure but it is still challenging to synthesize these nanomaterials herein pdte2 nanoparticles ptns with a 1t crystal symmetry and around 50 nm in size are prepared by an electrochemical exfoliation method and the corresponding photothermal performance irradiated under a nirii laser have been explored the encapsulation of distearoylsnglycerophosphoethanolaminepolyethylene glycol dspepeg endows ptns with water solubility enhanced photothermal stability and high biocompatibility notably ptndspepeg display a potent absorbance through the nirii zone and considerable photothermal conversion efficiency which is up to 68 when irradiated with a 1060 nm laser with these unique photothermal property excellent in vitro and in vivo tumor inhibition effect of ptndspepeg have been achieved under the irradiation of a nirii 1060 nm laser without visible toxicity to normal tissue suggesting that it is an efficient nirii photothermal nanoagent,"Animals, Antineoplastic Agents, Cell Line, Tumor, Female, Hydrophobic and Hydrophilic Interactions, Infrared Rays, Metal Nanoparticles, Mice, Inbred BALB C, Neoplasms, Palladium, Phosphatidylethanolamines, Photothermal Therapy, Polyethylene Glycols, Tellurium, Mice"
34110507,at the end of the 1990s with the advent of imatinib for chronic myeloid leukemia and rituximab for b cell lymphoproliferative disease with cd20 expression there wa a great conceptual evolution in the treatment of oncohematological disease researcher from around the world and the pharmaceutical industry began to focus their effort on the socalled target therapy used alone or associated with classic chemotherapeutic drug in chronic lymphocytic leukemia the development of secondgeneration anticd20 antibody biosimilars pi3k phosphatidylinositol kinase inhibitor btk brutons tyrosine kinase inhibitor and antibcl 2 drug represented mainly by venetoclax brought new broader and more effective opportunity in the treatment of this disease this breakthrough occurred mainly regarding patient with alteration in 17p or mutation of the p53 gene for whom selecting the new drug that act on b cell signaling btk and pi3k inhibitor in the first line is mandatory in fit patient with immunoglobulin heavy chain mutation it is still acceptable to use the chemotherapy regimen with fludarabine cyclophosphamide and rituximab fcr and in those who do not fit or are not igvhmutated bendamustinerituximab regimen however the firstline use of ibrutinib or venetoclax associated with immunotherapy within the concept of infinite ibrutinib or finite venetoclax treatment ha been increasingly used in the second line venetoclax ibrutinib and idelalisib have become the preferred treatment i believe that a process of instruction and decision shared with patient considering the risksbenefitscost and access to treatment should guide the choice within these concept another fundamental aspect to discus is the objective of the treatment for chronic lymphocytic leukemia cll for a specific patient the increase progressionfree survival and overall survival andor the achievement of minimal residual disease cll is the most common leukemia in adult with a median age at diagnosis of 72 year the clinical course is heterogeneous and outcome are influenced by individual clinical presentation and disease biology molecular and genomic factor including fluorescence in situ hybridization fish testing karyotype and immunoglobulin heavy chain variable region gene ighv mutational status are important to treatment decision and to predict the clinical course however despite disease biology the presence of active disease is the most important criterion to initiate treatment in the past decade target therapy that inhibit b cell receptor signaling pathway and more recently bcl2 antagonist have emerged a a new treatment paradigm chemofree with fixed duration therapy brutons tyrosine kinase inhibitor btk are a class of oral medication approved for frontline and relapsed disease effective for achieving lasting response and disease control with a good safety profile btk inhibitor are an attractive option for highrisk patient who are not candidate for an intensive regimen however it is a continuous therapy and drug resistance or severe adverse event could lead to treatment suspension bcl2 antagonist are an attractive alternative to btk inhibitor antiapoptotic bcl2 is associated with tumor genesis and chemotherapy resistance the bcl an antiapoptotic protein located in the mitochondrial membrane is a major contributor to the pathogenesis of lymphoid malignancy and is overexpressed in cll cell promoting clonal cell survival venetoclax is a potent and selective member of the bh3 mimetic drug and a physiologic antagonist of bcl venetoclax ha demonstrated quick and durable response in nave and relapsed or refractory cll rr cll patient including highrisk patient furthermore it ha shown deeper response achieving a higher incidence of negative minimal residual disease mrd with a fixed duration therapy in the past decade there wa a remarkable progress in cll treatment however neither of the new target therapy is considered curative or free of toxicity this article will focus on the treatment approach of cll patient with bcl2 antagonist treatment strategy combined versus monotherapy continuous versus limited duration therapy toxicity profile and future direction will be exposed in this review,"Agammaglobulinaemia Tyrosine Kinase, Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Proto-Oncogene Proteins c-bcl-2, Sulfonamides"
34109735,the somatic brafv600e mutation occurs in of pediatric case of langerhans cell histiocytosis lch vemurafenib vmf a braf inhibitor wa approved for refractory brafv600e mutated lch in adult vmf cause frequent cutaneous adverse event cae including skin tumor squamous cell carcinoma melanoma but little is known in child the objective of this study wa to evaluate the frequency clinical spectrum and severity of caes in child treated with vmf for lch in addition a correlation between cae occurrence and vmf dose residual plasma level rpls and efficacy wa searched for multicentric retrospective observational study including patient 18 year treated with vmf alone for refractory brafv600e mutated lch in 13 country between october 2013 and december fiftyseven patient 56 female median age year median treatment duration month fortyone patient 72 had at least one cae photosensitivity 40 keratosis pilaris 32 rash 26 xerosis 21 and neutrophilic panniculitis 16 no skin tumor wa observed five percent of caes were grade none were grade 4 or led to permanent vmf discontinuation dose reduction wa necessary for 12 of patient temporary treatment discontinuation for 16 none leading to loss of efficacy vmf dose median rpl and efficacy were not correlated with cae occurrence at do used for pediatric lch caes are frequent but rarely severe and have little impact on the continuation of treatment when managed appropriately regular dermatological followup is essential to manage caes and screen for possible induced skin tumor,"Adolescent, Child, Child, Preschool, Female, Histiocytosis, Langerhans-Cell, Humans, Infant, Male, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Skin Diseases, Skin Neoplasms, Vemurafenib"
34109484,purpose this phase 1a firstinhuman study assessed the safety maximum tolerated dose mtd pharmacokinetics pk and antitumor activity of fcn437c a cyclindependent kinase 4 and 6 cdk inhibitor method the study enrolled female patient with hr her advanced breast cancer bc who failed standard of care therapy a 3 3 doseescalation design wa utilized with a starting dose of 50 mg daily for 3 week on and 1 week off treatment in day cycle patient received escalating do of fcn437c monotherapy and 450 mg result seventeen patient received fcn437c 50 mg n 3 100 mg n 3 200 mg n 3 300 mg n 6 and 450 mg n 2 two patient who received the mg dose experienced doselimiting toxicity dlts grade 4 thrombocytopenia and neutropenia no dlt wa observed at any other dose level frequently reported treatmentemergent adverse event teaes of any grade were hematological leukopenia neutropenia anemia and thrombocytopenia grade teaes included neutropenia and leukopenia exposure of fcn437c increased almost proportionally to do ranging from 50 to 200 mg at do from 200 to 450 mg there appeared to be a trend of saturation the mtd wa determined to be 300 mg of 15 patient with measurable disease nine patient experienced stable disease no complete or partial response were observed conclusion these result established an acceptable safety profile for fcn437c in patient with advanced bc and there were no unexpected signal relative to other cdk inhibitor nct04488107 july 2020,"Adult, Aged, Female, Humans, Middle Aged, Antineoplastic Agents, Area Under Curve, Asian People, Breast Neoplasms, China, Cyclin-Dependent Kinase 4, Dose-Response Relationship, Drug, Half-Life, Maximum Tolerated Dose, Metabolic Clearance Rate, Protein Kinase Inhibitors"
34107744,achieving a balance between longterm efficacy and good quality of life qol is the main goal of treatment for patient with advanced soft tissue sarcoma some of whom experience prolonged survival without progression an awareness of the challenge particular to this complex set of disease can help preserve patient qol during treatment histology is among the main factor to consider when selecting treatment in advanced disease close attention to the toxicity profile of available regimen is of particular importance especially in more advanced line where the population is usually more vulnerable surgical outcome are significantly better in patient managed with expert care and early referral to sarcoma reference center is key to improving survival and qol,"Aged, Antineoplastic Agents, Clinical Decision-Making, Fatigue, Female, Goals, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Progression-Free Survival, Quality of Life, Risk Assessment, Sarcoma, Severity of Illness Index, Surgical Procedures, Operative, Time-to-Treatment, Treatment Outcome"
34106637,intraarterial chemotherapy iac ha been used successfully for unilateral and bilateral eye disease with advanced or le advanced intraocular disease and of child a young a 3 month of age in this study we expanded the use of iac to eye of two infant with very low birthweight birth weight of g and retinoblastoma the ophthalmologist refused to give patient intravenous chemotherapy ivc considering the risk of ivc because of the low body weight two patient were diagnosed unilateral eye retinoblastoma at 31 day old and 27 day old respectively when newborn fundus screening chemotherapeutic agent were injected into the ophthalmic artery during the four iac session the two patient ocular were preserved due to calcification during followup period to the final iac complication included eyelid edema in the patient 1 and neutropenia in both patient no fever sepsis and other systemic toxic effect were observed after two successful iac treatment for each patient their ocular were all preserved without serious complication our center for the first time reported the management of retinoblastoma in very low birthweight infant with especially challenging and we recommend this to be useful to the patient community,"Antineoplastic Agents, Female, Gestational Age, Humans, Infant, Newborn, Infant, Very Low Birth Weight, Infusions, Intra-Arterial, Ophthalmic Artery, Retinal Neoplasms, Retinoblastoma"
34105810,a high number of new drug have entered clinical development and many of them have recently been approved for patient with lymphoid malignancy the availability of new drug offer additional treatment option but it also requires particular attention for the emergence of adverse event in addition new drug may also have interaction with other drug which could further increase the risk of toxicity or result in decreased efficacy here we review potential drug interaction for nonchemotherapy new drug approved for patient with lymphoid malignancy,"Antineoplastic Agents, Drug Approval, Drug Interactions, Hematologic Neoplasms, Humans, Lymphoproliferative Disorders"
34105456,to analysis the relationship between different bmi body mass index and the clinical characteristic laboratory examination index of newly diagnosed adult patient with acute myeloid leukemia aml so a to investigate the effect of bmi to the efficacy of first induction chemotherapy the clinical data of 145 newly diagnosed adult aml patient treated in the first hospital of lanzhou university from august 2015 to august 2019 were retrospective analyzed according to the guideline for prevention and control of overweight and obesity in chinese adult the bmi kgm2 of the selected aml patient before induction chemotherapy wa calculated and the patient were divided into the low body mass group bmi the normal body mass group bmi and the overweight and obese group bmi 24 the clinical data of the patient including sex age risk stratificationthe type of leukemia gene mutation complication length of hospital stay and other clinical feature white blood cell wbc hemoglobin hb albumin triglyceride tg total cholesterol tc highdensity lipoprotein hdl low density lipoprotein ldl lactate dehydrogenase ldh and other laboratory index agranulocytosis with fever infection of etiology lack of granulocyte duration significant bleeding liver and kidney toxicity of chemotherapy adverse reaction associated indicator and morphological remission were collected the induction chemotherapy regimen wa the standard chemotherapy regimen anthracyclines combined with cytarabine among the 145 newly diagnosed adult aml patient there were 71 male and 74 female the median age wa 50 year oldrange 18 to 82 year old there were 21 patient in underweight group 79 patient in normal weight group and 45 patient in overweight and obese group the patient with higher bmi level showed the older in agep there were significant difference in sex between the patient in each groupp in overweight and obese patient the number of male wa significantly higher than female there were no statistical difference in aml classification comorbiditiesdiabetes hypertension coronary heart disease hospital day whether secondary aml and flt3 gene mutation among the patient in different bmi group there were significant difference in tg of the patient in the different group the overweight and obese patient were higher p there were no significant difference in wbc and hb count alb tc hdl ldl or ldh between the patient in each bmi group at newly diagnosed the complete remission rate of the patient in the low body mass group or overweight and obese group were lower than that in the normal body weight group p the rate of documented infection during the first induction chemotherapy were significantly higher for the patient in low body mass group than those in normal weight group or overweight and obese group p there wa no statistical difference in chemotherapy regimen the number of chemotherapy until cr febrile neutropenia bleeding and the time of neutropenia liver and kidney toxicity among each bmi group multivariate analysis showed that overweight and obese p flt3 mutation p were the risk factor affecting the cr rate of the patient and the patient with secondary aml highrisk type and newly diagnosed wbc 50l showed lower cr rate but there wa no statistical difference in the patient of each group in newly diagnosed adult patient with aml low body mass overweight and obesity and flt3 mutation were the factor reducing the early efficacy of aml patient there were more adverse reaction induced by chemotherapy in the low body mass group therefore inappropriate bmi level can be a risk factor for assessing the prognosis of adult with newly diagnosed aml bmiaml 2015820198aml145amlbmikgm2bmibmibmi24wbchbalbtgtchdlldlldh 1457149745150217945bmippamlamlflt3bmitgpwbchbalbtchdl ldlldhppbmipflt3pamlamlwbc50l amlflt3amlbmiaml,"Adolescent, Adult, Aged, Aged, 80 and over, Body Mass Index, Cytarabine, Female, Humans, Induction Chemotherapy, Leukemia, Myeloid, Acute, Male, Middle Aged, Prognosis, Retrospective Studies, Young Adult"
34103352,in this study we assessed the activity of durvalumab an antibody to programmed death ligand in two cohort of woman with advanced endometrial cancer aecmismatch repair proficient pmmr and mismatch repair deficient dmmr a multicenter phase two study wa performed in woman with aec with pmmr tumor progressing after one to three line of chemotherapy and woman with aec with dmmr tumor progressing after zero to three line of chemotherapy mismatch repair status wa based on immunohistochemistry expression all woman received durvalumab 1500 mg given every 4 week until progression or unacceptable toxicity the primary endpoint wa objective tumor response by recist v modified for immunebased therapeutic seventyone woman were recruited 35 dmmr and 36 pmmr median followup wa 19 v 21 month in dmmr versus pmmr respectively median age wa 67 year histology in dmmr versus pmmr included endometrioid 94 v 57 and serous 0 v 31 and wa high grade in 26 v 74 the objective tumor response rate otrr in the dmmr cohort wa 47 95 ci 32 to 63 including 6 complete response and 11 partial response pr v 3 in the pmmr cohort 95 ci 1 to pr in the dmmr cohort durvalumab wa the firstline therapy in 58 otrr 57 and the secondline therapy in 39 otrr 38 median progressionfree survival wa month in the dmmr cohort v month in the pmmr cohort the month overall survival o rate wa 71 in dmmr v 51 in pmmr with median o not reached for dmmr v 12 month for pmmr immunerelated adverse event occurred in 14 woman mostly grade durvalumab monotherapy showed promising activity and acceptable safety in aec with dmmr regardless of prior line of chemotherapy but activity wa limited in aec with pmmr anzgog actrn and nct,"Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, DNA Mismatch Repair, Drug Administration Schedule, Endometrial Neoplasms, Female, Humans, Middle Aged, Survival Analysis, Treatment Outcome"
34102607,although immune checkpoint inhibitor icis have provided practicechanging outcome in treating many cancer icirelated gastrointestinal toxicity can limit their use upper gastrointestinal toxicity is not common nor a well described a lower gastrointestinal toxicity we aimed to characterize the clinical presentation endoscopic and histologic feature treatment response and outcome of icirelated esophagitis we retrospectively studied patient at the university of texas md anderson cancer center in whom esophagitis developed after receiving icis from june 2011 through january we included patient with endoscopic evidence of esophagitis and excluded those with other obvious cause of esophagitis a chisquare test wa used to as association between categorical variable the mannwhitney u test wa used to compare difference between continuous variable of 657 consecutive patient who underwent esophagogastroduodenoscopy egd during or within 6 month of completing icibased therapy 21 3 had esophagitis deemed to be from icis of these patient 1 5 received an inhibitor of ctla4 alone 15 71 received antipd1 or pdl1 monotherapy and 5 24 received a combination of these median time from ici initiation to onset of esophagitis wa 4 month upon evaluation with egd only 3 patient 14 had isolated esophageal involvement 18 86 had concurrent involvement of the stomach duodenum or both most patient 67 were treated with proton pump inhibitor and 4 19 received steroid prednisone or budesonide the mortality rate wa 38 median followup 15 month esophagitis associated with ici use is rare the diagnosis is one of exclusion because it clinical presentation appears similar to that of inflammation resulting from other cause it often occurs in conjunction with other upper gastrointestinal toxicity symptom are mild and respond well to nonimmunosuppressive treatment with few severe complication,"Endoscopy, Digestive System, Esophagitis, Humans, Immune Checkpoint Inhibitors, Neoplasms, Retrospective Studies"
34102298,radiation dermatitis is one of the most common acute toxicity induced by chemoradiation therapy crt for head and neck cancer hnc the benefit of topical steroid in the management of radiation dermatitis is still unclear this phase multiinstitutional randomized doubleblind placebocontrolled trial evaluated the efficacy and safety of topical steroid for radiation dermatitis in patient with locally advanced hnc receiving crt eligible patient were scheduled to receive bilateral neck irradiation 66 gy with concurrent cisplatin 200 mgm2 a definitive or postoperative crt patient were randomly assigned to receive either topical steroid or placebo when grade 1radiation dermatitis wa observed or the total radiation dose reached 30 gy basic skin care including gentle washing and moistening in the head and neck region wa performed in both group the primary endpoint wa the frequency of grade 2 radiation dermatitis in accordance with the national cancer institute common terminology criterion for adverse event version grading of radiation dermatitis wa performed by independent central review using photograph taken weekly a total of 211 patient were enrolled intention to treat steroid 101 and placebo 102 the frequency of grade 2 radiation dermatitis wa not significantly reduced with the steroid 95 confidence interval compared with the placebo 95 confidence interval p 23 whereas the steroid significantly reduced the frequency of grade 3 radiation dermatitis v p 034 no significant difference in adverse event including local infection or compliance with crt were observed between the group topical steroid may reduce the severity of radiation dermatitis in patient with hnc and thus may become an important therapeutic tool in the management of radiation dermatitis,"Chemoradiotherapy, Cisplatin, Head and Neck Neoplasms, Humans, Radiodermatitis, Steroids"
34101874,although immune checkpoint inhibitor icis have shown clinical benefit for patient with nonsmall cell lung cancer nsclc the efficacy of the combination of icis targeting different pathway is still unclear we performed this metaanalysis to explore the efficacy of cytotoxic tlymphocyteassociated protein 4 ctla4 inhibitor plus programmed cell death 1 receptor pd1programmed cell death receptor ligand 1 pdl1 inhibitor therapy cp for nsclc iiibiv patient we systematically searched the main database for relevant study the main outcome were overall survival o and progressionfree survival pfs we identified 3526 article including 5 randomized controlled trial rcts 4377 patient in our metaanalysis we conducted two comparison of cp versus chemotherapy or pdpdl1 inhibitor p compared with chemotherapy cp wa more effective with better o hazard ratio hr 95 ci confidence interval p better pfs hr 95 ci p and comparable objective response rate orr risk ratio rr 95 ci p in term of toxicity cp wa comparable to chemotherapy across allgrade adverse event aes rr 95 ci p and grade aes rr 95 ci p compared with p cp had no superiority in efficacy in term of the o hr 95ci p pfs hr 95ci p and the orr rr 95 ci p but cp wa more effective than p when pdl1 expression wa 1 rr 95ci p in term of toxicity cp wa associated with increased allgrade aes rr 95 ci p and grade aes rr 95 ci p cp is a beneficial therapeutic schedule with longer pfs and o than chemotherapy and ha an acceptable manageable grade ae rate in iiibiv nsclc however compared with p cp result in better o only in patient with pdl1 expression 1,"Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Humans, Immune Checkpoint Inhibitors, Lung Neoplasms, Neoplasm Staging, Randomized Controlled Trials as Topic"
34101756,immune checkpoint inhibitor approved for the treatment of various type of cancer are known to cause a unique spectrum of side effect including acute kidney injury aki the aim of this study wa to describe the incidence risk factor renal outcome and mortality of aki in patient receiving checkpoint inhibitor patient receiving checkpoint inhibitor between january 2013 and may 2020 at the university medical center utrecht the netherlands were identified using the utrecht patient oriented database aki wa defined a an increase in serum creatinine of time the baseline value based on the kidney disease improving global outcome criterion cox proportional hazard regression analysis wa used to as risk factor for aki and to evaluate the relationship between aki and mortality persistent renal dysfunction wa diagnosed in aki patient with a final serum creatinine measurement of time the baseline value among 676 patient receiving checkpoint inhibitor the overall incidence of aki wa baseline variable independently associated with aki were a gynecologic malignancy monotherapy with ipilimumab and the use of a diuretic angiotensinconverting enzyme inhibitor or angiotensinreceptor blocker or proton pump inhibitor at baseline aki wa checkpoint inhibitorassociated in one third of all patient with aki checkpoint inhibitorassociated aki wa mostly lowgrade occurred a median of 15 week after checkpoint inhibitor initiation and resulted in persistent renal dysfunction in approximately 40 of the patient patient with allcause aki had a twofold increased mortality risk but checkpoint inhibitorassociated aki wa not associated with increased mortality in this study patient receiving checkpoint inhibitor frequently developed aki due to various etiology aki directly related to the effect of checkpoint inhibitor toxicity did not increase mortality however aki not related to the effect of checkpoint inhibitor toxicity wa associated with increased mortality,"Acute Kidney Injury, Aged, Female, Follow-Up Studies, Humans, Immune Checkpoint Inhibitors, Incidence, Male, Middle Aged, Neoplasms, Netherlands, Prognosis, Retrospective Studies, Risk Factors, Survival Rate"
34101408,due to conventional photodynamic therapy encountering serious problem of phototoxicity and low tissuepenetrating depth of light other dynamic therapybased therapeutic method such a sonodynamic therapy sdt are expected to be developed to improve the therapeutic response to sdt more effective sonosensitizers are imperative in this study a novel watersoluble iridiumiiiporphyrin sonosensitizer irtmpps wa synthesized and used for sdt irtmpps generated ample singlet oxygen 1o2 under u irradiation and especially showed distinguished usactivatable ability at more than 10 cm deeptissue depth interestingly under u irradiation irtmpps sonocatalytically oxidized intracellular nadh which would enhance sdt efficiency by breaking the redox balance in the tumor moreover irtmpps displayed great sonocytotoxicity toward various cancer cell and in vivo experiment demonstrated efficient tumor inhibition and antimetastasis to the lung in the presence of irtmpps and u irradiation this report give a novel idea of metalbased sonosensitizers for sonotherapy by fully taking advantage of noninvasiveness water solubility and deep tumor therapy,"Animals, Antineoplastic Agents, Cell Line, Tumor, Iridium, Mice, NAD, Neoplasms, Oxidation-Reduction, Porphyrins, Radiation-Sensitizing Agents, Singlet Oxygen, Ultrasonic Waves, Zebrafish"
34101389,the current firstline treatment of locally advanced head and neck carcinoma lahnc is concurrent chemoradiation with threeweekly cisplatin 100 mgm2 however prescribing cisplatin at this dose increase the treatment toxicity which may compromise the treatment result an alternative schedule is weekly 40 mgm2 cisplatin to compare the acute hematologic and renal toxicity of these two regimen this randomized clinical trial included 77 lahnc patient who were allocated to a high dose 100 mgm2 every 3 week or low dose 40 mgm2 weekly cisplatin group concurrent with radiotherapy hematologic and renal index were measured weekly during chemoradiation the average age of patient wa year overall of patient were treated in a definitive setting the incidence of severe hematologic event wa not significantly different however the average estimated glomerular filtration rate egfr wa significantly greater in the threeweekly group v mlmin per m2 pvalue 02 cumulative cisplatin dose of 240 mgm2 wa significantly greater in the weekly group totally treatment break occurred in of patient due to treatment toxicity treatment interruption wa primarily due to neutropenia in the threeweekly and renal dysfunction and thrombocytopenia in the weekly group severe acute hematologic toxicity were comparable for threeweekly and weekly group the decrease in egfr through treatment wa more significant with weekly cisplatin further followup however is needed to confirm it impact on delayed renal function,"Adult, Aged, Antineoplastic Agents, Chemoradiotherapy, Cisplatin, Drug Administration Schedule, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Prospective Studies, Squamous Cell Carcinoma of Head and Neck"
34100178,stereotactic radiosurgery sr is a standard of care for brain metastasis bm patient yet large bm are at a greater risk for radionecrosis and local progression lp concomitant bevacizumab and radiotherapy ha been shown to improve outcome in primary and metastatic brain tumor this retrospective study investigated the efficacy and safety of concurrent bevacizumab and sr for large bm from 2015 to patient with a bm diameter 2 cm who received either combination therapy n sr bvz group or sr alone n sr group were enrolled bevacizumab wa given periradiosurgically with a week interval radiographic response wa assessed using the recist version competing risk and logistic regression analysis were performed to evaluate prognostic factor radiographic response wa achieved in 41 patient 84 in the sr bvz group and 37 patient 51 in the sr group p in the multivariate regression analysis concurrent bevacizumab wa independently associated with a better radiographic response p the cumulative incidence of lp and grade 2 radionecrosis at 12 month between the sr bvz group and sr group were 2 versus and versus respectively for patient with bm size 3 cm the cumulative incidence of lp wa significantly lower in the sr bvz group p no grade 4 toxicity wa observed in either group concurrent bevacizumab and sr for large bm is highly effective with a better radiographic response and minimal excessive treatmentrelated toxicity periradiosurgical bevacizumab preferentially reduced the risk of lp especially for bm size 3 cm,"Bevacizumab, Brain Neoplasms, Combined Modality Therapy, Humans, Radiation Injuries, Radiosurgery, Retrospective Studies"
34099106,tumor cell predominantly express selfantigens and overcoming selftolerance is the primary challenge to effective immunotherapy tumor also express ligand for coinhibitory molecule on immune cell in order to suppress antitumor immunity over a decade ago the first antibody generated to block the coinhibitory molecule ctla4 wa tested in patient with metastatic melanoma result from this landmark trial have informed not only the current landscape of checkpoint blockade but also the way in which immunotherapy trial outcome are determined antibody targeting pd1 and it ligand pdl soon followed and use of these checkpoint inhibitor icis have expanded exponentially ici treatment ha shown longlasting clinical benefit in several tumor type and patient refractory to other treatment can often respond to ici therapy on the other hand in some tumor type the response to ici is shortlived and tumor eventually recur current clinical trial are focused on enhancing antitumor effect through combination of multiple icis with agent which cause tumor death particularly in solid tumor in order to enhance antigen presentation it is also important to define which patient will respond to therapy with icis a over half of all patient suffer from immunerelated adverse event irae some of which are severe and longlasting,"Antibodies, Monoclonal, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms"
34098035,platinum compound cisplatin and carboplatin represent the most active anticancer agent in clinical use both of lung cancer in monoand combination therapy however platinum resistance limit it clinical application it is necessary to understand the molecular mechanism of platinum resistance identify predictive marker and develop newer more effective and le toxic agent to treat platinum resistance in lung cancer here it summarizes the main molecular mechanism associated with platinum resistance in lung cancer and the development of new approach to tackle this clinically relevant problem moreover it could lead to the development of more effective treatment for refractory lung cancer in future,"Animals, Antineoplastic Agents, Biomarkers, Tumor, Carboplatin, Cisplatin, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms, Signal Transduction"
34098030,the excellent prognosis of patient with lowrisk human papillomavirus hpv associated oropharyngeal squamous cell carcinoma ha led to concern about overtreatment and excessive toxicity with radiation therapy and cisplatin leading to interest in deintensification trial we investigated whether cetuximab an epidermal growth factor receptor targeting antibody when combined with radiation therapy would result in a decrease in symptom burden and toxicity with similar efficacy compared with weekly cisplatin trog a randomized multicenter trial involving 15 site in australia and new zealand enrolled patient with hpvassociated oropharyngeal squamous cell carcinoma american joint committee on cancer 7th edition stage iii excluding tn1 or stage iv excluding t4 andor n3 andor n2bc if smoking history 10 pack year andor distant metastasis patient were randomized 11 to receive radiation therapy 70 gy in 35 fraction with either weekly cisplatin 7 do of 40 mgm or cetuximab loading dose of 400 mgm2 followed by 7 weekly do of 250 mgm the primary outcome wa symptom severity assessed by the md anderson symptom inventory head and neck symptom severity scale from baseline to 13 week postcompletion of radiation therapy using the area under the curve trial wa registered on clinicaltrialsgov nct between june and june 189 patient were enrolled with 92 in cisplatin arm and 90 in cetuximab included in the main analysis there wa no difference in the primary endpoint of symptom severity difference in area under the curve cetuximabcisplatin wa 95 confidence interval ci p the tscore mean number of grade 3 acute adverse event wa standard deviation in the cisplatin arm and standard deviation in the cetuximab arm p the year failurefree survival rate were 93 95 ci 8697 in the cisplatin arm and 80 95 ci 7087 in the cetuximab arm hazard ratio 95 ci p for patient with lowrisk hpvassociated oropharyngeal cancer radiation therapy and cetuximab had inferior failurefree survival without improvement in symptom burden or toxicity compared with radiation therapy and weekly cisplatin radiation therapy and cisplatin remain the standard of care,"Antineoplastic Combined Chemotherapy Protocols, Cetuximab, Chemoradiotherapy, Cisplatin, Head and Neck Neoplasms, Humans, Oropharyngeal Neoplasms, Overtreatment, Papillomavirus Infections, Squamous Cell Carcinoma of Head and Neck"
34097960,targeted delivery and controlled release of drug are attractive method for avoiding the drug leakage during blood circulation and burst release of the drug we prepared a nano cellulosebased drug delivery system dd for the effective delivery of curcumin cur in the present scenario the role of nanoparticles in fabricating the dd is an important one and wa characterized using various technique the drug loading capacity wa high a at ph and also the maximum drug release take place at ph in vitro cell viability study of dd on mda mb231 breast cancer cell demonstrated it cytotoxicity towards cancer cell the prepared dd wa also examined for apoptosis hemocompatibility and chorioallantoic membrane cam study to as it pharmaceutical field application and the investigation result recommended that it may serve a a potential device for targeted delivery and controlled release of cur for cancer treatment,"Animals, Antineoplastic Agents, Phytogenic, Apoptosis, Breast Neoplasms, Cell Line, Tumor, Cell Survival, Cellulose, Cerium, Chick Embryo, Cross-Linking Reagents, Curcumin, Delayed-Action Preparations, Drug Carriers, Drug Compounding, Drug Liberation, Epoxy Compounds, Female, Folic Acid, Humans, Hydrogen-Ion Concentration, Methacrylates, Nanoparticles, Sulfates"
34097901,cancer patient undergoing radiotherapy chemotherapy or targeted cancer therapy are exposed to the risk of several side effect because of the heavy production of ro by ionizing radiation or some chemotherapy drug damage to dna mitochondrion membrane and other organelle within normal tissue cell such a cardiomyocytes and endothelial cell lead to the release of some toxin which are associated with triggering inflammatory cell to release several type of cytokine chemokines ro and rn the release of some molecule following radiotherapy or chemotherapy stimulates reductionoxidation redox reaction redox reaction cause remarkable change in the level of reactive oxygen specie ro and reactive nitrogen specie rn excessive production of ro and rn or suppression of antioxidant defense enzyme lead to damage to critical macromolecule which may continue for long time increased level of some cytokine and oxidative injury are hallmark of heart injury following cancer therapy redox reaction may be involved in several heart disorder such a fibrosis cardiomyopathy and endothelium injury in the current review we explain the cellular and molecular mechanism of redox interaction following radiotherapy chemotherapy and targeted cancer therapy afterward we explain the evidence of the involvement of redox reaction in heart disease,"Humans, Oxidation-Reduction, Neoplasms, Animals, Antineoplastic Agents, Reactive Oxygen Species, Reactive Nitrogen Species, Cardiotoxicity, Oxidative Stress, Heart Diseases"
34096894,letrozole is a nonsteroidal aromatase inhibitor used to treat hormonereceptorpositive breast cancer variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure which may be influenced by germline variant in the enzyme responsible for letrozole metabolism including cytochrome p450 2a6 cyp2a6 the objective of this genomewide association study gwas wa to identify polymorphism associated with steadystate letrozole concentration the exemestane and letrozole pharmacogenetics elph study randomized postmenopausal patient with hormonereceptorpositive nonmetastatic breast cancer to letrozole or exemestane treatment germline dna wa collected pretreatment and blood sample were collected after 1 or 3 month of treatment to measure steadystate letrozole and exemestane plasma concentration via hplcms genomewide genotyping wa conducted on the infinium global screening array 650 000 variant followed by imputation the association of each germline variant with age and bmiadjusted letrozole concentration wa tested in selfreported white patient via linear regression assuming an additive genetic model there were 228 patient who met the studyspecific inclusion criterion and had both dna and letrozole concentration data for this gwas the association for one genotyped polymorphism rs7937 with letrozole concentration surpassed genomewide significance p explaining 13 of the variability in untransformed steadystate letrozole concentration imputation around rs7937 and in silico analysis identified r a variant in the cyp2a6 intron that may affect cyp2a6 expression and activity rs7937 wa associated with age and bmiadjusted letrozole level even after adjusting for genotypepredicted cyp2a6 metabolic phenotype p our gwas finding confirm that steadystate letrozole plasma concentration are partially determined by germline polymorphism that affect cyp2a6 activity including variant near rs7937 such a the intronic rs56113850 variant further research is needed to confirm whether rs56113850 directly affect cyp2a6 activity and to integrate nonexonic variant into cyp2a6 phenotypic activity prediction system,"Aromatase Inhibitors, Breast Neoplasms, Cytochrome P-450 CYP2A6, Female, Genome-Wide Association Study, Genotype, Humans, Letrozole"
34096893,cardiotoxicity is a frequent complication secondary to the use of anthracyclines for cancer chemotherapy evidence suggests that certain polymorphic genetic variant modify the risk for anthracyclinerelated cardiotoxicity report documenting the impact of genetic polymorphism on anthracyclinecardiotoxicity risk in pediatric patient with cancer from latin american country are scarce the objective of this study wa to evaluate association between ncf4 r cbr3 rs1056892 and abcc1 rs3743527 genotype status and echocardiographic parameter indicative of anthracyclinecardiotoxicity in a group of mexican child with acute lymphoblastic leukemia all sixtyseven child year old with all were treated at the state cancer center in durango mexico ncf cbr and abcc1 genotype were examined by realtime pcr left ventricular ejection fraction and diastolic filling ratio were examined a marker of systolic and diastolic anthracyclinetoxicity ncf4 rs1883112 genotype status wa significantly associated with the risk of doxorubicin cardiotoxicity odds ratio or 95 confidence interval ci p there wa a significant association between heterozygous cbr3 rs1056892 genotype status and anthracyclinecardiotoxicity risk or 95 ci p heterozygosis for the abcc1 rs3743527 allele wa associated with protection from anthracyclinecardiotoxicity or 95 ci p this pilot study suggests that selected polymorphic variant may impact the risk for anthracyclinecardiotoxicity in pediatric patient with all treated with a contemporary chemotherapeutic regimen in mexico,"Adolescent, Alcohol Oxidoreductases, Cardiotoxicity, Child, Child, Preschool, Doxorubicin, Humans, NADPH Oxidases, Pilot Projects, Polymorphism, Genetic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Stroke Volume, Ventricular Function, Left"
34093867,the tumor suppressor protein p53 remains in a wild type but inactive form in 50 of all human cancer thus activating it becomes an attractive approach for targeted cancer therapy in this regard our lab ha previously discovered a small molecule inauhzin inz a a potent p53 activator with no genotoxicity method to improve it efficacy and bioavailability here we employed nanoparticle encapsulation making inzc an analog of inz to nanoparticleencapsulated inzc ninzc result this approach significantly improved p53 activation and inhibition of lung and colorectal cancer cell growth by ninzc in vitro and in vivo while it displayed a minimal effect on normal human wi38 and mouse mef cell the improved activity wa further corroborated with the enhanced cellular uptake observed in cancer cell and minimal cellular uptake observed in normal cell in vivo pharmacokinetic evaluation of these nanoparticles showed that the nanoparticle encapsulation prolongates the halflife of inzc from h to 5 h in mouse conclusion these result demonstrate that we have established a nanoparticle system that could enhance the bioavailability and efficacy of inzc a a potential anticancer therapeutic,"Animals, Antineoplastic Agents, Biological Availability, Cell Line, Tumor, Cell Movement, Cell Proliferation, Colorectal Neoplasms, Humans, Indoles, Lung Neoplasms, Mice, Mice, Inbred C57BL, Microscopy, Electron, Transmission, Nanoparticles, Phenothiazines, Spectroscopy, Fourier Transform Infrared, Tumor Suppressor Protein p53, Xenograft Model Antitumor Assays"
34092748,clinical trial data of carmustine implant gliadel wafer in japanese patient with malignant glioma are limited thus we conducted a postmarketing surveillance study to evaluate the safety of gliadel in realworld clinical practice in japan in this postmarketing surveillance study all patient who received gliadel placement for malignant glioma surgery from it market launch january 2013 to july 2013 were enrolled from 229 institution using a central registration system up to eight wafer of gliadel containing mg of carmustine were used to cover the site of brain tumor resection intraoperatively according to the size and shape of the tumor resection cavity the observation period lasted 3 month after gliadel placement patient were followed up for 1 year postoperatively safety wa assessed by the incidence of adverse event aes and adverse drug reaction adrs in total 558 patient were included most patient received eight gliadel wafer the percentage of patient with adrs wa 365 adr episode in 199 patient of the aes of special interest the most common were cerebral edema patient convulsion patient impaired healing patient and infection patient this first allcase postmarketing surveillance report of the safety of gliadel in realworld clinical practice in japan suggests that the risk of toxicity with gliadel placement is relatively tolerable the survival benefit of gliadel placement should be evaluated and considered carefully by the clinician taking into account possible toxicity,"Antineoplastic Agents, Alkylating, Brain Neoplasms, Carmustine, Decanoic Acids, Glioma, Humans, Japan, Polyesters, Treatment Outcome"
34090039,the use of natural product a potential ligand ha been explored a a strategy in the development of metalbased chemotherapy since ruthenium complex are promising alternative to traditional antitumor agent this study evaluated the antimelanoma potential of two rutheniumii complex containing the naphthoquinone ligand lapachol lap rulapdppm2pf and lawsone law rulawdppm2pf in addition to the bisdiphenylphosphinomethane dppm ligand referred to a complex 1 and 2 respectively using a syngeneic murine melanoma model activation of the apoptotic pathway by the treatment wa assessed by immunohistochemistry in tumor tissue additionally toxicity of the treatment wa evaluated by variation in body and organ weight quantification of biochemical indicator of renal damage and genotoxicity in bone marrow and hepatocytes first the antiproliferative activity of 1 and 2 wa observed in b16f10 cell with ic50 value of and m respectively the result obtained in mouse showed that unlike complex 1 2 posse significant antimelanoma activity demonstrated by a reduction in tumor volume and mass a well a in mitosis frequency additionally complex 2 increased the level of cleaved caspase inducing tumor cell apoptosis when compared to the metallodrug cisplatin complex 2 exhibited similar antimelanoma activity and lower toxicity considering all parameter evaluated in silico study demonstrated no difference in the binding energy of the naphthoquinone complex between complex 1 and 2 however the complex containing the lawsone ligand ha a lower molar volume which may be important for interaction with minor dna groove the present result demonstrate the antitumor efficiency of complex 2 and a significantly lower systemic toxicity compared to cisplatin,"Animals, Antineoplastic Agents, Cell Line, Tumor, Cell Proliferation, Coordination Complexes, Ligands, Male, Melanoma, Mice, Inbred C57BL, Naphthoquinones, Phosphines, Ruthenium, Mice"
34088724,rituximab and lenalidomide are effective for previously untreated and relapsedrefractory rr indolent nonhodgkin lymphoma inhl however longterm survival and predictive biomarkers are not well described we conducted two phase ii openlabel trial involving 60 patient with previously untreated and rr advancedstage inhl patient received lenalidomide and rituximab induction followed by continuous lenalidomide until disease progression or unacceptable toxicity the primary endpoint wa overall response rate orr correlative study included plasma cytokine monitoring flow cytometry of peripheral blood mononuclear cell pbmc day and 60 and rna sequencing rnaseq of pretreatment tumor biopsy at a median followup of 63 month for previously untreated and 100 month for rr orr wa 82 for both the 11 rr patient who achieved complete remission remained in continuous remission for 16 to 141 month thereafter median overall survival o wa not reached in the previously untreated and wa 140 month 95 confidence interval 140 in the rr group a mixedeffects linear regression model identified significant association between granzyme b granb cd t cell and longterm complete response ltcr p e4 furthermore prior to start of therapy treatment response could be predicted by bcell and granb cd tcell level total lymphocyte rituximab plus lenalidomide followed by continuous lenalidomide is effective with manageable toxicity in patient with previously untreated and rr inhl this regimen produce durable remission even in heavily pretreated patient with some lasting greater than 10 year granb cd t cell b cell and plasma ifn allowed prediction of ltcr but need validation in larger trial,"Antineoplastic Combined Chemotherapy Protocols, CD8-Positive T-Lymphocytes, Follow-Up Studies, Humans, Lenalidomide, Leukocytes, Mononuclear, Lymphoma, Non-Hodgkin, Rituximab"
34088513,treatment of patient with platinum resistantrefractory epithelial ovarian cancer eoc is an unmet need we evaluated the role of oral metronomic therapy in this setting between october 2017 and september 2019 seventy five patient with platinum resistantrefractory eoc were enrolled patient received oral etoposide 50 mg day 1 to cyclophosphamide 50 mg day 1 to every 4 week arm a n 38 patient in arm b n 37 received pazopanib 400 mg once daily in addition to etoposide and cyclophosphamide quality of life qol wa evaluated using the eortc questionnaire serum vegf and pdgf were estimated at baseline after 3rd and 6th cycle the primary endpoint wa progression free survival pfs secondary endpoint were overall survival o toxicity and qol patient characteristic were well matched median pfs wa higher in arm b month 95 ci to compared to month 95 ci to in arm a p median o ha not reached in arm b compared to month 95 ci not reached in arm a p therapy wa tolerated well oral mucositis p and fatigue p being more in arm b qol assessment revealed modest improvement in symptom scale in arm b serum vegf and pdgf level decreased with therapy in both arm arm ap arm bp addition of pazopanib to etoposide and cyclophosphamide could be a novel oral combination for metronomic therapy for platinum resistantrefractory eoc ctri,"Administration, Metronomic, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Ovarian Epithelial, Cyclophosphamide, Drug Resistance, Neoplasm, Etoposide, Female, Humans, Indazoles, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Progression-Free Survival, Pyrimidines, Quality of Life, Sulfonamides"
34087405,previously we isolated and identified antimutagenic and antiinflammatory component from vitis coignetiae crimson glory vine known a yamabudo in japan a dimethoxybenzoquinone dbq fertaric acid and caftaric acid we also reported that the oral intake of a partially purified fraction from yamabudo juice yamabudofr or dbq affords significant protection against twostage skin carcinogenesis in mouse in this study we found that oral intake of yamabudofr or dbq affords significant protection against a tobaccospecific nitrosamine methylnitrosaminopyridylbutanone nnkinduced mouse model of lung tumorigenesis furthermore we investigated the antitumorigenic mechanism of yamabudo juice and dbq nnk is known to be a dnamethylating and alkylating agent thus we investigated the antitumorigenic mechanism of yamabudo juice and dbq in relation to dna methylation pretreatment with yamabudofr or dbq dosedependently decreased formation of omethylguanine and nmethylguanine in dna of the a549 human lung epitheliallike cell line treated with a methylating agent methylnitronitrosoguanidine yamabudo juice and dbq inhibited the mutagenicity of nnk in the ames test using salmonella typhimurium ta1535 but not s typhimurium yg an alkylguanine dna alkyltransferasedeficient strain same a ta1535 but adastkmr ogtstcmr yamabudo juice and dbq might accelerate the repair of dna damage caused by nnk and reduce dna damage to cell we also investigated the effect of yamabudo juice and dbq on signaling pathway in a549 cell with or without epidermal growth factor stimulation phosphorylation of erk akt and stat3 in a549 cell wa significantly decreased in the presence of yamabudo juice or dbq indicating that yamabudo juice and dbq suppressed pi3kakt mapkerk and jakstat3 signaling pathway these result suggest that both initiation and growthprogression step in carcinogenesis especially antioxidant effect stimulation of repair of alkyl dna adduct and suppressed growth signaling pathway are potential antitumorigenic target of yamabudo juice and dbq in nnkinduced lung tumorigenesis,"A549 Cells, Animals, Anticarcinogenic Agents, Antimutagenic Agents, Antineoplastic Agents, Phytogenic, Benzoquinones, Carcinogens, DNA Repair, Female, Humans, Lung Neoplasms, Mice, Nitrosamines, Phosphorylation, Vitis"
34087342,doxorubicin represents the mainstay in the upfront treatment of diffuse large bcell lymphoma dlbcl patient however it administration is sometimes hampered by the coexistence of former comorbiditiescardiac issue especially in the elderly population liposome encapsulated drug delivery system have been adopted to reduce the exposure of normal tissue to the drug both in solid cancer and lymphoma despite claim for lower toxicity the efficacy of nonpegylated liposome doxorubicin npld in dlbcl a compared to standard doxorubicin ha never been established we systematically reviewed relevant literature of npld in lymphoma treatment adjusting for agecomorbidities our metanalysis revealed that the use of combination including npld rcomp were noninferior in term of response overall and progressionfree survival to the standard of care rchop in overlapping series of dlbcl patient rcomp may represent a safe and active option for elderly patient with dlbcl or for those with some extent of cardiac impairment at baseline,"Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Humans, Lymphoma, Large B-Cell, Diffuse, Prednisone, Rituximab, Treatment Outcome, Vincristine"
34087126,in a phase 1b study intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42 and wa well tolerated in patient with heavily pretreated multiple myeloma we aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progressionfree survival versus pomalidomide and dexamethasone alone in patient with previously treated multiple myeloma in this ongoing openlabel randomised phase 3 trial apollo done at 48 academic centre and hospital across 12 european country eligible patient were aged 18 year or older had relapsed or refractory multiple myeloma with measurable disease had an eastern cooperative oncology group performance status of had at least one previous line of therapy including lenalidomide and a proteasome inhibitor had a partial response or better to one or more previous line of antimyeloma therapy and were refractory to lenalidomide if only one previous line of therapy wa received patient were randomly assigned 11 by an interactive webresponse system in a random block size of two or four to receive pomalidomide and dexamethasone alone or daratumumab plus pomalidomide and dexamethasone randomisation wa stratified by number of previous line of therapy and international staging system disease stage all patient received oral pomalidomide 4 mg once daily on day and oral dexamethasone 40 mg once daily on day and 22 20 mg for those aged 75 year or older at each day cycle the daratumumab plus pomalidomide and dexamethasone group received daratumumab 1800 mg subcutaneously or 16 mgkg intravenously weekly during cycle 1 and every 2 week during cycle and every 4 week thereafter until disease progression or unacceptable toxicity the primary endpoint wa progressionfree survival in the intentiontotreat population safety wa analysed in all patient who received at least one dose of study medication this trial is registered with clinicaltrialsgov nct between june and june 304 patient median age 67 year iqr 161 53 men and 143 47 woman were randomly assigned to the daratumumab plus pomalidomide and dexamethasone group n151 or the pomalidomide and dexamethasone group n153 at a median followup of 169 month iqr 146 the daratumumab plus pomalidomide and dexamethasone group showed improved progressionfree survival compared with the pomalidomide and dexamethasone group median 124 month 95 ci 83 v 69 month 53 hazard ratio 063 95 ci 085 twosided p00018 the most common grade 3 or 4 adverse event were neutropenia 101 68 of 149 patient in the daratumumab plus pomalidomide and dexamethasone group v 76 51 of 150 patient in the pomalidomide and dexamethasone group anaemia 25 17 v 32 21 and thrombocytopenia 26 17 v 27 18 serious adverse event occurred in 75 50 of 149 patient in the daratumumab plus pomalidomide and dexamethasone group versus 59 39 of 150 patient in the pomalidomide and dexamethasone group pneumonia 23 15 v 12 8 patient and lower respiratory tract infection 18 12 v 14 9 were most common treatmentemergent death were reported in 11 7 patient in the daratumumab plus pomalidomide and dexamethasone group versus 11 7 patient in the pomalidomide and dexamethasone group among patient with relapsed or refractory multiple myeloma daratumumab plus pomalidomide and dexamethasone reduced the risk of disease progression or death versus pomalidomide and dexamethasone alone and could be considered a new treatment option in this setting european myeloma network and janssen research and development,"Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Neutropenia, Progression-Free Survival, Proportional Hazards Models, Thalidomide"
34086514,no preferred firstline chemotherapy regimen exists for advanced esophagogastric adenocarcinoma addition of docetaxel to cisplatin and fluorouracil dcf ha been shown to improve survival but is associated with increased toxicity in this randomized noncomparative phase 2 trial we tested carboplatin docetaxel and capecitabine ctx a potentially useful modification of dcf nct02177552 patient with advanced hernegative esophagogastric adenocarcinoma not previously treated in the firstline setting were randomized to intravenous docetaxel 60 mgm2 and carboplatin auc5 plus oral capecitabine 1000 mgm2 bd day q4w ctx or intravenous epirubicin 50 mgm2 and oxaliplatin 130 mgm2 on day 1 plus oral capecitabine 625 mgm2 bd day q3w epirubicin oxaliplatin and capecitabine eox treatment continued until progression intolerance or for a maximum of nine cycle the primary endpoint wa year survival for patient treated with ctx between june 2014 and january a total of 98 eligible patient were randomized the year survival rate wa 95 ci with ctx and 95 ci with eox progressionfree survival and overall survival were month 95 ci and month 95 ci with ctx and month 95 ci and month 95 ci with eox respectively related grade 3 or 4 treatmentemergent adverse event aes occurred in 86 of patient on ctx and 69 on eox febrile neutropenia occurred in of patient on ctx and on eox firstline ctx showed insufficient efficacy and caused a high rate of febrile neutropenia ctx could not therefore be recommended for further study this trial add to current knowledge of docetaxel combined with platinum and fu that the combination is associated with increased toxicity and it use should be limited to fit patient in need of a response,"Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Carboplatin, Docetaxel, Epirubicin, Fluorouracil, Humans, Oxaliplatin, Stomach Neoplasms, Treatment Outcome"
34086477,for unresectable gallbladder cancer gbc gemcitabine and platinum is standard combination however outcome is poor we conducted this study to find feasibility of modified flourouracil oxaliplatin and irinotecan in this group we conducted a prospective phase ii singlearm pilot study inclusion criterion were histologically proven gbc and eastern cooperative oncology group primary end point were overall response rate and overall survival the following treatment wa given oxaliplatin 85 mgm leucovorin 400 mgm and irinotecan 150 mgm all once on day fluorouracil mgm2 continuous intravenous infusion over 46 hour repeated every 2 week and maximum 12 do with primary granulocyte colonystimulating factor prophylaxis between february 2019 and july 29 patient with unresectable gbc were enrolled the median age wa 52 year and 18 were female the eastern cooperative oncology group wa 0 in five had bilirubin normal and 15 each had high serum alkaline phosphatase and carbohydrate antigen twentyfive patient had stage iv disease and remaining unresectable locally advanced disease a median of cycle wa given and 11 completed treatment nine stopped chemotherapy because of progression and one because of toxicity and treatment is ongoing in three twentytwo required dose reduction a treatment delay of week wa seen in 25 patient best response wa complete response partial response 13 overall response rate and stable disease four patient with metastatic disease underwent r0 resection a on cutoff date nine are surviving three without disease eighteen died of pd and in two cause wa unknown there wa no toxic death the median overall survival and progressionfree survival were 309 and 252 day respectively twentythree patient experienced grade iii or iv toxicity and common were diarrhea 13 vomiting 12 and anemia 7 firstline modified flourouracil oxaliplatin and irinotecan is feasible in unresectable gbc with encouraging response toxicity are higher but manageable higher response rate make this an option to explore in borderline resectable case,"Antineoplastic Combined Chemotherapy Protocols, Female, Fluorouracil, Gallbladder Neoplasms, Humans, Irinotecan, Leucovorin, Middle Aged, Oxaliplatin, Pancreatic Neoplasms, Pilot Projects, Prospective Studies"
34086171,in herpositive breast cancer her bc neoadjuvant chemotherapy nact with dual hertargeted therapy achieves high pathologic complete response pcr rate anthracyclinefree nact regimen avoid toxicity associated with anthracyclines but every week tchp also ha substantial side effect we hypothesized that a weekly regimen might have equivalent efficacy with le toxicity we also investigated whether poorly responding patient would benefit from switching to ac patient with clinical stage iiiii her bc received weekly paclitaxel 80 mgm2 and carboplatin auc2 with every week trastuzumab and pertuzumab wpcbtp with the option of splitting the pertuzumab loading dose after 12 week responding patient continued wpcbtp for another 6 week while nonresponders switched to ac dose modification and postop therapy were at investigator discretion in 30 evaluable patient the pcr rate wa 77 95 ci 86 in ernegative and 69 in erpositive only two patient transitioned to ac for nonresponse of which one achieved pcr there were no episode of febrile neutropenia or grade 3 peripheral neuropathy though several patient who continued wpcbtp stopped before week splitdose pertuzumab wa associated with le grade 2 diarrhea 40 than the standard loading dose 60 pcr rate with our regimen were a high a reported with tchp with fewer grade 3 toxicity though diarrhea remains a concern too few patient had a suboptimal response to adequately test switching to ac the wpcbtp regimen should be considered an alternative to tchp a neoadjuvant therapy for her bc clinicaltrialsgov identifier nct,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carboplatin, Female, Humans, Neoadjuvant Therapy, Paclitaxel, Receptor, ErbB-2, Trastuzumab, Universities"
34085572,an alternative to reduce the undesirable effect of antineoplastic agent ha been the combination of classical treatment with nutritional strategy aimed at reducing systemic toxicity without decreasing the antitumor activity of already used drug within this context this study evaluated the possible reduction of toxicity when cisplatin treatment is combined with watermelon pulp juice supplementation in c57bl6 mouse with melanoma watermelon is a fruit rich in vitamin mineral protein lycopene carotene and xanthophyll which ha shown effectiveness in the treatment of cardiovascular disease weight loss urinary infection gout hypertension and mutagenicity the following parameter were analyzed animal survival bone marrow genotoxicity serum creatinine and urea histopathological feature of the tumor tissue tumor weight and volume and weight of nontumor tissue kidney liver spleen heart and lung the result showed that watermelon had no antitumor effect but reduced the toxicity of cisplatin a demonstrated by an increase in the number of bone marrow cell and a decrease in serum creatinine and urea level the data suggest that watermelon pulp juice can be an alternative for reducing the side effect of antineoplastic agent,"Animals, Antineoplastic Agents, Cisplatin, Citrullus, Creatinine, Melanoma, Mice, Mice, Inbred C57BL, Urea"
34081269,highgrade glioma are among the most aggressive central nervous system primary tumor with a high risk of recurrence and a poor prognosis reoperation reirradiation chemotherapy are option in this setting nobest therapy ha been established bevacizumab wa approved on the basis of two phase 2 trial that evaluated it efficacy in patient with recurrent glioblastoma we have retrospectively review data of patient with highgrade glioma treated at our institution that undergone radiological or histological progression after at least one systemic treatment for recurrent disease bevacizumab wa administered alone or in combination with chemotherapy until disease progression or unacceptable toxicity bevacizumab regimen wa analyzed to as pfs and o histological molecular and clinical feature of the entire cohort were collected we reviewed data from 92 patient treated from april 2009 to november with histologically confirmed diagnosis of highgrade glioma and recurrent disease a pfs of and wa observed at 12 and 24 month respectively performance status age at diagnosis 65 or 65 y and use of corticosteroid during bevacizumab therapy were strongly associated with pfs the o wa at 6 month at 12 month at 24 month in our cohort were longterm responder pfs 6 month globally bevacizumab treatment wa well tolerated our analysis confirms the efficacy of bevacizumab in recurrent highgrade glioma patient with an acceptable toxicity profile in keeping with it known safety in the literature,"Adult, Aged, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Brain Neoplasms, Female, Glioblastoma, Glioma, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Retrospective Studies, Survival Analysis"
34078718,there is no agreement on the gold standard for detection and grading of chemotherapyinduced peripheral neurotoxicity cipn in clinical trial the objective is to perform an observational prospective study to as and compare patientbased and physicianbased method for detection and grading of cipn consecutive patient aged 18 year or older candidate for neurotoxic chemotherapy were enrolled in the united state european union or australia a trained investigator performed physicianbased scale total neuropathy scoreclinical tnsc used to calculate total neuropathy scorenurse tnsn and supervised the patientcompleted questionnaire functional assessment of cancer treatmentgynecologic oncology groupneurotoxicity factgogntx evaluation were performed before and at the end of chemotherapy on participant without neuropathy at baseline we assessed the association between tnsc tnsn and factgogntx considering a previously established minimal clinically important difference mcid for factgogntx we identified participant with and without a clinically important deterioration according to this scale then we calculated the mcid for tnsc and tnsn a the difference in the mean change score of these scale between the 2 group data from 254 participant were available 180 71 had normal neurologic status at baseline at the end of the study 88 of participant developed any grade of neuropathy tnsc tnsn and factgogntx showed good responsiveness standardized mean change from baseline to end of chemotherapy 1 for all scale on the 153 participant without neuropathy at baseline and treated with a known neurotoxic chemotherapy regimen we verified a moderate correlation in both tnsc and tnsn score with factgogntx spearman correlation index r on the same sample considering a clinically important a change in the factgogntx score of at least point the mcid wa for tnsc and for the tnsn mcid for tnsc and tnsn were calculated and the tnsn can be considered a reliable alternative objective clinical assessment if a more extended neurologic examination is not possible the factgogntx score can be reduced to 7 item and these item correlate well with the tnsc and tnsn this study provides class iii evidence that a patientcompleted questionnaire and nurseassessed scale correlate with a physicianassessed scale,"Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Diagnostic Techniques, Neurological, Humans, Middle Aged, Neoplasms, Neurotoxicity Syndromes, Nurses, Patients, Peripheral Nervous System Diseases, Physicians, Prospective Studies, Psychometrics, Severity of Illness Index, Young Adult"
34078521,hematological toxicity induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice we hypothesized that inhibition of the reninangiotensin system ra can ameliorate pemetrexedinduced hematological toxicity through drugdrug interaction involving organic anion transporter thus this study aimed to clarify whether ra inhibitor rasis could prevent pemetrexed plus platinuminduced hematological toxicity we retrospectively analyzed data from 305 consecutive patient with nonsmall cell lung cancer or malignant pleural mesothelioma who received their first cycle of a pemetrexed plus platinum regimen and were treated with or without rasis the primary endpoint wa the incidence of severe myelosuppression after the first cycle propensity score psmatched psadjusted and inverse probability of treatment weighting iptw analysis were used the number of patient with grade 3 hematological toxicity wa 27 psmatched analysis revealed that the concomitant use of rasis wa slightly associated with a lower risk of grade 3 hematological toxicity odds ratio or 95 confidence interval ci p additionally sensitivity analysis using psadjusted and iptw method demonstrated similar result or 95 ci p and or 95 ci p respectively these finding suggest that rasis might prevent pemetrexed plus platinuminduced hematological toxicity,"Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Pemetrexed, Platinum, Propensity Score, Renin-Angiotensin System, Retrospective Studies"
34078134,lay abstract in the era of precision medicine the challenge is to identify the patient who are most likely to benefit from different treatment strategy we believe that finding of the present network metaanalysis may facilitate individualized treatment strategy based on adverse event to guide regarding the potentially best tolerated approach for patient with urothelial carcinoma of the bladder immunotherapy especially a single regimen demonstrated the highest favorable tolerability to most adverse event,"Antineoplastic Agents, Immunological, Carcinoma, Transitional Cell, Humans, Immunotherapy, Network Meta-Analysis, Salvage Therapy, Urinary Bladder Neoplasms"
34074038,glioblastoma multiforme gbm ha remained one of the most lethal and challenging cancer to treat previous study have shown encouraging result when irinotecan wa used in combination with temozolomide tmz for treating gbm however irinotecan ha a narrow therapeutic index a slight dose increase in irinotecan can induce toxicity that outweigh it therapeutic benefit sn38 is the active metabolite of irinotecan that account for both it antitumor efficacy and toxicity in our previous paper we showed that sn38 embedded into 5050 biodegradable polydllactidecoglycolide plga microparticles smps provides an efficient delivery and sustained release of sn38 from smps in the brain tissue of rat these property of smps give them potential for therapeutic application due to their high efficacy and low toxicity in this study we tested the antitumor activity of smpbased interstitial chemotherapy combined with tmz using tmzresistant human glioblastoma cell linederived xenograft model our data suggest that treatment in which smps are combined with tmz reduces tumor growth and extends survival in mouse bearing xenograft tumor derived from both tmzresistant and tmzsensitive human glioblastoma cell line our finding demonstrate that combining smps with tmz may have potential a a promising strategy for the treatment of gbm,"Animals, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Brain Neoplasms, Cell Line, Tumor, Cell Proliferation, Drug Delivery Systems, Drug Liberation, Drug Resistance, Neoplasm, Glioblastoma, Humans, Irinotecan, Mice, Microplastics, Microscopy, Electron, Scanning, Polylactic Acid-Polyglycolic Acid Copolymer, Rats, Temozolomide, Xenograft Model Antitumor Assays"
34071152,prostate cancer pca is the second most common cancer in men causing more than death every year worldwide due to their superior cellkilling ability and the relative simplicity of their preparation immunotoxin molecule have great potential in the clinical treatment of cancer and several such molecule have been approved for clinical application in this study we adopted a relatively simple strategy based on a singledomain antibody sdab and an improved pseudomonas exotoxin a pe toxin pe24x7 to prepare a safer immunotoxin against prostatespecific membrane antigen psma for pca treatment the designed antipsma immunotoxin jvmpe24x wa conveniently prepared in it soluble form in an escherichia coli e coli system avoiding the complex renaturation process needed for immunotoxin preparation by the conventional strategy the product wa very stable and showed a very strong ability to bind the psma receptor cytotoxicity assay showed that this molecule at a very low concentration could kill psmapositive pca cell with an ec50 value concentration at which the cell viability decreased by 50 of pm against psmapositive lncap cell moreover this molecule showed very good killing selectivity between psmapositive and psmanegative cell with a selection ratio of more than fold animal study showed that this molecule at a very low dosage 5 mgkg once every three day completely inhibited the growth of pca tumor and the maximum tolerable dose mtd wa more than 15 mgkg indicating it very potent tumortreatment ability and a wide therapeutic window use of the new pe toxin pe24x a the effector moiety significantly reduced offtarget toxicity and improved the therapeutic window of the immunotoxin the above result demonstrate that the designed antipsma immunotoxin jvmpe24x ha good application value for the treatment of pca,"Adenocarcinoma, Animals, Antibody Specificity, Antigen-Antibody Reactions, Antigens, Neoplasm, Antigens, Surface, Antineoplastic Agents, Immunological, Cell Line, Tumor, Drug Screening Assays, Antitumor, Glutamate Carboxypeptidase II, Humans, Immunotoxins, Male, Maximum Tolerated Dose, Mice, Mice, Inbred NOD, Mice, SCID, Models, Molecular, Molecular Targeted Therapy, Prostatic Neoplasms, Protein Conformation, Recombinant Fusion Proteins, Single-Domain Antibodies, Xenograft Model Antitumor Assays"
34071132,demethoxycurcumin dmc a derivate of curcumin ha been shown to induce apoptotic cell death in human glioblastoma multiforme gbm 8401 cell via cell cycle arrest and induction of cell apoptosis however there is no report showing dmc suppresses glioblastoma multiforme cell in vivo in the present study we investigated the effect of dmc on gbm8401 cell in vivo at first we established a luciferaseexpressing stable clone named gbm luc second mouse were inoculated subcutaneously with gbm luc2 cell to generate a xenograft tumor mouse model after inoculation tumor volume reached mm and all mouse were randomly divided into three group group i wa treated with 110 l phosphatebuffered solution pb containing dimethyl sulfoxide group ii with 30 mgkg of dmc and group iii with 60 mgkg of dmc mouse from each group were given the oral treatment of dmc by gavage for 21 day the body weight and tumor volume were recorded every 3 day dmc significantly decreased the tumor volume and 60 mgkg treatment showed a higher decrease in tumor volume than that of 30 mgkg however dmc did not affect the body weight the photon emitted from mouse tumor were detected with xenogen ivis imaging system dmc at both do decreased the total photon flux and 60 mgkg treatment of dmc ha low total photon flux than that of 30 mgkg the tumor volume and weight in 60 mgkg treatment of dmc were lower than that of 30 mgkg immunohistochemical analysis wa used to measure protein expression of tumor and result showed that dmc treatment led to lightly staining with antibcl2 and xiap and 60 mgkg treatment of dmc ha lighter staining with antibcl2 and xiap than that of 30 mgkg the higher dose 60 mgkg of dmc ha higher signal of cleavedcaspase3 than that of the lower dose 30 mgkg furthermore the hematoxylin and eosin he staining of liver tissue showed no significant difference between dmctreated and controlgroups overall these observation showed that dmc suppressed tumor property in vivo and dmc may be used against human glioblastoma multiforme in the future,"Animals, Antineoplastic Agents, Phytogenic, Apoptosis, Brain Neoplasms, Cell Line, Tumor, Diarylheptanoids, Genes, Reporter, Glioblastoma, Humans, Liver, Male, Mice, Mice, Nude, Neoplasm Proteins, Proto-Oncogene Proteins c-bcl-2, Random Allocation, Tumor Burden, X-Linked Inhibitor of Apoptosis Protein, Xenograft Model Antitumor Assays, bcl-2-Associated X Protein"
34070464,personalized therapy is becoming increasingly popular in oncological scenario not only based on molecular pharmacological target but also preventing any drugdruggene interaction ddgi which could lead to severe toxicity single nucleotide polymorphism snp the individual germline sequence variation in gene involved in drug metabolism are correlated to interindividual response to drug and explain both efficacy and toxicity profile reported by patient we present the case of a woman suffering from triplepositive breast cancer she had earlystage disease at the onset and after four year developed metastatic disease during her history she presented different toxicity due to antineoplastic treatment particularly hypertransaminasemia wa found during every line of treatment nevertheless we were able to guarantee the patient an excellent therapeutic adhesion thanks to the supportive treatment and the reduction of drug dosage moreover we conducted a simultaneous analysis of the patient biochemical and genomic data thanks to drugpin software and we found several significant snp of the main enzyme and transporter involved in drug metabolism our case report demonstrated the relevance of ddgi in clinical practice management of a patient treated for advanced breast cancer suggesting the role of drugpin software a an easytouse tool to prevent adverse event during cancer treatment and to help physician in therapeutic algorithm however further study are needed to confirm these result,"Antineoplastic Agents, Breast Neoplasms, Female, Humans, Precision Medicine, Survivors"
34069161,the dimeric dihydropyrimidine dehydrogenase dpd metalloenzyme an adjunct anticancer drug target contains highly specialized 4 fe cluster per chain these cluster facilitate the catalysis of the ratelimiting step in the pyrimidine degradation pathway through a harmonized electron transfer cascade that trigger a redox catabolic reaction in the process the bulk of the administered fluorouracil fu cancer drug is inactivated while a small proportion is activated to nucleic acid antimetabolite the occurrence of missense mutation in dpd protein within the general population including those of african descent ha adverse toxicity effect due to altered fu metabolism thus deciphering mutation effect on protein structure and function is vital especially for precision medicine purpose we previously proposed combining molecular dynamic md and dynamic residue network drn analysis to decipher the molecular mechanism of missense mutation in other protein however the presence of fe cluster in dpd pose a challenge for such in silico study the existing amber force field parameter can not accurately describe the fe center coordination exhibited by this enzyme therefore this study aimed to derive amber force field parameter for dpd enzyme fe center using the original seminario method and the collation feature visual force field derivation toolkit a a supportive approach allatom md simulation were performed to validate the result both approach generated similar force field parameter which accurately described the human dpd protein fe cluster architecture this information is crucial and open new avenue for in silico cancer pharmacogenomics and drug discovery related research on fu drug efficacy and toxicity issue,"Animals, Antineoplastic Agents, Computer Simulation, Dihydrouracil Dehydrogenase (NADP), Enzyme Stability, Fluorouracil, Humans, Iron-Sulfur Proteins, Molecular Conformation, Molecular Dynamics Simulation, Neoplasms, Pharmacogenetics, Principal Component Analysis, Protons, Quantum Theory, Structural Homology, Protein, Swine, Thermodynamics"
34068561,several type of cancer share cellular and molecular behavior although many chemotherapy drug have been designed to weaken the defense of cancer cell these drug may also have cytotoxic effect on healthy tissue fucoidan a sulfated fucosebased polysaccharide from brown algae ha gained much attention a an antitumor drug owing to it anticancer effect against multiple cancer type among the anticancer mechanism of fucoidan are cell cycle arrest apoptosis evocation and stimulation of cytotoxic natural killer cell and macrophage fucoidan also protects against toxicity associated with chemotherapeutic drug and radiationinduced damage the synergistic effect of fucoidan with existing anticancer drug ha prompted researcher to explore it therapeutic potential this review compiles the mechanism through which fucoidan slows tumor growth kill cancer cell and interacts with cancer chemotherapy drug the obstacle involved in developing fucoidan a an anticancer agent are also discussed in this review,"Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Apoptosis, Cell Cycle, Humans, Neoplasms, Polysaccharides"
34068184,the marine ecosystem populated by a myriad of animal plant and microorganism is an inexhaustible reservoir of pharmacologically active molecule among the multiple secondary metabolite produced by marine source there are anthraquinones and their derivative besides being mainly known to be produced by terrestrial specie even marine organism and the uncountable kingdom of marine microorganism biosynthesize anthraquinones anthraquinones posse many different biological activity including a remarkable antitumor activity however due to their peculiar chemical structure anthraquinones are often associated with toxicological issue even relevant such a genotoxicity and mutagenicity the aim of this review is to critically describe the anticancer potential of anthraquinones derived from marine source and their genotoxic and mutagenic potential marinederived anthraquinones show a promising anticancer potential although clinical study are missing additionally an indepth investigation of their toxicological profile is needed before advocating anthraquinones a a therapeutic armamentarium in the oncological area,"Animals, Anthraquinones, Antineoplastic Agents, Aquatic Organisms, Cell Line, Tumor, Humans, Mutagens, Neoplasms"
34067288,folfirinox ffx and gemcitabine nabpaclitaxel gn are the most common chemotherapy regimen in firstline treatment of metastatic pancreatic cancer pc they have not been compared each other in a prospective trial but only in retrospective study which can thus be affected by several bias in order to overcome these bias we took advantage of matchingadjusted indirect comparison maic that allows an indirect comparison by reducing crosstrial difference and compared data from 268 patient treated with gn in a realworld setting with data from the 171 patient included in the ffx arm of the prodige trial survival outcome did not differ between the two population overall survival wa month for both treatment hazard ratio hr of ffx 95 confidence interval ci p progressionfree survival wa month with gn and month with ffx hr of ffx 95 ci p on the other hand we observed a difference in the toxicity profile grade anemia wa more frequent with gn whereas a higher occurrence of grade vomiting and diarrhea wa reported with ffx ffx and gn show an equivalent efficacy but different safety profile in the firstline therapy of metastatic pancreatic cancer searching for reliable predictive biomarkers is advised in order to improve therapeutic strategy in metastatic pc,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Disease-Free Survival, Female, Fluorouracil, Humans, Irinotecan, Leucovorin, Male, Middle Aged, Neoplasm Metastasis, Oxaliplatin, Paclitaxel, Pancreatic Neoplasms, Survival Rate, Gemcitabine"
34066963,leukemia is a leukocyte cancer that is characterized by anarchic growth of immature immune cell in the bone marrow blood and spleen there are many form of leukemia and the best course of therapy and the chance of a patient survival depend on the type of leukemic disease different form of drug have been used to treat leukemia due to the adverse effect associated with such therapy and drug resistance the search for safer and more effective drug remains one of the most challenging area of research thus new therapeutic approach are important to improving outcome almost half of the drug utilized nowadays in treating cancer are from natural product and their derivative medicinal plant have proven to be an effective natural source of antileukemic drug the cytotoxicity and the mechanism underlying the toxicity of these plant to leukemic cell and their isolated compound were investigated effort ha been made throughout this comprehensive review to highlight the recent development and milestone achieved in leukemia therapy using plantderived compound and the crude extract from various medicinal plant furthermore the mechanism of action of these plant are discussed,"Antineoplastic Agents, Phytogenic, Cell Line, Tumor, Clinical Trials as Topic, Humans, Leukemia, Plants, Medicinal"
34064873,cardiac glycoside cgs toxin wellknown for numerous human and cattle poisoning are natural compound the biosynthesis of which occurs in various plant and animal a a selfprotective mechanism to prevent grazing and predation interestingly some insect specie can take advantage of the cgs toxicity and by absorbing them they are also protected from predation the mechanism of action of cgs toxicity is inhibition of nakatpase the sodiumpotassium pump nka which disrupts the ionic homeostasis leading to elevated ca concentration resulting in cell death thus nka serf a a molecular target for cgs although it is not the only one and even though cgs are toxic for human and some animal they can also be used a remedy for various disease such a cardiovascular one and possibly cancer although the anticancer mechanism of cgs ha not been fully elucidated yet it is thought to be connected with the second role of nka being a receptor that can induce several cell signaling cascade and even serve a a growth factor and thus inhibit cancer cell proliferation at low nontoxic concentration these growth inhibitory effect are often observed only in cancer cell thereby offering a possibility for cgs to be repositioned for cancer treatment serving not only a chemotherapeutic agent but also a immunogenic cell death trigger therefore here we report on cgs chemical structure production optimization and biological activity with possible use in cancer therapy a well a discus their antiviral potential which wa discovered quite recently special attention ha been devoted to digitoxin digoxin and ouabain,"Animals, Antineoplastic Agents, Cardiac Glycosides, Cattle, Digitoxin, Digoxin, Humans, Molecular Targeted Therapy, Neoplasms, Ouabain, Sodium-Potassium-Exchanging ATPase"
34063867,aplysinopsins are a class of marine indole alkaloid that exhibit a wide range of biological activity although both the indole and nbenzyl moiety of aplysinopsins are known to posse antiproliferative activity against cancer cell their mechanism of action remains unclear through in vitro and in vivo proliferation and viability screening of newly synthesized aplysinopsin analog on myelogenous leukemia cell line and zebrafish toxicity test a well a analysis of differential toxicity in noncancerous rpmi 1788 cell and pbmcs we identified ee84 a a promising novel drug candidate against chronic myeloid leukemia this indole derivative demonstrated druglikeness in agreement with lipinskis rule of five furthermore ee84 induced a senescentlike phenotype in k562 cell in line with it cytostatic effect eetreated k562 cell underwent morphological change in line with mitochondrial dysfunction concomitant with autophagy and er stress induction finally we demonstrated the synergistic cytotoxic effect of ee84 with a bh3 mimetic the mcl1 inhibitor a against imatinibsensitive and resistant k562 cell highlighting the inhibition of antiapoptotic bcl2 protein a a promising novel senolytic approach against chronic myeloid leukemia,"Animals, Antineoplastic Agents, Apoptosis, Autophagy, Cell Cycle, Cell Death, Cell Line, Cytotoxins, Drug Synergism, Endoplasmic Reticulum Stress, Humans, Indoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloid Cell Leukemia Sequence 1 Protein, Sulfonamides, Tryptophan, Zebrafish"
34063119,one of the promising strategy for improvement of cancer treatment is application of a combination therapy the aim of this study wa to investigate the anticancer activity of nanoformulations containing doxorubicin and iron oxide particle covered with polymeric shell bearing cholesterol moiety it wa postulated that due to high affinity to cell membrane particle comprising polycholesteryl acrylate can sensitize cancer cell to doxorubicin chemotherapy the performed analysis revealed that the developed system are effective against the human breast cancer cell line mcf7 and mdamb231 even at low do of the active compound applied m additionally high compatibility and lack of toxicity of the tested material against human red blood cell immune monocytic thp1 cell and cardiomyocyte h9c2 cell wa demonstrated synergistic effect observed upon administration of doxorubicin with polymeriron oxide hybrid comprising polycholesteryl acrylate may provide an opportunity to limit toxicity of the drug and to improve it therapeutic efficiency at the same time,"Animals, Breast Neoplasms, Cell Line, Tumor, Cholesterol, Dose-Response Relationship, Drug, Doxorubicin, Dynamic Light Scattering, Female, Humans, Magnetic Phenomena, Materials Testing, Polymers, Rats, Spectroscopy, Fourier Transform Infrared, Static Electricity, Thermogravimetry"
34062206,quinacrine sterilization q is a nonsurgical female method used by more than woman in over 50 country with fda approval q is expected to be used by hundred of million of woman the negative international health consequence of the result of a year rat study in 2010 by cancel et al in regulatory toxicology and pharmacology rtp 56 are incalculable s1cr2 wa ignored in this study including the fundamental concept of maximum tolerated dose mtd which resulted in the use of massive do up to 35 time the mtd which killed many of the rat and destroyed the uterus of survivor the design of this rat study wa built on the false assertion that this study mimic what happens in woman cancel et al 2010 concludes it seems most likely that genotoxicity wa a major factor in the carcinogenicity observed prompting the fda to halt further research of q in rtp mcconnell et al 2010 and haseman et al 2015 using the author data definitively determined the carcinogenicity to be secondary to necrosis and chronic inflammation decision made in the design conduct analysis interpretation and reporting in this study lack scientific foundation this paper explores these decision,"Animals, Data Accuracy, Drug Approval, Female, Humans, Maximum Tolerated Dose, Quinacrine, Rats, Research Design, Sterilization, Reproductive, Toxicity Tests, Chronic, United States, United States Food and Drug Administration"
34061498,targeted delivery and extended blood circulation of anticancer drug have been the challenge for decreasing the adverse side effect and improving the therapeutic efficiency in cancer chemotherapy herein we present a drug delivery system dd based on biodegradable dendritic polyglycerol sulfatebearing polycaprolactone dpgspcl chain which ha been synthesized on 20 g scale using a straightforward twostep protocol in vivo fluorescence imaging demonstrated a significant accumulation of the dd in the tumor environment sunitinib an anticancer drug wa loaded into the dd and the druginduced toxicity wa investigated in vitro and in vivo the drug encapsulated in dpgspcl and the free drug showed similar toxicity in a431 and ht29 cell and the cellular uptake wa comparable the straightforward and largescale synthesis the organic solventfree drugloading approach together with the tumor targetability of the biodegradable dendritic polyglycerols render this copolymer a promising candidate for targeted cancer nanomedicine drug delivery system,"Antineoplastic Agents, Cytostatic Agents, Glycerol, Humans, Neoplasms, Polymers, Sulfates"
34060438,despite the introduction of effective combination antiretroviral therapy cart aidsrelated kaposi sarcoma aidsks remains the most common malignancy in hiv positive patient in advanced stage or progressive form chemotherapy ct in combination with cart is the treatment of choice the aim of the study is to evaluate efficacy and tolerability of pegylated liposomal doxorubicin pld a first line ct in aidsks in this single institution retrospective study pld 20 mgm2 iv every 2 week for 6 or 12 cycle in combination with cart wa administered in poor risk and some case of good prognosis or limited cutaneous disease response rate and adverse event to treatment wa evaluated we enrolled 33 patient with aidsks median age 44ys male caucasian cartnave simultaneous diagnosis of hiv infection and k median lymphocyte cd count 134cells median hiv viral load log10 copiesml 32 patient were assigned to a poor risk k stage grade toxicity wa reported in 9 patient no cardiovascular event or severe sepsis were described complete response wa reported in 25 of 31 patient evaluable for efficacy after a median followup of 52 month the year pfs wa pld associated with cart is an effective feasible and well tolerated firstline ct in advanced aidsks,"AIDS-Related Opportunistic Infections, Adult, Antibiotics, Antineoplastic, CD4 Lymphocyte Count, Doxorubicin, Female, Humans, Male, Middle Aged, Polyethylene Glycols, Retrospective Studies, Sarcoma, Kaposi, Viral Load"
34058149,nanomaterials such a graphene oxide go are increasingly being investigated for their suitability in biomedical application tubulin is the key molecule for the formation of microtubule crucial for cellular function and proliferation and a such an appealing target for developing anticancer drug here we employ biophysical technique to study the effect of go on tubulin structure and how the change affect the tubulinmicrotubule assembly go disrupts the structural integrity of the protein with consequent retardation of tubulin polymerization investigating the anticancer potential of go we found that it is more toxic to human colon cancer cell hct116 a compared to human embryonic kidney epithelial cell hek293 immunocytochemistry indicated the disruption of microtubule assembly in hct116 cell go arrested cell in the s phase with increased accumulation in subg1 population of cell cycle inducing apoptosis by generating reactive oxygen specie ro in a dose and timedependent manner go inhibited microtubule formation by intervening into the polymerization of tubulin heterodimers both in vitro and ex vivo resulting in growth arrest at the s phase and ro induced apoptosis of hct116 colorectal carcinoma cell there wa no significant harm to the hek293 kidney epithelial cell used a control our report of pristine go causing rosinduced apoptosis of cancer cell and inhibition of tubulinmicrotubule assembly can be of interest in cancer therapeutic and nanomedicine,"Humans, Graphite, Microtubules, HEK293 Cells, HCT116 Cells, Colorectal Neoplasms, Tubulin, Apoptosis, Reactive Oxygen Species, Antineoplastic Agents"
34057299,while docetaxelcisplatinfluorouracil dcf outperforms cf in firstline gastric adenocarcinoma toxicity remains an issue this multicenter phase ii trial randomized chemonave metastatic gastric adenocarcinoma patient to fractionated weekly dcf d 40 mgm2 c 35 mgm f 1800 mgm over 24 h on day 1 and 8 every 3 week arm 1 or fortnightly dcf d 50 mgm2 c 50 mgm f 2000 mgm over 48 h every 2 week arm 2 prophylactic granulocyte colonystimulating factor gcsf wa not allowed the primary endpoint wa the rate of febrile neutropenia within the first six treatment week early fn a total of 106 eligible patient were recruited the early and overall fn rate were and 17 in arm respectively and and 8 in arm respectively grade 3 toxicity occurred in 81 of patient in arm 1 and 90 of patient in arm the most common being neutropenia 33 v 61 fatigue 27 v 25 vomiting 21 v 12 anorexia 19 v 18 and diarrhea 17 v 10 median progressionfree survival and overall survival were 95 ci and month 95 ci respectively in arm 1 and 95 ci and month 95 ci respectively in arm fractionated weekly and fortnightly dcf regimen are associated with a low risk of early fn and a better hematological toxicity profile a compared to historical dcf without compromising efficacy both regimen offer greater convenience removing the need for systematic use of prophylactic gcsf,"Adenocarcinoma, Adult, Aged, Aged, 80 and over, Anorexia, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Diarrhea, Docetaxel, Drug Administration Schedule, Esophagogastric Junction, Fatigue, Febrile Neutropenia, Female, Fluorouracil, Granulocyte Colony-Stimulating Factor, Humans, Male, Middle Aged, Neutropenia, Progression-Free Survival, Stomach Neoplasms, Vomiting"
34054056,the objective of this study wa to evaluate the utility of serum creactive protein crp a biomarker for the early diagnosis of immunerelated adverse event iraes in melanoma patient treated with immune checkpoint inhibitor icis in the adjuvant setting and it potential correlation with relapsefree survival rf prospectively collected data from 72 melanoma patient treated with adjuvant icis were pooled crp value at diagnosis of 10 iraes were descriptively analysed correlation between rf and the occurrence of iraes the grade of the irae the extent of crpelevation and the use of corticosteroid for irae treatment were investigated a total of 191 iraes grade n 182 grade n 9 occurred in 64 patient skin toxicity n 70 fatigue n 50 thyroiditis n 12 musculoskeletal toxicity n 11 sicca syndrome n 10 other n 23 pneumonitis n 6 colitis n 4 hepatitis n 3 and hypophysitis n 2 in pneumonitis and hypophysitis the median crp level at diagnosis exceeded the upper limit of normal uln 5 mgl after a median followup of month 28 patient 39 had been diagnosed with a melanoma relapse patient who experienced no irae were at the highest risk for relapse p a trend wa observed for patient diagnosed with an irae that wa associated with an elevated crp 2xuln to be at higher risk for relapse a compared to those diagnosed with an irae and crp uln p crp ha potential a biomarker for the early detection of selected iraes dynamic evaluation can guide irae diagnosis regression or relapse the observed correlation between iraes associated with an elevated crp and risk for recurrence deserves further investigation,"Biomarkers, Tumor, C-Reactive Protein, Female, Humans, Immune Checkpoint Inhibitors, Male, Melanoma, Skin Neoplasms"
34052929,background patient with multiple relapsedrefractory germ cell tumour gcts have an extremely poor prognosis parp polyadpribose polymerase is overexpressed in gcts compared to normal testis and parp overexpression is an early event in gct development this study aimed to determine the efficacy and toxicity of gemcitabine carboplatin and the parp inhibitor veliparib in patient with multiple relapsedrefractory gcts method fifteen patient with multiple relapsedrefractory gcts were enrolled in this phase ii study from october 2016 to october gemcitabine wa administered at a dose of 800 mgm2 on day 1 and 8 every 3 week carboplatin at a target auc of 4 on day 1 every 3 week and veliparib at a dose of 250 mg bid throughout the primary end point wa month progressionfree survival pfs result the median number of treatment cycle wa 4 range twelvemonth pfs wa achieved in 1 patient the median pfs wa month 95 ci and the median overall survival wa month 95 ci partial remission wa achieved in 4 patient and disease stabilization wa observed in 5 patient a favourable response wa achieved in 3 patient treatment wa well tolerated however 11 patient experienced grade neutropenia 10 experienced thrombocytopenia 5 anaemia and 2 febrile neutropenia conclusion this study failed to achieve it primary endpoint and our data suggest limited efficacy of gemcitabine carboplatin and veliparib for multiple relapsedrefractory gcts clinicaltrialsgov identifier nct registered august,"Adult, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carboplatin, Deoxycytidine, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Poly(ADP-ribose) Polymerase Inhibitors, Progression-Free Survival, Young Adult, Gemcitabine"
34052550,sorafenib lenvatinib and apatinib a multitargeted tyrosine kinase inhibitor with antiproliferative and antiangiogenic effect are widely used for systemic therapy in advanced hepatocellular carcinoma patient nevertheless insufficient efficacy or adverse effect often appear due to the significant interindividual variability of plasma concentration for these drug in order to carry out therapeutic drug monitoring of these drug and then ensure the effectiveness and safety of the medical treatment the first method allowing to quantify sorafenib lenvatinib and apatinib simultaneously in human plasma wa developed in this study the analysis wa performed by uplcmsms system and the chromatographic separation wa achieved on a c18 column using a gradient elution of wateracetonitrile in min this method presented satisfactory result in term of specificity precision coefficient of variation of intraday and interday accuracy matrix effect extraction recovery a well a stability in human plasma and even whole blood under certain condition this sensitive rapid and simple method wa successfully applied to the analysis of sorafenib lenvatinib and apatinib for therapeutic drug monitoring in hepatocellular carcinoma patient and it wa expected to be applied to further study about clarifying the concentration efficacy and concentrationtoxic relationship of sorafenib lenvatinib and apatinib in hepatocellular carcinoma patient,"Chromatography, High Pressure Liquid, Chromatography, Liquid, Drug Monitoring, Humans, Liver Neoplasms, Pharmaceutical Preparations, Phenylurea Compounds, Pyridines, Quinolines, Reproducibility of Results, Sorafenib, Tandem Mass Spectrometry"
34052176,in the era of tyrosine kinase inhibitor tkis chronic myeloid leukemia cml patient generally live close to a normal lifespan and the number of elderly patient with cml with comorbidities is increasing we retrospectively compared the efficacy and safety of frontline imatinib between elderly patient 60 year old and younger patient 60 year old with cml the study included 33 elderly and 125 younger patient elderly patient had significantly higher charlson comorbidity index cci score efficacy and toxicity were comparable among the older patient with cci score of 0 and there were significantly more hematologic adverse event aes in elderly patient p 005 although not significant nonhematologic aes were also more common in older case p 056 elderly patient had significantly higher rate of imatinib dose reduction p 001 cumulative response rate were similar in both group eventfree survival wa comparable and overall survival oswhen noncmlrelated death were censoredwas also similar in the multivariate analysis age at diagnosis and cci were associated with o and patient 60 year of age had a time higher risk of death compared with the patient 60 year of age p 011 similarly patient with cci score 2 had a time higher risk of death compared with patient with a cci score of 0 p 033 upfront imatinib wa generally well tolerated among elderly turkish patient with cml with noninferior response and longterm outcome when compared with younger patient comorbidities can be problematic in elderly patient and today the survival of patient with cml is determined mostly by comorbidities,"Aged, Aged, 80 and over, Antineoplastic Agents, Comorbidity, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Protein Kinase Inhibitors, Retrospective Studies, Survival Analysis, Treatment Outcome, Turkey"
34051880,understanding patient experience of cancer treatment is important we aimed to evaluate patientreported outcome pro with atezolizumab plus bevacizumab versus sorafenib in patient with advanced hepatocellular carcinoma in the imbrave150 trial which ha already shown significant overall survival and progressionfree survival benefit with this combination therapy we did an openlabel randomised phase 3 trial in 111 hospital and cancer centre across 17 country or region we included patient aged 18 year or older with systemic treatmentnaive histologically cytologically or clinically confirmed unresectable hepatocellular carcinoma and an eastern cooperative oncology group ecog performance status of 0 or with disease that wa not amenable to curative surgical or locoregional therapy or progressive disease after surgical or locoregional therapy participant were randomly assigned 21 using permuted block randomisation block of six stratified by geographical region macrovascular invasion extrahepatic spread or both baseline alphafetoprotein concentration and ecog performance status to receive 1200 mg atezolizumab plus 15 mgkg bevacizumab intravenously once every 3 week or 400 mg sorafenib orally twice a day until loss of clinical benefit or unacceptable toxicity the independent review facility for tumour assessment wa masked to the treatment allocation previously reported coprimary endpoint were overall survival and independently assessed progressionfree survival per response evaluation criterion in solid tumor prespecified secondary and exploratory analysis descriptively evaluated treatment effect on patientreported quality of life functioning and disease symptom per the european organisation for research and treatment of cancer eortc qualityoflife questionnaire for cancer qlqc30 and qualityoflife questionnaire for hepatocellular carcinoma qlqhcc18 time to confirmed deterioration of pro wa analysed in the intentiontotreat population all other analysis were done in the proevaluable population patient who had a baseline pro assessment and at least one assessment after baseline the trial is ongoing enrolment is closed this trial is registered with clinicaltrialsgov nct between march and jan 725 patient were screened and 501 patient were enrolled and randomly assigned to atezolizumab plus bevacizumab n336 or sorafenib n165 309 patient in the atezolizumab plus bevacizumab group and 145 patient in the sorafenib group were included in the proevaluable population at data cutoff aug 2019 the median followup wa 86 month iqr 68 eortc qlqc30 completion rate were 90 or greater for 23 of 24 treatment cycle in both group range in the atezolizumab plus bevacizumab group and in the sorafenib group eortc qlqhcc18 completion rate were 90 or greater for 20 of 24 cycle in the atezolizumab plus bevacizumab group range and 21 of 24 cycle in the sorafenib group range compared with sorafenib atezolizumab plus bevacizumab reduced the risk of deterioration on all eortc qlqc30 generic cancer symptom scale that were prespecified for analysis appetite loss hazard ratio hr 0 95 ci 081 diarrhoea 0 034 fatigue 0 081 pain 0 062 and two of three eortc qlqhcc18 diseasespecific symptom scale that were prespecified for analysis fatigue 0 080 and pain 0 092 but not jaundice 0 007 at day 1 of treatment cycle five after which attrition in the sorafenib group wa more than 50 the mean eortc qlqc30 score change from baseline in the atezolizumab plus bevacizumab versus sorafenib group were 329 sd 1756 versus 583 2063 for quality of life 402 1942 versus 976 2133 for role functioning and 377 1282 versus 760 1554 for physical functioning prespecified analysis of pro data showed clinically meaningful benefit in term of patientreported quality of life functioning and disease symptom with atezolizumab plus bevacizumab compared with sorafenib strengthening the combination therapy positive benefitrisk profile versus that of sorafenib in patient with unresectable hepatocellular carcinoma f hoffmannla roche and genentech,"Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Patient Reported Outcome Measures, Progression-Free Survival, Protein Kinase Inhibitors, Quality of Life, Sorafenib, Time Factors"
34051217,gold nanoparticles aunps have been attracted interest in the various area of clinical therapeutic in this study we investigated the anticancer and antiviral potential activity of aunps against influenza a virus and human glioblastoma gmb u87 and u251 cell line gold nanoparticles aunps were synthesized by citrate reduction method then ultravioletvisible spectrophotometry uvvis spectrum and electron microscopy analysis confirmed the type size mean diameter of 17 nm and distribution of the particle the aunps in vitro antiviral and anticancer effect wa evaluated by hemagglutination inhibition hai tissue culture infectious dose 50 tcid50 realtime pcr mtt flow cytometry and scratch assay the aunps were synthesized in spherical with a mean diameter of 17 2 nm and an absorbance peak at 520 nm the aunps were well tolerable by mdck cell at concentration up to gml and they significantly inhibited the hemagglutination and virus infectivity particularly when added pre or during virus infection furthermore anticancer result indicated that aunps treatment caused the marked induction of apoptosis and reduced growth and migration capability of u87 and u251 cell line in a timedependent manner the present result suggest that aunps provide promising antiviral and anticancer approach further research is needed to fully elucidate the mode of antiviral and anticancer action of aunps against influenza virus infection and human glioblastoma cell line,"Animals, Antineoplastic Agents, Antiviral Agents, Cell Line, Tumor, Cell Migration Assays, Dogs, Glioblastoma, Gold, Humans, Madin Darby Canine Kidney Cells, Metal Nanoparticles"
34051177,standard treatment for highrisk nonmuscleinvasive bladder cancer is transurethral resection of bladder tumour followed by intravesical bcg immunotherapy however despite high initial response rate up to 50 of patient have recurrence or become bcgunresponsive pd1 pathway activation is implicated in bcg resistance in the keynote057 study we evaluated pembrolizumab a pd1 inhibitor in bcgunresponsive nonmuscleinvasive bladder cancer we did this openlabel singlearm multicentre phase 2 study in 54 site hospital and cancer centre in 14 country in cohort a of the trial adult aged 18 year or older with histologically confirmed bcgunresponsive carcinoma in situ of the bladder with or without papillary tumour with an eastern cooperative oncology group performance status of and who were ineligible for or declined radical cystectomy were enrolled all enrolled patient were assigned to receive pembrolizumab 200 mg intravenously every 3 week for up to 24 month or until centrally confirmed disease persistence recurrence or progression unacceptable toxic effect or withdrawal of consent the primary endpoint wa clinical complete response rate absence of highrisk nonmuscleinvasive bladder cancer or progressive disease assessed by cystoscopy and urine cytology approximately 3 month after the first dose of study drug patient followup were done every 3 month for the first 2 year and every 6 month thereafter for up to 5 year efficacy wa assessed in all patient who received at least one dose of the study drug and met bcgunresponsive criterion safety wa assessed in all patient who received at least one dose of the study drug this trial is registered with clinicaltrialsgov number nct and is ongoing between dec and april we screened 334 patient for inclusion 186 patient did not meet inclusion criterion and 47 patient were assigned to cohort b patient with bcgunresponsive high grade ta or any grade t1 papillary disease without carcinoma in situ result will be reported separately 101 eligible patient were enrolled and assigned to receive pembrolizumab all 101 patient received at least one dose of the study drug and were included in the safety analysis five patient had disease that did not meet the u food and drug administration definition of bcgunresponsive nonmuscleinvasive bladder cancer and were therefore not included in the efficacy analysis n96 median followup wa 364 month iqr 327 39 41 95 ci 301 of 96 patient with bcgunresponsive carcinoma in situ of the bladder with or without papillary tumour had a complete response at 3 month grade 3 or 4 treatmentrelated adverse event occurred in 13 13 patient the most common were arthralgia in two 2 patient and hyponatraemia in three 3 patient serious treatmentrelated adverse event occurred in eight 8 patient there were no death that were considered treatment related pembrolizumab monotherapy wa tolerable and showed promising antitumour activity in patient with bcgunresponsive nonmuscleinvasive bladder cancer who declined or were ineligible for radical cystectomy and should be considered a a clinically active nonsurgical treatment option in this difficulttotreat population merck sharp dohme,"Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, BCG Vaccine, Carcinoma in Situ, Carcinoma, Papillary, Drug Resistance, Neoplasm, Female, Humans, Immune Checkpoint Inhibitors, Male, Middle Aged, Time Factors, Treatment Outcome, Urinary Bladder Neoplasms"
34050586,because s1 is orally administered oxiris doe not necessitate the continuous infusion of fu and is more convenient the recommended dose of oxiris wa determined to be level 1 oxaliplatin 65 mgm2 irinotecan 100 mgm2 s 80 mgm2 which ha manageable safety and promising anticancer activity oxiris is a new combination therapy of oxaliplatin irinotecan and s1 for unresectable pancreatic ductal adenocarcinoma pdac which may be beneficial because s1 is administered orally and continuous infusion of fluorouracil fu is not needed patient who had not received prior therapy for unresectable pdac were enrolled adenocarcinoma or adenosquamous histology wa required oxaliplatin and irinotecan were administered on day 1 and 15 s1 wa administered orally twice a day on day followed by 14 day of rest one cycle primary endpoint were doselimiting toxicity dlt and maximum tolerated dose mtd secondary endpoint were safety overall response rate orr progressionfree survival pfs and overall survival o in level 0 oxaliplatin 85 mgm2 irinotecan 100 mgm2 s 80 mgm2 two of five patient experienced dlt in level 1 oxaliplatin 65 mgm2 irinotecan 100 mgm2 s 80 mgm2 dlt could not be evaluated in two of eight patient because one cycle wa not completed one of the remaining six patient experienced dlt anemia thrombocytopenia fatigue nausea anorexia diarrhea and peripheral sensory neuropathy were seen frequently in level 0 and orr wa 30 in level 0 and median progressionfree survival and median overall survival were month 95 confidence interval ci month and month 95 ci month respectively mtd of oxiris therapy wa estimated to be level and the recommended dose rd for future trial wa level,"Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Colorectal Neoplasms, Fluorouracil, Humans, Irinotecan, Oxaliplatin, Oxonic Acid, Pancreatic Neoplasms, Tegafur"
34050255,pazopanib is active in refractory softtissue sarcoma sts and significantly prolongs pfs prior study of combination of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patient with sarcoma this prospective single arm phase ii study evaluated the efficacy of the combination of pazopanib with topotecan in patient with metastatic or unresectable nonadipocytic sts furthermore it incorporated exploratory arm for osteosarcoma and liposarcoma the primary endpoint wa progressionfree rate at 12 week in the nonadipocytic sts cohort of patient in the nonadipocytic sts cohort were progression free at 12 week which did not meet the primary endpoint of the study 66 the exploratory osteosarcoma cohort exceeded previously established phase ii trial comparator data benchmark of 12 with a pfr at 12 week of treatment with the combination of pazopanib and topotecan wa accompanied by a grade 3 or 4 toxicity in most patient in this prospective trial in refractory metastatic or unresectable sts and osteosarcoma the combination of pazopanib with topotecan did not meet it primary endpoint of progressionfree rate at 12 week the combination of pazopanib with topotecan wa associated with a high degree of toxicity,"Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Drug Administration Schedule, Humans, Indazoles, Male, Middle Aged, Neoplasm Metastasis, Osteosarcoma, Prospective Studies, Pyrimidines, Sarcoma, Sulfonamides, Topotecan, Treatment Outcome, Young Adult"
34049821,programmed cell death ligand 1 is a biomarker of immune checkpoint inhibitor icis for treating advanced nonsmallcell lung cancer nsclc here we evaluated serum protein from patient with advanced nsclc treated with icis to determine their potential a noninvasive predictive biomarkers for efficacy and immunerelated adverse event iraes patient with advanced nsclc who received nivolumab or pembrolizumab monotherapy until disease progression or unacceptable toxicity were integrated with previously reported nivolumabtreated patient blood sample were collected serially from baseline until the disease progressed serum protein level were quantified using the luminex assay association of clinical benefit cb and onset of iraes with serum protein level were evaluated sixtythree patient with advanced nsclc were studied and we used 63 and 47 paired serum sample at baseline and the second sampling point respectively for efficacy analysis baseline growthregulated oncogene 1 gro1 level were significantly lower in durable cb dcb patient than in nondcb patient p 05 change in monocyte chemoattractant protein 1 mcp1 level significantly decreased between baseline and the second sampling point p 05 patient with the low grodecreased mcp1 subtype showed significantly longer progressionfree survival pfs and overall survival o than the high groincreased mcp1 subgroup did median pfs not reached v 47 day p 0001 median o 985 day v 148 day p respectively elevated gro1 level were associated with immunerelated adverse event onset serum gro1 and mcp1 level can identify patient with advanced nsclc who are likely to benefit from ici treatment timecourse tracing of these protein level might be valuable in ici treatment,"Aged, Aged, 80 and over, Biomarkers, Carcinoma, Non-Small-Cell Lung, Cytokines, Female, Humans, Immune Checkpoint Inhibitors, Lung Neoplasms, Male, Middle Aged, Programmed Cell Death 1 Receptor, Treatment Outcome"
34048683,chimeric antigen receptor car are fusion protein containing an antigenrecognition domain coupled to a tcell activation domain eg cd3 cd247 and to a costimulatory domain eg cd28 or bb tnfrsf also known a cd137 the bcell maturation antigen bcma tnfrsf17 is an attractive target for car tcell therapy because it is only expressed by normal and malignant plasma cell and by a subset of mature b cell several trial of antibcma car t cell have shown highquality response including minimal residual diseasenegativity in patient with multiple myeloma who were heavily pretreated phase 3 trial are currently evaluating car tcell therapy versus standardofcare regimen in patient in earlier stage of the disease trial are also ongoing in newly diagnosed patient with highrisk cytogenetic profile or with residual disease after transplantation car t cell targeting other multiple myeloma antigen such a cd cd cd138 synd1 and slamf are also being explored toxicity associated with car t cell include cytokinerelease syndrome different type of cytopenia infection and neurotoxicity although some subset of patient have sustained response for more than 1 year most patient eventually relapse which might be related to the loss of car t cell loss of antigen expression on the tumour cell surface or to an immunosuppressive microenvironment that impairs the activity of t cell effort to improve the effectiveness of car tcell therapy include optimising car design and adapting the manufacturing process to generate cell product enriched for specific subset of t cell eg early memory cell other strategy explored in trial include dualantigen targeting to prevent antigen escape and rational combination therapy to enhance persistence several approach are also being developed to improve the safety of car tcell therapy such a the incorporation of a suicide gene safety system,"Animals, Cytokine Release Syndrome, Drug Resistance, Neoplasm, Humans, Immunotherapy, Adoptive, Multiple Myeloma, Neurotoxicity Syndromes, Receptors, Chimeric Antigen, Single-Chain Antibodies"
34048681,background lenalidomide maintenance improves progressionfree survival for patient with multiple myeloma although it optimal duration is unknown clearance of minimal residual disease mrd in the bone marrow result in superior outcome although it attainment or sustainment doe not alter clinical decisionmaking study that have evaluated mrd serially are limited in length we therefore aimed to evaluate longitudinal change in mrdstatus dynamic and their association with progressionfree survival in patient with multiple myeloma in this singlecentre singlearm phase 2 study we enrolled patient aged 18 year and older from the memorial sloan kettering cancer center new york ny usa who had newly diagnosed multiple myeloma following unrestricted frontline therapy and an eastern cooperative oncology group performance status of 2 or lower including patient who started maintenance before study enrolment all participant received lenalidomide maintenance at 10 mg for 21 day of day cycle until progression or unacceptable toxic effect for up to 5 year on protocol the primary endpoint wa progressionfree survival at 60 month per protocol and key secondary endpoint were mrd rate after completion of the 12th 24th and 36th cycle of maintenance and the association between progressionfree survival and annual measurement of mrd status mrd wa assessed from firstpull bone marrow aspirate at baseline and annually by flow cytometry per international myeloma working group criterion limit of detection of at least 1 up to a maximum of 5 year patient who completed at least four cycle of treatment were included in the analysis of the primary endpoint and patient who had completed at least one dose of treatment on protocol were assessable for secondary endpoint the study wa registered at clinicaltrialsgov nct and is now closed to accrual between sept and jan 108 patient 100 evaluable for the primary endpoint were enrolled median followup wa 407 month 95 ci 380 at 60 month progressionfree survival wa 64 95 ci median progressionfree survival wa unreached 95 ci unreachedunreached mrd dynamic were assessed using 340 mrd assessment done over 5 year for 103 evaluable patient patient who sustained mrd negativity for 2 year n34 had no recorded disease progression at median 198 month 95 ci 153 past the year maintenance landmark by contrast patient who lost their mrdnegative response n10 were more likely to progress than those with sustained mrd negativity hr infinite p00001 and those with persistent mrd positivity hr 5 95 ci 133 p0015 at the year landmark haematological and nonhaematological serious adverse event occurred in 19 patient 18 the most common adverse event of grade 3 or worse were decreased lymphocyte count in 48 44 patient and decreased neutrophil count in 47 44 patient one death occurred on study due to sepsis and heart failure and wa considered unrelated to the study drug serial measurement of mrd allow for dynamic assessment of risk for disease progression early intervention should be investigated for patient with loss of mrd negativity sustained mrd positivity is not categorically an unfavourable outcome and might portend prolonged stability of lowlevel disease memorial sloan kettering and celgene,"Administration, Oral, Aged, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Neoplasm Grading, Neoplasm, Residual, Progression-Free Survival"
34047177,maintenance therapy containing methotrexate and mercapto purine is essential to cure acute lymphoblastic leukemia all cytotoxicity is elicited by incorporation of thioguanine nucleotide into dna dnatg and higher leukocyte dnatg is associated with increased relapsefree survival a thioguanine provides fold higher cytosolic level of thioguanine nucleotide than doe mercapto purine we added lowdose thioguanine to methotrexate mercapto purine maintenance therapy to explore if this combination result in significantly higher dnatg the target population of the thiopurine enhanced all maintenance therapy team study wa 30 patient with nonhighrisk all aged year on methotrexatemercaptopurine maintenance therapy receiving no other systemic chemotherapy incremental do of thioguanine were added to methotrexatemercaptopurine maintenance therapy starting thioguanine dose mgmday maximum mgmday the primary endpoint wa dnatg increment thirtyfour patient were included and 30 patient completed maintenance therapy according to the team strategy of these 30 patient 26 87 tolerated mgmday a the maximum thioguanine dose team resulted in significantly higher dnatg level compared to those in both team patient before their inclusion in team on average 251 fmolmg dna higher 95 confidence interval p and with historical patient receiving standard methotrexatemercapto purine maintenance therapy on average 272 fmolmg dna higher 95 confidence interval p team did not increase myelotoxicity or hepatotoxicity in conclusion team is an innovative and feasible approach to improve maintenance therapy and result in higher dnatg level without inducing additional toxicity it may therefore be an effective strategy to reduce the risk of all relapse through increased dnatg this will be tested in a randomized alltogether1 substudy,"Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, DNA, Humans, Infant, Mercaptopurine, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Thioguanine, Young Adult"
34045849,although temozolomide ha been extensively used to treat various tumor there is a lack of largecohort study on temozolomides toxicity profile the toxicity profile and associated factor in patient treated with temozolomidecontaining regimen were analyzed patient treated with temozolomidecontaining regimen in the affiliated union hospital of huazhong university of science and technology from january 2008 to december 2019 were included a retrospective analysis of the clinical data of patient treated with temozolomidecontaining regimen wa performed univariate chisquare test and multivariate logistic regression analysis were employed to identify factor associated with the occurrence of toxicity among the 1057 patient received temozolomidecontaining regimen 922 patient were included in our analysis of the 922 patient 484 patient experienced toxicity univariate analysis revealed that radiotherapy chemotherapy cycle chemotherapy regimen and clinical stage were significantly associated with the toxicity during temozolomide treatment p the chemotherapy regimen chemotherapy cycle and clinical stage were significantly associated with the overall occurrence of toxicity p a chemotherapy regimen chemotherapy cycle and clinical stage were associated with the hematological system toxicity whereas gender age clinical diagnosis and clinical stage were related to gastrointestinal toxicity p clinical diagnosis chemotherapy regimen and age were associated with liver toxicity p toxicity are common among patient receiving temozolomidecontaining regimen clinician should be aware of factor associated with toxicity to minimize the impact of the toxicity,"Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Dose-Response Relationship, Drug, Female, Hospitals, Humans, Infant, Male, Middle Aged, Neoplasms, Retrospective Studies, Temozolomide, Young Adult"
34044928,herein a novel targeted delivery system wa developed for intracellular codelivery of doxorubicin dox a a chemotherapeutic drug antimir21 a an oncogenic antagomir in this system dox wa loaded into mesoporous silica nanoparticles msns and chitosan wa applied to cover the surface of msns as1411 aptamer a targeting nucleolin and antimir21 were electrostatically attached onto the surface of the chitosancoated msns and formed the final nanocomplex aacs nanocomplex the study of drug release wa based on dox release under ph and cellular toxicity and cellular uptake assessment of aacs nanocomplex were carried out in nucleolin positive c mcf and 4t1 and nucleolin negative cho cell line using mtt assay and flow cytometry analysis respectively also antitumor efficacy of aacs nanocomplex wa evaluated in c26 tumorbearing mouse overall the result show that the combination therapy of dox and antimir using aacs nanocomplex could combat the cancer cell growth rate,"Animals, Antagomirs, Antineoplastic Agents, Aptamers, Nucleotide, CHO Cells, Cell Line, Tumor, Chitosan, Cricetulus, Doxorubicin, Drug Carriers, Drug Liberation, Humans, Immobilized Nucleic Acids, Mice, MicroRNAs, Nanoparticles, Neoplasms, Oligodeoxyribonucleotides, Silicon Dioxide"
34044797,despite considerable medical proceeding cancer is still a leading cause of death major problem for tumor therapy are chemoresistance a well a toxic side effect in recent year the additional treatment with the antidiabetic drug metformin during chemotherapy showed promising result in some case the aim of this study wa to develop an in vitro tumor therapy model in order to further investigate the potential of a combined chemotherapy with metformin cytotoxic effect of a combined treatment on balbc fibroblast were proven by the resazurin assay based on the balbc cell transformation assay the balbc tumor therapy model wa established successfully with four different and widely used chemotherapeutics from different category namely doxorubicin a a typeii isomerase inhibitor docetaxel a a spindle toxin mitomycin c a an alkylating agent and fluorouracil a an antimetabolite moreover glucose consumption in the medium supernatant wa measured and protein expression were determined by western blotting initial test for the combined treatment with metformin indicated unexpected result a metformin could partly mitigate the cytotoxic effect of the chemotherapeutic agent these result were further confirmed a metformin induced resistance to some of the drug when applied simultaneously in the tumor therapy model mechanistically an increased glucose consumption wa observed in nontransformed cell a well a in the mixed population of malignant transformed cell focus and nontransformed monolayer cell suggesting that metformin could also increase glucose consumption in transformed cell in conclusion this study suggests a cautious use of metformin during chemotherapy moreover the balbc tumor therapy model offer a potent tool for further mechanistic study of drugdrug interaction during cancer therapy,"Animals, Antineoplastic Combined Chemotherapy Protocols, BALB 3T3 Cells, Carcinogens, Cell Survival, Cell Transformation, Neoplastic, Culture Media, Docetaxel, Doxorubicin, Drug Evaluation, Preclinical, Drug Interactions, Fluorouracil, Glucose, Humans, Metformin, Methylcholanthrene, Mice, Mitomycin, Neoplasms"
34044546,immune checkpoint inhibitor icis are a recent breakthrough in antitumor drug although their overall safety ha not been fully defined compared to conventional chemotherapy icis exhibit different pattern of immunotoxicity and immunerelated adverse event iraes have an immunological basis that is more toxic than usual and have a broad spectrum of manifestation involving different organ system early recognition of symptom and timely intervention are very important in managing immunerelated adverse event iraes in this study we report a case of delayed immune thrombocytopenia in a patient treated with nivolumab for small cell lung cancer sclc we found that thrombocytopenia wa associated with the presence of platelet antibody autoantibody and thyroglobulin antibody accompanied by a decrease in the number of helper t cell and regulatory t cell platelet returned to normal after the removal of antibody by plasma exchange and methylprednisolone we hypothesized that thrombocytopenia in patient wa an antibodydriven and tcellmediated process although these observation indirectly suggest that cytokine change contribute to immune dysregulation during irae prospective validation is needed to explain the confounding etiology that may contribute to cytokine dysregulation therefore studying the relationship between t cell subpopulation cytokine and irae in a larger population may be crucial for identifying biomarkers for ici,"Humans, Immune Checkpoint Inhibitors, Lung Neoplasms, Nivolumab, Prospective Studies, Thrombocytopenia"
34043412,to report the toxicity and pathologic response rate after adding neoadjuvant capecitabine and oxaliplatin capox followed by concurrent radiation and capecitabine caprt and surgery in patient with locally advanced rectal cancer we retrospectively analyzed medical record of 301 patient between january 2007 and december patient were treated with four cycle of neoadjuvant chemotherapy comprising capox followed by radiotherapy at do of gy in fraction with concurrent capecitabine a response assessment scan wa performed at week postradiation followed by surgical evaluation at week pathologic tumor and nodal response rate a well a circumferential resection margin were assessed on surgical specimen the median age of the patient wa 43 year range overall 227 patient were able to complete four cycle of capox neoadjuvant chemotherapy wa welltolerated with no serious adverse effect the most common toxicity wa diarrhea grade n 108 grade n 57 grade n 25 followed by neuropathy grade n 132 grade n 54 and oral mucositis grade n 108 grade n 47 grade n 9 a total of 229 patient underwent surgery pathologic complete response wa seen in 52 95 ci 13 to 28 whereas 200 95 ci 82 to 99 patient had a negative circumferential resection margin on pathology neoadjuvant chemotherapy with capox before caprt and planned total mesorectal excision surgery result in good tumor regression and substantial pathologic complete response rate with acceptable toxicity with growing interest in organ preservation in rectal cancer the strategy of completing all chemotherapy and chemoradiotherapy before planned surgery offer a favorable paradigm however further randomized clinical trial are needed to support this evidence,"Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cancer Care Facilities, Capecitabine, Humans, Middle Aged, Neoadjuvant Therapy, Oxaliplatin, Pakistan, Rectal Neoplasms, Retrospective Studies, Treatment Outcome, Young Adult"
34042274,arsenic trioxide ato ha been used for the treatment of acute promyelocytic leukemia apl although ato modulates cell cycle progression and apoptosis in apl cell it exact mechanism of action remains elusive in this research we investigated it effect on e2f cyclin e p prb and pi3k signaling molecule by western blotting immunocytochemistry andor confocal imaging we found that ato inhibited the proliferation of apl cell through downregulation of e2f1 and cyclin e expression and stimulation of prb it also reduced the interaction of prb and e2f1with binding to the e2f1 promoter by stimulating prb association ato also effected the phosphorylation of prb at s608 and t373 residue and association of e2f prb and p simultaneously however in pknockdown nb4 cell ato did not significantly reduce e2f1 and cyclin e expression our finding demonstrate that ato inhibits apl cell growth through reduced expression of e2f cyclin e and stimulation of prb it also effected both interaction and association of e2f prb and p53 by phosphorylation of prb at t373 and s608 residue and reduced phosphorylation of pi3k signaling molecule this novel mode of action of ato in apl cell may be useful for designing new apl drug,"Antineoplastic Agents, Apoptosis, Arsenic Trioxide, Arsenicals, Cell Line, Tumor, Cyclin E, E2F1 Transcription Factor, Humans, Leukemia, Promyelocytic, Acute, Oxides, Phosphatidylinositol 3-Kinases, Phosphorylation"
34041833,the clinical application of chemodynamic therapy is impeded by the insufficient intracellular h2 o2 level in tumor tissue herein we developed a supramolecular nanoparticle via a simple onestep supramolecular polymerizationinduced selfassembly process using platinum iv complexmodified cyclodextrinferrocene conjugate a supramolecular monomer the supramolecular nanoparticles could dissociate rapidly upon exposure to endogenous h2 o2 in the tumor and release hydroxyl radical a well a platinum iv prodrugs in situ which is reduced into cisplatin to significantly promote the generation of h2 o2 in the tumor tissue thus the supramolecular nanomedicine overcomes the limitation of conventional chemodynamic therapy via the selfaugmented cascade radical generation and drug release in addition dissociated supramolecular nanoparticles could be readily excreted from the body via renal clearance to effectively avoid systemic toxicity and ensure long term biocompatibility of the nanomedicine this work may provide new insight on the design and development of novel supramolecular nanoassemblies for cascade chemochemodynamic therapy,"Animals, Antineoplastic Agents, Cell Line, Tumor, Coordination Complexes, Drug Carriers, Drug Liberation, Female, Ferrous Compounds, Hydrogen Peroxide, Hydroxyl Radical, Metallocenes, Mice, Inbred BALB C, Nanomedicine, Nanoparticles, Neoplasms, Platinum, Polymerization, Polymers, Prodrugs, beta-Cyclodextrins, Mice"
34041638,purpose this study investigated the relationship between the pharmacokinetics and pharmacodynamics of everolimus in patient with metastatic breast cancer mbc in realworld practicemethods twentytwo patient with mbc treated with everolimus plus exemestane were enrolled blood everolimus concentration were measured at outpatient visit the inhibition of the mammalian target of rapamycin mtor activity in peripheral blood mononuclear cell pbmcs wa examined the efficacy and safety endpoint were progressionfree survival pfs and the cumulative incidence of doselimiting toxicity dlts respectively result blood sample were obtained from 19 consenting patient everolimus did not completely inhibit mtor activity in pbmcs at therapeutic concentration 56 maximal inhibition the most common adverse event wa stomatitis any grade 77 the trough concentration ctrough wa significantly higher in patient experiencing dlts than in those without any dlts p the optimal ctrough cutoff predicting dlt development wa ngml the cumulative incidence of dlts wa significantly higher in patient with ctrough ngml than in other patient subhazard ratio 95 confidence interval ci p furthermore the median pfs wa numerically longer in patient who maintained a steadystate ctrough below the threshold than in those who did not 327 day 95 ci day v 194 day 95 ci 45 daysnot estimable p conclusion the suggested upper threshold for the therapeutic window of everolimus ctrough wa ngml pharmacokinetically guided dosing may improve the efficacy and safety of everolimus for mbc warranting further investigation in a larger studyclinical trial registry not applicable,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Dose-Response Relationship, Drug, Everolimus, Female, Genotype, Humans, Maximum Tolerated Dose, Middle Aged, Progression-Free Survival, Prospective Studies, TOR Serine-Threonine Kinases"
34040175,berzosertib formerly m vx970 is a highly potent and selective firstinclass inhibitor of ataxia telangiectasia and radrelated protein kinase atr we assessed multiple ascending do of berzosertib gemcitabine cisplatin in patient with resistantrefractory advanced solid tumour we evaluated the safety tolerability pharmacokinetics pk and preliminary efficacy of intravenous berzosertib gemcitabine cisplatin using a standard 3 3 doseescalation design the starting do were berzosertib 18 mgm gemcitabine 875 mgm2 and cisplatin 60 mgm fiftytwo patient received berzosertib gemcitabine and eight received berzosertib gemcitabine cisplatin four patient receiving berzosertib gemcitabine had a total of seven doselimiting toxicity dlts and three receiving berzosertib gemcitabine cisplatin had a total of three dlts berzosertib 210 mgm2 day 2 and 9 gemcitabine 1000 mgm2 day 1 and 8 q3w wa established a the recommended phase 2 dose rp2d no rp2d wa determined for berzosertib gemcitabine cisplatin neither gemcitabine nor cisplatin affected berzosertib pk most patient in both arm achieved a best response of either partial response or stable disease berzosertib gemcitabine wa well tolerated in patient with advanced solid tumour and showed preliminary efficacy sign nct,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Deoxycytidine, Drug Administration Schedule, Female, Humans, Isoxazoles, Male, Middle Aged, Neoplasms, Pyrazines, Survival Analysis, Treatment Outcome, Gemcitabine"
34040174,berzosertib formerly m vx970 is a highly potent and selective firstinclass ataxia telangiectasiamutated and radrelated protein kinase atr inhibitor we assessed the safety tolerability pharmacokinetics and preliminary efficacy of berzosertib plus cisplatin adult patient with advanced solid tumour refractory or resistant to standard of care therapy received ascending do of cisplatin day 1 and berzosertib day 2 and 9 every 3 week q3w thirtyone patient received berzosertib mgm2 and cisplatin mgm2 across seven dose level the most common grade 3 treatmentemergent adverse event were neutropenia and anaemia there were two doselimiting toxicity a grade 3 hypersensitivity reaction and a grade 3 increase in alanine aminotransferase berzosertib 140 mgm2 day 2 and 9 and cisplatin 75 mgm2 day 1 q3w wa determined a the recommended phase 2 dose cisplatin had no apparent effect on berzosertib pharmacokinetics of the 31 patient four achieved a partial response two confirmed and two unconfirmed despite having previously experienced disease progression following platinumbased chemotherapy berzosertib plus cisplatin is well tolerated and show preliminary clinical activity in patient with advanced solid tumour warranting further evaluation in a phase 2 setting nct,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Humans, Isoxazoles, Male, Middle Aged, Neoplasms, Pyrazines, Treatment Outcome"
34039375,this retrospective study wa to as and compare the toxicity and efficacy of concurrent chemoradiotherapy ccrt with s1 or docetaxel and cisplatin in patient with locally advanced esophageal squamous cell carcinoma escc patient with locally advanced escc who received ccrt with s1 70 mgm2 twice daily on day every 3 week for 2 cycle s1 group or docetaxel 25 mgm2 and cisplatin 25 mgm2 on day 1 weekly dp group between 2014 and 2016 were retrospectively analyzed radiotherapy wa delivered in gy per fraction to a total dose of gy treatmentrelated toxicity common terminology criterion for adverse event version response rate and survival outcome were compared between group a total of 175 patient were included in this study 72 in the s1 group and 103 in the dp group baseline characteristic were well balanced between the two group the incidence of grade adverse event were significantly lower in the s1 group than that of the dp group v p in the dp group elderly patient 60 year had a significantly higher rate of grade adverse event than younger patient v p the objective overall response rate complete response partial response wa in the s1 group and the dp group p the year overall survival wa in the s1 group and in the dp group p the year progression free survival in the dp group wa higher than that in the s1 group but without significant difference v p ccrt with s1 is not inferior to ccrt with docetaxel and cisplatin and is better tolerated in in elderly patient with locally advanced escc,"Aged, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Cisplatin, Docetaxel, Dose Fractionation, Radiation, Drug Combinations, Drug-Related Side Effects and Adverse Reactions, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Female, Humans, Male, Middle Aged, Oxonic Acid, Retrospective Studies, Survival Rate, Tegafur, Treatment Outcome"
34039310,cc chemokine receptor 4 ccr4 the receptor for ccl22 and ccl is expressed on the surface of effector tregs that have the highest suppressive effect on antitumor immune response ccr4 is also widely expressed on the surface of tumor cell from patient with adult tcell leukemialymphoma atl peripheral tcell lymphoma ptcl and cutaneous tcell lymphoma ctcl mogamulizumab is a humanized igg1 kappa monoclonal antibody that is directed against ccr by reducing the number of ccrpositive tregs and tumor cell the mogamulizumab can reduce tumor burden and boost antitumor immunity to achieve antitumor effect we examined the pubmed and clinicaltrialsgov until 1 february considering variability in different study we selected the adverse event aes overall survival o progressionfree survival pfs objective response rate orr and hazard ratio hr for pfs to evaluate the safety and efficacy profile of mogamulizumab when patient were treated with mogamulizumab monotherapy the most common allgrade aes were lymphopenia infusion reaction fever rash and chill while the most common grade 3 aes were lymphopenia neutropenia and rash when patient were treated with combined therapy of mogamulizumab and other drug the most common allgrade aes were neutropenia anaemia lymphopenia and gastrointestinal disorder while the most common grade 3 aes wa lymphopenia for patient treated with mogamulizumab monotherapy the pooled orr and mean pfs were 95 ci and month 95 ci respectively for patient treated with combined therapy of mogamulizumab and other drug the pooled orr wa 95 ci while the pooled pfs and o were month 95 ci and month 95 ci respectively based on present evidence we believed that mogamulizumab had clinically meaningful antitumor activity with acceptable toxicity which is a novel therapy in treating patient with cancer,"Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Drug-Related Side Effects and Adverse Reactions, Humans, Neoplasms, Progression-Free Survival, Randomized Controlled Trials as Topic, Receptors, CCR4"
34036513,immune checkpoint inhibitor have opened a new scenario in the treatment of cancer these agent can elicit adverse event which may affect different system and organ including the endocrine system the aim of this study were to evaluate the impact of the antipd1 molecule nivolumab and pembrolizumab on endocrine toxicity and on patient outcome a retrospective and multicentre study wa designed which involved a total of 251 patient affected by different tumor mostly nonsmall cell lung cancer and melanoma and treated with the pd1 inhibitor nivolumab or pembrolizumab for up to 60 month clinical and biochemical data were recorded until july endocrine toxicity occurred in 70 out of 251 patient it wa mostly related to thyroid dysfunction and in 75 of case occurred within 6 month from the beginning of therapy a previous endocrine morbidity and female gender were predictor of endocrine toxicity there wa no association between endocrine dysfunction and patient outcome however when all toxicity ie endocrine and non endocrine were considered a significant association with progressionfree survival and overall survival wa found thyroid alteration are frequently observed in cancer patient treated with anti pd1 drug particularly in woman and in the presence of a previous endocrinopathy we suggest that regular thyroid assessment should be performed in these patient especially in the first month of therapy finally the onset of side effect related to anti pd1 agent appears to be associated with a better outcome,"Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Retrospective Studies, Thyroid Gland"
34035370,data suggest that for newly approved cancer drug safety and tolerability are worse than in control arm of registration trial le is known about the balance between efficacy and toxicity of drug studied in unselected phase 3 randomized controlled trial rcts including those not resulting in regulatory approval we searched clinicaltrialsgov to identify phase 3 rcts in patient with advanced breast colorectal lung or prostate cancer completed between january 2005 and october we extracted efficacy and safety data from publication for efficacy hazard ratio hr for progressionfree survival pfs and overall survival o were extracted for safety we computed odds ratio or and 95 confidence interval ci for toxic death treatment discontinuation without progression and commonly reported grade adverse event aes data were then pooled in a metaanalysis of 377 rcts identified initially 143 rcts comprising patient were included in the analysis of these 79 57 trial met their primary endpoint compared to control group both pfs hr 95 ci and o hr 95 ci were improved with experimental drug toxic death or 95 ci treatment discontinuation without progression or 95 ci and grade aes were also more common with experimental drug compared to respective control group therapy just over half of phase 3 rcts in common solid tumor met their primary endpoint and in nearly half experimental therapy had worse safety compared to control arm,"Antineoplastic Agents, Clinical Trials, Phase III as Topic, Female, Humans, Male, Neoplasms, Odds Ratio, Randomized Controlled Trials as Topic, Survival Analysis, Treatment Outcome"
34035112,experimental cancer vaccine are traditionally administered by injection in subcutaneous tissue or muscle commonly with adjuvant that create chronic inflammatory depot injection of melanomaderived peptide induces t cell response however the depot that form following injection may inhibit optimization of the immune response in skin epidermal langerhans cell lc are a dominant source of professional antigen presenting cell we hypothesized that 1 applying melanomaderived peptide topically in proximity to lc could be immunogenic and safe with low vaccinesite toxicity and 2 topical tolllike receptor 7 tlr7 agonist would increase immunogenicity of the peptide vaccine twelve melanoma peptide plus a tetanus helper peptide were combined with granulocyte macrophage colony stimulating factor gmcsf and were administered topically on day and to 28 patient randomized to one of four adjuvant preparation 1 incomplete freunds adjuvant ifa 2 ifa plus a tlr7 agonist imiquimod administered on day 14 3 dimethyl sulfoxide dmso or 4 dmso imiquimod administered on day every 3 week thereafter x 6 the peptide were combined with gmcsf and were injected into the dermis and subcutis in an emulsion with ifa toxicity were recorded and immune response assayed by elispot cd t cell response to transdermal vaccination in dmso occurred in 83 of participant in group 3 and 86 in group and response to vaccination in ifa were observed in 29 of participant in group 1 and 14 in group overall 61 of participant had cd t cell immune response to the tetanus peptide with large durable response in group 3 and five of seven participant in group 4 had a severe rash one that wa dose limiting tenyear overall survival wa 67 and diseasefree survival wa 44 these data provide proof of principle for immunogenicity in human of transdermal immunization using peptide in dmso further study is warranted into the pharmacokinetics and immunobiology of tlr agonist a vaccine adjuvant during transcutaneous application overall survival is high supporting further investigation of this immunization approach,"Adjuvants, Immunologic, Administration, Cutaneous, Adolescent, Adult, Aged, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cancer Vaccines, Female, Freund's Adjuvant, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Imiquimod, Immunogenicity, Vaccine, Injections, Intradermal, Injections, Subcutaneous, Lipids, Male, Melanoma, Melanoma-Specific Antigens, Middle Aged, Skin Neoplasms, Time Factors, Toll-Like Receptor 7, Treatment Outcome, Vaccination, Vaccines, Subunit, Young Adult"
34032710,concurrent chemoradiotherapy is widely utilised a a standardized primary method of treatment for patient with advanced nasopharyngeal carcinoma npc however the combination of concurrent chemoradiotherapy and adjuvant chemotherapy for treating npc patient remain unclear therefore this study attempt to elucidate the efficiency and safety of concurrent chemoradiotherapy combined with adjuvant chemotherapy gemcitabine plus cisplatin versus fluorouracil plus cisplatin for treating patient with npc this study is a randomized multicentral openlabelled trial to as the clinical efficiency and safety of using concurrent chemoradiotherapy combined with adjuvant chemotherapy a a therapeutic measure for advanced npc patient a total of 50 patient will be randomly assigned into 2 group namely treatmentgroupone and treatmentgrouptwo eligible patient will be administered with concurrent chemoradiotherapy and subsequentially with adjuvant chemotherapy gemcitabine plus cisplatin or fluorouracil plus cisplatin moreover the primary endpoint is a comparison of progressionfree survival between concurrent chemoradiotherapy and subsequentially adjuvant gemcitabine and cisplatin and chemoradiotherapy which is proceeded by adjuvant fluorouracil and cisplatin in advanced npc patient overall survival overall response rate incidence of acute and late toxicity and adverse event are the minor endpoint statistical analysis will be performed with spss software the current research evaluates the clinical efficiency and safety of utilising concurrent chemoradiotherapy combined with adjuvant chemotherapy a a therapeutic strategy to treat advanced npc patient the work done in this study will provide a clinical basis for concurrent chemoradiotherapy in combination with adjuvant chemotherapy for treating advanced npc doi osfio5upvm,"Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Chemotherapy, Adjuvant, Cisplatin, Deoxycytidine, Drug Administration Schedule, Fluorouracil, Follow-Up Studies, Humans, Multicenter Studies as Topic, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Neoplasm Staging, Progression-Free Survival, Radiotherapy, Intensity-Modulated, Randomized Controlled Trials as Topic, Gemcitabine"
34031784,background cd30 is highly expressed in some patient with nonseminomatous germcell tumor brentuximab vedotin is an antibodydrug conjugate directed to cd we report a phase 2 trial of brentuximab vedotin in patient with chemorefractory gct patient and method this is a single arm two cohort phase 2 trial investigating brentuximab vedotin mgkg iv every 3 week until disease progression or intolerable toxicity in patient with relapsed gct who have no curative option patient with mgct who progressed after first line cisplatinbased chemotherapy and after at least 1 salvage regimen highdose or standarddose chemotherapy were eligible cd30 expression wa assessed and two cohort defined cd30 positive and cd30 negativeunknown result 18 patient were enrolled median age range all patient had nonseminoma median afp range 345 and hcg 282 range five patient had late relapse 2 year median number of previous chemotherapy regimen wa 3 range ten patient received prior highdose chemotherapy seven patient had positive cd30 staining there were two grade 3 treatmentrelated adverse event no partial or complete response were observed 6 patient achieved radiographic stable disease range 9 week 5 had elevated afp or hcg at trial entry and all 5 had transient 50 decline in baseline afphcg 4 had cd30 ve and 2 had cd30 ve staining 10 patient had progression of disease a their best response 2 were not evaluable for response conclusion brentuximab vedotin doe not appear to have clinically meaningful singleagent activity in patient with refractory gct,"Adult, Antineoplastic Agents, Immunological, Brentuximab Vedotin, Female, Humans, Ki-1 Antigen, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms"
34031756,this phase i trial wa performed to determine the maximumtolerated dose mtd doselimiting toxicity dlts preliminary efficacy and pharmacokinetics pk of ly a novel liposomeencapsulated irinotecan in patient with advanced esophageal squamous cell carcinoma escc this trial wa conducted in two stage in the doseescalation stage patient with advanced escc refractory or intolerant to previous chemotherapy received escalating do of ly a recommended dose based on patient tolerance wa then expanded in the second stage ly01610 wa administered intravenously every 2 week except that the first cycle in dose escalation wa 3 week to allow observation of dlts twentyfour patient were enrolled across 4 dose level 90 and 120 mgm2 the dlts included vomiting and febrile neutropenia and the mtd wa 90 mgm the most common grade adverse event were leukopenia in six patient anemia in six patient and neutropenia in five patient one patient achieved complete response and four had partial response including one patient receiving ly01610 at the starting dose of 30 mgm compared with conventional irinotecan the pk profile of ly01610 wa characterized by increased and prolonged exposure of total irinotecan and the active metabolite sn38 in plasma ly01610 demonstrated manageable toxicity and promising antitumor activity in patient with advanced escc future clinical development of ly01610 a single agent or in combination with other anticancer agent in treating escc patient is warranted nct04088604 at clinicaltrialsgov,"Adult, Dose-Response Relationship, Drug, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Female, Humans, Irinotecan, Liposomes, Male, Maximum Tolerated Dose, Middle Aged, Neutropenia, Topoisomerase I Inhibitors"
34031312,recent development of immunotherapy ha led to remarkable advancement in cancer therapy drug that inhibit the cytotoxic tlymphocyteassociated protein ctla4 and programmed death1 pd1 immune checkpoint pathway have shown improved patient survival however by altering the immune response to fight cancer a new class of adverse reaction ha emerged known a immunerelated adverse event these adverse event are due to overactivation of the immune system in almost any organ of the body can occur at any point in a patient treatment course and may become lifethreatening this article describes how to promptly recognize and manage these toxicity,"Humans, Immune Checkpoint Inhibitors, Immunologic Factors, Immunotherapy, Neoplasms"
34031056,double inhibition of epidermal growth factor receptor egfr using a tyrosine kinase inhibitor plus a monoclonal antibody may be a novel treatment strategy for nonsmall cell lung cancer nsclc we assessed the efficacy and toxicity of afatinib cetuximab versus afatinib alone in the firstline treatment of advanced egfrmutant nsclc in this phase ii randomized openlabel study patient with stage iiiiv egfrpositive nsclc were randomly assigned 11 to receive afatinib group a or afatinib cetuximab group a c oral afatinib 40 mg wa given once daily cetuximab 250 mgm wa administered intravenously on day 15 of cycle then every 2 week at 500 mgm for 6 month the primary endpoint wa time to treatment failure ttf rate at 9 month exploratory analysis of egfr circulating tumor dna in plasma wa performed between june 2016 and november 59 patient were included in group a and 58 in group a c the study wa ended early after a futility analysis wa performed the percentage of patient without treatment failure at 9 month wa similar for both group for group a v for group a c and median ttf wa 95 ci and month respectively other endpoint including progressionfree survival and overall survival also showed no improvement with the combination versus afatinib alone there wa a slight numerical increase in grade 3 adverse event in group a c allele frequency of the egfr gene mutation in circulating tumor dna at baseline wa associated with shorter pfs regardless of the treatment received these result suggest that addition of cetuximab to afatinib doe not warrant further investigation in treatmentnave advanced egfrmutant nsclc,"Adult, Afatinib, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cetuximab, ErbB Receptors, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Treatment Outcome"
34030768,irinotecan a topoisomerase inhibitor is a common cytotoxic agent prescribed for metastatic colorectal cancer mcrc patient diarrhea is the most common adverse event ae the underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by sn38 active metabolite of irinotecan hydrolyzed from sn38g inactive metabolite by bacterial glucuronidase g according to an animal study silymarin reduces the activity of bacterial g without impairing antitumor efficacy we conducted a prospective openlabel pilot study to evaluate the effect of silymarin a supplementation in reducing toxicity of mcrc patient undergoing irinotecanbased chemotherapy we enrolled and randomized 70 mcrc patient receiving firstline folfiri fluorouracilleucovorinirinotecan plus bevacizumab in each treatment cycle the study group wa administered silymarin capsule 150 mg three time daily for 7 day the study group experienced le aes in diarrhea v p and nausea v p in comparison with the control group but no significant difference in hepatic toxicity were observed in conclusion simultaneous administration of silymarin is a potential effective supplementation for reducing toxicity in mcrc patient undergoing firstline folfiri plus bevacizumab especially in diarrhea and nausea,"Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Colorectal Neoplasms, Diarrhea, Dietary Supplements, Female, Fluorouracil, Humans, Irinotecan, Leucovorin, Male, Middle Aged, Nausea, Pilot Projects, Prospective Studies, Protective Agents, Silymarin, Treatment Outcome, Young Adult"
34029766,graftversushost disease gvhd is a frequent complication in the first year after allogeneic stem cell transplantation allohct recipient of reducedintensity ri or nonmyeloablative nma conditioning combined with calcineurin inhibitor cnibased gvhd prophylaxis frequently develop gvhd in the context of immunosuppression taper ixazomib is an oral proteasome inhibitor with a wide safety profile that ha demonstrated immunomodulatory property inhibition of proinflammatory cytokine and antitumor activity we hypothesized that switchmaintenance gvhd prophylaxis using ixazomib would facilitate cni taper without increased gvhd frequency and severity while maintaining graftversustumor gvt effect and an acceptable safety profile we conducted an openlabel prospective singlecenter pilot study in patient with hematologic malignancy who received an ri or nma conditioning and cnibased gvhd prophylaxis that were within day 100 to 150 after hct n 18 patient were treated with ixazomib once weekly on a day cycle 3 week on 1 week off treatment wa safe most adverse event were grade 1 or with cytopenia and elevation in transaminase the most common five patient were removed from the study because of toxicity or side effect only 5 of 18 patient developed gvhd during the study and it severity wa driven by acute manifestation while chronic involvement wa mild the cumulative incidence of grade iiiv acute and chronic gvhd at year after hct wa 33 95 confidence interval ci no patient died during the study and only 1 had malignant relapse an additional patient relapsed after completion of the study but within 1 year after hct the probability of progressionfree survival and gvhdfreerelapsefree survival composite endpoint at 1 year were 89 95 ci and 78 95 ci respectively immune reconstitution analysis showed a rapid and sustained recovery in tcell subpopulation and b cell reconstitution and vaccine response in a subset of patient demonstrated continuing or de novo positive protective antibody titer this study demonstrated low incidence of recurrent and late acute and chronic gvhd within 1 year after hct possible associated with switchmaintenance gvhd prophylaxis using ixazomib this approach allowed for cni taper while preserving gvt effect without aggravating gvhd our finding support further development of this approach and provide a proofofconcept for switchmaintenance gvhd prophylaxis,"Boron Compounds, Glycine, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Pilot Projects, Prospective Studies, Proteasome Inhibitors"
34029250,paronychia is a common toxicity associated with targeted anticancer therapy antibiotic and steroid are the standard treatment for severe paronychia yet they are often inadequate prolonging the patient suffering and resulting in change to effective cancer therapy this article describes the clinical course of druginduced paronychia and attempt to identify circumstance under which nail surgery may be beneficial this is a retrospective case series from a single institution electronic medical record for patient on paronychiainducing anticancer therapy with nail disease visit diagnosis code the author identified 36 nail procedure performed on 12 patient all of whom were managed with conservative steroid and antibiotic therapy with varying degree of improvement however no further improvement wa seen after 90 day partial matricectomy nail avulsion debridementclipping and incision and drainage were performed with resolution rate of 100 and 0 respectively the average time to surgical intervention wa 196 day and the average time to resolution wa 268 day this series highlight the prolonged course of severe druginduced paronychia and the importance of surgical intervention to reduce pain and impact on cancer treatment partial matricectomy should be considered for paronychia unresponsive to conservative therapy by 3 month,"Adult, Aged, Anti-Bacterial Agents, Antineoplastic Agents, Combined Modality Therapy, Drainage, Female, Glucocorticoids, Humans, Male, Middle Aged, Molecular Targeted Therapy, Nails, Neoplasms, Paronychia, Retrospective Studies, Skin, Treatment Outcome"
34028986,patient with mibgavid highrisk neuroblastoma were eligible after the first two patient to receive protocol therapy developed severe sinusoidal obstruction syndrome so the trial wa redesigned to include an 131 imibg dose escalation and 18 mcikg with a required week gap before bumel administration patient who completed induction chemotherapy were evaluable for assessment of 131 imibg feasibility those who completed 131 imibg therapy were evaluable for assessment of 131 imibg bumel feasibility fiftynine of 68 patient who completed induction chemotherapy received 131 imibg thirtyseven of 45 patient evaluable for 131 imibg bumel received this combination among those who received 131 imibg after revision of the study design one patient per dose level developed severe so rate of moderate to severe so at and 18 mcikg were and respectively there wa one toxic death the 131 imibg and 131 imibgbumel feasibility rate at the 15 mcikg dose level designated for further study were 95 ci and 95 ci this pilot trial demonstrated feasibility and tolerability of administering 131 imibg followed by myeloablative therapy with bumel to newly diagnosed child with highrisk neuroblastoma in a cooperative group setting laying the groundwork for a cooperative randomized trial nct03126916 testing the addition of 131 imibg during induction therapy,"3-Iodobenzylguanidine, Busulfan, Feasibility Studies, Humans, Iodine Radioisotopes, Neoplasm Recurrence, Local, Neuroblastoma, Pilot Projects"
34028113,to evaluate the efficacy and safety profile of firstline etoposide ifosfamide and cisplatin and primary prophylaxis with pegfilgrastim a firstline chemotherapy for disseminated germ cell cancer this study reviewed 154 consecutive patient with previously untreated disseminated germ cell cancer who received firstline etoposide ifosfamide and cisplatin between 1995 and of these 54 patient were managed with primary prophylaxis using pegfilgrastim primary prophylaxis group and 100 were managed with the therapeutic use of shortacting granulocyte colonystimulating factor nonprimary prophylaxis group the international germ cell cancer collaborative group classification identified 90 5840 2624 16 patient with goodintermediatepoor prognosis respectively overall 139 patient 90 were disease free after etoposide ifosfamide and cisplatin withwithout postchemotherapy surgery the median relative dose intensity of etoposide ifosfamide and cisplatin wa 96 and there wa a significant difference between the primary prophylaxis and nonprimary prophylaxis group 100 v 90 p the year salvage treatmentfree and overall survival rate were 83 and 94 respectively in total 138 patient 90 developed grade 4 hematological toxicity and there were no treatmentrelated death due to myelosuppression grade 4 neutropenia wa le commonly observed in the primary prophylaxis group compared with the nonprimary prophylaxis group 80 v 95 p this is the largest study of firstline etoposide ifosfamide and cisplatin and it sufficient efficacy and safety profile are confirmed in current clinical practice primary prophylaxis using pegfilgrastim might further improve the feasibility of etoposide ifosfamide and cisplatin,"Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Etoposide, Feasibility Studies, Humans, Ifosfamide, Neoplasms, Germ Cell and Embryonal"
34027908,to describe a patient with metastatic clear cell renal cell carcinoma in remission on maintenance nivolumab therapy who developed lateonset ocular toxicity manifesting a creamy chorioretinal lesion with exudative retinal detachment concerning for choroidal metastasis case report main outcome measure include ophthalmoscopic examination fundus photography fundus autofluorescence fluorescein angiography indocyanine green angiography spectral domain optical coherence tomography and bscan ultrasonography a yearold woman with a medical history of metastatic clear cell renal cell carcinoma in remission for two year after immunotherapy with four cycle of ipilimumab and nivolumab followed by maintenance nivolumab infusion developed lesion concerning for choroidal metastasis in her right eye optical coherence tomography of the lesion revealed a bacillary layer detachment containing possible fibrinous exudate organized into layer and underlying choroidal thickening with chorioretinal fold later choroidal thickening and chorioretinal fold also occurred in the left eye given that pan imaging detected no metastasis and the posterior segment abnormality resolved after cessation of nivolumab and treatment with systemic corticosteroid the patient wa diagnosed with nivolumabinduced vogtkoyanagiharadalike uveitis this case expands on the clinical spectrum of nivolumabinduced vogtkoyanagiharadalike uveitis a condition that can also present with bacillary layer detachment mimicking an early choroidal metastasis manifest asymmetrically in each eye and develop after longstanding treatment,"Female, Humans, Middle Aged, Uveomeningoencephalitic Syndrome, Nivolumab, Carcinoma, Renal Cell, Bacillus, Uveitis, Fluorescein Angiography, Tomography, Optical Coherence"
34024062,preliminary research conformed that neoadjuvant immunotherapy combined with chemotherapy had a significant shortterm effect in resectable nonsmall cell lung cancer nsclc but there were few clinical trial about neoadjuvant chemoimmunotherapy in china we aimed to as retrospectively the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage ibiiib nsclc twenty patient who had been diagnosed a stage ibiiib nsclc and received chemoimmunotherapy a neoadjuvant treatment between november 2019 and december in beijing chest hospital capital medical university were recruited these patient received neoadjuvant treatment for 21 day a a cycle and antitumour activity and safety were evaluated every two cycle of 20 patient received neoadjuvant chemoimmunotherapy 17 patient underwent surgical resection 16 patient had r0 resection no residual tumor resection and 1 patient had r1 resection microscopic residual tumor resection radiographic objective response rate orr wa 4 complete response 13 partial response of patient had stable disease and of patient had progression disease the major pathologic response mpr wa and complete pathologic response cpr wa 1 case developed grade iv immunerelated pneumonia irp and 9 case had grade iii hematologic toxicity immunotherapy combined with chemotherapy a neoadjuvant therapy ha a better efficiency and tolerable adverse effect for patient with resectable nsclc in stage ibiiib ibiiib 201911202012ibiiib20 objective response rate orr413121716r0no residual tumor1r1microscopic residual tumormajor pathologic response mprcomplete pathologic response cpriv1iii9,"Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Therapy, Combination, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Neoadjuvant Therapy, Pneumonectomy, Retrospective Studies"
34023919,actinomycind and vincristine are cytotoxic drug commonly used to treat cancer in child this prospective study assessed pharmacokinetic variability and toxicity of these drug in child blood sample were collected in 158 patient actinomycind or vincristine concentration were quantified using highperformance liquid chromatographytandem mass spectrometry pharmacokinetic parameter were estimated using noncompartmental method target toxicity were collected prospectively actinomycind pharmacokinetics n 52 patient were highly variable the median coefficient of variation cv area under the concentrationtime curve auc wa 332 ngmlh 110 clearance wa lhm2 90 halflife wa 25 h 60 no patient met the defined criterion for myelosuppression in multivariate analysis none of the demographic nor pharmacokinetic parameter wa predictor of acute hepatotoxicity vincristine pharmacokinetics n 132 patient demonstrated substantial variability the median cv auc wa 78 ngmlh 98 clearance wa lhm2 67 halflife wa h 73 in multivariate analysis the effect of increasing age for a given bsa wa an increase in neuropathy while the effect of increasing bsa for a given age wa a decrease in neuropathy conclusion pharmacokinetics of both drug were highly variable for actinomycind there wa no correlation between demographic or pharmacokinetic parameter and target toxicity for vincristine the correlation of age and bsa and neuropathy are confounded by the correlation between age and bsa in child and the ability to ascertain neuropathy in infant variability may be attributed to dose reduction and capped do for both drug investigation of bsabased dosing in young child is warranted to decrease variability of exposure,"Adolescent, Antineoplastic Agents, Area Under Curve, Child, Child, Preschool, Dactinomycin, Female, Half-Life, Humans, Infant, Male, Neoplasms, Prospective Studies, Vincristine"
34022697,induction chemotherapy ict with cisplatin p fu f and taxanes t is a therapeutical option in patient suffering from locally advanced or unresectable stage iii or iv squamous cell carcinoma of the head and neck scchn the role of ict is controversial and toxicity andor delay of radiotherapy rt may reduce the potential benefit of this treatment regimen here we report the result of a randomised phase ii trial comparing tpf with tp cetuximab c in this trial 100 patient with locally advanced stage iii or iv scchn were included in the analysis patient were randomly assigned to either tpfict n 49 or tpcict n 51 both followed by rt c the primary endpoint of the study wa overall response rate orr three month after rt c wa finished on an intentiontotreat basis the orr complete remission partial remission wa in the tpc arm compared with in the tpf arm p o wa similar in both arm 400 day after treatment wa initiated 95 confidence interval ci in the tpc arm and 95 ci in the tpf arm tpc resulted in slightly le serious adverse event and in le haematological but more skin toxicity two patient randomised in the tpc arm died during ict and rt four patient in the tpf arm died after completion of rt no delay from the end of ict to rt c wa observed a total of of patient 80 in the tpc arm 86 in the tpf arm received rt without dose reduction andor modification tpccontaining ict for patient with locally advanced scchn wa found to be an effective and tolerable oneday regimen further prospective evidence from larger trial is warranted,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Austria, Cetuximab, Cisplatin, Docetaxel, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Induction Chemotherapy, Male, Middle Aged, Neoplasm Staging, Remission Induction, Squamous Cell Carcinoma of Head and Neck, Time Factors, Treatment Outcome"
34022150,there are no clinical trial involving patient with diffuse large bcell lymphoma dlbcl in subsaharan africa since antiretroviral therapy art for hiv became widely available in this region we aimed to establish the safety and efficacy of rituximab plus cyclophosphamide doxorubicin vincristine and prednisone rchop in patient with dlbcl in malawi this prospective singlearm nonrandomised phase clinical trial wa done at kamuzu central hospital cancer clinic lilongwe malawi eligible patient were adult aged year with newly diagnosed dlbcl an eastern cooperative oncology group performance status of a cd4 count of 100 cell per l or higher if hivpositive measurable disease by physical examination an absolute neutrophil count of 1000 109 cell per l or higher a platelet count of 100 109 platelet per l or higher a serum creatinine concentration of 13260 moll or le a total bilirubin concentration of 3421 moll or le a negative urine pregnancy test in woman of childbearing potential and no previous cytotoxic therapy pregnant or breastfeeding woman and individual with cns involvement from dlbcl chronic hepatitis b infection unless they were receiving tenofovir plus lamivudine or any other comorbidities that would compromise the protocol objective were excluded eligible patient received intravenous rituximab 375 mgm cyclophosphamide 750 mgm doxorubicin 50 mgm and vincristine 14 mgm2 maximum 2 mgm2 and oral prednisone 100 mg or an equivalent drug every 21 day for up to six cycle hivpositive patient received concurrent art the primary outcome wa the proportion of patient with national cancer institute common terminology criterion for adverse event grade 3 or 4 nonhaematological toxic effect or treatmentrelated death after six cycle of treatment secondary efficacy outcome included the proportion of patient with a complete response after six cycle of treatment and progressionfree survival and overall survival at 12 month and 24 month this trial is registered with clinicaltrialsgov nct between aug and july 76 patient were screened of whom 37 were eligible for the study and received rchop the median age of patient wa 44 year iqr and 16 43 were woman of all 37 patient 20 54 had stage iii or iv dlbcl and the ageadjusted international prognostic index wa 2 or higher in 25 68 patient 27 73 patient were hivpositive with a median cd4 count of 208 cell per l iqr and 21 78 patient were receiving art at enrolment patient completed a median of six cycle iqr grade 3 or 4 nonhaematological toxic effect were reported in 12 32 95 ci patient the most common of which wa infection nine 24 patient of 16 43 death ten were due to progression of dlbcl four were due to treatmentrelated complication and two were due to other cause yielding a treatmentrelated mortality of 11 95 ci grade 3 or 4 neutropenia wa observed in 26 70 patient and grade 3 or 4 anaemia wa observed in 11 29 patient a total of 22 59 patient had a complete response overall survival wa 68 95 ci at 12 month and 55 at 24 month and progressionfree survival wa 59 at 12 month and 53 at 24 month rchop could be feasible safe and efficacious in patient with dlbcl in malawi this is the first completed clinical trial on dlbcl focused on subsaharan african population given the paucity of data on treatment of dlbcl from this region these result could inform emerging cancer treatment programme in subsaharan africa the university of north carolina lineberger comprehensive cancer center,"Adult, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Lymphoma, Large B-Cell, Diffuse, Malawi, Male, Middle Aged, Prednisone, Prospective Studies, Rituximab, Treatment Outcome, Vincristine"
34021591,there is a concern that influenza vaccination may increase the incidence of immunerelated adverse event in patient receiving immune checkpoint inhibitor icis the aim of this systematic review wa to summarize the available data on the safety and efficacy of influenza vaccination in cancer patient receiving icis study reporting safety and efficacy outcome of influenza vaccination in cancer patient receiving icis were included only descriptive statistic were conducted to obtain a pooled rate of immunerelated adverse event in vaccinated patient ten study assessing the safety and eight assessing the efficacy of influenza vaccination in cancer patient receiving icis were identified for a total of 1124 and 986 vaccinated patient respectively most patient had melanoma or lung cancer and received a single agent antipd but also other tumour type and immunotherapy combination were represented no severe vaccinationrelated toxicity were reported the pooled incidence of any grade immune checkpoint inhibitorrelated adverse event wa in the 6 study specifying the incidence of grade toxicity the pooled incidence wa no grade 5 toxicity were reported no pooled descriptive analysis wa conducted in study reporting efficacy outcome due to the heterogeneity of endpoint and data reporting nevertheless among the eight study included seven reported positive efficacy outcome of influenza vaccination the result of this systematic review support the safety and efficacy of influenza vaccination in cancer patient receiving icis these result are particularly relevant in the context of the sarscov2 pandemic,"COVID-19, Case-Control Studies, Drug Interactions, Humans, Immune Checkpoint Inhibitors, Immunogenicity, Vaccine, Influenza Vaccines, Influenza, Human, Neoplasms, SARS-CoV-2"
34021118,although casecontrol analysis have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone rd there are not phase iii trial confirming these result in this phase iii trial 286 patient with mm ineligible for asct received rd with or without clarithromycin until disease progression or unacceptable toxicity the primary endpoint wa progressionfree survival pfs with a median followup of 19 month range no significant difference in the median pfs were observed between the two arm crd 23 month rd 29 month hr p despite a higher rate of complete response cr or better in the crd group v p the most common g adverse event were neutropenia 12 v 19 and infection 30 v 25 similar between the two arm however the percentage of toxic death wa higher in the crd group 72 v 55 p the addition of clarithromycin to rd in untreated transplant ineligible mm patient doe not improve pfs despite increasing the cr rate due to the higher number of toxic death in the crd arm side effect related to overexposure to steroid due to it delayed clearance induced by clarithromycin in this elderly population could explain these result the trial wa registered in clinicaltrialsgov with the name gemclaridex ld v bird and with the following identifier nct the full trial protocol can be accessed from clinicaltrialsgov this study received financial support from bmscelgene,"Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Clarithromycin, Dexamethasone, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Male, Multiple Myeloma, Transplantation, Autologous, Treatment Outcome"
34019700,cigb552 is a synthetic peptide that interacts with commd1 and upregulates it protein level the objective of this phase i study were safety pharmacokinetic profile evaluation of the lymphocyte cd and cd and preliminary activity in patient with advanced tumor a 3 3 doseescalation design with seven dose level wa implemented patient were included until a grade 3 related adverse event occurred and the maximum tolerated dose wa reached the patient received subcutaneous administration of cigb552 three time per week for 2 week singledose plasma pharmacokinetics wa characterized at two dose level and tumor response were classified by recist twentyfour patient received cigb doselimiting toxicity wa associated with a transient grade 3 pruritic maculopapular rash at a dose of mg the maximum tolerated dose wa defined a mg ten patient were assessable for immunological status seven patient had significant change in the ratio cdcd8 in response to cigb552 treatment three patient did not modify the immunological status stable disease wa observed in five patient including two metastatic soft sarcoma we conclude that cigb552 at dose mg wa well tolerated with no significant adverse event and appeared to provide some clinical benefit,"Adaptor Proteins, Signal Transducing, Adult, Antineoplastic Agents, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cell-Penetrating Peptides, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Maximum Tolerated Dose, Middle Aged, NF-kappa B, Neoplasm Staging, Neoplasms, Research Design, Treatment Outcome"
34019214,background folfoxiri plus bevacizumab is the firstline treatment for metastatic colorectal cancer mcrc but demonstrates high neutropenia incidence among asian patient hence we conducted the randomized phase ii quattroii study clinicaltrialsgov identifier nct04097444 japan registry of clinical trial identifier jrtcs041190072 to evaluate the safety and efficacy of capecitabine oxaliplatin and irinotecan capoxiri combination plus bevacizumab versus folfoxiri plus bevacizumab expecting a lower incidence of neutropenia without compromising the efficacy method we investigated the recommended do rd of oxaliplatin and irinotecan a a safety leadin portion of step 1 before initiating the randomized portion a step four dose level of capoxiri fixed dose of capecitabine 1600 mgm2 escalateddeescalated do of oxaliplatin and irinotecan plus bevacizumab mgkg were investigated in a 3 3 manner a dose level of of doselimiting toxicity dlt case wa expected a the rd result in step we included nine patient three and six in level 0 and respectively level 0 irinotecan 200 mgm2 oxaliplatin 100 mgm2 did not demonstrate dlts in level 1 irinotecan 200 mgm2 oxaliplatin 130 mgm2 although one patient experienced grade 4 febrile neutropenia no further safety concern were observed a a preliminary efficacy result the objective response rate in all nine patient wa 89 100 and 83 in level 0 and respectively conclusion the rd of capoxiri plus bevacizumab wa and 1600 mgm2 for irinotecan oxaliplatin and capecitabine respectively and mgkg for bevacizumab the randomized portion is still ongoing,"Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Capecitabine, Colorectal Neoplasms, Dose-Response Relationship, Drug, Female, Fluorouracil, Humans, Irinotecan, Leucovorin, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Oxaliplatin"
34018126,several medicine including cancer therapy are known to alter the electrophysiological function of ventricular myocytes resulting in abnormal prolongation and dispersion of ventricular repolarization quantified by multilead qtc measurement this effect could be amplified by other concomitant factor eg combination with other drug affecting the qt andor electrolyte abnormality such a especially hypokalemia hypomagnesaemia and hypocalcemia usually this condition result in higher risk of torsade de point and other lifethreatening arrhythmia related to unrecognized unpaired cardiac ventricular repolarization reserve vrr being vrr a dynamic phenomenon qt prolongation might often not be identified during the s standard lead ecg recording at rest leaving the patient at increased risk for lifethreatening event we report the case of a year woman undergoing tamoxifen therapy for breast cancer which alteration of ventricular repolarization reserve persisting also after correction of concomitant recurrent hypokalemia wa evidenced only after manual measurement of the corrected qt qtc interval from selected interval of the lead ecg holter monitoring this otherwise missed finding wa fundamental to drive the discontinuation of tamoxifen shifting to another safer therapeutic option and to avoid the use of potentially arrhythmogenic antibiotic when treating a bilateral pneumonia in recent covid,"Action Potentials, Anti-Bacterial Agents, Arrhythmias, Cardiac, Breast Neoplasms, COVID-19, Carcinoma, Intraductal, Noninfiltrating, Drug Substitution, Electrocardiography, Estrogen Antagonists, Female, Heart Conduction System, Heart Rate, Humans, Middle Aged, Predictive Value of Tests, Risk Assessment, Risk Factors, Tamoxifen, COVID-19 Drug Treatment"
34014777,the aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine tdm1 in case with metastatic breast cancer mbc in different line of treatment retrospective analysis of tdm1 result of human epidermal growth factor receptor 2 her2 positive 414 case with mbc from 31 center in turkey except all of the case were female with a median age of tdm1 had been used a secondline therapy in of the case and the median number of tdm1 cycle wa progressionfree survival pfs and overall survival o time were different according to the line of treatment the median o wa found a 23 and 17 month for 1st 2nd 3rd 4th and 5th line respectively p while the median pfs wa found a 8 and 8 month respectively p treatment wa well tolerated by the patient the most common grade adverse effect were thrombocytopenia and increased serum gammaglutamyl transferase 2 the best of our knowledge this is the largest reallife experience about the safety and efficacy of tdm1 use in case with mbc after progression of her2 targeted treatment this study suggests and support that tdm1 is more effective in earlier line of treatment and is a reliable option for mbc,"Ado-Trastuzumab Emtansine, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasm Metastasis, Receptor, ErbB-2, Retrospective Studies, Survival Analysis, Treatment Outcome, Turkey"
34010932,pegteograstim neulapeg is a recombinant human granulocyte colonystimulating factor conjugated with methoxymaleimidepolyethylene glycol we conducted a singlearm study investigating it safety and noninferiority to conventional filgrastim in child and adolescent patient younger than 21 year with solid tumor were eligible for the study pegteograstim wa administered on day 7 of the fourth chemotherapy cycle toxicity were monitored and the change in absolute neutrophil count wa compared with that of the historic control conventional filgrastim this trial wa registered at clinicaltrialsgov a nct thirtytwo patient were enrolled adverse event possibly related to pegteograstim were musculoskeletal pain n3 skin nodule n1 paroxysmal cough n1 urticaria n2 rash n1 and itching n1 these adverse event were all grade 1 or duration of neutropenia ancl wa shorter in the pegteograstim group compared with the historic control median v 10 d p the time from day 0 to neutrophil recovery ancl wa shorter in the pegteograstim group median 15 v 18 d p pegteograstim is safe and show comparable efficacy to conventional filgrastim in child and adolescent randomized controlled trial are needed to confirm it safety and efficacy,"Adolescent, Antineoplastic Agents, Child, Filgrastim, Granulocyte Colony-Stimulating Factor, Humans, Neoplasms, Neutropenia, Polyethylene Glycols, Recombinant Proteins"
34010146,thirtyseven patient with advanced gastroenteropancreatic neuroendocrine tumor gepnets were treated on a prospective phase ii singlecenter study with four cycle of gbq 177luoctreotate combined with capecitabine and temozolomide chemotherapy captem each week cycle combined radiopeptide therapy with 14 day of capecitabine 1500 mgm2 and 5 day of temozolomide 200 mgm2 the incidence of grade 3 hematologic toxicity wa analyzed at a median followup of year range six 16 patient developed persistent hematologic toxicity pht defined a sustained grade 3 hematologic toxicity beyond month followup and three 8 developed mdsal with a median timetoevent of 46 and 34 month respectively the estimated cumulative incidence of mdsal wa 11 95 ci development of pht wa the only significant risk factor for secondary mdsal rr 16 95 ci to p the median pfs wa 48 month 95 ci and the median o wa 86 month 95 ci twentyone death were recorded including 13 62 due to progressive disease and all 3 14 patient with mdsal 177luoctreotate captem therapy for gepnets is associated with a risk of longterm hematologic toxicity the rising cumulative incidence of mdsal 10 mandate the longterm monitoring of treated patient however time to onset is unpredictable and incidence doe not correlate with conventional baseline risk factor novel method are required for the stratification of prospective patient based on genetic risk,"Capecitabine, Humans, Intestinal Neoplasms, Neuroendocrine Tumors, Octreotide, Pancreatic Neoplasms, Prospective Studies, Retrospective Studies, Stomach Neoplasms, Temozolomide, Treatment Outcome"
34008039,endometrial cancer emc is one of the complicated gynecological cancer affecting more than three million woman worldwide anticancer strategy such a chemotherapy radiation and surgery are found to be ineffective and are associated with patient incompliances the aim of the present study is to repurpose nononcological drug ie pioglitazone a peroxisome proliferatoractivated receptor gamma ppar agonist in the treatment of endometrial cancer the study group consist of 50 female swiss albino mouse out of which 40 had endometrial cancer induced with nethylnnitrosourea enu and estradiol hexadrobenzoate ehb the other group received saline ehb paclitaxel and different test do of pioglitazones different preliminary parameter such a weekly body weight mean survival time percentage increase in life span and uterine tissue weight were analyzed along with histopathological analysis we observed a significant change in weekly body weight improvement in percentage life span and partial restoration of uterine tissue weight to normal compared to a standard drug paclitaxel in the present preliminary evaluation we have identified that pioglitazone exhibited a significant dosedependent anticancer activity against enu and ehbinduced endometrial cancer compared to the standard paclitaxel,"Animals, Antineoplastic Agents, Body Weight, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Repositioning, Endometrial Neoplasms, Estradiol, Ethylnitrosourea, Female, Mice, Paclitaxel, Pioglitazone, Survival Rate, Uterus"
34003566,therapy for childhood acute lymphoblastic leukemia all is associated with substantial health care utilization and burden on family little is known about health care utilization during specific treatment phase we identified child with all diagnosed during in ontario canada and treated according to childrens oncology group cog protocol disease and treatment data were chart abstracted populationbased health care database identified all outpatient visit emergency department ed visit and hospitalization in addition to comparing standard and intensified version of treatment phase we compared patient receiving different steroid dexamethasone v prednisone and different version of interim maintenance im capizzi v highdose methotrexate hdmtx six hundred thirtyseven child met inclusion criterion during intensified consolidation of patient were hospitalized at least once compared to only of patient receiving standard consolidation p 0001 similarly of patient receiving intensified delayed intensification di were hospitalized during this phase compared to of patient receiving standard di p 0001 among patient receiving a fourdrug induction those receiving dexamethasone had an 85 higher rate of ed visit adjusted rate ratio arr 95th confidence interval 95ci p 01 and a 44 higher rate of hospitalization arr 95ci compared to those receiving prednisone among highrisk ball and tall patient in im capizzi mtx wa not associated with an increased rate of ed visit versus hdmtx these result can be used to inform anticipatory guidance for family particularly those undergoing intensified therapy our result also suggest that increased toxicity rate associated with dexamethasone during induction seen in clinical trial reflect realworld practice,"Antineoplastic Combined Chemotherapy Protocols, Child, Dexamethasone, Emergency Service, Hospital, Hospitalization, Humans, Methotrexate, Ontario, Outpatients, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prednisone"
34003395,the use of cytokine in harnessing the immune system to eradicate cancer ha been an important treatment modality however the doselimiting toxicity of these cytokine limited their usage in clinic here we review the basic biology of cytokine involved in the treatment of melanoma and discus their therapeutic application moreover we describe several innovative technological approach that have been developed to improve the pharmacokinetics safety and efficacy of these cytokine the safety and the antitumor activity of newly engineered cytokine including pegylated il2 nktr214 pegylated il10 am0010 and il15 super agonist alt803 have been evaluated in clinical trial with encouraging clinical activity and acceptable safety profile both a single agent and in combination with immunooncology agent a greater understanding of the mechanism of action and effective dosing of these newly engineered cytokine together with determination of optimum combination therapy regimen may yield greater clinical benefit in the future,"Cytokines, Humans, Interferon-alpha, Interleukin-10, Interleukin-15, Interleukin-2, Melanoma"
34003074,gastric cancer is the fifth most common neoplasm worldwide with high rate of mortality afatinib a low molecular irreversible potent inhibitor of erbb transmembrane receptor family ha shown promising result according to preclinical and phase i clinical trial data when combined with chemotherapy we aimed at evaluating the safety and efficacy of the combination of cisplatin 5fu with afatinib in molecularly unselected patient with advanced gastric cancer patient with locally advanced or metastatic gastricgastroesophageal junction adenocarcinoma received first line combination therapy of cisplatin 5fu and afatinib every 21 day followed by afatinib maintenance monotherapy the primary endpoint wa the objective response rate orr secondary endpoint included overall survival o progression free survival pfs and the safety profile unplanned exploratory analysis of her2 and tumor mutational profile wa performed among 55 patient itt population enrolled 19 achieved an objective tumor response stable disease wa observed in 16 patient and progressive disease in 10 patient the orr in the per protocol population pp wa within a median followup of 56 month the median pfs and o in the itt population wa and month respectively seven of the 47 her2 informative case carried her2 positive tumor while tp brca2 and smad4 were the most frequently mutated gene the most common toxicity were neutrophil count and white blood cell decrease occurring in of patient followed by anemia hyperglycemia 40 and diarrhea the combination of cisplatin5fu with afatinib did not surpass the benchmark of efficacy of the contemporary therapeutic regimen that are being applied for the treatment of patient with advanced gastric cancer however the observed efficacy and the improved safety profile support that our administration schedule may be further investigated to overcome toxicity problem when integrating afatinib to cytotoxic chemotherapy nct,"Adenocarcinoma, Afatinib, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Esophagogastric Junction, Fluorouracil, Humans, Treatment Outcome"
34001158,lymph node metastasis presenting with locally advanced cervical cancer are poor prognostic feature modern radiotherapy approach enable dose escalation to radiologically abnormal node this study report the result of a policy of a simultaneous integrated boost sib in term of treatment outcome patient treated with radical chemoradiation with weekly cisplatin for locally advanced cervical cancer including an sib to radiologically abnormal lymph node were analysed all patient received a dose of 45 gy in 25 fraction and a sib dose of 60 gy in 25 fraction using intensity modulated radiotherapyvolumetric modulated arc therapy followed by high dose rate brachytherapy of 28 gy in 4 fraction a control cohort with radiologically negative lymph node wa used to compare impact of the sib in node positive patient treatment outcome were measured by overall survival o post treatment tumour response and toxicity the tumour response wa based on cross sectional imaging at 3 and 12 month and recorded a local recurrence free survival lrfs regional recurrence free survival rrfs and distant recurrence free survival drfs in between january 2015 and june a total of 69 patient with a median follow up of month 23 sib patient and 46 control patient were identified the complete response rate at 3 month wa 100 in the primary tumour and 83 in the nodal volume receiving sib the o lrfs rrfs and drfs at 3 year of the sib cohort were 69 91 79 and 77 respectively high do can be delivered to regional pelvic lymph node using sib without excessive toxicity using a sib a total dose of 60 gy in 25 fraction chemoradiation can be delivered to radiologically abnormal pelvic node with no increase in toxicity compared to node negative patient the adverse impact of positive nodal status may be negated by high dose deposition using sib but larger prospective study are required to confirm this observation,"Adult, Aged, Aged, 80 and over, Brachytherapy, Chemoradiotherapy, Cisplatin, Dose Fractionation, Radiation, Female, Humans, Lymph Nodes, Lymphatic Irradiation, Lymphatic Metastasis, Middle Aged, Pelvis, Positron-Emission Tomography, Radiation Injuries, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Intensity-Modulated, Treatment Outcome, Uterine Cervical Neoplasms"
34000921,development in targeted molecular therapy have considerably improved patient survival in cancer panitumumab is a monoclonal antibody against the epidermal growth factor receptor egfr it is used to treat metastatic colorectal carcinoma although panitumumab is well tolerated in most patient pulmonary toxicity especially interstitial lung disease ild is a lifethreatening condition the presentation of panitumumabinduced ild with spontaneous pneumomediastinum and subcutaneous emphysema is rarely reported we describe a yearold male with metastatic colorectal carcinoma treated with folfiri folinic acid fluorouracil irinotecan and panitumumab he presented to our hospital with a complaint of severe dyspnea on the evaluation of dyspnea the patient wa diagnosed with ild after exclusion of other common cause of pneumomediastinum and subcutaneous emphysema panitumumab wa attributed a a cause of ild oxygen therapy via high flow nasal cannula and intravenous methylprednisolone regimen wa started after two week the patient became asymptomatic with the radiologic amelioration panitumumabinduced ild is associated with a poor prognosis and might occur randomly in one year after the drug administration the possibility of the disease should be considered on every admission early recognition discontinuation of causative medication and immediate glucocorticoid therapy are essential to reduce mortality,"Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Fluorouracil, Humans, Leucovorin, Lung Diseases, Interstitial, Male, Mediastinal Emphysema, Middle Aged, Panitumumab"
34000920,functional variant of the methylenetetrahydrofolate reductase mthfr gene the c677t and a1298c have largely investigated in pharmacogenomics of methotrexate mtx in acute lymphoblastic leukemia all yet the conclusion are inconsistent in addition most of these study do not analyze haplotype here we investigate the mthfr genotype and the haplotype and characterize the mtx response in northern african all patient genomic dna wa extracted from whole venous from a total of 28 patient with all genotyping were carried out with restriction fragment length polymorphism rflp a toxicity score t is calculated for each patient and correlate to the haplotype the allelic frequency of mthfr 677t1298c haplotype wa in all patient according to the toxicity score t there wa no significant difference between haplotype group p t wa higher with wild type of mthfr t sem followed by combined genotype 677t1298c t sem and isolated variant c677t or a1298c t sem despite the limitation of this study our result suggest that the mthfr 677t1298c haplotype is common in all and may be a promising hdmtx chemotherapyrelated adverse effect biomarker,"Humans, Methotrexate, Haplotypes, Methylenetetrahydrofolate Reductase (NADPH2), Genotype, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Polymorphism, Single Nucleotide"
34000917,trastuzumab emtansine tdm1 is an antibodydrug conjugate which combine trastuzumab t a monoclonal antibody targeting the human epidermal growth factor receptor2 her2 and a cytotoxic molecule derived from maytansine dm1 we report the first case of tdmassociated pleural and pericardial effusion three week after the second course of tdm1 in a patient with breast cancer druginduced pleural and pericardial effusion wa implicated in the absence of other etiology the naranjo scale indicated a probable druginduced adverse reactionmanagement outcome the patient fully recovered after thoracentesis and discontinuation of tdm the patient ha reported no side effect after the sixth course of trastuzumab to our knowledge this is the first case in the literature of bilateral pleural and pericardial effusion in a patient treated with tdm the successful initiation of treatment with trastuzumab following withdrawal of tdm1 suggests that emtansine played a role in the development of bilateral pleural and pericardial effusion we hypothesize that the patient condition wa a result of a local inflammatory reaction to emtansine by direct toxicity,"Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, Breast Neoplasms, Female, Humans, Maytansine, Pericardial Effusion, Receptor, ErbB-2, Trastuzumab"
34000246,before february there wa no standard treatment regimen for locally advanced basal cell carcinoma after firstline hedgehog inhibitor hhi therapy cemiplimab a pd1 antibody is approved for treatment of advanced cutaneous squamous cell carcinoma and ha shown clinical activity a monotherapy in firstline nonsmallcell lung cancer here we present the primary analysis data of cemiplimab in patient with locally advanced basal cell carcinoma after hhi therapy we did an openlabel multicentre singlearm phase 2 trial across 38 outpatient clinic primarily at academic medical centre in canada europe and the usa eligible patient aged 18 year and with an eastern cooperative oncology group performance status of 0 or 1 with a histologically confirmed diagnosis of metastatic basal cell carcinoma group 1 or locally advanced basal cell carcinoma group 2 who had progressed on or were intolerant to previous hhi therapy were enrolled patient were not candidate for further hhi therapy due to progression of disease on or intolerance to previous hhi therapy or having no better than stable disease after 9 month on hhi therapy patient received cemiplimab 350 mg intravenously every 3 week for up to 93 week or until progression or unacceptable toxicity the primary endpoint wa objective response by independent central review analysis were done a per the intentiontotreat principle the safety analysis comprised all patient who received at least one dose of cemiplimab the primary analysis is reported only for group 2 group 1 data have not reached maturity and will be reported when the timepoint according to the statistical analysis plan ha been reached this study is registered with clinicaltrialsgov nct and is no longer recruiting new participant between nov and jan 84 patient were enrolled and treated with cemiplimab at data cutoff on feb median duration of followup wa 15 month iqr an objective response per independent central review wa observed in 26 31 95 ci of 84 patient including two partial response that emerged at tumour assessment before the data cutoff and were confirmed by tumour assessment done subsequent to the data cutoff the best overall response wa five 6 patient with a complete response and 21 25 with a partial response grade treatmentemergent adverse event occurred in 40 48 of 84 patient the most common were hypertension four 5 of 84 patient and colitis four 5 serious treatmentemergent adverse event occurred in 29 35 of 84 patient there were no treatmentrelated death cemiplimab exhibited clinically meaningful antitumour activity and an acceptable safety profile in patient with locally advanced basal cell carcinoma after hhi therapy regeneron pharmaceutical and sanofi,"Adult, Aged, Anilides, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Basal Cell, Drug Resistance, Neoplasm, Female, Hedgehog Proteins, Humans, Immune Checkpoint Inhibitors, Male, Middle Aged, Neoplasm Recurrence, Local, Programmed Cell Death 1 Receptor, Pyridines, Skin Neoplasms"
34000245,the catnon trial investigated the addition of concurrent adjuvant and both current and adjuvant temozolomide to radiotherapy in adult with newly diagnosed 1p19q noncodeleted anaplastic glioma the benefit of concurrent temozolomide chemotherapy and relevance of mutation in the idh1 and idh2 gene remain unclear this randomised openlabel phase 3 study done in 137 institution across australia europe and north america included patient aged 18 year or older with newly diagnosed 1p19q noncodeleted anaplastic glioma and a who performance status of patient were randomly assigned 1111 centrally using a minimisation technique to radiotherapy alone 594 gy in 33 fraction threedimensional conformal radiotherapy or intensitymodulated radiotherapy radiotherapy with concurrent oral temozolomide 75 mgm2 per day radiotherapy with adjuvant oral temozolomide 12 week cycle of mgm2 temozolomide given on day or radiotherapy with both concurrent and adjuvant temozolomide patient were stratified by institution who performance status score age 1p loss of heterozygosity the presence of oligodendroglial element on microscopy and mgmt promoter methylation status the primary endpoint wa overall survival adjusted by stratification factor at randomisation in the intentiontotreat population a second interim analysis requested by the independent data monitoring committee wa planned when twothirds of total required event were observed to test superiority or futility of concurrent temozolomide this study is registered with clinicaltrialsgov nct between dec and sept 751 patient were randomly assigned 189 to radiotherapy alone 188 to radiotherapy with concurrent temozolomide 186 to radiotherapy and adjuvant temozolomide and 188 to radiotherapy with concurrent and adjuvant temozolomide median followup wa 557 month iqr 413 the second interim analysis declared futility of concurrent temozolomide median overall survival wa 669 month 95 ci 453 with concurrent temozolomide v 604 month 455 without concurrent temozolomide hazard ratio hr 097 991 ci 028 p076 by contrast adjuvant temozolomide improved overall survival compared with no adjuvant temozolomide median overall survival 823 month 95 ci 676 v 469 month 379 hr 064 95 ci 079 p00001 the most frequent grade 3 and 4 toxicity were haematological occurring in no patient in the radiotherapy only group 16 9 of 185 patient in the concurrent temozolomide group and 55 15 of 368 patient in both group with adjuvant temozolomide no treatmentrelated death were reported adjuvant temozolomide chemotherapy but not concurrent temozolomide chemotherapy wa associated with a survival benefit in patient with 1p19q noncodeleted anaplastic glioma clinical benefit wa dependent on idh1 and idh2 mutational status merck sharpe dohme,"Adolescent, Adult, Aged, Australia, Chemotherapy, Adjuvant, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, Combined Modality Therapy, Dacarbazine, Europe, Female, Glioma, Humans, Isocitrate Dehydrogenase, Loss of Heterozygosity, Male, Middle Aged, North America, Radiotherapy, Conformal, Temozolomide, Young Adult"
33998997,ra gene are commonly mutated in human cancer despite many possible mutation individual cancer type often have a tropism towards a specific subset of ra mutation a driver mutation these pattern ostensibly originate from normal cell high oncogenic ra activity cause oncogenic stress and different oncogenic mutation can impart different level of activity suggesting a relationship between oncoprotein activity and ra mutation tropism here we show that changing rare codon to common in the murine kras gene to increase protein expression shift tumor induced by the carcinogen urethane from arising from canonical q61 to biochemically le active g12kras driver mutation despite the carcinogen still being biased towards generating q61 mutation conversely inactivating the tumor suppressor p53 to blunt oncogenic stress partially reversed this effect restoring q61 mutation one interpretation of these finding is that the ra mutation tropism of urethane arises from selection in normal cell for specific mutation that impart a narrow window of signaling that promotes proliferation without causing oncogenic stress,"Animals, Carcinogenesis, Cell Transformation, Neoplastic, Genes, ras, Lung Neoplasms, Mice, Mice, 129 Strain, Mutation, Urethane"
33994435,treatment with antiprogrammed cell death1 pd1 antibody improves the anticancer immune response and can provide a meaningful clinical benefit to cancer patient however this treatment can result in specific autoimmune toxicity termed immunerelated adverse event iraes although iraes are well recognized the development of infectious disease due to this treatment is not often observed some recent report have indicated that patient who receive antipd1 antibody are at a higher risk for tuberculosis than others however report on nontuberculous mycobacterial infection during antipd1 antibody treatment are still rare we herein report the first case of mycobacterium mageritense infection during antipd1 antibody treatment,"Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Breast Neoplasms, Female, Humans, Mycobacteriaceae, Nivolumab, Programmed Cell Death 1 Receptor"
33994039,capecitabine ha been more recognized for it cardiotoxicity with an incidence that varies widely it demonstrates it toxicity in the form of acute coronary syndrome arrhythmia and to a lesser extent cardiomyopathy there are several proposed theory including coronary vasospasm endothelial injury and oxidative stress we present a case of capecitabineinduced cardiomyopathy in a patient with pancreatic cancer and mild coronary artery disease and shed light on other cardiotoxic agent their proposed mechanism of cardiotoxicity and on cardiomyopathy in general,"Capecitabine, Humans, Incidence, Neoplasms, Takotsubo Cardiomyopathy"
33993741,lay abstract many patient with metastatic colorectal cancer need a sequence of different treatment over time regorafenib and trifluridinetipiracil also called tas102 are two drug which are both used late in this sequence of treatment but there is no rule a to which should be used first both drug have very different mechanism of action and it might be beneficial to patient to administer them both at the same time a a combination treatment instead of sequential treatment we therefore conducted a phase ib study with a small number of patient to investigate whether this combined treatment would be feasible and safe the study wa designed to test the drug combination at different do and we found that treatment with trifluridinetipiracil at 25 mgm2 twice daily combined with regorafenib at 120 mg daily had acceptable side effect and is likely to be safe for use in future clinical trial efficacy result suggest that combined treatment with both drug may extend patient life span however these observation are preliminary and need testing in further clinical trial clinical trial registration eudract 11 nct03305913 clinicaltrialsgov,"Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Drug Resistance, Neoplasm, Feasibility Studies, Female, Humans, Hypertension, Male, Maximum Tolerated Dose, Middle Aged, Phenylurea Compounds, Progression-Free Survival, Pyridines, Pyrrolidines, Response Evaluation Criteria in Solid Tumors, Thymine, Trifluridine"
33993266,ageritin is the prototype of a new ribotoxinlike protein family which ha been recently identified also in basidiomycete the protein exhibit specific rnase activity through the cleavage of a single phosphodiester bond located at sarcinricin loop of the large rrna thus inhibiting protein biosynthesis at early stage conversely to other ribotoxins it activity requires the presence of divalent cation in the present study we report the activity of ageritin on both prokaryotic and eukaryotic cell showing that the protein ha a prominent effect on cancer cell viability and no effect on eukaryotic and bacterial cell in order to rationalize these finding the ability of the protein to interact with various liposome mimicking normal cancer and bacterial cell membrane wa explored the collected result indicate that ageritin can interact with dppcdppschol vesicle used a a model of cancer cell membrane and with dppcdppg vesicle used a a model of bacterial cell membrane suggesting a selective interaction with anionic lipid however a different perturbation of the two model membrane mediated by cholesterol redistribution wa observed and this might be at the basis of ageritin selective toxicity towards cancer cell,"Agrocybe, Animals, Antineoplastic Agents, Bacteria, Basidiomycota, Calorimetry, Cell Line, Cell Membrane, Cell Survival, Cholesterol, Liposomes, Mice, Mycotoxins, Neoplasms, Protein Biosynthesis, RNA, Ribosomal, Ribonucleases, Ribosomes"
33992717,chemotherapy and concurrent thoracic radiation therapy cctrt followed by prophylactic cranial irradiation pci is the standard of care for limitedstage small cell lung cancer lssclc we aimed to compare the efficacy and toxicity of moderately hypofractionated oncedaily cctrt with that of a standard twicedaily regimen this multicenter phase randomized study enrolled patient aged 18 to 75 year old who had pathologically confirmed lssclc and an eastern cooperative oncology group performance status of 0 to eligible patient received 4 to 6 cycle of etoposidecisplatin chemotherapy and were randomized to receive twicedaily cctrt at 45 gray gy in 30 fraction or oncedaily cctrt at 65 gy in 26 fraction commencing with cycle 1 to 3 of chemotherapy pci wa given to good responder the primary endpoint wa progressionfree survival pfs the analysis included 182 patient with 94 in the twicedaily group and 88 in the oncedaily group cctrt started with cycle 3 of chemotherapy for most patient at a median followup of month the median pfs wa month 95 confidence interval ci in the twicedaily group versus month 95 ci in the oncedaily group p 031 with year pfs rate of 95 ci and 95 ci respectively the estimated overall survival wa month in the twicedaily group versus month in the oncedaily group p 137 the median locoregional pfs wa month in the twicedaily group and wa not reached in the oncedaily group p 017 the incidence of most toxicity were similar in both group except for a higher incidence of grade 3 acute lymphopenia in the oncedaily group v in the twicedaily group p 001 there wa no difference in the incidence of grade 3 esophagitis v respectively pneumonitis v respectively or treatmentrelated death v respectively between the oncedaily and twicedaily group moderately hypofractionated oncedaily cctrt showed improved pfs and similar toxicity compared with twicedaily cctrt in lssclc this regimen should be evaluated for comparison in a phase 3 randomized trial,"Adult, Aged, Chemoradiotherapy, Cisplatin, Etoposide, Female, Humans, Lung Neoplasms, Male, Middle Aged, Radiation Dose Hypofractionation, Small Cell Lung Carcinoma"
33992087,little is known about the safety and efficacy of concurrent capecitabine and stereotactic radiotherapy in the setting of breast cancer brain metastasis bcbm twentythree patient with bcbm underwent 31 stereotactic session to 90 lesion from 2005 to 2019 with receipt of capecitabine the kaplanmeier method wa used to calculate overall survival o local control lc and distant intracranial control dic from the date of stereotactic radiation imaging wa independently reviewed by a neuroradiologist median followup from stereotactic radiation wa month receptor type of patient treated included triple negative n 7 hormone receptor hrher n 7 hrher n 6 and hrher n 3 fourteen patient had stage iv disease prior to bcbm diagnosis the median number of brain metastasis treated per patient wa 3 1 to 12 the median dose of stereotactic radiosurgery sr wa 21 gy range gy treated in a single fraction and for lesion treated with fractionated stereotactic radiation therapy fsrt 25 gy gy in a median of 5 fraction range of the 31 stereotactic session 71 occurred within 1 month of capecitabine no increased toxicity wa noted in our series with no case of radionecrosis the year o lc and dic were and 30 respectively in our single institution experience we demonstrate stereotactic radiation and capecitabine to be a safe treatment for patient with bcbm with adequate lc further study is needed to determine the potential synergy between stereotactic radiation and capecitabine in the management of bcbm,"Adult, Aged, Brain, Brain Neoplasms, Breast Neoplasms, Capecitabine, Chemoradiotherapy, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Middle Aged, Necrosis, Neoplasm Staging, Radiation Injuries, Radiosurgery, Retrospective Studies, Treatment Outcome"
33990415,adoptive cell therapy with t cell genetically engineered to express a chimeric antigen receptor cart or tumorinfiltrating t lymphocyte til demonstrates impressive clinical result in patient with cancer lymphodepleting preconditioning prior to cell infusion is an integral part of all adoptive t cell therapy however to date there is no standardization and no data comparing different nonmyeloablative nma regimen in this study we compared nma therapy with different do of cyclophosphamide or total body irradiation tbi in combination with fludarabine and evaluated bone marrow suppression and recovery cytokine serum level clinical response and adverse event we demonstrate that a cumulative dose of 120 mgkg cyclophosphamide and 125 mgm2 fludarabine 120cy125flu and 60cy125flu preconditioning were equally efficient in achieving deep lymphopenia and neutropenia in patient with metastatic melanoma whereas absolute lymphocyte count alcs and absolute neutrophil count were significantly higher following 200 cgytbi75fluinduced nma thrombocytopenia wa most profound in 120cy125flu patient 30cy75fluinduced preconditioning in patient with acute lymphoblastic leukemia resulted in a minor alc decrease had no impact on platelet count and did not yield deep neutropenia following cell infusion 120cy125flu patient with objective tumor response had significantly higher alc and significant lower inflammatory index such a neutrophiltolymphocyte ratio nlr and platelettolymphocyte ratio plr receiveroperating characteristic curve analysis 7 day after cell infusion wa performed to determine the cutoff which distinguish between responding and nonresponding patient in the 120cy125flu cohort nlr and plr were associated with clinical response and overall survival cytokine serum level did not associate with clinical response in patient with til patient in the 120cy125flu cohort developed significantly more acute nmarelated adverse event including thrombocytopenia febrile neutropenia and cardiotoxicity and stayed significantly longer in hospital compared with the 60cy125flu and tbi75flu cohort bone marrow depletion and recovery were equally affected by 120cy125flu and 60cy125flu preconditioning however toxicity and consequently duration of hospitalization were significantly lower in the 60cy125flu cohort patient in the 30cy75flu and tbi75flu group rarely developed nmainduced adverse event however both regimen were not efficient in achieving deep bone marrow suppression among the regimen 60cy125flu preconditioning seems to achieve maximum effect with minimum toxicity,"Adult, Clinical Trials, Phase II as Topic, Cyclophosphamide, Cytokines, Female, Humans, Immunotherapy, Adoptive, Length of Stay, Lymphocyte Depletion, Male, Melanoma, Middle Aged, Myeloablative Agonists, Receptors, Chimeric Antigen, Recovery of Function, Skin Neoplasms, T-Lymphocytes, Time Factors, Transplantation Conditioning, Treatment Outcome, Vidarabine, Whole-Body Irradiation"
33990361,doxorubicin cardiac toxicity is widely misunderstood largely preventable and start with the first dose this article review the history of doxorubicin cardiac toxicity and strategy for minimizing it dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor activity allowing doxorubicin administration beyond the reported maximum lifetime dosesee related article by van tine et al p 3854 and jones et al p,"Cardiotoxicity, Dexrazoxane, Doxorubicin, Humans, Razoxane, Sarcoma"
33989769,the introduction in clinical practice of the immune checkpoint inhibitor icis radically changed the treatment algorithm of lung cancer to characterize the toxicity of icis atezolizumab durvalumab nivolumab pembrolizumab is important for personalizing treatment we performed a systematic review and metaanalysis of phase iii randomized controlled trial assessing icis from inception until april 23rd we extracted the data from the ici arm of each trial for indirect comparison to estimate relative risk for immunerelated adverse event iraes severe grade 3 iraes drug discontinuation due to iraes or toxic death sixteen trial included a total of 6226 subject randomized to the experimental immunotherapy arm immunotherapy wa administered in monotherapy 8 trial in combination with chemotherapy 6 trial or other ici 2 trial any grade iraes and severe iraes for ici were and respectively discontinuation due to any grade iraes and severe iraes were and respectively toxic death were in the immunotherapy arm pooled data on any severe and organspecific iraes showed that immunotherapy ha a significantly lower risk of iraes compared to immunochemotherapy especially when analysis wa restricted to monoimmunotherapy like drug discontinuation and toxic death all p detailed comparison between different icis provided treatmentrelated risk profile for organspecific iraes our finding contribute to clarifying frequency and feature of immunerelated toxicity between different icis in lung cancer patient including any grade iraes severe iraes drug discontinuation and toxic death and may be useful to inform the selection of treatment,"Humans, Immune Checkpoint Inhibitors, Immunotherapy, Lung Neoplasms, Nivolumab"
33989558,patient with relapsed or refractory diffuse large bcell lymphoma dlbcl who do not respond to or who have progressive disease after salvage therapy have a poor prognosis loncastuximab tesirine is a cddirected antibodydrug conjugate with encouraging phase 1 singleagent antitumour activity and acceptable safety in nonhodgkin lymphoma we aimed to evaluate the antitumour activity and safety of loncastuximab tesirine in patient with relapsed or refractory dlbcl we did a multicentre 28 hospital site in the usa uk italy and switzerland openlabel singlearm phase 2 trial lotis2 in patient aged 18 year or older with relapsed or refractory dlbcl after two or more multiagent systemic treatment who had measurable disease and eastern cooperative oncology group performance status eligible patient received loncastuximab tesirine intravenously on day 1 of each day cycle at 150 gkg for two cycle then 75 gkg thereafter for up to 1 year or until disease relapse or progression unacceptable toxicity death major protocol deviation pregnancy or patient investigator or sponsor decision the primary endpoint wa overall response rate assessed by central review primary antitumour activity and safety analysis were done in the astreated population patient who received at least one dose of loncastuximab tesirine when all responding patient had at least 6 month of followup after initial documented response enrolment is complete this trial is registered with clinicaltrialsgov nct between aug and sept 184 patient were assessed for eligibility and 145 79 were enrolled and received at least one dose of loncastuximab tesirine including patient with highrisk characteristic for poor prognosis such a doublehit triplehit transformed or primary refractory dlbcl 70 of 145 patient had complete or partial response overall response rate 483 95 ci 397 35 had complete response and 35 had partial response the most common grade 3 or higher treatmentemergent adverse event were neutropenia 37 26 of 145 patient thrombocytopenia 26 18 and increased gammaglutamyltransferase 24 17 serious adverse event were reported in 57 39 of 145 patient treatmentemergent adverse event with a fatal outcome occurred in eight 6 of 145 patient none were considered related to loncastuximab tesirine loncastuximab tesirine ha substantial singleagent antitumour activity and produce durable response with an acceptable safety profile potentially offering a new therapeutic option for heavily pretreated patient with relapsed or refractory dlbcl adc therapeutic,"Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized, Antigens, CD19, Benzodiazepines, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Immunoconjugates, Italy, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Neoplasm Recurrence, Local, Recurrence, Switzerland, Young Adult"
33989557,antipd1 therapy hereafter referred to a antipd1 induces longterm disease control in approximately 30 of patient with metastatic melanoma however twothirds of patient are resistant and will require further treatment we aimed to determine the efficacy and safety of ipilimumab plus antipd1 pembrolizumab or nivolumab compared with ipilimumab monotherapy in patient who are resistant to antipdl1 therapy hereafter referred to a antipdl1 this multicentre retrospective cohort study wa done at 15 melanoma centre in australia europe and the usa we included adult patient aged 18 year with metastatic melanoma unresectable stage iii and iv who were resistant to antipdl1 innate or acquired resistance and who then received either ipilimumab monotherapy or ipilimumab plus antipd1 pembrolizumab or nivolumab based on availability of therapy or clinical factor determined by the physician or both tumour response wa assessed a per standard of care ct or petct scan every 3 month the study endpoint were objective response rate progressionfree survival overall survival and safety of ipilimumab compared with ipilimumab plus antipd we included 355 patient with metastatic melanoma resistant to antipdl1 nivolumab pembrolizumab or atezolizumab who had been treated with ipilimumab monotherapy n162 46 or ipilimumab plus antipd1 n193 54 between feb and feb at a median followup of 221 month iqr 99 the objective response rate wa higher with ipilimumab plus antipd1 60 31 of 193 patient than with ipilimumab monotherapy 21 13 of 162 patient p00001 overall survival wa longer in the ipilimumab plus antipd1 group median overall survival 204 month 95 ci 128 than with ipilimumab monotherapy 88 month 63 hazard ratio hr 0 95 ci 066 p00001 progressionfree survival wa also longer with ipilimumab plus antipd1 median 30 month 95 ci 26 than with ipilimumab 26 month 29 hr 0 95 ci 087 p00019 similar proportion of patient reported grade adverse event in both group 59 31 of 193 patient in the ipilimumab plus antipd1 group v 54 33 of 162 patient in the ipilimumab group the most common grade adverse event were diarrhoea or colitis 23 12 of 193 patient in the ipilimumab plus antipd1 group v 33 20 of 162 patient in the ipilimumab group and increased alanine aminotransferase or aspartate aminotransferase 24 12 v 15 9 one death occurred with ipilimumab 26 day after the last treatment a colon perforation due to immunerelated pancolitis in patient who are resistant to antipdl ipilimumab plus antipd1 seemed to yield higher efficacy than ipilimumab with a higher objective response rate longer progressionfree and longer overall survival with a similar rate of grade toxicity ipilimumab plus antipd1 should be favoured over ipilimumab alone a a secondline immunotherapy for these patient with advanced melanoma none,"Aged, Antibodies, Monoclonal, Humanized, Cohort Studies, Drug Resistance, Neoplasm, Female, Humans, Immune Checkpoint Inhibitors, Ipilimumab, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Nivolumab, Positron Emission Tomography Computed Tomography, Programmed Cell Death 1 Receptor, Progression-Free Survival, Retrospective Studies"
33988833,antibodydrug conjugate adcs are new treatment option for certain cancer especially those in advanced state with limited treatment option their unique design provides targeted therapy with toxin that otherwise would not be available but they manifest toxicity that require risk minimization intervention to optimize their tolerability we summarize selected toxicity for adcs that have been approved through the end of 2020 and three investigational adcs which include both payload and linker a described in the u prescribing information the european summary of product characteristic and study protocol these toxicity include peripheral neuropathy pulmonary skin hepatic and ocular toxicity hyperglycemia left ventricular dysfunction and fluidrelated event we also review the risk minimization approach to managing these toxicity a described in the product label and study protocol our general observation suggests that the selected toxicity of the approved adcs are primarily associated with offtarget effect of the drug payload we also observed that the risk minimization approach used to manage the selected toxicity are similar across product label and study protocol adcs provide a unique treatment approach that is currently focused on advanced or refractory cancer the risk minimization approach for the selected toxicity for the approved adcs per product label or the study protocol for those in clinical investigation are similar to those of standard chemotherapy agent and other pharmaceutical agent for the treatment of advanced malignancy these risk minimization measure align with standard medical practice and are likely familiar to and feasible for physician who prescribe for and to other healthcare practitioner who care for patient treated with adcs,"Antineoplastic Agents, Humans, Immunoconjugates, Neoplasms"
33987959,apatinib is an oral antiangiogenic drug it efficacy and prognosis in cervical carcinoma are unclear this study evaluates the effectiveness and prognostic factor of apatinib in the treatment of recurrent or advanced cervical carcinoma patient with recurrent or advanced cervical cancer who agreed to take apatinib were recruited into this singlecenter and retrospective study and administrated apatinib with or without combination of chemo or radiotherapy until progressive disease pd or unacceptable toxicity from march 2017 to february 53 patient were reviewed among them 2 patient occurred complete response 16 patient showed partial response 27 patient had stable disease and 8 patient had pd the objective response rate and disease control rate dcr of these patient were and respectively the dcr of patient younger than nonsquamous carcinoma firstline apatinib therapy combined radiotherapy lesion within radiation field surgical history and eastern cooperative oncology group ecog performance status score of 0 or 1 were significantly higher than other patient p the median progressionfree survival pfs and overall survival o were month 95 ci and month 95 ci respectively the univariable and multivariable analysis showed that the patient with an ecog performance status score of 2 and further line therapy were associated with poor prognosis in both pfs and o pfs hr p hr p o hr p hr p respectively the most common adverse effect aes were handfoot syndrome hypertension and fatigue no grade 3 aes and drugrelated death occurred the efficacy and prognosis of patient who are in good general condition and firstline apatinib combination therapy may be better than other patient but further phase iii clinical trial should be taken to prove this hypothesis,"Adenocarcinoma, Analysis of Variance, Angiogenesis Inhibitors, Antineoplastic Agents, Carcinoma, Squamous Cell, Combined Modality Therapy, Fatigue, Female, Hand-Foot Syndrome, Humans, Hypertension, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Progression-Free Survival, Pyridines, Treatment Outcome, Uterine Cervical Neoplasms"
33986267,a a potent lymphocyte activator interleukin2 il2 is an fdaapproved treatment for multiple metastatic cancer however it clinical use is limited by short halflife low potency and severe in vivo toxicity current il2 engineering strategy exhibit evidence of peripheral cytotoxicity here we address these issue by engineering an il2 prodrug proil2 we mask the activity of a cd8 t cellpreferential il2 muteinfc fusion protein with il2 receptor beta linked to a tumorassociated protease substrate proil2 restores activity after cleavage by tumorassociated enzyme and preferentially activates inside tumor where it expands antigenspecific cd8 t cell this significantly reduces il2 toxicity and mortality without compromising antitumor efficacy proil2 also overcomes resistance of cancer to immune checkpoint blockade lastly neoadjuvant proil2 treatment can eliminate metastatic cancer through an abscopal effect taken together our approach present an effective tumor targeting therapy with reduced toxicity,"Animals, Antineoplastic Agents, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Female, Humans, Immunotherapy, Interleukin-2, Lymphocyte Activation, Lymphotoxin-alpha, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Prodrugs, Recombinant Fusion Proteins, Recombinant Proteins"
33986125,sipuleucelt is a u food and drug administrationapproved autologous cellular immunotherapy that improves survival in patient with metastatic castrationresistant prostate cancer mcrpc we examined whether administering ipilimumab after sipuleucelt could modify immune andor clinical response to this treatment a total of 50 patient with mcrpc were enrolled into a clinical trial nct clinicaltrialsgov where they received ipilimumab either immediately or delayed 3 week following completion of sipuleucelt treatment blood wa collected at various timepoints of the study luminex assay for antiprostatic acid phosphatase pap and antipaspecific serum immunoglobulin g igg and elispot for interferon ifn production against pap and pa2024 were used to as antigenspecific b and t cell response respectively clinical response wa defined a 30 reduction in serum prostatespecific antigen level compared with pretreatment level the frequency and state of circulating immune cell were determined by mass cytometry by timeofflight and statistical scaffold analysis we found the combination to be well tolerated with no unexpected adverse event occurring the timing of ipilimumab did not significantly alter the rate of antigenspecific b and t cell response the primary endpoint of the clinical trial clinical response were observed in 6 of 50 patient with 3 having response lasting longer than 3 month the timing of ipilimumab did not significantly associate with clinical response or toxicity the combination treatment did induce cd4 and cd8 t cell activation that wa most pronounced with the immediate schedule lower frequency of ctla4 positive circulating t cell even prior to treatment were associated with better clinical outcome interestingly these difference in ctla4 expression were associated with prior localized radiation therapy rt to the prostate or prostatic fossa prior radiation treatment wa also associated with improved radiographic progressionfree survival combining ctla4 blockade with sipuleucelt resulted in modest clinical activity the timing of ctla4 blockade following sipuleucelt did not alter antigenspecific response clinical response were associated with both lower baseline frequency of ctla4 expressing t cell and a history of rt prior cancer therapy may therefore result in longlasting immune change that influence responsiveness to immunotherapy with sipuleucelt and antictla,"Aged, Biomarkers, Tumor, CTLA-4 Antigen, Cancer Vaccines, Cells, Cultured, Humans, Immune Checkpoint Inhibitors, Ipilimumab, Lymphocyte Activation, Lymphocytes, Tumor-Infiltrating, Male, Middle Aged, Prostatic Neoplasms, Castration-Resistant, Th1 Cells, Time Factors, Tissue Extracts, Treatment Outcome, Tumor Microenvironment"
33985455,pancreatic ductal adenocarcinoma pdac is still a highly fatal malignancy among the most common cancer more powerful treatment are expecting to bring hope for patient biweekly gemcitabinenabpaclitaxels1 gas wa proved safe and effective for patient with locally advanced pancreatic cancer in japan the objective of this study is to evaluate the feasibility and toxicity of gas repeated every 3 week in the treatment of locally advanced or advanced pancreatic cancer and determine the recommended dose of s1 in this combination this is an openlabel singlearm and singlecenter phase i trial patient who have been diagnosed with locally advanced or advanced pdac pathologically without previous systemic treatment will be enrolled and be treated with gas chemotherapy every 3 week nabpaclitaxel 125 mgm ivgtt day 8 gemcitabine 1000 mgm day 8 different do of s1 within a dose escalation scheme until the presence of disease progression pd intolerable adverse event aes or requirement of patient and researcher the primary endpoint are maximum tolerated dose mtd and doselimiting toxicity dlt the secondary endpoint include safety objective response rate orr progressionfree survival pfs and overall survival o this trial will adjust the administration of gas to make it more effective for chinese patient while exploring the toxicity and feasibility of this adjustment chictr chictr1900027833 registered 30 november,"Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Albumins, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Deoxycytidine, Drug Combinations, Gemcitabine, Oxonic Acid, Paclitaxel, Pancreatic Neoplasms, Tegafur, Clinical Trials, Phase I as Topic"
33985435,chemotherapyinduced neutropenia cin ha been demonstrated to be a prognostic factor in several cancer condition we previously found a significant prognostic value of cin on overall survival o in a pooled dataset of patient with advanced nonsmallcell lung cancer nsclc receiving first line chemotherapy from 1996 to however the prognostic role of cin in nsclc is still debated we performed a post hoc analysis pooling data prospectively collected in six randomized phase 3 trial in nsclc conducted from 2002 to patient who never started chemotherapy and those for whom toxicity data were missing were excluded neutropenia wa categorized on the basis of worst grade during chemotherapy absent grade 0 mild grade or severe grade the primary endpoint wa o multivariable cox model wa applied for statistical analysis in the primary analysis a minimum time landmark at 180 day from randomization wa applied in order to minimize the timedependent bias overall 1529 patient who received chemotherapy were eligible 572 of them who received 6 cycle of treatment represented the landmark population severe cin wa reported in 143 patient and mild cin in 135 at multivariable o analysis cin wa significantly predictive of prognosis although it prognostic value wa entirely driven by severe cin hazard ratio hr of death 95ci while it wa not evident with mild cin hr 95ci consistent result were observed in the outoflandmark group including 957 patient where both severe and mild cin were significantly associated with a reduced risk of death the pooled analysis of six large trial of nsclc treatment show that cin occurrence is significantly associated with a longer overall survival particularly in patient developing severe cin confirming our previous finding,"Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neutropenia, Prospective Studies, Randomized Controlled Trials as Topic, Retrospective Studies"
33983833,oncology ha seen growing use of newly developed targeted therapy although this ha resulted in dramatic improvement in progressionfree and overall survival challenge in the management of toxicity related to longerterm treatment of these therapy have also become evident although a targeted approach often exploit the difference between cancer cell and noncancer cell overlap in signaling pathway necessary for the maintenance of function and survival in multiple cell type ha resulted in systemic toxicity in particular cardiovascular toxicity are of important concern in this review we highlight several targeted therapy commonly used across a variety of cancer type including her2 human epidermal growth factor receptor 2 targeted therapy tyrosine kinase inhibitor immune checkpoint inhibitor proteasome inhibitor androgen deprivation therapy and mek mitogenactivated protein kinase kinasebraf vraf murine sarcoma viral oncogene homolog b inhibitor we present the oncological indication heart failure incidence hypothesized mechanism of cardiotoxicity and potential mechanistic rationale for specific cardioprotective strategy,"Androgen Antagonists, Anthracyclines, Antineoplastic Agents, Immunological, Cardiotonic Agents, Cardiotoxicity, Heart Failure, Humans, Immunotherapy, Incidence, Molecular Targeted Therapy, Neoplasms, Proteasome Inhibitors, Protein Kinase Inhibitors"
33983589,monitoring of patient and tumor during chemotherapy is important to determine whether the chemotherapy is effective to the patient variant affect drug enzyme activity and altered enzyme activity can be potential predictor for chemotherapeutic agent including cyclophosphamide and paclitaxel response to chemotherapy is primarily based on somatic mutation but germline variant may predict cancer cell sensitivity to chemotherapeutic agent furthermore patient genetic variation of immune system wa reported to be associated with drug response and toxicity recently the somaric and germilne genomic variation influence the pharmacokinetics of chemotherapy and these variation can be biomarkers for chemotherapy,"Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Humans, Paclitaxel"
33983395,older andor frail patient are underrepresented in landmark cancer trial tailored research is needed to address this evidence gap the go2 randomized clinical trial sought to optimize chemotherapy dosing in older andor frail patient with advanced gastroesophageal cancer and explored baseline geriatric assessment ga a a tool for treatment decisionmaking this multicenter noninferiority openlabel randomized trial took place at oncology clinic in the united kingdom with nurseled geriatric health assessment patient were recruited for whom fulldose combination chemotherapy wa considered unsuitable because of advanced age andor frailty there were 2 randomization that were performed chemointensity compared oxaliplatincapecitabine at level a oxaliplatin 130 mgm2 on day capecitabine 625 mgm2 twice daily on day on a day cycle level b do time a or level c do time a alternatively if the patient and clinician agreed the indication for chemotherapy wa uncertain the patient could instead enter chemobsc comparing level c v best supportive care first broad noninferiority of the lower do v reference level a wa assessed using a permissive boundary of 34 day reduction in progressionfree survival pfs hazard ratio hr selected a acceptable by a forum of patient and clinician then the patient experience wa compared using overall treatment utility otu which combine efficacy toxic effect quality of life and patient valueacceptability for chemobsc the main outcome measure wa overall survival a total of 514 patient entered chemointensity of whom 385 75 were men and 299 58 were severely frail with median age 76 year noninferior pfs wa confirmed for level b v a hr 95 ci and c v a hr 95 ci level c produced le toxic effect and better otu than a or b no subgroup benefited from higher do level c produced better otu even in younger or le frail patient a total of 45 patient entered the chemobsc randomization overall survival wa nonsignificantly longer with chemotherapy median v month hr 95 ci p 34 in multivariate analysis in 522 patient with all variable available baseline frailty quality of life and neutrophil to lymphocyte ratio were independently associated with otu and can be combined in a model to estimate the probability of different outcome this phase 3 randomized clinical trial found that reducedintensity chemotherapy provided a better patient experience without significantly compromising cancer control and should be considered for older andor frail patient baseline geriatric assessment can help predict the utility of chemotherapy but did not identify a group benefiting from higherdose treatment isrctnorg identifier isrctn,"Aged, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Frail Elderly, Humans, Male, Oxaliplatin, Quality of Life, Stomach Neoplasms"
33980886,glioblastoma gbm is an aggressive brain tumor with a strong tendency of relapse and resistance to chemotherapy but we currently lack nontoxic agent that effectively treat gbm in this study highthroughput screening of fdaapproved drug wa performed to identify safe and effective molecule and test their effect on gbm cell line ln u87 and t98g cough suppressant oxelaidin and butamirate inhibited gbm growth a ra family gtpase rasrelated associated with diabetes rrad contributes to activation of stat which is essential for survival and growth of many cancer type interestingly oxelaidin and butamirate did not affect proliferation in rrad negative gbm cell docking simulation analysis revealed selective interaction between oxelaidin and rrad the mechanism by which butamirate and oxelaidin inhibits gbm cell growth involves the suppression of stat3 transcriptional activity leading to downregulation of cyclin d1 and survivin in addition component of rradassociated signaling cascade including pegfr pakt and pstat were inhibited upon oxelaidin treatment intraperitoneal administration of oxelaidin or butamirate markedly suppressed tumor growth in a glioblastoma xenograft mouse model without significant adverse effect our collective finding indicate that oxelaidin and butamirate exert antitumor effect in glioblastoma supporting it utility a a novel therapeutic candidate for glioblastoma,"Animals, Antineoplastic Agents, Antitussive Agents, Apoptosis, Binding Sites, Cell Line, Tumor, Cell Proliferation, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Repositioning, Drug Screening Assays, Antitumor, ErbB Receptors, Gene Expression Regulation, Neoplastic, Glioma, Humans, Mice, Models, Molecular, Phenylbutyrates, Protein Binding, STAT3 Transcription Factor, Signal Transduction, Structure-Activity Relationship, Xenograft Model Antitumor Assays"
33980053,multiple myeloma is the second most common hematological malignancy ixazomib is the first oral proteasome inhibitor approved in the united state for the management of multiple myeloma who have received at least one prior treatment the availability of oral chemotherapeutic agent for the management of multiple myeloma ha made it easier for patient who do not have to come to the hospital for chemotherapy infusion however many barrier are associated with oral chemotherapy and one of them is a misinterpretation of instruction which can have deleterious effect in this case report we present a case of a yearold male with multiple myeloma who accidentally took ixazomib daily for 3 day instead of the weekly regimen and thus coming into the hospital with an overdose in this report we focus on the adverse effect associated with ixazomib toxicity and how to manage the adverse reaction although there is no antidote available for ixazomib supportive care is very essential in these patient,"Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Boron Compounds, Drug Overdose, Glycine, Humans, Male, Multiple Myeloma"
33979647,in woman globally breast cancer is responsible for most cancerrelated death and thus new effective therapeutic strategy are required to treat this malignancy platinumbased compound like cisplatin are widely used to treat breast cancer however they come with limitation such a poor solubility adverse effect and drug resistance to overcome these limitation complex containing other platinum group metal such a palladium have been studied and some have already entered clinical trial here we investigated the anticancer activity of a palladium complex btc in mcf7 oestrogen receptor positive er and mdamb231 triple negative tn human breast cancer cell a well a in a human breast cancer xenograft chick embryo model btc2 exhibited an average ic50 value of m a desirable selectivity index of inhibited the migration of er and tn breast cancer cell and displayed anticancer stem cell activity we demonstrate that btc2 induced dna double strand break increased level of h2ax and activated the patmpchk2 and ppmapk pathway resulting in s and gmphase cell cycle arrest importantly btc2 sensitised breast cancer cell by triggering the intrinsic cleaved caspase 9 and extrinsic cleaved caspase 8 apoptotic a well a necroptotic prip3 and pmlkl cell death pathway and inhibiting autophagy and it prosurvival role furthermore in the xenograft in vivo model btc2 displayed limited toxicity and arrested the tumour growth of breast cancer cell over a day period in a manner comparable to that of the positive control drug paclitaxel btc2 thus displayed promising antibreast cancer activity,"Animals, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Chick Embryo, Female, Humans, MCF-7 Cells, Neoplastic Stem Cells, Paclitaxel, Palladium, Xenograft Model Antitumor Assays"
33979489,hairycell leukemia hcl is a cd indolent bcell cancer in which a braf v600e kinaseactivating mutation play a pathogenetic role in clinical trial involving patient with refractory or relapsed hcl the targeting of braf v600e with the oral braf inhibitor vemurafenib led to a response in 91 of the patient 35 of the patient had a complete response however the median relapsefree survival wa only 9 month after treatment wa stopped in a phase singlecenter academic trial involving patient with refractory or relapsed hcl we assessed the safety and efficacy of vemurafenib 960 mg administered twice daily for 8 week plus concurrent and sequential rituximab 375 mg per square meter of bodysurface area administered for 8 do over a period of 18 week the primary end point wa a complete response at the end of planned treatment among the 30 enrolled patient with hcl the median number of previous therapy wa a complete response wa observed in 26 patient 87 in the intentiontotreat population all the patient who had hcl that had been refractory to chemotherapy 10 patient or rituximab 5 and all those who had previously been treated with braf inhibitor 7 had a complete response thrombocytopenia resolved after a median of 2 week and neutropenia after a median of 4 week of the 26 patient with a complete response 17 65 were cleared of minimal residual disease mrd progressionfree survival among all 30 patient wa 78 at a median followup of 37 month relapsefree survival among the 26 patient with a response wa 85 at a median followup of 34 month in post hoc analysis mrd negativity and no previous braf inhibitor treatment correlated with longer relapsefree survival toxic effect mostly of grade 1 or were those that had previously been noted for these agent in this small study a short chemotherapyfree nonmyelotoxic regimen of vemurafenib plus rituximab wa associated with a durable complete response in most patient with refractory or relapsed hcl funded by the european research council and others hclpg03 eudract number,"Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Leukemia, Hairy Cell, Male, Middle Aged, Neoplasm, Residual, Neutropenia, Progression-Free Survival, Recurrence, Remission Induction, Rituximab, Thrombocytopenia, Vemurafenib"
33977607,threemonth adjuvant capecitabine plus oxaliplatin in combination capox appeared to reduce recurrence with mild toxicity in postcurative resection of colorectal cancer liver metastasis clm recurrence in patient who underwent the month adjuvant capox after resection of clm wa most commonly at extrahepatic site the role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable colorectal cancer liver metastasis clm is still unclear we evaluated the feasibility of month adjuvant treatment with capecitabine plus oxaliplatin in combination capox for postcurative resection of clm patient received one cycle of capecitabine followed by four cycle of capox a adjuvant chemotherapy after curative resection of clm oral capecitabine wa given a mgm2 twice daily for 2 week in a week cycle and capox consisted of oral capecitabine plus oxaliplatin 130 mgm2 on day 1 in a week cycle primary endpoint wa the completion rate of adjuvant chemotherapy secondary endpoint included recurrencefree survival rf overall survival o dose intensity and safety twentyeight patient were enrolled median age wa year 54 of patient had synchronous metastasis and 29 were bilobar mean number of lesion resected wa two and mean size of the largest lesion wa 31 mm among patient 20 95 confidence interval completed the protocol treatment and met it primary endpoint the most common grade 3 or higher toxicity wa neutropenia 29 fiveyear recurrencefree survival and overall survival were and respectively threemonth adjuvant treatment with capox is tolerable and might be a promising strategy for postcurative resection of clm,"Aged, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Chemotherapy, Adjuvant, Colorectal Neoplasms, Fluorouracil, Hepatectomy, Humans, Liver Neoplasms, Neoplasm Recurrence, Local, Oxaliplatin"
33975561,folfirinox ffx and gemcitabine plus nabpaclitaxel gnp have been recommended a the firstline chemotherapy for metastatic pancreatic cancer mpc however the evidence is lacking comparing not only two regimen but also sequential treatment ffxgnp v gnpffx data of 528 patient ffx n 371 gnp n 157 with mpc were collected retrospectively propensity score matching wa conducted to alleviate imbalance of the two group overall survival o progression free survival pfs and toxicity of patient were analyzed in the whole population o month v month p and pfs month v month p were longer in the ffx group before matching and after matching o month v month p pfs month v month p for sequential treatment o and pfs showed no significant difference interruption of chemotherapy due to toxicity were more frequent v p in the gnp group and cessation of chemotherapy showed a significant association with mortality z p ffx achieved a longer overall survival than gnp in mpc but not in the comparison for sequential treatment more frequent adverse event followed by treatment interruption during gnp might lead to a poor survival outcome therefore ffx would be a better firstline treatment option than gnp for mpc,"Aged, Albumins, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Fluorouracil, Humans, Irinotecan, Leucovorin, Male, Middle Aged, Neoplasm Metastasis, Oxaliplatin, Paclitaxel, Pancreatic Neoplasms, Propensity Score, Gemcitabine"
33974471,oxaliplatin resistance is one of the main cause of failed colorectal cancer treatment followed by recurrence and metastasis in this study we found that colorectal cancer cell secrete a high level of hyaluronic acid ha which interacts with it receptor cd44v6 to mediate colorectal cancer resistance to chemotherapy ha oligosaccharide oha is a degradation product of ha we found that it competitively bind to cd44v reversing the hacd44vmediated effect of ha on oxaliplatin resistance in addition oha showed no toxicity or immunogenicity but exhibited good biocompatibility and tumortargeting capability therefore we synthesized ohaloaded oxaliplatin liposome nanoparticles ohalipidoxa using a thinfilm hydration method the cytotoxicity of ohalipidoxa wa assessed in vitro using flow cytometry which revealed greater lethality than oxaliplatin alone finally we established a tumorbearing nude mouse model and separately injected ohalipidoxa lipidoxa oxa oha and phosphatebuffered saline pb into the tail vein to observe the antitumor effect of nanoparticles in vivo the ohalipidoxa group exhibited the highest tumor suppression rate but the weight loss wa not obvious hematoxylin and eosin staining showed greatest lymphocyte and macrophage infiltration in the ohalipidoxa group moreover ohalipidoxa induced tumor cell apoptosis and necrosis most robustly compared with the other group we showed that ohalipidoxa ha excellent histocompatibility and cd44vtargeting capability thus greatly increasing the sensitivity to oxaliplatin and reducing adverse reaction accordingly ohalipidoxa ha a broad potential for therapeutic application,"Animals, Apoptosis, Cell Line, Tumor, Cell Survival, Chemistry, Pharmaceutical, Colorectal Neoplasms, Drug Carriers, Humans, Hyaluronan Receptors, Hyaluronic Acid, Liposomes, Male, Mice, Mice, Nude, Nanoparticles, Oligosaccharides, Oxaliplatin, Tumor Burden"
33974005,androgen deprivation therapy adt is one of the typical treatment used for patient with prostate cancer pca adt however may fail when pca develops castrationresistance fatty acid synthase fasn a critical enzyme involved in fatty acid synthesis is found to be upregulated in pca since enzalutamide and adt are frequently used for the treatment of pca the present study aimed to unravel the underlying mechanism of combination of orlistat an fasn inhibitor and enzalutamide using pc3 cell line and orlistat and castration in pc3 tumorbearing animal model cytotoxicity wa determined by alamarblue assay drug effect on the cell cycle and protein expression were assayed by the flow cytometry and western blot electromobility shift assay wa used to evaluate the nfb activity the tumor growth delay expression of the signalingrelated protein and histopathology post treatment of orlistat and castration were evaluated in pc3 tumorbearing mouse model the result showed that orlistat arrested the pc3 cell at the g1 phase of the cell cycle and enhanced the cytotoxic effect of enzalutamide synergistically pretreatment with orlistat combined with castration inhibited the tumor growth significantly compared with those of castration and orlistat treatment alone in pc3 tumorbearing mouse combination treatment reduced both fasn and nfb activity and their downstream effector protein the present study demonstrated the synergistic effect of orlistat combined with enzalutamide in vitro and castration in vivo on human pca,"Animals, Antineoplastic Agents, Benzamides, Cell Cycle, Enzyme Inhibitors, Fatty Acid Synthase, Type I, Humans, Male, Mice, Mice, Nude, NF-kappa B, Nitriles, Orchiectomy, Orlistat, PC-3 Cells, Phenylthiohydantoin, Prostatic Neoplasms"
33973307,on march the u food and drug administration fda granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of patient with hepatocellular carcinoma hcc previously treated with sorafenib the recommended approved dosage wa nivolumab 1 mgkg iv plus ipilimumab 3 mgkg iv every 3 week for four cycle followed by nivolumab 240 mg iv every 2 week the approval wa based on data from cohort 4 of checkmate which randomized patient with advanced unresectable or metastatic hcc previously treated with or who were intolerant to sorafenib to receive one of three different dosing regimen of nivolumab in combination with ipilimumab investigatorassessed overall response rate orr wa the primary endpoint and orr assessed by blinded independent central review bicr wa an exploratory endpoint bicrassessed orr and duration of response dor form the primary basis of the fda regulatory decision and bicrassessed orr wa comparable in all three arm at 3132 with 95 confidence interval ci 1847 the dor ranged from to month across the three arm with overlapping 95 ci adverse event aes were generally consistent with the known ae profile of nivolumab and ipilimumab and no new safety event were identified this article summarizes the fda review of the data supporting the approval of nivolumab and ipilimumab for the treatment of hcc implication for practice nivolumab and ipilimumab combination therapy is another option for patient with advanced hepatocellular carcinoma who experience radiographic progression during or after sorafenib or sorafenib intolerance no new toxicity were identified but a expected increased toxicity wa observed with the addition of ipilimumab to nivolumab a compared with nivolumab alone which is also approved for the same indication whether to administer nivolumab a a single agent or in combination with ipilimumab is expected to be a joint decision between the oncologist and patient taking into consideration the potential for a higher likelihood of response and the potentially higher rate of toxicity with the combination,"Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Humans, Ipilimumab, Liver Neoplasms, Nivolumab, Sorafenib, United States, United States Food and Drug Administration"
33973301,chemotherapyinduced toxicity lead to therapy dose reduction or delay affecting patient outcome this systematic review and metaanalysis evaluated the impact of relative dose intensity rdi on survival in adult patient with solid tumor cancer on nonadjuvantbased chemotherapy regimen pubmed embase and web of science database were searched for peerreviewed english journal article or congress abstract evaluating association between rdi and survival observational study case series of 20 patient and clinical trial published between 2013 and 2020 were eligible metaanalyses were conducted to quantify the association between rdi level and overall survival o among study reporting a hazard ratio hr for o by similar tumor type regimen and rdi forest plot represented summary hr and 95 confidence interval ci cochran q and i2 test evaluated study heterogeneity overall 919 article were reviewed and 22 included seven were eligible for metaanalysis significantly shorter o at rdi 80 versus 80 and 85 versus 85 wa observed upon metaanalysis of four carboplatinbased study for breast nonsmall cell lung or ovarian cancer hr 95 ci and three folfox folfiri or folfirinoxbased study for colorectal or pancreatic cancer hr 95 ci grade 3 or higher hematologic toxicity were higher for carboplatinbased regimen thrombocytopenia 1422 anemia 1519 neutropenia 2458 than folfox folfiri or folfirinoxbased regimen thrombocytopenia 14 anemia 519 neutropenia 1947 the result suggested longer o with rdi 80 or 85 for both regimen indicating that management of toxicity across treatment modality may contribute to maintenance of higher rdi and benefit survival for patient with advanced solid tumor chemotherapyinduced toxicity lead to dose reduction andor treatment delay thus affecting patient outcome result of this systematic review and metaanalysis evaluating the impact of relative dose intensity rdi on survival of patient with solid tumor on nonadjuvantbased chemotherapy regimen demonstrate a longer overall survival with rdi level of at least 80 for patient with solid tumor on carboplatinbased and folfox folfiri or folfirinoxbased chemotherapy regimen suggesting a protective effect of maintaining rdi 80 or 85 although grade 3 or higher hematologic toxicity occurred more in carboplatinbased study managing toxicity across treatment regimen may contribute to maintenance of higher rdi and ultimately benefit overall survival,"Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Humans, Pancreatic Neoplasms"
33973081,to understand the extent to which metastatic colorectal cancer mcrc patient receive education on the prevention and management associated with skin rash following vectibix treatment furthermore to investigate how this adverse event affect a patient quality of life qol and influence their treatment decision a crosssectional survey wa administered to 200 mcrc patient 100 vectibix user and 100 vectibix nonusers after excluding respondent who had used cetuximab 61 vectibix user and 56 vectibix nonusers remained most vectibix user 79 experienced a skin rash in response to treatment of which 65 considered the rash moderate 27 mild and 8 severe vectibix user generally felt they were adequately informed about the rash 83 with the most common message received related to sun protection however sunscreen wa used by only 42 of patient prior to rash and 60 of patient following the appearance of rash the use of oral antibiotic wa low prior to rash 21 and following rash 46 among patient experiencing a rash within the past week n16 75 reported the rash had a large negative impact on their qol based on the dermatology life quality index there wa a disconnect between patient feeling they were adequately informed and use of prevention and management strategy such a sun protection this suggests a gap in patient education and adoption currently exists on management strategy both prior to and following the appearance of rash given the negative impact that skin toxicity ha on the patient quality of life it is essential that patient receive and subsequently utilize all information that can minimize rash severity,"Antineoplastic Agents, Cetuximab, Colorectal Neoplasms, Cross-Sectional Studies, ErbB Receptors, Exanthema, Humans, Panitumumab, Quality of Life, Surveys and Questionnaires, United States"
33972742,this openlabel phase 1b2 study evaluated the highly selective met inhibitor tepotinib in systemic anticancer treatment sactnaive asian patient with advanced hepatocellular carcinoma ahcc with met overexpression in phase 2b tepotinib wa orally administered once daily 500 or mg to asian adult with ahcc the primary endpoint were doselimiting toxicity dlts and adverse event aes phase 2 randomised sactnaive asian adult with ahcc with met overexpression to tepotinib recommended phase 2 dose rp2d or sorafenib 400 mg twice daily the primary endpoint wa independently assessed time to progression ttp in phase 1b n 27 no dlts occurred the rp2d wa 500 mg in phase 2 n 45 patient per arm the primary endpoint wa met independently assessed ttp wa significantly longer with tepotinib versus sorafenib median versus month hr 90 confidence interval p progressionfree survival and objective response also favoured tepotinib treatmentrelated grade 3 ae rate were with tepotinib and with sorafenib tepotinib improved ttp versus sorafenib and wa generally well tolerated in sactnaive asian patient with ahcc with met overexpression clinicaltrialsgov nct,"Administration, Oral, Adult, Aged, Asian People, Carcinoma, Hepatocellular, Drug Administration Schedule, Female, Humans, Liver Neoplasms, Male, Middle Aged, Piperidines, Proto-Oncogene Proteins c-met, Pyridazines, Pyrimidines, Sorafenib, Survival Analysis, Treatment Outcome, Up-Regulation"
33972235,current melphalanbased intravitreal regimen for retinoblastoma rb vitreous seed cause retinal toxicity we assessed the efficacy and toxicity of topotecan monotherapy compared with melphalan in our rabbit model and patient cohort rabbit experiment empiric pharmacokinetics were determined following topotecan injection for topotecan 15 g or 30 g melphalan g or saline toxicity wa evaluated by serial electroretinography erg and histopathology and efficacy against vitreous seed xenograft wa measured by tumour cell reduction and apoptosis induction retrospective cohort study of 235 patient receiving 990 intravitreal injection of topotecan or melphalan intravitreal topotecan 30 g equal 60 g in human achieved the ic90 across the rabbit vitreous three weekly topotecan injection either 15 g or 30 g caused no retinal toxicity in rabbit whereas melphalan g equal 25 g in human reduced erg amplitude 4279 intravitreal topotecan 15 g wa equally effective to melphalan to treat werirb1 cell xenograft in rabbit 96 reduction for topotecan v saline p 88 reduction for melphalan v saline p topotecan v melphalan p in our clinical study patient received 881 monotherapy injection 48 topotecan 833 melphalan patient receiving 20 g or 30 g topotecan demonstrated no significant erg reduction melphalan caused erg reduction of v for every injection of 25 g p or 30 g p most patient treated with intravitreal topotecan also received intravitreal melphalan at some point during their treatment course among those eye treated exclusively with topotecan monotherapy all eye were salvaged taken together these experiment suggest that intravitreal topotecan monotherapy for the treatment of rb vitreous seed is nontoxic and effective,"Animals, Antineoplastic Agents, Alkylating, Humans, Intravitreal Injections, Melphalan, Neoplasm Seeding, Rabbits, Retinal Neoplasms, Retinoblastoma, Retrospective Studies, Topotecan, Vitreous Body"
33971834,oxaliplatinbased therapy with folfox4 or capox administered over 6 month remains the standard adjuvant treatment for stage iii colon cancer cc patient however many patient experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity which may increase the risk of early recurrence the objective of this study wa to analyze the relationship between the relative dose intensity of oxaliplatin rdio and early recurrence among stage iii cc patient the study included 365 patient treated at five oncology center in poland between 2000 and survival analysis wa performed using the kaplanmeier method univariate analysis wa performed using the cox proportional hazard model multivariate analysis wa performed with the stepwise forward approach for all analysis the level of wa employed the median followup wa month range early recurrence 36 month after surgery occurred in 130 patient in this group 51 and 87 of patient were low and highrisk respectively receipt 60 of rdio wa associated with early recurrence within 18 month after surgery or 95ci p especially in lowrisk group hr 95ci p in the multivariate analysis early recurrence wa correlated with grade or 95 ci p pn or 95 ci p the number of lymph node harvested or 95 ci p and rdio or 95ci p the early v late recurrence negatively correlated with o regardless of the rdio hr 95ci p rdio 60 in adjuvant therapy among stage iii cc especially in lowrisk group increase the risk of early recurrence within 18 month of surgery patient with early recurrence showed worse overall survival regardless of the rdio,"Adult, Aged, Aged, 80 and over, Chemotherapy, Adjuvant, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Oxaliplatin, Retrospective Studies"
33971386,neratinib is approved in the european union for extended adjuvant treatment of human epidermal growth factor receptor positivehormone receptorpositive copositive early breast cancer 1 year of completion of prior trastuzumabbased therapy here we report analysis of the hormone receptorpositive subgroup n 1631 from the extenet trial performed for the german health technology assessment hta with 2 year of median followup hta analysis revealed a significant advantage in diseasefree survival dfs for neratinib v placebo absoluterelative risk reduction hazard ratio hr 95 confidence interval ci p consistent with distant dfs absoluterelative risk reduction hr 95 ci p the year followup confirmed this outcomequality of life analysis did not show clinically relevant difference over all time point only at month the functional assessment of cancer therapy general total score revealed a statistically relevant difference to the disadvantage of neratinib classified a clinically relevant the tolerability profile of neratinib wa dominated by gastrointestinal event mainly diarrhoea all grade grade iii no systematic antidiarrhoeal prophylaxis nausea all gradesgrade iii vomiting abdominal pain fatigue and rash no cumulative or irreversible toxicity were observed a shown in the control study and instituted via a risk management plan diarrhoea management can reduce frequency cumulative duration and severity of diarrhoea extended adjuvant neratinib provides a clinically relevant benefit with further incremental reduction of relapse risk in the curative setting accordingly the german hta authority ha granted an added benefit for this new treatment option,"Adult, Aged, Aged, 80 and over, Antidiarrheals, Antineoplastic Agents, Breast Neoplasms, Chemotherapy, Adjuvant, Clinical Trials, Phase III as Topic, Diarrhea, Disease-Free Survival, Drug Administration Schedule, Female, Germany, Humans, Middle Aged, Protein Kinase Inhibitors, Quality of Life, Quinolines, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Technology Assessment, Biomedical, Time Factors, Young Adult"
33969772,immune checkpoint inhibitor icis are an emerging treatment in cancer therapy for prolonging life minimizing symptom and selectively targeting cancer program death 1 pd1 inhibitor such a nivolumab fall within this class enabling the patient immune system to detect and destroy cancer the introduction of icis is changing cancer therapy with new drug and new toxicitiesan evolving area encountered by pharmacist this study aim to compare the pattern of nivolumabinduced adverse event observed in practice when compared with clinical trial and literature data the secondary aim of the study is to identify the presentation and treatment modality initiated in practice we performed a retrospective case note review across 2 south australian hospital to identify the common toxicity and symptomatic treatment experienced by patient receiving nivolumab result were compared with clinical trial data from product innovator bristolmyer squib and other published literature seventy patient were included in the study of these 60 86 experienced any grade adverse event a total of 59 84 of 70 experienced mild to moderate grade 1 to grade 2 adverse event and 10 14 of 70 patient experienced severe grade 3 to grade 4 adverse event displaying some consistency with clinical trial and published literature data together the prevalence of adverse event with detail on presentation and treatment illustrates possible pharmacy practice strategy and area for intervention the listed prevalence of adverse event and practice strategy identified throughout this study highlight how pharmacist may assist in the identification of predictable ici toxicity associated with gastrointestinal endocrine dermatological toxicity and fatigue,"Australia, Humans, Immunotherapy, Neoplasms, Nivolumab, Pharmacists, Retrospective Studies"
33969525,the combined treatment with multiple drug are very common in the contemporary medicine especially for medical oncology therefore we developed a bayesian adaptive phase i clinical trial design entitled escalation with overdoing control using normalized equivalent toxicity score for estimating maximum tolerated dose mtd contour of two drug combination ewocnetscom used for oncology trial the normalized equivalent toxicity score net a the primary endpoint of clinical trial is assumed to follow quasibernoulli distribution and treated a quasicontinuous random variable in the logistic linear regression model which is used to describe the relationship between the do of the two agent and the toxicity response four parameter in the dosetoxicity model were reparameterized to parameter with explicit clinical meaning to describe the association between net and do of two agent noninformative prior were used and markov chain monte carlo wa employed to update the posterior of the four parameter in dosetoxicity model extensive simulation were conducted to evaluate the safety trial efficiency and mtd estimation accuracy of ewocnetscom under different scenario using the ewoc a reference the result demonstrated that ewocnetscom not only efficiently estimate mtd contour of multiple drug but also provides better trial efficiency by fully utilizing all toxicity information,"Antineoplastic Agents, Bayes Theorem, Clinical Trials as Topic, Computer Simulation, Dose-Response Relationship, Drug, Drug Combinations, Humans, Maximum Tolerated Dose, Neoplasms, Research Design"
33967202,platinum doublet is the standard chemotherapy regimen for unresectable nonsmallcell lung cancer nsclc without a driver mutation however for squamous cell lung cancer the most effective cytotoxic regimen is not yet established combination therapy of gemcitabine with a platinum agent is a highly effective treatment among the platinum doublet regimen and is promising a a treatment for advanced squamous cell lung carcinoma in this study we prospectively evaluated the efficacy of gemcitabine platinum combination therapy followed by maintenance gemcitabine monotherapy in untreated advanced squamous cell lung cancer patient with squamous cell lung cancer received four cycle of gemcitabine platinum combination therapy every 3 or 4 week after the induction therapy gemcitabine maintenance therapy wa administered every 3 or 4 week until disease progression or unacceptable toxicity of 18 patient enrolled the median progressionfree survival wa month only six patient received maintenance chemotherapy with gemcitabine the median survival time of all enrolled patient wa month cytopenia of any grade occurred in at least 70 of the enrolled patient however severe adverse event were observed in only a few case gemcitabine maintenance therapy after gemcitabine plus platinum agent is a suggested treatment for unresectable squamous cell lung cancer while the overall toxicity profile of this therapy is acceptable attention should be paid to bone marrow suppression,"Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cisplatin, Deoxycytidine, Drug Administration Schedule, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Progression-Free Survival, Gemcitabine"
33966624,the design of anticancer therapy with high antitumour efficacy and reduced toxicity continues to be challenging anticancer prodrug and antibodydrugconjugate adc strategy that can specifically and efficiently deliver cytotoxic compound to cancer cell have been used to overcome some of the challenge the key to the success of many of these strategy is a selfimmolative linker which after activation can release the drug payload various type of triggerable selfimmolative linkers are used in prodrugs and adcs to improve their efficacy and safety numerous patent have reported the significance of selfimmolative linkers in prodrugs and adcs in cancer treatment based on the recent patent literature we summarise method for designing the sitespecific activation of nontoxic prodrugs and adcs in order to improve selectivity for killing cancer cell in this review an integrated view of the potential use of prodrugs and adcs in cancer treatment are provided this review present recent patent and related publication over the past ten year uptill the recent patent literature ha been summarised for a wide variety of selfimmolative pabc linkers which are cleaved by factor including responding to the difference between the extracellular and intracellular environment ph ro glutathione through overexpressed enzyme cathepsin plasmin glucuronidase or bioorthogonal activation the mechanism for selfimmolation involves the linker undergoing a or elimination via electron cascade or intramolecular cyclisation to release cytotoxic drug at the targeted site this review provides the commonly used strategy from recent patent literature in the development of prodrugs based on targeted cancer therapy and antibodydrug conjugate which show promise in therapeutic application,"Antineoplastic Agents, Cell Line, Tumor, Drug Delivery Systems, Drug Design, Drug Liberation, Humans, Immunoconjugates, Neoplasms, Patents as Topic, Prodrugs"
33965731,human thymidine phosphorylase htp is overexpressed in several solid tumor and is commonly associated with aggressiveness and unfavorable prognosis dihydroxypropanylaminomethyliodopyrimidine1h3hdione cpbmf223 is a noncompetitive htp inhibitor which ha been described a a tumor angiogenesis inhibitor the present study investigated the effect of cpbmf223 in a xenograft tumor induced by human colorectal carcinoma cell hct116 additionally cpbmf223 capacity to reduce cell migration it toxicological profile and pharmacokinetic characteristic were also evaluated the intraperitoneal treatment with cpbmf223 markedly prevented the relative tumor growth with an efficacy similar to that observed for fluorouracil interestingly number of vessel were significantly decreased in the treated group moreover cpbmf223 significantly reduced the migration of cell line hct in the ames assay and in an acute oral toxicity test the molecule did not alter any evaluated parameter using the zebrafish toxicity model cardiac and locomotor parameter were slightly changed regarding the pharmacokinetics profile cpbmf223 showed clearance of lhkg after intravenous administration oral bioavailability of and a halflife of h our finding shed new light on the role of htp in colorectal cancer induced by hct116 cell in mouse pointing out cpbmf223 a hopefully a promising drug candidate,"Angiogenesis Inhibitors, Animals, Antimetabolites, Antineoplastic, Antineoplastic Agents, Cell Line, Tumor, Colorectal Neoplasms, Enzyme Inhibitors, Female, Fluorouracil, HCT116 Cells, Half-Life, Humans, Male, Mice, Mice, Inbred BALB C, Mutagenicity Tests, Thymidine Phosphorylase, Xenograft Model Antitumor Assays, Zebrafish"
33964572,combined mtorc1 inhibition with everolimus eve and phosphatidylinositol kinase catalytic subunit p110 blockade with alpelisib alp ha demonstrated synergistic efficacy in preclinical model and support testing the combination of alp and eve in the clinical setting the primary objective wa to determine the maximum tolerated dose mtdrecommended dose for expansion rde of alp in combination with eve and in combination with eve and exemestane exe and subsequently as safety preliminary efficacy and effect of alp on the pharmacokinetics of eve and determine the magnitude of the drugdrug interaction dose escalation phase were conducted in patient with advanced solid tumour and in postmenopausal woman with hormone receptorpositive hr human epidermal growth factor receptor negative her advanced breast cancer abc the dose expansion phase wa conducted in patient with pancreatic neuroendocrine tumour and renal cell carcinoma rcc both mechanistic target of rapamycin inhibitor mtorinaive in patient with mtoripretreated solid tumour and in postmenopausal woman with hr her abc during the doublet escalation phase doselimiting toxicity dlts were reported in 5 of 10 50 patient one patient had grade gr 2 hyperglycemia and one patient had gr 3 diarrhoea in the 300 mg dose group one patient had gr 2 hyperglycemia and one patient had gr 4 hypocalcaemia in the 250 mg dose group and one patient in the 200 mg dose group had gr 3 diarrhoea and gr 3 stomatitis the combination of alp 250 mg eve mg wa declared a the mtdrde in subject with advanced solid tumour in the triplet escalation phase one patient who received alp 200 mg eve mg exe 25 mg had a dlt of gr 3 acute kidney injury this dose combination wa declared a the mtd and rde in subject with advanced hrpositive hernegative bc the common adverse event 30 patient occurring across all phase were hyperglycaemia stomatitis diarrhoea nausea asthenia decreased appetite and fatigue the sixteenweek progressionfree survival rate wa 90 confidence interval ci in the rcc cohort 90 ci in the prior pnet cohort and 90 ci in the prior mtori cohort the pharmacokinetics of mg of eve wa largely unchanged in the presence of alp independent of the dose 250 mg or 300 mg there were no clinically relevant drugdrug interaction observed between alp and eve the overall safety profile of alp with eve and exe is manageable and reversible no unexpected safety signal were noted compared with the individual safety profile pharmacokinetics of alp eve and exe wa largely unchanged in combination with each other,"Adult, Aged, Aged, 80 and over, Androstadienes, Antineoplastic Combined Chemotherapy Protocols, Drug Interactions, Europe, Everolimus, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Thiazoles, Treatment Outcome, United States"
33963013,synovial sarcoma s and myxoidround cell liposarcoma mrcl are ideal solid tumor for the development of adoptive cellular therapy act targeting nyeso a a high frequency of tumor homogeneously express this cancertestes antigen data from early phase clinical trial have shown antitumor activity after the adoptive transfer of nyesospecific t cell in these study persistence of nyeso1 specific t cell is highly correlated with response to act but patient often continue to have detectable transferred cell in their peripheral blood following progression we performed a phase i clinical trial evaluating the safety of nyesospecific endogenous t cell etc following cyclophosphamide conditioning peripheral blood mononuclear cell pbmcs from treated patient were evaluated by flow cytometry and gene expression analysis a well a through ex vivo culture assay with and without il four patient were treated in a cohort using etc targeting nyeso1 following cyclophosphamide conditioning treatment wa well tolerated without significant toxicity but all patient ultimately had disease progression in two of four patient we obtained posttreatment tumor tissue and in both nyeso1 antigen wa retained despite clear detectable persisting nyesospecific t cell in the peripheral blood despite a memory phenotype these persisting cell lacked marker of proliferation or activation however in ex vivo culture assay they could be induced to proliferate and kill tumor using il these result were also seen in pbmcs from two patient who received geneengineered tcell receptorbased product at other center etc targeting nyeso1 with singleagent cyclophosphamide alone conditioning wa well tolerated in patient with s and those with mrcl il15 can induce proliferation and activity in persisting nyesospecific t cell even in patient with disease progression following act these result support future work evaluating whether il15 could be incorporated into act trial postinfusion or at the time of progression,"Adult, Antigens, Neoplasm, Cell Line, Tumor, Cell Proliferation, Coculture Techniques, Cyclophosphamide, Cytotoxicity, Immunologic, Humans, Immunologic Memory, Immunotherapy, Adoptive, Interleukin-15, Liposarcoma, Myxoid, Lymphocyte Activation, Membrane Proteins, Memory T Cells, Middle Aged, Myeloablative Agonists, Pilot Projects, Sarcoma, Synovial, Time Factors, Transplantation Conditioning, Treatment Outcome, Tumor Microenvironment"
33963010,clinical trial of immunotherapy have excluded patient with preexisting autoimmune disease while the safety and efficacy of single agent ipilimumab and antipd1 antibody in patient with autoimmune disease ha been examined in retrospective study no data are available for combination therapy which ha significantly higher toxicity risk we sought to establish the safety and efficacy of combination immunotherapy for patient with advanced melanoma and preexisting autoimmune disease we performed a retrospective study of patient with advanced melanoma and preexisting autoimmune disease who received combination ipilimumab and antipd1 at 10 international center from march 2015 to february data regarding the autoimmune disease treatment toxicity and outcome were examined in patient of the 55 patient who received ipilimumab and antipd the median age wa 63 year range fortysix were treated with ipilimumab and nivolumab and nine with ipilimumab and pembrolizumabeighteen patient 33 had a flare of their autoimmune disease including 4 of 7 with rheumatoid arthritis 3 of 6 with psoriasis 5 of 10 with inflammatory bowel disease 3 of 19 with thyroiditis 1 of 1 with sjogrens syndrome 1 of 1 with polymyalgia and 1 of 1 with behcets syndrome and psoriasis eight 44 patient ceased combination therapy due to flare thirtyseven patient 67 had an unrelated immunerelated adverse event irae and 20 36 ceased combination immunotherapy due to iraes there were no treatmentrelated death patient on immunosuppression or p had a higher risk of flarethe overall response rate wa 55 with 77 of response ongoing median progression free survival and overall survival were 10 and 24 month respectively patient on baseline immunosuppression had an overall survival of 11 month 95 ci to compared with 31 month without 95 ci to p in patient with preexisting autoimmune disease not on immunosuppression and advanced melanoma combination ipilimumab and antipd1 ha similar efficacy compared with previously reported trial there is a risk of flare of preexisting autoimmune disorder particularly in patient with inflammatory bowel disease and rheumatologic condition and patient on baseline immunosuppression,"Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Autoimmune Diseases, Autoimmunity, CTLA-4 Antigen, Female, Humans, Immune Checkpoint Inhibitors, Immunosuppressive Agents, Ipilimumab, Male, Melanoma, Middle Aged, Nivolumab, Programmed Cell Death 1 Receptor, Progression-Free Survival, Retrospective Studies, Skin Neoplasms, Time Factors, Young Adult"
33962475,adrenocortical carcinoma acc is a rare and aggressive malignancy for stage i and ii tumor surgery is a curative option but even in these case recurrence is frequent practical guideline advocate a combination of mitotane with etoposide doxorubicin and cisplatin a firstline therapy for metastatic adrenocortical carcinoma however this scheme present limited efficacy and high toxicity the use of immune checkpoint inhibitor ici and multityrosine kinase inhibitor mtki ha modified the approach of multiple malignancy the expectation of their applicability on advanced adrenocortical carcinoma is high but the role of these new therapy persists unclear this article provides a short summary of last year finding targeting outcome limitation and adverse effect of these new therapeutic approach the result of recent trial and case series pointed pembrolizumab a the most promising drug among these new therapy it is the most often used ici and the one presenting the best result with le related adverse effect when in comparison to the standard treatment with mitotane hereafter the identification of specific molecular biomarkers or immune profile associated with ici or mtki good response will facilitate the selection of candidate for these therapy so far microsatellite instability and lynch syndrome related germline mutation are suggested a predictive biomarkers of good response contrarywise cortisol secretion ha been associated with more aggressive acc tumor and potentially poor response to immunotherapy,"Adrenal Cortex Neoplasms, Adrenocortical Carcinoma, Animals, Drug Therapy, Combination, Humans, Immune Checkpoint Inhibitors, Protein Kinase Inhibitors"
33961292,older patient with acute myeloid leukaemia aml account for nearly half of those with the disease because they are perceived to be unfit for unwilling to receive or unlikely to benefit from conventional chemotherapy they represent an important unmet need tosedostat is a selective oral aminopeptidase inhibitor which in phase iii trial showed acceptable toxicity and encouraging efficacy we report the only randomised study of lowdose cytosine arabinoside ldac combined with tosedostat ldact versus ldac in untreated older patient not suitable for intensive treatment a total of 243 patient were randomised 11 a part of the pickawinner li1 trial there wa a statistically nonsignificant increase in the complete remission cr rate with the addition of tosedostat ldact 19 versus ldac 12 odds ratio or 0 95 confidence interval ci 023 p 017 for overall response crcr with incomplete recovery of count there wa little evidence of a benefit to the addition of tosedostat 25 v 18 or 0 95 ci 027 p 022 however overall survival o showed no difference year o 16 v 12 hazard ratio 0 95 ci 028 p 08 exploratory analysis failed to identify any subgroup benefitting from tosedostat despite promising preclinical early nonrandomised clinical data with acceptable toxicity and an improvement in response we did not find evidence that the addition of tosedostat to ldac produced a survival benefit in this group of patient with aml international standard randomised controlled trial number isrctn,"Age Factors, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Enzyme Inhibitors, Female, Glycine, Humans, Hydroxamic Acids, Leukemia, Myeloid, Acute, Male, Middle Aged, Survival Analysis"
33961140,in this review we summarize the major known cardiac toxicity of common chemotherapeutic agent and the role of nuclear cardiac imaging for the surveillance and assessment of cancer therapeuticsrelated cardiac dysfunction in routine clinical practice cardiotoxicity from chemotherapy cause a significant mortality and limit potentially lifesaving treatment in cancer patient close monitoring of cardiac function during chemotherapy is an accepted method for reducing these adverse effect especially in patient with cancer therapeuticsrelated cardiac dysfunction nuclear imaging is a sensitive specific and highly reproducible modality for assessment of cardiac function nuclear imaging technique including equilibrium radio nucleotide angiography myocardial perfusion imaging and novel experimental molecular imaging are the various objective tool available in addition to conventional echocardiography and cardiac magnetic resonance imaging in the surveillance assessment and followup of cancer therapeuticsrelated cardiac dysfunction,"Antineoplastic Agents, Cardiotoxicity, Echocardiography, Heart Diseases, Humans, Neoplasms"
33961019,we present the result of a phase 2 study evaluating the combination of obinutuzumab idelalisib in relapsedrefractory rr waldenstrm macroglobulinemia wm the goal wa to determine the safety and efficacy of a fixedduration chemotherapyfree treatment during the induction phase patient received idelalisib obinutuzumab for 6 cycle followed by a maintenance phase with idelalisib alone for 2 year fortyeight patient with rr wm were treated with the induction combination and 27 patient participated in the maintenance phase the best response reached after a median of month interquartile range range month were very good partial response in 5 patient partial response in 27 patient and minor response in 3 patient leading to overall response rate and major response rate estimate of 95 confidence interval ci and 95 ci respectively with a median followup of month median progressionfree survival wa month 95 ci univariate analysis focusing on molecular screening found no significant impact of cxcr4 genotype on response and survival but a deleterious impact of tp53 mutation on survival although there wa no grade 5 toxicity 26 patient were removed from the study because of side effect the most frequent were neutropenia diarrhea and liver toxicity the combination of idelalisib obinutuzumab is effective in rr wm nonetheless the apparent lack of impact of genotype on outcome could give new meaning to targeting of the phosphatidylinositol kinase pathway in wm this trial wa registered at a nct,"Antibodies, Monoclonal, Humanized, Humans, Neoplasm Recurrence, Local, Purines, Quinazolinones, Waldenstrom Macroglobulinemia"
33960681,a with other alkylating agent cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcoma sts or recurrent ovarian cancer roc where treatment option for advanced disease are still limited cardiac safety for trabectedin monotherapy t for sts or in combination with pegylated liposomal doxorubicin tpld for roc wa evaluated in this retrospective postmarketing regulatory commitment patient data for multiple cardiacrelated treatmentemergent adverse event cteaes were evaluated in pooled analysis of ten phase 2 trial one phase 3 trial in sts n 982 and two phase 3 trial in roc n 1231 multivariate analysis on pooled trabectedin data revealed that cardiovascular medical history risk ratio rr 95 ci p and age 65 year rr 95 ci p were associated with increased risk for cteaes multivariate analysis showed increased risk of experiencing cteaes with tpld compared to pld monotherapy rr 95 ci p and with history of prior cardiac medication rr 95 ci p for patient with sts or roc who still have limited treatment option trabectedin may be initiated after carefully considering benefit versus risk trial registration clinicaltrialsgov nct01343277 nct00113607 nct,"Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating, Antineoplastic Combined Chemotherapy Protocols, Cardiotoxicity, Cardiovascular Diseases, Child, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Dacarbazine, Doxorubicin, Female, Heart, Humans, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local, Ovarian Neoplasms, Polyethylene Glycols, Product Surveillance, Postmarketing, Retrospective Studies, Sarcoma, Soft Tissue Neoplasms, Stroke Volume, Trabectedin, Ventricular Function, Left, Young Adult"
33960535,primary central nervous system lymphoma pcnsl is a rare type of aggressive lymphoma of the central nervous system treatment strategy improved significantly over the past decade differ regionally but mainly consist of rituximab and highdosed methotrexate mtxbased therapy we assessed clinical outcome of 100 patient with newly diagnosed pcnsl between at the university hospital of cologne germany patient were year of age and either treated with mtxbased regimen primain marta matrix individual regimen or best supportive care respectively overall response rate were generally high but different organ toxicity required dose adjustment in most group twoyear overall survival rate were primain marta matrix and other respectively out of 9 patient suffering from relapse 12 month from primary diagnosis 7 patient received methotrexatebased salvage therapy with year overall survival of patient although a relevant proportion of patient are not eligible for clinical trial due to age performance status or comorbidities these result prove feasibility of different mtxbased treatment strategy in clinical routine even elderly patient displayed surprisingly favorable outcome however with compromising organ toxicity reduction of intensity should be part of strategy in future clinical trial,"Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Neoplasms, Combined Modality Therapy, Female, Germany, Humans, Lymphoma, Male, Methotrexate, Middle Aged, Practice Patterns, Physicians', Prognosis, Recurrence, Retreatment, Survival Analysis, Treatment Outcome, Young Adult"
33960145,anlotinib significantly extended progressionfree survival pfs and overall survival o in smallcell lung cancer sclc a third or later line treatment in this study we retrospectively analyzed the efficacy and safety of anlotinib in the clinical practice and aimed to identify risk factor for predicting the clinical benefit of anlotinib in sclc patient 29 sclc patient treated with anlotinib monotherapy or combination therapy a second or later line treatment were included pfs o objective response rate orr disease control rate dcr and adverse event aes were analyzed in whole patient the median pfs wa month 95 confidence interval ci month the orr and dcr were and respectively the median o wa month 95ci month cox regression analysis demonstrated that response to firstline treatment wa the independent risk factor for pfs the orr v 0 and dcr v were promoted in patient treated with anlotinib combination therapy comparing to anlotinib monotherapy the most common aes were hoarseness fatigue decreased appetite oral mucositis and anemia no treatmentrelated aes graded 3 or more anlotinib is an effective option for sclc patient with tolerable toxicity a second or later line treatment patient sensitive to firstline treatment had longer pfs when treated with anlotinib anloitnib combined with other therapy increased the efficacy without adding toxicity,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Confidence Intervals, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Progression-Free Survival, Protein Kinase Inhibitors, Quinolines, Regression Analysis, Retrospective Studies, Risk Factors, Small Cell Lung Carcinoma, Time Factors, Treatment Outcome"
33960102,this article present the clinical trial protocol for a phase i open label doseescalation study to evaluate the tolerability safety and immunological efficacy of suburothelial durvalumab injection in adult with muscleinvasive or highrisk nonmuscleinvasive bladder cancer nmibc the suburothelial durvalumab injection1 study subdue1 the primary objective of this study are to as the safety of suburothelial injection of durvalumab using patient reported outcome measure and observed local or systemic adverse event the secondary objective are to examine the local immunological efficacy of suburothelial administration of durvalumab the subdue1 trial will include adult patient with either highrisk nmibc or mibc who are scheduled for radical cystectomy or who have refused or are unsuitable for systemic neoadjuvant chemotherapy three fixed total dose level of durvalumab 150 mg will be studied to identify a dose suitable to be taken forward into phase ii trial the primary endpoint is to evaluate the safety and tolerability of the trial intervention in term of the incidence and severity of adverse event and the potential establishment of doselimiting toxicity the secondary efficacy endpoint include rate of pt0 status at resection lymph node status a well a the change in distribution of tumourinfiltrating lymphocyte and tumouractivated macrophage between pre and postinjection bladder biopsy translational study will focus on bladder tumour molecular subtyping immune infiltrate characterisation and immune checkpoint protein expression relative to efficacy endpoint if proven safe and effective this novel strategy comprising suburothelial durvalumab injection aimed at promoting an antitumour immune reaction will provide additional treatment option for reducing tumour recurrence and progression in treatmentnave patient with highrisk nmibc or in patient with bacille calmettegurinrefractory nmibc local administration of durvalumab may be associated with a reduced rate of immunological sideeffects and lower cost when compared to systemic delivery,"Adult, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Clinical Trials, Phase I as Topic, Humans, Injections, Intralesional, Neoplasm Invasiveness, Risk Assessment, Treatment Outcome, Urinary Bladder Neoplasms, Urothelium"
33958640,nudt15 and tpmt variant are strong genetic determinant of thiopurineinduced hematological toxicity despite the impact of homozygous crim1 on thiopurine toxicity several patient with wildtype nudt tpmt and crim1 experience thiopurine toxicity therapeutic failure and relapse of acute lymphoblastic leukemia all novel pharmacogenetic interaction associated with thiopurine intolerance from hematological toxicity were investigated using wholeexome sequencing for lastcycle mercaptopurine dose intensity percentage dip tolerated by pediatric all patient n 320 il6 rs13306435 carrier n 19 exhibited significantly lower dip than noncarriers n p and by t test and multiple linear regression respectively among 19 carrier 7 with both heterozygous il6 rs13306435 and crim1 rs3821169 showed significantly decreased dip than those with il6 n or crim1 n variant il6 and crim1 variant showed marked interethnic variability fourgeneinterplay model revealed the best odds ratio and potential population impact relative risk population attributable fraction 58 number needed to treat and number needed to genotype interplay between il6 rs13306435 and crim1 rs3821169 wa suggested a an independent andor additive genetic determinant of thiopurine intolerance beyond nudt15 and tpmt in pediatric all,"Adolescent, Bone Marrow, Bone Morphogenetic Protein Receptors, Child, Child, Preschool, Ethnicity, Female, Humans, Infant, Interleukin-6, Male, Mercaptopurine, Methyltransferases, Pharmacogenetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrophosphatases, Republic of Korea, Exome Sequencing, Young Adult"
33958211,we reviewed our institutional data to evaluate toxicity and efficacy outcome of pembrolizumablenvatinib in recurrent endometrial cancer in a realworld clinical setting and to compare the impact of reduced lenvatinib starting dose on outcome retrospectively we reviewed toxicity treatment response and survival outcome of patient with recurrent endometrial cancer who received 1 cycle of pembrolizumablenvatinib we compared subgroup based on lenvatinib starting dose recommended 20 mg v reduced 20 mg and histologic type we analyzed 70 patient recommended dose cohort n 16 reduced dose cohort n 54 the most common starting dose wa 14 mg daily compared to the reduced dose cohort the recommended dose cohort had a significantly higher mean number of lenvatinib dose reduction due to side effect v p and significantly shorter median time to treatment toxicity v day p response rate did not differ significantly between the recommended and reduced dose cohort v respectively p two patient both in the reduced dose cohort had complete response patient with carcinosarcoma histology had response and clinical benefit rate of 25 3 of 12 and 7 of 12 respectively there were no difference between the 2 dose cohort with respect to progressionfree p or overall survival p in clinical practice a lower starting dose of lenvatinib 14 mg daily in combination with pembrolizumab wa safe and efficacious in recurrent endometrial cancer the combination produced response in endometrial carcinosarcoma larger study are required to validate these finding,"Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinosarcoma, Cohort Studies, Endometrial Neoplasms, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local, Phenylurea Compounds, Quinolines, Retrospective Studies"
33957881,the aim of this multicenter randomized phase ii study wa to analyze the feasibility and safety of alternateday s an oral fluoropyrimidine for adjuvant chemotherapy in patient with completely resected pathological stage i tumor diameter 2 cm nonsmall cell lung cancer nsclc patient were randomly assigned to receive adjuvant chemotherapy for 1 year comprising either alternateday oral administration of s1 80 mgmday for 4 day a week group a or a week oral administration of s1 80 mgmday followed by 1 week of rest group b the primary endpoint wa feasibility which wa defined a the proportion of patient who completed the allocated intervention for 6 month with a relative dose intensity rdi of 70 or more ninetythree patient were enrolled of whom 90 patient received s1 treatment median followup wa month the treatment completion rate based on an rdi of 70 or more for 6 month wa 95ci in group a and 95ci in group b there were no grade 4 adverse event in either group moderate or severe adverse event grade 2 or grade 3 were significantly more frequent in group b 67 compared with group a 29 p the year relapsefree survival rate wa and for group a and b respectively p the year overall survival rate for all patient n 93 wa 100 and for group a and b respectively p alternateday oral administration of s1 for 1 year a adjuvant chemotherapy wa demonstrated to be feasible with low toxicity in completely resected stage i tumor diameter 2 cm nsclc trial registration number umin000011994 date of registration,"Adult, Aged, Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant, Drug Administration Schedule, Drug Combinations, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Oxonic Acid, Tegafur"
33957442,this openlabel phase iii study evaluated safety and efficacy for firstline liposomal irinotecan oxaliplatin fluorouracil leucovorin nalirifox patient aged 18 year had locally advancedmetastatic pancreatic ductal adenocarcinoma mpdac with an eastern cooperative oncology group performance status score of and adequate organ function primary objective were to determine the maximum tolerated dose mtd and to evaluate safety and tolerability treatmentemergent adverse event teaes were graded using national cancer institute common terminology criterion for adverse event v efficacy endpoint included progressionfree survival pfs and overall survival o disease assessment used response evaluation criterion in solid tumor the mtd liposomal irinotecan 50 mgm2 freebase equivalent oxaliplatin 60 mgm fluorouracil 2400 mgm leucovorin 400 mgm2 every 2 week wa based on doselimiting toxicity and cumulative safety data in four doseexploration cohort the mtd wa received by 32 of 56 patient seven during dose exploration and 25 during dose expansion median age year range 28 with metastatic disease at diagnosis 29 at study entry and one receiving study treatment at data cutoff 26 february 2020 of these patient 22 of 32 had grade 3 treatmentrelated teaes most commonly neutropenia febrile neutropenia and hypokalaemia ten had serious treatmentrelated teaes and three died from teaes considered unrelated to treatment median pfs and o were 95 ci and month respectively firstline nalirifox for patient with locally advancedmpdac wa generally manageable and tolerable a randomised controlled phase iii study is underway,"Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Australia, Carcinoma, Pancreatic Ductal, Female, Fluorouracil, Humans, Irinotecan, Leucovorin, Liposomes, Male, Maximum Tolerated Dose, Middle Aged, Oxaliplatin, Pancreatic Neoplasms, Progression-Free Survival, Spain, Time Factors, United States"
33956047,primary central nervous system lymphoma pcnsl requires induction and consolidation to achieve potential cure highdose therapy and autologous hematopoietic cell transplant ahct is an accepted and effective consolidation strategy for pcnsl but no consensus exists on the optimal conditioning regimen to as the outcome in patient with pcnsl undergoing ahct with the 3 most commonly used conditioning regimen thiotepabusulfancyclophosphamide tbc thiotepacarmustine ttbcnu and carmustineetoposidecytarabinemelphalan beam this observational cohort study used registry data from the center for international blood and marrow transplant research registry the center is a working group of more than 380 transplantation center worldwide that contributed detailed data on hct to a statistical center at the medical college of wisconsin milwaukee the participant data were from 603 adult patient with pcnsl who underwent ahct a initial or subsequent consolidation between january 2010 and december patient were excluded if they had a nonhodgkin lymphoma subtype other than diffuse large bcell lymphoma systemic nonhodgkin lymphoma or hiv received an uncommon conditioning regimen or were not in partial remission or complete remission prior to ahct statistical analysis wa performed from july to march patient received 1 of 3 conditioning regimen tbc n 263 ttbcnu n 275 and beam n 65 the primary outcome wa progressionfree survival secondary outcome included hematopoietic recovery incidence of relapse nonrelapse mortality and overall survival of 603 patient the mean age wa 57 range year and 318 53 were male the year adjusted progressionfree survival rate were higher in the tbc cohort 75 and ttbcnu cohort 76 compared with the beam cohort 58 p 03 owing to a higher relapse risk in the beam cohort hazard ratio hr 95 ci p 001 in a multivariable regression analysis compared with the tbc cohort patient who received ttbcnu had a higher relapse risk hr 95 ci p 03 lower risk of nonrelapse mortality nrm hr 95 ci p 01 and similar risk of allcause mortality more than 6 month after hct hr 95 ci p 10 age of 60 year or older karnofsky performance status le than and an hctcomorbidity index greater than or equal to 3 were associated with lower rate of survival across all 3 cohort subgroup analysis demonstrated that patient aged 60 year and older had considerably higher nrm with tbc in this cohort study thiotepabased conditioning regimen wa associated with higher rate of survival compared with beam despite higher rate of early toxic effect and nrm these finding may assist clinician in choosing between tbc or ttbcnu based on patient and disease characteristic,"Aged, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System, Cohort Studies, Cyclophosphamide, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Neoplasm Recurrence, Local, Thiotepa"
33952483,regorafenib reg and trifluridinetipiracil ftdtpi have have been shown to improve overall survival in patient with refractory metastatic colorectal cancer the aim of our study wa to evaluate the efficacy and safety profile of these agent administered in sequence in real world practice clinical data of patient treated beyond the 2line with reg or ftdtpi between january 2016 and august were retrospectively collected from eight institute in the lazio region we included 49 patient treated with both drug sequence a total of 28 gg4 toxicity event were recorded in the ftdtpitoreg sequence v 24 in the reverse sequence median overall survival for the patient included in the ftptpitoreg group wa 20 month 95ci v 27 month in the reverse group 95ci the disease control rate wa for patient treated with the regtoftdtpi sequence v in those treated with the ftdtpitoreg sequence p the sequence regtoftdtpi and vice versa can extend survival whereas only regtoftdtpi stabilizes cancer growth,"Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Drug Administration Schedule, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Phenylurea Compounds, Progression-Free Survival, Pyridines, Pyrrolidines, Thymine, Trifluridine"
33952409,pancreatic cancer is the 8th commonest cancer and the 5th commonest cause of cancerrelated death in australia with a 9 average year survival this study aim to investigate the effect of neoadjuvant treatment on overall survival o and recurrencefree survival rf in borderline resectable brpc and locally advanced lapc pancreatic adenocarcinoma followed by curative resection prospectivelycollected demographic medical surgical and pathological data of patient with brpc and lapc treated with both neoadjuvant therapy nat and surgery at a single tertiary referral centre in australia were reviewed and analysed between 2012 and 60 patient 34 with brpc and 26 with lapc were treated with nat followed by curative resection the commonest neoadjuvant chemotherapy regimen were gemcitabine abraxane and folfirinox with of patient additionally receiving neoadjuvant radiotherapy median rf wa 30 month and median o wa 35 month on multivariable analysis inferior o wa predicted by enlarged locoregional lymph node on initial computed tomography p larger tumour size postnat p and common terminology criterion for adverse event postnat toxicity greater than grade 2 p lapc patient received more neoadjuvant chemotherapy p and radiotherapy p than brpc and achieved a superior pathological response p patient who respond to nat likely have a favourable disease biology and will progress well following resection it is these patient who should be selected for more aggressive upfront management and those with resistant disease should be spared from highrisk surgery,"Adenocarcinoma, Adult, Aged, Albumin-Bound Paclitaxel, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Fluorouracil, Humans, Irinotecan, Leucovorin, Lymph Nodes, Male, Middle Aged, Neoadjuvant Therapy, Oxaliplatin, Pancreatectomy, Pancreatic Neoplasms, Pancreaticoduodenectomy, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated, Survival Rate, Tumor Burden, Gemcitabine"
33951900,we report two patient who developed toxic keratopathy following highdose cytarabine chemotherapy and whose symptom resolved following topical loteprednol etabonate treatment a yearold woman and a yearold man with acute myeloid leukemia were referred to our department with symptom of ocular discomfort photophobia and blurred vision after consolidation chemotherapy central corneal epithelial microcysts were observed bilaterally in both patient and in vivo confocal microscopy showed highly reflective disseminated granular and irregular intraepithelial opacity mainly in the basal epithelial layer loteprednol etabonate relieved both patient symptom in le than a week and the microcysts disappeared in 2 to 3 week of treatment although there is no standardized treatment protocol for cytarabineinduced corneal toxicity dexamethasone and prednisolone phosphate were reported to be effective in the resolution of discomfort and symptom in the two patient we report herein loteprednol etabonate four time daily wa also effective in suppressing the symptom,"Adult, Anti-Allergic Agents, Antimetabolites, Antineoplastic, Cornea, Corneal Diseases, Cytarabine, Female, Humans, Leukemia, Myeloid, Acute, Loteprednol Etabonate, Male, Microscopy, Confocal, Ophthalmic Solutions"
33951292,sarcopenia ha recently emerged a a new condition with increasing importance in lung cancer patient the aim of this study wa to investigate the influence of sarcopenia on tolerance and efficacy of afatinib we retrospectively evaluated 35 patient with epidermal growth factor receptor egfr mutant advanced nonsmall cell lung cancer nsclc treated with firstline afatinib skeletal muscle area sma wa measured at the third lumbar vertebra using routine conducted computed tomography ct image for evaluation of disease burden sarcopenia wa defined a skeletal muscle index smi smaheight2 cm2 m2 for woman and cm2 m2 for men based on previous criterion fisher exact test kaplanmeier method and logistic regression modeling were used the median age at diagnosis wa 65 year range year a total of 24 patient were diagnosed with sarcopenia the most frequent adverse event aes related to afatinib were diarrhea followed by rash and paronychia 60 overall 19 patient had dose reduction sarcopenic patient had a significantly higher rate of grade 2 diarrhea v p and toxicityrelated dose reduction v p multivariate analysis also showed that sarcopenia odds ratio or 95 confidence interval ci p wa an independent risk factor for dose reduction of afatinib the median progressionfree survival pfs for afatinib wa month 95 ci both dose reduction and sarcopenia did not affect therapeutic efficacy toxicityrelated dose reduction is common with initiation of afatinib 40 mgday sarcopenic patient might begin treatment with a low dose of afatinib according to tolerance,"Adult, Afatinib, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Protein Kinase Inhibitors, Sarcopenia"
33948856,cancer stem cell cscs are a unique population that ha been linked to drug resistance and metastasis and recurrence of prostate cancer the sonic hedgehog shh signal regulates stem cell in normal prostate epithelium by affecting cell behavior survival proliferation and maintenance aberrant shh pathway activation lead to an unsuitable expansion of stem cell lineage in the prostate epithelium and the transformation of prostate cscs pcscs zoledronic acid zol one of the thirdgeneration bisphosphonates effectively prevented bone metastasis and treated advanced prostate cancer despite androgen deprivation therapy despite strong evidence for the involvement of the shh in human pcscs survival and drug resistance the role of shh in the pcscsrelated resistance to zol remain to be fully elucidated the present study aimed to investigate the role of the shh pathway in zol resistance of pcscs in 2d and three 3d cell culture condition for this purpose we isolated cd133high cd44high pcscs using a flow cytometer following zol treatment mrna and protein expression of the component of the shh signaling pathway in pcscs and noncscs were analyzed using qrtpcr and immunofluorescence staining respectively our finding suggested that shh signaling may be activated by different mechanism that lead to avoidance of the inhibition effect of zol thereby shh pathway may be associated with the resistance to zol developed by prostate cscs inhibition of cscsrelated shh signaling along with zol treatment should be considered to achieve improvement in survival or delayed treatment failure and prevention of the cscsrelated drug resistance,"AC133 Antigen, Antineoplastic Agents, Bone Density Conservation Agents, Cell Line, Tumor, Drug Resistance, Neoplasm, Hedgehog Proteins, Humans, Hyaluronan Receptors, Male, Neoplastic Stem Cells, Prostatic Neoplasms, Signal Transduction, Zoledronic Acid"
33948697,the survival benefit of patient with inoperable hepatocellular carcinoma hcc who undergo transarterial chemoembolization tace and receive sorafenib therapy remain controversial we aimed to identify clinical predictor in patient with inoperable hcc undergoing tace and receiving sorafenib between january 2014 and december 148 consecutive patient with inoperable hcc who were treated with tace plus sorafenib were retrospectively analyzed critical clinical factor associated with overall survival o were identified by cox regression model analysis kaplanmeier method were used to calculate the survival time which were compared with the logrank test macrovascular invasion mvi radiologic response and sorafenibrelated dermatologic toxicity were identified a independent factor associated with o mvi is a known prognostic factor before treatment the median o of patient with either radiologic response or dermatologic toxicity wa significantly improved compared with that of patient without it both v month p the median o of patient with a combination of radiologic response and dermatologic toxicity wa significantly longer than that of patient with either radiologic response or dermatologic toxicity a well a no response v v month respectively p and the predictive value wa confirmed across patient with different baseline characteristic in term of mvi fetoprotein level performance status and liver function the combination of radiologic response and sorafenibrelated dermatologic toxicity is the most robust predictor of survival benefit for hcc patient after tace plus sorafenib therapy level,"Adult, Antineoplastic Agents, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Combined Modality Therapy, Female, Humans, Liver Neoplasms, Male, Middle Aged, Retrospective Studies, Sorafenib, Treatment Outcome"
33947698,inhibition of histone deacetylase 6 hdac6 is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response this study describes the development of a novel hdac6 inhibitor ka2507 wa characterized in hdac biochemical and cellular target engagement assay and in preclinical efficacy model of melanoma and colorectal cancer in a phase i study ka2507 wa administered orally using a doseescalation design nct03008018 ka2507 is a potent and selective inhibitor of hdac6 biochemical ic50 nmoll preclinical model demonstrated antitumor efficacy in syngeneic tumorbearing mouse with translational study highlighting modulation of the antitumor immune response twenty patient were treated in a phase i study ka2507 wa well tolerated doselimiting toxicity wa not observed up to the maximum dose administered pharmacokinetic profiling supported twicedaily oral dosing pharmacodynamic analysis demonstrated selective hdac6 target engagement in peripheral blood cell free from offtarget class i hdac activity stable disease wa the best clinical response 7 patient three of these patient adenoid cystic carcinoma n 2 rectal adenocarcinoma n 1 had prolonged disease stabilization that lasted for and month respectively ka2507 is a potent and selective inhibitor of hdac6 showing antitumor efficacy and immune modulatory effect in preclinical model in a phase i study ka2507 showed selective target engagement no significant toxicity and prolonged disease stabilization in a subset of patient further clinical study of ka2507 are warranted a a single agent or preferably combined with other immunooncology drug,"Animals, Antineoplastic Agents, Histone Deacetylase 6, Histone Deacetylase Inhibitors, Humans, Mice, Neoplasms"
33947690,this study investigated the efficacy and safety of oral parp inhibitor veliparib plus carboplatin and etoposide in patient with treatmentnave extensivestage small cell lung cancer edsclc patient were randomized 111 to veliparib 240 mg twice daily bid for 14 day plus chemotherapy followed by veliparib maintenance 400 mg bid veliparib throughout veliparib plus chemotherapy followed by placebo veliparib combination only or placebo plus chemotherapy followed by placebo control patient received cycle of combination therapy then maintenance until unacceptable toxicityprogression the primary endpoint wa progressionfree survival pfs with veliparib throughout versus control overall n 181 pfs wa improved with veliparib throughout versus control hazard ratio hr 80 confidence interval ci p median pfs wa and month respectively there wa a trend toward improved pfs with veliparib throughout versus control in slfnpositive patient hr 80 ci median overall survival o wa versus month in the veliparib throughout and control arm respectively hr 80 ci grade adverse event were experienced by 82 88 and 68 of patient in the veliparib throughout veliparib combinationonly and control arm most commonly hematologic veliparib plus platinum chemotherapy followed by veliparib maintenance demonstrated improved pfs a firstline treatment for edsclc with an acceptable safety profile but there wa no corresponding benefit in o further investigation is warranted to define the role of biomarkers in this setting,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carboplatin, Double-Blind Method, Etoposide, Female, Humans, Lung Neoplasms, Male, Middle Aged, Small Cell Lung Carcinoma, Treatment Outcome"
33947608,combined axitinib and immunooncology io therapy is approved for firstline advanced renal cell carcinoma overlapping toxicity represent a clinical challenge calculating the time to resolution ttr of common axitinibrelated adverse event aes after treatment interruption may help to identify ae etiology and determine appropriate management strategy data from 5 randomized or singlearm axitinib monotherapy or combination study were analyzed patient with histologically confirmed clear cell advanced renal cell carcinoma were pooled into 3 cohort based on treatment received axitinib monotherapy axitinib io and other tyrosine kinase inhibitor tki any grade and grade 3 treatmentemergent diarrhea fatigue hypertension nausea and palmarplantar erythrodysesthesia syndrome were assessed ttr wa defined a the time from treatment interruptiondiscontinuation to resolution the axitinib monotherapy cohort comprised 532 patient the axitinib io cohort 541 patient and the other tki cohort 882 patient median ttr for all aes any grade in the axitinib monotherapy cohort ranged from 1 to 3 day except for fatigue 8 day for diarrhea hypertension nausea and palmarplantar erythrodysesthesia syndrome median ttrs were longer in the axitinib io day and other tki day cohort versus the monotherapy cohort result were similar when only aes of grade 3 were considered the ttr of monotherapeutic axitinibrelated aes is 3 day except for fatigue and generally shorter than for other singleagent tkis and axitinib io this ha important implication for identifying ae etiology with combined axitinibio therapy and implementation of appropriate management strategy clinicaltrialsorg identifier nct nct nct nct nct,"Axitinib, Carcinoma, Renal Cell, Hand-Foot Syndrome, Humans, Kidney Neoplasms, Protein Kinase Inhibitors"
33947461,differentiation syndrome d is a lifethreatening complication that may be seen in patient with acute promyelocytic leukaemia undergoing induction therapy with alltrans retinoic acid or arsenic trioxide it can lead to severe inflammatory response syndrome and shock if adequate measure are not taken immediately the radiological feature of lung nodule with change in groundglass opacity can represent d the principal unique feature of the case reported here is that the diagnosis of d wa based on imaging result in the absence of a low total leukocyte count a yearold indian girl diagnosed with acute promyelocytic leukaemia currently undergoing a chemotherapy regimen that included alltrans retinoic acidarsenic trioxide wa sent to the radiology department for investigation of respiratory distress which she had developed soon after the initiation of chemotherapy her chest radiograph showed bilateral lower zone lung infiltrates computed tomography ct revealed change in groundglass opacity in the lower lobe with multiple lung nodule differential diagnosis included bacterial viral or fungal infection leukemic infiltrates drug toxicity pulmonary haemorrhage or leukostasis she wa started on dexamethasone immediately after stopping the chemotherapy with alltrans retinoic acidarsenic trioxide and given ventilatory support her condition subsequently improved and her followup chest radiograph and ct scan showed a significant reduction of abnormal lung finding based on the clinical improvement and the resolution of finding on imaging following the withdrawal of alltrans retinoic acidarsenic trioxide we made the diagnosis of d though a rather unusual possibility the treatment history of the patient enabled a rather crucial diagnosis in the nick of time and imaging played a pivotal role this case further iterates the importance of keeping d in mind when dealing with similar patient in the future,"Adolescent, Antineoplastic Combined Chemotherapy Protocols, Arsenic Trioxide, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Leukemia, Promyelocytic, Acute, Syndrome, Tretinoin"
33946916,despite enormous progress in the treatment of many malignancy the development of cancer resistance is still an important reason for cancer chemotherapy failure increasing knowledge of cancer molecular complexity and mechanism of their resistance to anticancer drug a well a extensive clinical experience indicate that an effective fight against cancer requires a multidimensional approach multitarget chemotherapy may be achieved using drug combination codelivery of medicine or designing hybrid drug hybrid drug simultaneously targeting many point of signaling network and various structure within a cancer cell have been extensively explored in recent year the single hybrid agent can modulate multiple target involved in cancer cell proliferation posse a simpler pharmacokinetic profile to reduce the possibility of drug interaction occurrence and facilitates the process of drug development moreover a single medication is expected to enhance patient compliance due to a le complicated treatment regimen a well a a diminished number of adverse reaction and toxicity in comparison to a combination of drug a a consequence many effort have been made to design hybrid molecule of different chemical structure and function a a mean to circumvent drug resistance the enormous number of study in this field encouraged u to review the available literature and present selected research result highlighting the possible role of hybrid drug in overcoming cancer drug resistance,"Animals, Antineoplastic Agents, Biomarkers, Drug Design, Drug Resistance, Neoplasm, Humans, Ligands, Molecular Structure, Signal Transduction, Structure-Activity Relationship"
33946310,her2 targeted therapy have significantly improved prognosis of herpositive breast and gastric cancer her2 overexpression and mutation is the pathogenic driver in nonsmall cell lung cancer nsclc and colorectal cancer however to date there are no approved hertargeted therapy with these indication trastuzumab deruxtecan tdxd is a novel herdirected antibody drug conjugate showing significant antitumor activity in heavily pretreated herpositive breast and gastric cancer patient preliminary data have shown promising objective response rate in patient with herpositive nsclc and colorectal cancer tdxd ha an acceptable safety profile however with concern regarding potentially serious treatmentemergent adverse event in this review we focus on the pharmacologic characteristic and toxicity profile of tdxd and provide an update on the most recent result of clinical trial of tdxd in solid tumor the referenced paper were selected through a pubmed search performed on 16 march 2021 with the following searching term tdxd and breast cancer or gastric cancer or nonsmall cell lung cancer nsclc or colorectal cancer oral presentation abstract and poster presented at the american society of clinical oncology asco alexandria va usa 2020 and the european society for medical oncology esmo lugano switzerland 2020 annual meeting were retrieved for data on tdxd we also overview ongoing research and data of combination therapy currently under investigation which will impact on future therapeutic strategy clinicaltrialsgov wa searched to identify ongoing clinical trial of tdxd alone or in combination in solid tumor,"Animals, Antineoplastic Agents, Immunological, Camptothecin, Clinical Trials as Topic, Humans, Immunoconjugates, Neoplasms, Receptor, ErbB-2, Trastuzumab"
33945215,to investigate whether the addition of fluorouracil to docetaxel and cisplatin induction chemotherapy ic can truly improve the prognosis of patient with locoregionally advanced nasopharyngeal carcinoma npc a total of 801 patient newly diagnosed with nonmetastatic locoregionally advanced npc were included a the subject in this study propensity score matching psm wa used for analysis of overall survival o distant metastasisfree survival dmfs progressionfree survival pfs and locoregional relapsefree survival lrrfs and the chisquared test or fisher exact test wa used to investigate toxic reaction patient received treatment with docetaxel and cisplatin tp or docetaxel cisplatin and fluorouracil tpf with a median followup time of 60 month range month the tpf group had better year o v p pfs v p and dmfs v p than the tp group after psm 258 patient were matched in each cohort the kaplanmeier analysis showed that the year o pfs and dmfs were and respectively in the tpf group higher than the and respectively in the tp group p and respectively moreover the multivariate analysis revealed that different ic regimen were independent prognostic factor for pfs and dmfs p and respectively this study found that compared with the tp regimen tpf induction chemotherapy is associated with improved survival in patient with locoregionally advanced npc tpf can produce more mucosal and nauseavomiting adverse reaction than tp,"Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Cisplatin, Docetaxel, Fluorouracil, Humans, Induction Chemotherapy, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Neoplasm Recurrence, Local, Propensity Score, Retrospective Studies"
33942817,nanozymes a a kind of artificial mimic enzyme have superior catalytic capacity and stability a lack of o2 in tumor cell can cause resistance to drug we designed drug delivery liposome mnoptxce6lips loaded with catalaselike nanozymes of manganese dioxide nanoparticles mno2 np paclitaxel ptx and chlorin e6 ce6 to consume tumor native h2o2 and produce o based on the catalysis of mno2 np a large amount of oxygen wa produced by mnoptxce6lips to burst the liposome and achieve a responsive release of the loaded drug paclitaxel and the released o2 relieved the chemoresistance of tumor cell and provided raw material for photodynamic therapy subsequently mno2 np were decomposed into mn in an acidic tumor environment to be used a contrast agent for magnetic resonance imaging the mnoptxce6lips enhanced the efficacy of chemotherapy and photodynamic therapy pdt in bearingtumor mouse even achieving complete cure these result indicated the great potential of mnoptxce6lips for the modulation of the tme and the enhancement of chemotherapy and pdt along with mri tracing in the treatment of tumor,"Animals, Antineoplastic Agents, Phytogenic, Cell Survival, Chlorophyllides, Contrast Media, Humans, Hydrogen Peroxide, Light, Liposomes, Magnetic Resonance Imaging, Manganese Compounds, Mice, Nanoparticles, Nanostructures, Neoplasms, Oxides, Oxygen, Paclitaxel, Photochemotherapy, Photosensitizing Agents, Porphyrins, Theranostic Nanomedicine"
33941055,to determine the effectiveness and safety of atezolizumab nivolumab and pembrolizumab in patient with nonsmall cell lung cancer this is a retrospective observational study including patient treated in second line and beyond the effectiveness of treatment wa assessed by mean of overall survival and progression free survival measurement toxicity wa described according to the common criterion for adverse event terminology v the study included 8 patient treated with atezolizumab19 with nivolumab and 16 with pembrolizumab median progression free survival with atezolizumab wa month 95ci 2 month 95ci for nivolumab and month 95ci for pembrolizumab median overall survival wa month 95ci for nivolumab both pfs and o were statistically higher in patient with grade metastasis in the case of nivolumab and in ecog patient for pembrolizumab median overall survival wa not reached for atezolizumab or pembrolizumab around 85 of patient suffered adverse effect of some degree two of the patient treated with nivolumab developed vitiligo overall survival of both wa higher than year for the patient included in the sample nivolumab wa le effective in those with two or more metastasis the effectiveness of pembrolizumab wa lower in ecog2 patient vitiligo wa related to a more durable response to treatment objetivo efectividad y seguridad de atezolizumab nivolumab y embrolizumab en cncer de pulmn no microctico metastsicomtodo estudio observacional retrospectivo en pacientes con cncer de pulmn no microctico metastsico tratados en segunda lnea o posteriores la efectividad fue evaluada mediante supervivencia global y supervivencia libre de progresin la toxicidad mediante los criterios comunes de terminologa de efectos adversos vresultados se incluyeron 8 pacientes con atezolizumab 19 con nivolumab y 16 con pembrolizumab la mediana de supervivencia libre de progresin con atezolizumab fue me intervalo de confianza del 95 ic95 2 me ic95 para nivolumab me ic95 para pembrolizumab la mediana de supervivencia global con nivolumab fue me ic95 9 y no se alcanz para atezolizumab y pembrolizumab ambas fueron superiores para los pacientes con metstasis para nivolumab y en los pacientes con ecog para pembrolizumab alrededor de un 85 de los pacientes sufrieron efectos adversos do pacientes tratados con nivolumab experimentaron vitligo con una supervivencia global mayor de aosconclusiones en la muestra analizada la efectividad de nivolumab e menor en pacientes con do o m metstasis y la de pembrolizumab e menor en pacientes con ecog la aparicin de vitligo se relacion con una respuesta duradera,"Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Nivolumab"
33939895,pregnancy associated breast cancer is a rare disease it present a unique entity of breast cancer with aggressive phenotype the main aim wa to evaluate how the international guideline were followed in daily practice data concerning patient and tumour characteristic management delivery and maternal outcome were recorded from institutional electronic database in this paper a case series of pregnant breast cancer patient treated at single tertiary institution between 2007 and 2019 are presented and the key recommendation on managing such patient are summarized fourteen patient met the search criterion the majority of tumour were high grade triple negative or her2 positive two patient were de novo metastatic treatment plan wa made for each patient by multidisciplinary team eight patient were treated with systemic chemotherapy with no excess toxicity or severe maternalfetal adverse effect in all but two patient delivery wa on term and without major complication only one event which wa not in whole accordance with international guideline wa identified it wa the use of blue dye in one patient woman with pregnancy associated breast cancer should be managed like nonpregnant breast cancer patient and should expect a similar outcome without causing harm to the unborn child to achieve a good outcome in pregnancy associated breast cancer a multidisciplinary approach is mandatory,"Adult, Antineoplastic Agents, Biopsy, Biopsy, Large-Core Needle, Breast, Breast Neoplasms, Female, Guideline Adherence, Humans, Mastectomy, Pregnancy, Pregnancy Complications, Neoplastic, Pregnancy Trimesters, Retrospective Studies, Triple Negative Breast Neoplasms"
33939662,positively charged amino acid aa such a argininelysine are coinfused with radiolabeled somatostatin analog to reduce rate of nephrotoxicity in the phase 3 netter1 trial commercial aa formulation were used in association with 177ludotatyroctreotate dotatate these formulation were also used in an earlyaccess program eap before regulatory approval of 177ludotatate our program transitioned to compounded larginine llysine in nacl after commercial approval of 177ludotatate we sought to compare rate of nauseavomiting with argininelysine versus commercial parenteral aa formulation rate of nauseavomiting of all 20 eap patient who received commercial aa 15 clinisol were compared with the first 29 patient to receive 177ludotatate after commercial approval and coinfused with argininelysine other parameter reviewed included infusion rate need for prn nausea medication and other toxicity seventeen percent of patient who received compounded argininelysine experienced nausea compared with 100 of patient in the eap group p infusionrelated reaction occurred in 3 of the argininelysine cohort versus 35 in the eap group infusion duration were substantially shorter in the argininelysine cohort reduced by 61 coinfusions of argininelysine with radiolabeled somatostatin analog result in substantially lower rate of nauseavomiting compared with commercial aa formulation designed for parenteral nutrition,"Aged, Aged, 80 and over, Amino Acids, Arginine, Combined Modality Therapy, Female, Humans, Infusion Pumps, Lysine, Male, Middle Aged, Nausea, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Outcome Assessment, Health Care, Parenteral Nutrition, Radiopharmaceuticals, Receptors, Peptide, Retrospective Studies, Vomiting"
33939491,to provide recommendation for appropriate dosing of systemic antineoplastic agent in obese adult with cancer a systematic review of the literature collected evidence regarding dosing of chemotherapy immunotherapy and targeted therapy in obese adult with cancer pubmed and the cochrane library were searched for randomized controlled trial metaanalyses or cohort study published from november through march asco convened an expert panel to review the evidence and formulate recommendation sixty study primarily retrospective were included in the review overall the evidence supported previous finding that obese adult patient tolerate full bodysizebased dosing of chemotherapy a well a nonobese patient fewer study have addressed the dosing of targeted therapy and immunotherapy in relation to safety and efficacy in obese patient the panel continues to recommend that full weightbased cytotoxic chemotherapy do be used to treat obese adult with cancer new to this version of the guideline the panel also recommends that full approved do of immunotherapy and targeted therapy be offered to obese adult with cancer in the event of toxicity the consensus of the panel is that dose modification of systemic antineoplastic therapy should be handled similarly for obese and nonobese patient important area for future research include the impact of sarcopenia and other measure of body composition on optimal antineoplastic dosing and more customized dosing based on pharmacokinetic or pharmacogenetic factorsadditional information is available at,"Antineoplastic Agents, Humans, Neoplasms, Obesity, Systematic Reviews as Topic"
33939107,mutation in isocitrate dehydrogenase gene idh1 and idh2 are common in acute myeloid leukemia aml occurring in up to 30 of aml case mutation in idh lead to abnormal epigenetic regulation in aml cell and block differentiation inhibitor of mutated idh1 and idh ivosidenib and enasidenib respectively were recently approved by the fda for relapsedrefractory aml ivosidenib is also approved for newly diagnosed aml patient not fit for standard chemotherapy here we discus the clinical development of idh inhibitor their unique side effect and outline future combination approach in aml idh inhibitor are welltolerated but can induce differentiation of aml cell which lead to the ontarget side effect of differentiation syndrome in up to 20 of patient although idh inhibitor demonstrate efficacy a monotherapy recent trial have shown that they have higher response rate in combination with hypomethylating agent hmas current trial of idh inhibitor include combination with standard induction chemotherapy a maintenance therapy and in combination with venetoclaxbased regimen idh inhibitor are active and have a favorable toxicity profile in aml therapy current clinical trial are evaluating how to best incorporate idh inhibitor into combination therapy to optimize outcome and duration of response for aml patient with idh mutation,"Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Drug Development, Drug Resistance, Neoplasm, Enzyme Inhibitors, Humans, Induction Chemotherapy, Isocitrate Dehydrogenase, Leukemia, Myeloid, Acute, Maintenance Chemotherapy, Mutation, Treatment Outcome"
33938967,intensitymodulated radiotherapy imrt for cervical cancer yield favorable result in term of oncological outcome acute toxicity and late toxicity limited data are available on clinical result with volumetric modulated arc therapy vmat this study purpose is to compare outcome and toxicity with vmat to conventional 3d conformal radiotherapy 3dcrt giving special consideration to the influence of patient and treatmentrelated parameter on side effect patient with cervical cancer stage iiva underwent radiotherapy alone or chemoradiotherapy using 3dcrt n 75 or vmat n 30 survival endpoint were overall survival progressionfree survival and locoregional control the national cancer institute common terminology criterion for adverse event and the late effect of normal tissue criterion were used for toxicity assessment toxicity and patient and treatmentrelated parameter were included in a multivariable model there were no difference in survival rate between treatment group vmat significantly reduced late small bowel toxicity or p additionally vmat wa associated with an increased risk of acute urinary toxicity or p a low body mass index bmi or p and overall acute toxicity grade 2 or p were associated with increased overall late toxicity we demonstrated significant reduction of late small bowel toxicity with vmat treatment an improvement in longterm morbidity is conceivable vmattreated patient experienced acute urinary toxicity more frequently further analysis of patient and treatmentrelated parameter indicates that the close monitoring of patient with low bmi and of patient who experienced relevant acute toxicity during followup care could improve late toxicity profile,"Adult, Aged, Aged, 80 and over, Brachytherapy, Chemoradiotherapy, Cisplatin, Female, Follow-Up Studies, Humans, Intestine, Small, Middle Aged, Multivariate Analysis, Progression-Free Survival, Radiation Injuries, Radiotherapy, Conformal, Radiotherapy, High-Energy, Radiotherapy, Intensity-Modulated, Survival Rate, Urinary Tract, Uterine Cervical Neoplasms"
33938097,chemotherapy for nonhodgkin lymphoma nhl in the hemodialysis hd patient is a challenging situation because many drug are predominantly eliminated by the kidney chemotherapy in the hd patient requires special consideration concerning dose adjustment to avoid overdose and toxicity conversely some drug are removed by hd and may expose the patient to undertreatment therefore the timing of drug administration in relation to hd session must be carefully planned also the metabolite of some drug show different toxicity and dialysability a compared with the parent drug therefore this must also be catered for however the pharmacokinetics of many chemotherapeutics and their metabolite in hd patient are unknown and the fact that nhl patient are often treated with distinct multiagent chemotherapy regimen make the situation more complicated in a realm where uncertainty prevails case report and case series reporting on actual treatment and outcome are extremely valuable and can aid physician in decision making from drug selection to dosing we carried out an exhaustive review of the literature and adopted 48 manuscript consisting of 66 hd patient undergoing 71 chemotherapy regimen for nhl summarized the data and provide recommendation concerning dose adjustment and timing of administration for individual chemotherapeutics where possible the chemotherapy regimen studied in this review include but are not limited to rituximab cyclophosphamide vincristine prednisolone cvp and cyclophosphamide doxorubicin vincristine prednisolone choplike regimen chlorambucil ibrutinib bendamustine methotrexate platinum compound cytarabine gemcitabine etoposide ifosfamide melphalan busulfan fludarabine mogamulizumab brentuximab vedotin and 90 yibritumomab tiuxetan,"Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Child, Cyclophosphamide, Doxorubicin, Drug Administration Schedule, Female, Hematopoietic Stem Cell Transplantation, Humans, Kidney, Lymphoma, Non-Hodgkin, Male, Middle Aged, Prednisone, Renal Dialysis, Rituximab, Vincristine, Young Adult"
33937956,immune checkpoint inhibitor icis have improved the survival of several cancer however they may cause a wide range of immunerelated adverse event iraes while most iraes are manageable with temporary cessation of ici and immunosuppression cardiovascular toxicity can be associated with high rate of morbidity and mortality a icis evolve to include highrisk patient with preexisting cardiovascular risk factor and disease the risk and relevance of iciassociated cardiotoxicity may be even higher several cardiovascular toxicity such a myocarditis stress cardiomyopathy and pericardial disease have been reported in association with icis recent finding also suggest an increased risk of atherosclerosis with ici use iciassociated myocarditis usually occurs early after initiation and can be fulminant a high index of suspicion is required for timely diagnosis prompt treatment with highdose corticosteroid is shown to improve outcome although the overall incidence is rare ici cardiotoxicity particularly myocarditis is associated with significant morbidity and mortality making it a major therapylimiting adverse event early recognition and prompt treatment with the cessation of ici therapy and initiation of highdose corticosteroid are crucial to improve outcome cardiooncologists will need to play an important role not just in the management of acute cardiotoxicity but also to reduce the risk of longterm sequela,"Atherosclerosis, COVID-19, Cardiotoxicity, Humans, Immune Checkpoint Inhibitors, Myocarditis, Neoplasms, Pandemics, Risk Factors, SARS-CoV-2"
33936037,immune checkpoint inhibitor therapy ha become a promising option for the treatment of latestage thymic epithelial tumor in this manuscript we presented a patient with metastatic thymoma administrated of antiprogrammed cell death protein 1 pd1 antibody pembrolizumab although the patient underwent a rapid and dramatic response to one dose of pembrolizumab she suffered a storm of immunetherapy related toxicity event iraes including liver and kidney dysfunction hypothyroidism and myocarditis we didnt observe grade 3 iraes and proceed with pembrolizumab therapy after the function recovered although no guideline recommend dose reduction of immunotherapy retreating following initial iraes we optimize dose of pembrolizumab to minimize the iraes induced by pd1 antibody while maintaining clinical effectiveness excitingly we observe remarkable tumor remission and mild toxicity of half dose of pembrolizumab in this case in conclusion the clinical utilization of immunotherapy is an encouraging therapeutic alternative for advanced thymomas at the same time patient have to be monitored very carefully because of the risk to develop iraes,"Antibodies, Monoclonal, Humanized, Drug Tapering, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Hypothyroidism, Immune Checkpoint Inhibitors, Middle Aged, Myocarditis, Neoplasm Metastasis, Programmed Cell Death 1 Receptor, Recovery of Function, Remission Induction, Thymoma, Thymus Neoplasms"
33934611,although cardiovascular toxicity from traditional chemotherapy ha been well recognized for decade the recent explosion of effective novel targeted cancer therapy with cardiovascular sequela ha driven the emergence of cardiooncology a a new clinical and research field cardiovascular toxicity associated with cancer therapy can manifest a a broad range of potentially lifethreatening complication including heart failure arrhythmia myocarditis and vascular event beyond toxicology the intersection of cancer and heart disease ha blossomed to include discovery of genetic and environmental risk factor that predispose to both there is a pressing need to understand the underlying molecular mechanism of cardiovascular toxicity to improve outcome in patient with cancer preclinical cardiovascular model ranging from cellular assay to large animal serve a the foundation for mechanistic study with the ultimate goal of identifying biologically sound biomarkers and cardioprotective therapy that allow the optimal use of cancer treatment while minimizing toxicity given that novel cancer therapy target specific pathway integral to normal cardiovascular homeostasis a better mechanistic understanding of toxicity may provide insight into fundamental pathway that lead to cardiovascular disease when dysregulated the goal of this scientific statement is to summarize the strength and weakness of preclinical model of cancer therapyassociated cardiovascular toxicity to highlight overlapping mechanism driving cancer and cardiovascular disease and to discus opportunity to leverage cardiooncology model to address important mechanistic question relevant to all patient with cardiovascular disease including those with and without cancer,"American Heart Association, Animals, Antineoplastic Agents, Cardiotoxicity, Cells, Cultured, Disease Models, Animal, Heart Diseases, Humans, Myocytes, Cardiac, Risk Assessment, Toxicity Tests, United States"
33934609,immunebased therapy have revolutionized cancer treatment cardiovascular sequela from these treatment however have emerged a critical complication representing new challenge in cardiooncology immune therapy include a broad range of novel drug from antibody and other biologics including immune checkpoint inhibitor and bispecific tcell engagers to cellbased therapy such a chimericantigen receptor tcell therapy the recognition of immunotherapyassociated cardiovascular side effect ha also catapulted new research question revolving around the interaction between the immune and cardiovascular system and the signaling cascade affected by t cell activation cytokine release and immune system dysregulation here we review the specific mechanism of immune activation from immunotherapy and the resulting cardiovascular toxicity associated with immune activation and excess cytokine production,"Animals, Antibodies, Bispecific, Cardiotoxicity, Cardiovascular Diseases, Cytokine Release Syndrome, Disease Models, Animal, Dogs, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Immunotherapy, Adoptive, Lymphocyte Activation, Mice, Neoplasms, Rats, Receptors, Chimeric Antigen, T-Lymphocytes"
33934417,bortezomibrelated peripheral neuropathy pn affect a relevant proportion of multiple myeloma mm patient treated with melphalan prednisone and bortezomib vmp empirical dose modification have attempted to reduce toxicity without compromising efficacy we retrospectively evaluated the doseresponse and dosetoxicity relationship in 114 unselected untreated mm patient intended for treatment with vmp with subcutaneous bortezomib sixtytwo patient 54 completed the 9 scheduled cycle median treatment duration wa 48 week range cumulative bortezomib dose wa mgm2 and median dose intensity wa mgm2 wk median progressionfree survival pfs and overall survival o for the full cohort were 86 week 95ci and 209 week 95 ci respectively patient who progressed 60 day after discontinuing bortezomib had received a significantly inferior mean cumulative dose mgm2 than the remaining individual p 023 pfs wa significantly improved for patient achieving a very good partial response vgpr or better p 00007 additional variable with a prognostic impact on pfs on univariate analysis included completion of the 9 scheduled cycle p 00002 patient with at least 50 week of treatment p 02 and patient receiving a cumulative dose of at least 49 mgm2 p 05 achievement of a vgpr hr 95ci p 00002 and a cumulative dose of 49 mgm2 hr 95ci p 003 were statistically independent prognostic factor for pfs toxicityrelated treatment dose reduction occurred in 75 individual 66 pn wa observed in 50 individual grade 3 in 9 8 the only prognostic factor for emergence of pn in multivariate analysis wa the presence of baseline pn biweekly fulldose treatment in the first cycle ha a major impact in depth of response depth of response cumulative bortezomib dose and treatment duration had an impact in prolongation of pfs,"Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Comorbidity, Disease Management, Drug Administration Schedule, Duration of Therapy, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multiple Myeloma, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Treatment Outcome"
33933896,kras mutation are found in of nonsquamous nonsmall cell lung cancer nsclc and therapy targeting the rasmekerk pathway are in development we performed a multicenter openlabel phase 1b trial to determine the recommended phase 2 dose and early antitumor activity of the mekinhibitor binimetinib combined with cisplatin and pemetrexed eligible patient pt had stage iiiiv nsclc unsuitable for curative treatment kras exon 2 or 3 codon 13 or 61 mutation no prior systemic therapy pt were enrolled into part 1 3 3 design with dose escalation in 2 dose level dl of binimetinib and part 2 expansion cohort at the maximum tolerated dose mtd pt received 4 cycle of cisplatin 75 mgm pemetrexed 500 mgm2and binimetinib 30 dl145 mg dl2 orally twice a day bid d q3w followed by pemetrexed and binimetinib until progressive disease pd or unacceptable toxicity from may 2017 to dec 18 pt 13 dose escalation 5 expansion cohort were enrolled median age wa 60 range kras mutation were at codon no dlt occurred in the dose escalation cohort median number of cycle wa 2 range treatment discontinuation wa mainly due to pd 33 or ptsphysicians decision 27 together with the expansion cohort 16 pt were evaluable for safety most frequent treatmentrelated grade 3 aes were lung infection 25 fatigue 19 anemia 19 overall response rate among 9 evaluable pt receiving binimetinib at mtd 45 mg bid wa 33 95 ci median progressionfree survival wa month 95 ci and overall survival month nr 95 ci pt treated with combination of cisplatin pemetrexed and binimetinib presented no unexpected toxicity no early signal of increased antitumor activity of binimetinib added to chemotherapy wa observed in our pt population,"Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carcinoma, Non-Small-Cell Lung, Cisplatin, Humans, Lung Neoplasms, Middle Aged, Mutation, Pemetrexed, Proto-Oncogene Proteins p21(ras)"
33933569,to evaluate efficacy and toxicity of weekly cisplatin chemoradiotherapy versus threeweekly cisplatin chemoradiotherapy and identify difference in clinical outcome and severe toxicity rate picosprisma method were used to identify study on pubmed embase and cochrane library six randomized clinical trial 554 patient were identified weekly cisplatin wa not associated with significant overall survival hr 95 ci and progressionfree survival hr 95 ci improvement compared with threeweekly regimen severe acute toxicity rr treatment compliance to chemotherapy rr and radiotherapy rr were similar between regimen weekly cisplatin is not associated with better clinical outcome compared to threeweekly cisplatin threeweekly cisplatin chemoradiotherapy should be considered the standard approach in the management of locally advanced head and neck cancer methodologically robust rcts design are needed to improve the quality of evidence difference on longterm toxicity and costeffectiveness remain to be tested,"Antineoplastic Agents, Chemoradiotherapy, Cisplatin, Head and Neck Neoplasms, Humans, Italy, Medical Oncology"
33932739,lasparaginase is an enzyme that catalyzes the degradation of asparagine and successfully used in the treatment of acute lymphoblastic leukemia lasparaginase toxicity is either related to hypersensitivity to the foreign protein or to a secondary lglutaminase activity that cause inhibition of protein synthesis pegylated version have been incorporated into the treatment protocol to reduce immunogenicity and an alternative lasparaginase derived from dickeya chrysanthemi is used in patient with anaphylactic reaction to the e coli lasparaginase alternative approach commonly explore new source of the enzyme a well a the use of protein engineering technique to create le immunogenic more stable variant with lower lglutaminase activity this article review the main strategy used to overcome lasparaginase shortcoming and introduces recent tool that can be used to create therapeutic enzyme with improved feature,"Animals, Antineoplastic Agents, Asparaginase, Glutaminase, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Engineering"
33932031,nelfinavir nfv an hiv1 protease inhibitor ha been shown to sensitize cancer cell to chemoradiation crt the objective of this phase 1 trial were to evaluate safety and identify the recommended phase 2 dose of nfv added to concurrent crt for locally advanced cervical cancer two dose level of nfv were evaluated 875 mg orally twice daily dose level 1 dl1 and 1250 mg twice daily dl2 nfv wa initiated 7 day before crt and continued through crt completion toxicity radiographic response and pathologic response were evaluated serial tumor biopsy baseline after nfv monotherapy on nfv crt and posttreatment were evaluated by immunohistochemistry nanostring and reversephaseproteinarray analysis nfv sensitized cervical cancer cell to radiation increasing apoptosis and tumor suppression in vivo patient n 13 with international federation of gynecology and obstetrics stage iia through iva squamous cell cervical carcinoma were enrolled including 7 patient at dl1 and 6 patient at dl at dl expansion to 6 patient wa required after a patient developed a doselimiting toxicity whereas no doselimiting toxicity occurred at dl therefore dl2 wa established a the recommended phase 2 dose all patient at dl2 completed crt and 1 of 6 experienced grade 3 or 4 anemia nausea and diarrhea one recurrence wa noted at dl with disease outside the radiation field ten of 11 evaluable patient remained without evidence of disease at a median followup of 50 month nfv significantly decreased phosphorylated akt level in tumor cell cycle and cancer pathway also were reduced by nfv and crt nfv with crt is well tolerated the response rate is promising compared with historic control in this patient population and warrant further investigation,"Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Chemoradiotherapy, Cisplatin, Female, Humans, Nelfinavir, Uterine Cervical Neoplasms"
33931014,this retrospective study aimed to evaluate the efficacy of epidermal growth factor receptor egfr tyrosine kinase inhibitor tkis with stereotactic body radiation therapy sbrt and to elucidate potential mechanism of acquired resistance patient with advanced nsclc harboring positive egfr mutation after initial tki therapy for at least 8 week were eligible for sbrt between august 2016 and august eligible patient were treated with thoracic sbrt and tki wa continued after sbrt until it wa considered ineffective the control group wa treated with tkis monotherapy propensity score matching psm ratio of 12 wa used to account for difference in baseline characteristic overall survival o progressionfree survival pfs treatment safety and resistance mechanism were evaluated three hundred eight patient were included in the study population among them 262 patient received tkis alone and 46 patient received tkis with sbrt baseline characteristic were not significantly different between the two cohort after psm the median pfs wa month in the tkis sbrt group compared to month in the tkis group p an influence on o ha not yet been shown p of the 135 patient evaluated after psm 28 and 71 patient in the tkis and tkis sbrt cohort respectively had plasma cellfree dna cfdna nextgeneration sequencing ng performed at baseline and disease progression in the tkis sbrt cohort the ng result showed that t790m mutation were detected in of patient patient in the tkis cohort exhibited fewer t790mpositive mutation p compared to patient in the tkis sbrt cohort real world data prove that tkis plus thoracic sbrt significantly extend pfs with tolerable toxicity the mutation ratio of t790m wa increased in the tkis sbrt group compared to the tkis only group further randomized study are warranted,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, DNA, Drug Resistance, Neoplasm, ErbB Receptors, Female, High-Throughput Nucleotide Sequencing, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Progression-Free Survival, Propensity Score, Protein Kinase Inhibitors, Radiosurgery, Retrospective Studies, Young Adult"
33930514,redox abnormality are at the crossroad of cardiovascular disease cancer and cardiotoxicity from anticancer treatment indeed disturbance of the redox equilibrium are common driver of these condition not only is an increase in oxidative stress a fundamental mechanism of action of anthracyclines which have historically been the most studied anticancer treatment but also this is at the basis of the toxic cardiovascular effect of antineoplastic targeted drug and radiotherapy here we examine the oxidative mechanism involved in the different cardiotoxicities induced by the main redoxbased antineoplastic treatment and discus novel approach for the treatment of such toxicity,"Anthracyclines, Antineoplastic Agents, Cardiotoxicity, Heart Diseases, Humans, Neoplasms, Oxidative Stress"
33930029,this retrospective correlation study investigated the putative link between methylene tetrahydrofolate reductase mthfr a1298c mutation and chemotherapyrelated brain function change in adult childhoodleukemia survivor to this end we determined the relationship between the particular mthfr1298 genotype aa ac or cc of 31 adult childhoodleukemia survivor and 1 their csf tau and phosphorylated tau ptau level at the time of treatment 2 their adult performance intelligence quotient piq and 3 their regional brain connectivity using diffusion magnetic resonance imaging dmri and restingstate functional mri rsfmri we confirmed that neuropathology marker tau and ptau significantly increased in csf of child after intrathecal methotrexate administration highest concentration of these toxicity marker were found during the induction phase of the therapy moreover csf concentration of tau and ptau during treatment were influenced by the childrens particular mthfr1298 genotype csf tau but not ptau level significantly dropped after folinic acid supplementation at adult age on average year since the end of their treatment their particular mthfr1298 genotype aa ac or cc influenced the change in piq and cortical connectivity that we found to be related to their childhood exposure to chemotherapeutics in summary we suggest that homozygous mthfr1298cc individual are more vulnerable to the adult sequela of antifolate chemotherapy,"Adolescent, Adult, Brain, Cancer Survivors, Child, Child, Preschool, Cognition, Diffusion Magnetic Resonance Imaging, Disease Progression, Drug Therapy, Drug-Related Side Effects and Adverse Reactions, Female, Folic Acid Antagonists, Genotype, Humans, Intelligence Tests, Magnetic Resonance Imaging, Male, Methotrexate, Methylenetetrahydrofolate Reductase (NADPH2), Polymorphism, Single Nucleotide, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Rest, Retrospective Studies, Young Adult, tau Proteins"
33929895,patient with metastatic urothelial carcinoma muc who progress on platinumbased combination chemotherapy plt and checkpoint inhibitor cpi have limited option that offer objective response rate orr of approximately 10 with a median overall survival o of month sacituzumab govitecan sg is a tropdirected antibodydrug conjugate with an sn38 payload that ha shown preliminary activity in muc trophyu01 clinicaltrialsgov identifier nct03547973 is a multicohort openlabel phase ii registrational study cohort 1 includes patient with locally advanced or unresectable or muc who had progressed after prior plt and cpi patient received sg 10 mgkg on day 1 and 8 of day cycle the primary outcome wa centrally reviewed orr secondary outcome were progressionfree survival o duration of response and safety cohort 1 included 113 patient 78 men median age 66 year visceral metastasis median of three range prior therapy at a median followup of month the orr wa 27 31 of 113 95 ci to 77 had decrease in measurable disease median duration of response wa month 95 ci to month with median progressionfree survival and o of month 95 ci to month and month 95 ci to month respectively key grade 3 treatmentrelated adverse event included neutropenia 35 leukopenia 18 anemia 14 diarrhea 10 and febrile neutropenia 10 with 6 discontinuing treatment because of treatmentrelated adverse event sg is an active drug with a manageable safety profile with most common toxicity of neutropenia and diarrhea sg ha notable efficacy compared with historical control in pretreated muc that ha progressed on both prior plt regimen and cpi the result from this study supported accelerated approval of sg in this population,"Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cohort Studies, Female, Humans, Immune Checkpoint Inhibitors, Immunoconjugates, Male, Middle Aged, Organoplatinum Compounds, Urologic Neoplasms"
33929648,aflibercept and arsenic trioxide drug apply a cytotoxic effect on some human cancer cell line however no more study ha followed the effect of both drug especially arsenic trioxide on oral squamous cell carcinoma occ we used three occ line a a model to show the effect of these drug on the genetically complex disease and investigate it targeted therapy in this study three human occ cell line were used from different patient we treated cell line with both medication to detect the effect and relevant molecular basis first methyl thiazolyl tetrazolium mtt assay wa performed to detect the cytotoxicity effect and cell growth second flow cytometry gene and protein expression were performed to evaluate the antiangiogenic effect on occ line next apoptosis wa analyzed by flow cytometry finally clonogenesis capacity and cell migration were assessed by colony formation assay and wound healing respectively aflibercept had no cytotoxic effect on the three occ cell line but decreased cell growth rate arsenic trioxide had a significant cytotoxic effect on three cell line our result demonstrated that both drug significantly decreased endoglin vegfa and vegfb expression in addition migration and colony formation assay confirmed that these drug have significant antiproliferative and antimigration effect on oral carcinoma cell these result revealed that both medication might be a potential drug for the management of oral cancer patient,"Antineoplastic Agents, Apoptosis, Arsenic Trioxide, Carcinoma, Squamous Cell, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Endoglin, Humans, Mouth Neoplasms, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Squamous Cell Carcinoma of Head and Neck, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor B"
33928747,over the past two decade therapy targeting angiogenesis have developed into a major class of cancer therapeutic the vascular endothelial growth factor vegf family of signaling protein a group of potent angiogenic growth factor and their receptor represent the main target of this therapeutic class to date 16 antiangiogenic agent have been approved in the united state for the treatment of cancer and several more are in development an important consideration with antiangiogenic therapy is toxicity in particular thrombotic and bleeding risk these complication have emerged a a major clinical concern that may affect the use of these agent in patient both with and without cancer who may already have an elevated risk of thrombosis and bleeding although these agent are frequently considered together a a class when contemplating their bleeding and thrombotic risk in fact the risk for venous thromboembolism arterial thrombosis and bleeding vary significantly between different class of antiangiogenic agent and even among different agent within a class in this narrative review we describe the literature investigating the venous and arterial thrombotic and bleeding risk associated with the currently available antiangiogenic drug in addition we discus these specific complication in the context of both cancer therapy a well a the management of nonmalignant disorder now managed with antiangiogenic agent including hereditary hemorrhagic telangiectasia and neovascular agerelated macular degeneration,"Angiogenesis Inhibitors, Hemorrhage, Humans, Neoplasms, Neovascularization, Pathologic, Thrombosis, Vascular Endothelial Growth Factor A"
33928618,although more than half a century ha passed since the discovery of fluoropyrimidines they are still used in the treatment of many type of cancer and it is estimated that annually two million patient undergo fluoropyrimidinebased chemotherapy the toxicity resulting from the use of fluoropyrimidines affect about of patient which in some case may prove to be lethal the key player in fluoropyrimidine toxicity is dpd activity and patient with deficit are more likely to develop significant adverse event in addition to genotyping dpyd variant associated with dpd deficiency overexpression of mir27 ha also been shown to be a predictive factor for fluoropyrimidine toxicity this review aim to relate what we know so far about the involvement of mirna in fluoropyrimidine toxicity and to open new perspective in this field,"Antimetabolites, Antineoplastic, Fluorouracil, Humans, MicroRNAs, Neoplasms"
33928486,we aimed to as the safety and efficacy of combination treatment with panitumumab plus trifluridinetipiracil ftdtpi in patient with wildtype ra metastatic colorectal cancer mcrc who were refractoryintolerant to standard therapy other than antiepidermal growth factor receptor therapy apollon wa an openlabel multicentre phase trial in the phase 1 part 3 3 deescalation design wa used to investigate the recommended phase 2 dose rp2d all patient in the phase 2 part received the rp2d the primary endpoint wa investigatorassessed progressionfree survival pfs rate at 6 month secondary endpoint included pfs overall survival o overall response rate orr disease control rate dcr time to treatment failure ttf and safety fiftysix patient were enrolled phase n 7 phase n 49 at 25 japanese centre no doselimiting toxicity were observed in patient receiving panitumumab 6 mgkg every 2 week plus ftdtpi 35 mgm2 twice daily day and in a day cycle which became rp2d pfs rate at 6 month wa 90 confidence interval ci median pfs o orr dcr and ttf were month 95 ci month 95 ci 95 ci 95 ci and month 95 ci respectively neutrophil count decreased wa the most common grade treatmentemergent adverse event no treatmentrelated death occurred panitumumab plus ftdtpi exhibited favourable antitumour activity with a manageable safety profile and may be a therapeutic option for pretreated mcrc patient,"Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Humans, Panitumumab, Pyrrolidines, Thymine, Trifluridine"
33926914,morab an antibodydrug conjugate containing farletuzumab and eribulin with a cathepsinb cleavable linker target folate receptor frexpressing tumor cell the primary objective of this firstinhuman study wa to evaluate the safety and tolerability of morab202 in patient with solid tumor patient 20 year with adequate organ function and frpositive solid tumor who failed to respond to standard therapy were eligible patient received morab202 intravenously at do of to mgkg once every three week endpoint included doselimiting toxicity safety tumor response pharmacokinetics and pharmacodynamics nct03386942 clinicaltrialsgov between november 2017 and june 22 patient median age year with advanced solid tumor were enrolled treatmentemergent adverse event occurred in 21 95 patient with leukopenia and neutropenia in 10 45 patient each one patient mgkg cohort experienced two grade 3 doselimiting toxicity serum alanine aminotransferase and glutamyl transferase increase following review by an independent adjudication committee grade interstitial lung disease thought to be related to morab202 wa identified in five 23 patient complete response partial response and stable disease were observed in one nine and eight patient respectively the normalized predose serum fr tended to be positively correlated with the maximum tumor shrinkage r 2 p the mtd of morab202 wa not reached morab202 demonstrated promising antitumor activity in frpositive solid tumor and wa generally welltolerated at the tested do further investigation are required to establish appropriate dosage and clinical utility of morab,"Adult, Aged, Antibodies, Monoclonal, Humanized, Female, Folate Receptor 1, Furans, Humans, Immunoconjugates, Ketones, Male, Middle Aged, Neoplasm Staging, Neoplasms, Retrospective Studies, Treatment Outcome"
33926427,cardamom elettaria cardamomum is a spice and exhibit potent antioxidant and biological activity through distinct molecular mechanism however the anticancer effect of cardamom wa not explored yet in ehrlich solid tumor estbearing mouse this investigation wa aimed to evaluate the anticancer effect of green cardamom gcar alone or combined with the anticancer drug cyclophosphamide in an in vivo model to explore it mechanistic role in tumor cell death in estbearing mouse ehrlich ascites tumor cell were injected in the mouse and 5 day later the animal treated with gcar andor cyclophosphamide for 10 day twentyfour hour from the last treatment animal were sacrificed for the different measurement data recorded for tumor size percentage of tumor growth inhibition tumor growth delay and mean survival time of estbearing mouse demonstrated the effective role of gcar alone or combined with cpo a a promising anticancer agent because it reduced tumor size gcar elevated the mean survival time of estbearing mouse compared to that of untreated est and est cpo group analysis of qpcr mrna gene and protein expression revealed that gcar alone or combined with cpo were promising anticancer agent after the treatment of est with gcar the apoptoticrelated gene and protein were significantly modulated gcar induced markedly significant decrease in oxidative stress biomarkers and a significant increment in glutathione level and that of antioxidant enzyme with a marked diminish in liver and kidney function biomarkers the result revealed that gcar could serve a an apoptotic stimulator agent presenting a novel and potentially curative approach for cancer treatment inducing fewer side effect than those of the commercially used anticancer drug such a cpo,"Animals, Antineoplastic Agents, Body Weight, Carcinoma, Ehrlich Tumor, Cyclophosphamide, Elettaria, Male, Mice, Mice, Inbred BALB C, Neoplasms, Experimental, Plant Extracts, Seeds"
33924068,chronic myeloid leukemia cml develops due to the presence of the bcrabl1 protein a target of tyrosine kinase inhibitor tkis such a imatinib im used in a cml therapy cml eradication is a challenge due to developing resistance to tkis bcrabl1 induces endogenous oxidative stress leading to genomic instability and development of tki resistance model cml cell susceptible or resistant to im a well a wildtype noncancer cell without the bcrabl1 protein were treated with im hydrogen peroxide h2o2 a a model trigger of external oxidative stress or with imh2o accumulation of reactive oxygen specie ro dna damage activity of selected antioxidant enzyme and glutathione gsh and mitochondrial potential mmp were assessed we observed increase in ro accumulation in bcrabl1 positive cell and distinct level of ro accumulation in imsusceptible cell when compared to imresistant one a well a increased dna damage caused by im action in sensitive cell depletion of gsh level and a decreased activity of glutathione peroxidase gpx in the presence of im wa higher in the cell susceptible to im imresistant cell showed an increase of catalase activity and a depletion of mmp bcrabl1 kinase alters ro metabolism and im resistance is accompanied by the change in activity of gpx catalase and alteration in mmp,"Animals, Antineoplastic Agents, Catalase, Cell Line, Tumor, DNA Damage, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl, Glutathione, Glutathione Peroxidase, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Membrane Potential, Mitochondrial, Mice, Oxidative Stress"
33921050,melanoma is known to aggressively metastasize and is one of the prominent cause of skin cancer mortality this study wa designed to as the molecular mechanism of decursinol angelate da against murine melanoma cell line b16f10 cell treatment of da resulted in growth inhibition and cell cycle arrest at gg1 p phase evaluated through immunoblotting moreover autophagyrelated protein such a atg5 p atg7 p beclin1 p and transition of lci to lcii p were markedly decreased indicating autophagosome inhibition additionally da treatment triggered apoptotic event which were corroborated by the occurrence of distorted nucleus elevated reactive oxygen specie ro level and reduction in the mitochondrial membrane potential subsequently there wa an increase in the expression of proapoptotic protein bax in a dosedependent manner with the corresponding downregulation of bcl2 expression and cytochrome c expression following 24 h da treatment in asm and b16f10 cell we substantiated our result for apoptotic occurrence through flow cytometry in b16f10 cell furthermore we treated b16f10 cell with nacetyllcysteine nac nac treatment upregulated atg5 p beclin1 p and lci to lcii p conversion which wa inhibited in the da treatment group we also noticed a systematic upregulation of important marker for progression of g1 cell phase such a cdk2 p cdk4 p cyclin d1 p and cyclin e p upon nac treatment in addition we also observed a significant fold reduction p in ro fluorescent intensity and the expression of bax p cytochrome c p cleaved caspase9 p and cleaved caspase3 p nac treatment wa able to ameliorate dainduced apoptosis and cell cycle arrest to support our finding our in vivo xenograft model also revealed similar finding such a downregulation of cdk2 p and cdk4 p and upregulation of bax p cytochrome c p cleaved caspase 3 p and cleaved caspase 9 p in summary our study revealed that da is an effective treatment against b16f10 melanoma cell and xenograft mouse model,"Acetylcysteine, Animals, Antineoplastic Agents, Apoptosis, Autophagosomes, Benzopyrans, Butyrates, Cell Cycle Checkpoints, Cell Line, Tumor, Cell Proliferation, Humans, Male, Melanoma, Melanoma, Experimental, Mice, Inbred BALB C, Mice, Nude, Mitochondria, Mitochondrial Membranes, Models, Biological, Reactive Oxygen Species, Skin Neoplasms, Mice"
33915323,growth factor and chemotherapybased stem cell mobilization strategy are commonly used to treat patient with multiple myeloma we retrospectively compared 398 patient mobilized between 2017 and 2020 using either cyclophosphamide 4 gm2 plus granulocyte colonystimulating factor gcsf or gcsf alone with on demand plerixafor pxf in both group although total cd yield wa higher after chemomobilization compared with gcsf pxf median kg versus kg p 01 achievement of 2 106 cd cell 95 versus p 61 and rate of mobilization failure 5 versus p 61 were similar fewer patient required pxf with chemomobilization versus p 01 and apheresis session were fewer median 1 range 1 to 4 versus 2 range 1 to 5 the rate of complication including neutropenic fever emergency department visit and hospitalization wa higher after chemomobilization 30 versus p 01 previous use of 6 cycle of lenalidomide did not impair cell yield in either group the median cost of mobilization wa lower in the gcsf pxf group p 01 between group difference in time to engraftment were not clinically significant given similar rate of successful mobilization similar engraftment time and le toxicity and lower cost compared with chemomobilization gcsf with ondemand pxf may be preferable in myeloma patient with adequate disease control and limited lenalidomide exposure,"Antigens, CD34, Benzylamines, Cyclams, Cyclophosphamide, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Heterocyclic Compounds, Humans, Lenalidomide, Multiple Myeloma, Retrospective Studies"
33914350,lurbinectedin is a selective inhibitor of oncogenic transcription reversible myelosuppression is it most relevant toxicity pharmacokineticpharmacodynamic analysis were conducted to characterize the time course of absolute neutrophil count and platelet count recovery and to detect and quantify the effect of relevant covariates in patient with advanced solid tumor treated with lurbinectedin absolute neutrophil count platelet count and lurbinectedin total plasma concentration were assessed in 244 patient treated with lurbinectedin with varied dosing schedule and do a reference extended semimechanistic pharmacokineticpharmacodynamic model of myelosuppression wa used granulocyte colonystimulating factor gcsf administration wa modeled a a dichotomous covariate and platelet transfusion were included a a bolus dose into the last compartment of the model representing the central circulation final model were suitable to describe the time course of absolute neutrophil count and platelet count recovery a lurbinectedin dose of mgm2 every 3 week can be administered without primary prophylaxis with gcsf gcsf followed by 2 dose reduction of 20 if needed gradually reduced grade 4 neutropenia from cycle 3 onward bsabased dosing reduced the incidence of grade 3 thrombocytopenia oneweek dose delay because of low absolute neutrophil count occurred in of patient thus supporting everyweek administration cyp3a inhibitor produced absolute and increase in grade 3 neutropenia and thrombocytopenia respectively neutropenia and thrombocytopenia after lurbinectedin administration to cancer patient are noncumulative reversible short lasting and clinically manageable with secondary prophylaxis of gcsf or platelet transfusion and if needed dose reduction,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carbolines, Dose-Response Relationship, Drug, Female, Granulocyte Colony-Stimulating Factor, Heterocyclic Compounds, 4 or More Rings, Humans, Male, Middle Aged, Models, Biological, Neoplasms, Neutropenia, Neutrophils, Patient Acuity, Platelet Count, Severity of Illness Index, Thrombocytopenia, Young Adult"
33914256,mb02 bevacizumab biosimilar showed similar structural functional and pharmacokinetic property to reference bevacizumab avastin eubevacizumab to confirm clinical similarity between mb02 and eubevacizumab a comparability study wa undertaken in the firstline treatment of stage iiibiv nonsquamous nonsmall cell lung cancer nsclc this multinational doubleblind randomized phase iii study stella compared mb02 or eubevacizumab 15 mgkg administered with chemotherapy paclitaxel 200 mgm2 and carboplatin auc6 on day 1 of every week cycle for 6 cycle week 18 followed by mbeubevacizumab in blinded monotherapy until disease progression unacceptable toxicity death withdrawal of consent or end of study week 52 the primary efficacy endpoint wa objective response rate orr evaluated by an independent radiological review committee irc at week 18 intenttotreat population secondary endpoint included progressionfree survival pfs overall survival o safety and immunogenicity a total of 627 subject were randomized 11 to mb02 n 315 or eubevacizumab n 312 orr assessed by the irc at week wa comparable in mb02 and eubevacizumab group orr risk ratio of 90 ci to 95 ci to and orr risk difference of 90 ci to 95 ci to were within the similarity predefined margin there were no significant difference between mb02 and eubevacizumab group in median pfs v week respectively hr 95 ci to and median o not achieved hr 95 ci to at the end of study the safety profile of mb02 and eubevacizumab regarding nature frequency and severity of the adverse event ae wa comparable the most frequent grade 3 investigationalproductrelated aes were hypertension and anemia with a difference between treatment group of 5 antidrug antibody ada and neutralizing ada nab incidence were similar in both treatment group mb02 demonstrated similar efficacy to eubevacizumab in combination with carboplatin and paclitaxel in subject with advanced nonsquamous nsclc with comparable safety and immunogenicity profile eudract no 26 clinicaltrialsgov nct,"Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Biosimilar Pharmaceuticals, Carboplatin, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Paclitaxel, Treatment Outcome"
33914097,prognosis for relapsed or refractory rr acute myeloid leukemia aml despite salvage therapy is dismal this phase i doseescalation trial assessed the safety and preliminary clinical activity of selinexor an oral exportin1 xpo1 inhibitor in combination with flagida in younger rr aml patient the aim wa to find the recommended phase 2 dose rp2d and maximum tolerated dose mtd fourteen patient were included and selinexor dosage wa 60 mg 3 patient 80 mg 3 patient and 100 mg 7 patient weekly no doselimiting toxicity were reported grade 3 nonhematologic adverse event aes occurred in of patient two patient were non mtd evaluable due to early death and overall 3 out of 14 patient had fatal aes five out of 12 42 response and mtd evaluable patient achieved a complete remission cr n4 or cr with incomplete hematologic recovery cri n1 and 4 patient 33 subsequently underwent allogeneic transplantation the median overall survival o and eventfree survival efs were range and month range respectively using selinexor 100 mgweekly crcri rate of o month range and efs month range at last followup 3 patient were alive selinexor 100 mgweekly with flagida combination in rr aml showed acceptable tolerability and efficacy establishing the rp2d of this regimen in future clinical trial clinicaltrialsgov identifier nct,"Adult, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Granulocyte Colony-Stimulating Factor, Humans, Hydrazines, Idarubicin, Leukemia, Myeloid, Acute, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Treatment Outcome, Triazoles, Vidarabine"
33911851,an oral tetraarsenic tetrasulfide as4s4 formula ha been recommended a an outpatient postremission treatment for chinese adult with acute promyelocytic leukemia apl but limited data are available for child in this exploratory study we aimed to evaluate the pharmacokinetics and safety of the as4s4 formula in child eleven newly diagnosed and one relapsed pediatric patient year of age treated with the as4s4 formula were included blood sample were collected from 12 child and drug concentration were quantified by icpms population pharmacokinetic analysis and montecarlo simulation were performed using nonmem software toxic effect were graded according to the ncictcae version a total of 107 arsenic concentration g l1 were used for population pharmacokinetic analysis the median range of estimated weightnormalized cl and volume distribution at steadystate were l h1 kg1 and l kg respectively no patient discontinued as4s4 treatment owing to adverse event and there were no drugrelated adverse event over grade all newly diagnosed apl patient were in mcr with a median followup of 28 month range 23 to 37 month both the estimated year efs and o rate were 100 the pharmacokinetics and safety oral as4s4 formula wa evaluated for the first time in pediatric apl the pharmacokinetic assessment demonstrated that the dosing regimen of 60 mgkgd tid resulted in a higher steadystate through concentration in child than that which wa achieved in adult the result of this study indicate that the as4s4 formula is safe in newly diagnosed pediatric apl patient,"Administration, Oral, Adolescent, Antineoplastic Agents, Arsenic, Asian People, Child, Child, Preschool, Humans, Leukemia, Promyelocytic, Acute, Prospective Studies"
33911320,acute leukemia are the most frequent malignancy in child advance in treatment have improved the overall survival to 80 almost 10 of child with cancer develop clinical cardiac toxicity total anthracycline cumulative dose is a risk factor for earlyonset cardiotoxicity to describe the incidence of earlyonset cardiotoxicity in child with acute leukemia treated with chemotherapy a prospective descriptive study of patient 1 y and 18 year diagnosed with acute leukemia assessed with electrocardiograma echocardiography and blood biomarkers at diagnosis and during the followup 94 patient with acute lymphoblastic leukemia and 18 with acute myeloid leukemia were included 20 patient developed earlyonset cardiotoxicity statistically significant data wa seen after anthracycline dose 150 mgm between the first echocardiographic evaluation and posterior analysis in the left ventricular fraction ejection with teicholz p simpson p and gls p in this study there wa no relation between blood biomarkers and cardiotoxicity cancer therapeuticrelated cardiac dysfunction is related to anthracycline cumulative dose in this study echocardiographic followup wa useful to predict risk factor for early cardiac dysfunction la leucemias son la principal causa de cncer infantil los avances en el tratamiento han llevado a los pacientes a una supervivencia global hasta del 80 cerca del 10 de los nios con cncer tienen toxicidad cardiovascular sintomtica la dosis acumulada de antraciclinas e un factor de riesgo para afeccin cardaca describir la frecuencia de afectacin cardaca temprana en nios con leucemias agudas que recibieron tratamiento antineoplsico estudio prospectivo observacional de pacientes 18 aos con diagnstico confirmado de leucemia aguda fueron evaluados con electrocardiograma ecocardiograma bidimensional y biomarcadores sricos en diferentes momentos durante el tratamiento se evaluaron 94 pacientes con leucemia linfoide aguda y 18 con leucemia mieloide aguda 20 pacientes tuvieron disfuncin cardiaca de inicio temprano se observaron diferencias estadsticamente significativas despus de recibir 150 mgm2 de antraciclinas entre la evaluacin del ecocardiograma basal y evaluaciones posteriores de la fraccin de eyeccin ventricular izquierda por teicholz p fraccin de eyeccin ventricular izquierda por simpson p y la deformacin longitudinal global p no se encontraron alteraciones en los niveles sricos de la troponinas y pptido natriurtico cerebral la disfuncin cardaca relacionada con quimioterapia estuvo directamente relacionada con la dosis acumuladas de antraciclinas en este estudio el uso del ecocardiograma como mtodo de seguimiento permiti identificar factores predictores de riesgo para disfuncin cardiaca temprana,"Adolescent, Anthracyclines, Antibiotics, Antineoplastic, Cardiotoxicity, Child, Child, Preschool, Humans, Infant, Leukemia, Prospective Studies"
33910927,treatment of cancer with egfr inhibitor is limited by ontarget skin toxicity induced by inhibition of the mapk pathway braf inhibitor are known to paradoxically activate the mapk downstream of egfr which we confirmed using human skin keratinocytes we then conducted a phase i clinical trial testing the hypothesis that topical therapy with the braf inhibitor lut014 could improve skin toxicity induced by egfr inhibitor ten patient with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohort lut014 wa well tolerated and there were no doselimiting toxicity the acneiform rash improved in the 6 patient who started with grade 2 rash in the low and intermediate cohort we conclude that topical lut014 is safe and efficacious in improving rash from egfr inhibitor consistent with the mechanism of action inducting paradoxical mapk activation significance braf inhibitor topical therapy could avoid dose reduction of egfr inhibitor locally treating the main doselimiting skin toxicity of this class of agentsthis article is highlighted in the in this issue feature p,"Adult, Aged, Female, Humans, Male, Middle Aged, Acneiform Eruptions, Administration, Cutaneous, Antineoplastic Agents, Immunological, Cetuximab, Colorectal Neoplasms, Dermatologic Agents, ErbB Receptors, Panitumumab, Proto-Oncogene Proteins B-raf, Treatment Outcome"
33910796,smallcell lung cancer sclc is a very fast growing form of cancer and is characterised by early metastasis a a result chemotherapy is the mainstay of treatment platinumcontaining combination regimen are the current treatment of choice for limited stagesclc and extensive stage sclc various adverse effect after cisplatin and etoposide chemotherapy include nausea nephrotoxicity cardiotoxicity hepatotoxicity neurotoxicity alopecia gastrointestinal toxicity and myelosuppression however severe headache ha not been reported yet here we report one such case of severe refractory headache postcisplatin and etoposide chemotherapy which responded only to change in chemotherapy regime all pertinent cause of headache were ruled out prior to changing the chemotherapy regimen,"Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Etoposide, Headache, Humans, Lung Neoplasms, Small Cell Lung Carcinoma"
33909232,background selinexor a firstinclass oral selective inhibitor of nuclear export sine compound inhibits exportin1xpo1 had demonstrated synergistic activity with many chemotherapy and conferred in vivo antitumor efficacy in hematologic a well a solid tumor method this openlabel singlecenter multiarm phase 1b study used a standard 3 3 design and a basket type expansion selinexor with intravenous topotecan wa given in one of the 13 parallel arm patient with advanced or metastatic relapsedrefractory solid tumor following prior systemic therapy or in whom the addition of selinexor to standard chemotherapy deemed appropriate were eligible result fourteen patient with the median age of 61 year range year were treated and the most common cancer type were gynecological cancer ovarian n 5 endometrial n 2 and 1 each with fallopian tube and vaginal cancer of the 14 patient treated 12 86 had at least one treatmentrelated adverse event trae the most common traes were anemia 71 thrombocytopenia 57 hyponatremia 57 vomiting 57 fatigue 50 nausea 50 and neutropenia 36 two patient had dose limiting toxicity one patient dosed at selinexor 80 mg had grade 3 nausea and vomiting and one patient dosed at selinexor 60 mg experienced grade 4 neutropenia and thrombocytopenia of the 13 efficacy evaluable patient one 8 with endometrial cancer achieved unconfirmed partial response upr and the timetotreatment failure ttf wa 48 week whereas 6 of the 13 46 patient had stable disease sd contributing to the clinical benefit rate of 46 the median ttf for all patient wa 9 week range week conclusion once weekly selinexor in combination with topotecan wa viable and showed some preliminary tumor efficacy the recommend phase 2 dose of selinexor wa 60 mg once weekly in combination with iv topotecantrial registration nct registered 14 april,"Active Transport, Cell Nucleus, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Female, Humans, Hydrazines, Karyopherins, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Receptors, Cytoplasmic and Nuclear, Topotecan, Triazoles, Exportin 1 Protein"
33909000,immunogenic cell death icd occurring by chemical and physical stimulus ha shown the potential to activate an adaptive immune response in the immunecompetent living body through the release of dangerassociated molecular pattern damp into the tumor microenvironment tme however limitation to the longterm immune response and systemic toxicity of conventional icd inducer have led to unsatisfactory therapeutic efficacy in icdbased cancer immunotherapy until now various nanoparticlebased icdinducers have been developed to induce an antitumor immune response without severe toxicity and to efficiently elicit an anticancer immune response against target cancer cell in this review we introduce a recent advance in the design and application of nanoparticlebased therapeutic to elicit icd for effective cancer immunotherapy in particular combination strategy of nanoparticlebased icd inducer with typical theranostic modality are introduced intensively subsequently we discus the expected challenge and future direction of nanoparticlebased icd inducer to provide strategy for boosting icd in cancer immunotherapy these versatile design and application of nanoparticlebased therapeutic for icd can provide advantage to improve the therapeutic efficacy of cancer immunotherapy,"Animals, Antineoplastic Agents, Humans, Immunogenic Cell Death, Immunotherapy, Nanoparticles, Neoplasms, Photosensitizing Agents, T-Lymphocytes, Cytotoxic, Theranostic Nanomedicine"
33908053,vemurafenib a b rapidly accelerated fibrosarcoma inhibitor is commonly used in combination of cobimetinib for the treatment of melanoma in the current study we evaluated the relationship between vemurafenib exposure a measured by the estimated apparent clearance clb at steady state and any grade 3 toxicity grade 3 skin rash or toxicity requiring dose modification using pooled data from 3 prospective clinical trial involving 898 patient a total of 69 had any grade 3 toxicity grade 3 skin rash in 15 and 47 had a dose reductioninterruption or cessation the median vemurafenib clb wa lh interquartile range lh lower vemurafenib clb wa significantly associated with an increased risk of grade 3 toxicity hazard ratio hr p 001 grade 3 rash hr p 001 and adverse event requiring vemurafenib dose reductioninterruption or cessation hr p 001 when the patient were divided into 3 group based on the vemurafenib clb threshold those with low clb lh had significantly increased incidence of any grade 3 toxicity or skin rash or dose adjustment interruption or cessation at 12 month and at day 28 when compared to those with medium and lh or high lh vemurafenib clb in conclusion the estimated clb of vemurafenib is associated with severe toxicity and dose adjustment or cessation suggesting that an early estimation of vemurafenib exposure may be useful in identifying patient at risk of experiencing toxicity,"Aged, Antineoplastic Agents, Azetidines, Dose-Response Relationship, Drug, Female, Humans, Male, Melanoma, Metabolic Clearance Rate, Middle Aged, Patient Acuity, Piperidines, Prospective Studies, Vemurafenib"
33907299,bruton tyrosine kinase btk inhibition is an effective therapy for many bcell malignancy acalabrutinib is a nextgeneration potent highly selective covalent btk inhibitor to characterize acalabrutinib tolerability we pooled safety data from 1040 patient with mature bcell malignancy treated with acalabrutinib monotherapy in nine clinical study treatmentnave n 366 35 relapsedrefractory n 674 65 median range age 67 year median range prior treatment 1 median range duration of exposure month the most common adverse event aes were headache 38 diarrhea 37 upper respiratory tract infection 22 contusion 22 nausea 22 fatigue 21 and cough 21 serious aes saes occurred in 39 of patient pneumonia 6 wa the only sae that occurred in 2 death due to aes occurred in 52 patient 5 pneumonia n 8 wa the only fatal ae to occur in 3 patient aes led to treatment discontinuation in 9 rate for the aes of interest all grade included infection 67 hemorrhage 46 neutropenia 16 anemia 14 second primary malignancy 12 thrombocytopenia 9 hypertension 8 and atrial fibrillation 4 this pooled analysis confirmed acalabrutinibs tolerability and identified no newly emerging late toxicity supporting acalabrutinib a a longterm treatment for patient with mature bcell malignancy,"Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Clinical Trials as Topic, Drug-Related Side Effects and Adverse Reactions, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Prognosis, Pyrazines, Retrospective Studies, Survival Rate, United States"
33906378,immune checkpoint inhibitor have been approved a adjuvant therapy adverse immune event occurred during the administration of treatment and delayed immunerelated event have low incidence a yearold man wa treated for hypopharynx cancer in in he wa treated for a new oropharynx cancer after undergoing surgery and complete response the patient received nivolumab a adjuvant treatment 5 month after the last dose of nivolumab he presented with grade iii diarrhea and abdominal pain for 3 week rectoscopy showed infiltration of mucous by lymphocyte corticosteroid wa started resulting in a rapid decrease in symptom severity with the increasing immune checkpoint inhibitor in adjuvant therapy strict surveillance and education of patient in remission is necessary lay abstract immune checkpoint inhibitor have changed the outcome of several cancer and have been approved after local treatment for melanoma or lung cancer the toxicity of this treatment were immunerelated adverse event and any organ can be involved usually toxicity occurred during the administration of treatment and delayed immunerelated event have low incidence here we presented a case report of a patient treated with antiprogrammed cell death protein 1 after locoregional treatment for head and neck cancer and presented with severe diarrhea 5 month after the last dose of treatment corticosteroid wa started resulting in a rapid decrease in symptom severity with the increasing immune checkpoint inhibitor in adjuvant therapy strict surveillance and education of patient in remission is necessary,"Aged, Chemotherapy, Adjuvant, Colitis, Humans, Immune Checkpoint Inhibitors, Male, Nivolumab, Oropharyngeal Neoplasms"
33906146,since their approval in immune checkpoint inhibitor icpis are increasingly used to treat several advanced cancer icpis target certain cellular molecule that regulate immune response resulting in antitumor activity the use of these new agent need careful monitoring since they brought a whole new spectrum of adverse event in this review we aim to describe different endocrine dysfunction induced by icpis and to underline the importance of diagnosing and managing these adverse effect immunerelated endocrine toxicity include thyroid dysfunction hypophysitis and le frequently type 1 diabetes primary adrenal insufficiency and hypoparathyroidism diagnosis of endocrine adverse event related to icpis therapy can be challenging due to nonspecific manifestation in an oncological scenario and difficulty in the biochemical evaluation despite the fact that these endocrine adverse event could lead to lifethreatening consequence the availability of effective replacement treatment enables continuing therapy and together with an interdisciplinary approach will impact positively on survival desde su aprobacin en el uso de los inhibidores de los puntos de control inmunes icpis se ha extendido para el tratamiento de diversas neoplasia en estadios avanzados los icpis tienen como blanco ciertas molculas de la clulas que regulan la respuesta inmune favoreciendo una actividad antitumoral el uso de estos nuevos agentes requiere un monitoreo especfico ya que se han vinculado con un amplio y nuevo espectro de efectos adversos el objetivo de esta revisin e describir la diferentes disfunciones endocrinas inducidas por los icpis y destacar la importancia del diagnstico y manejo oportuno de estos efectos adversos los efectos adversos inmunes endocrinos incluyen disfuncin tiroidea hipofisitis y con menor frecuencia diabetes tipo insuficiencia suprarrenal primaria e hipoparatiroidismo el diagnstico de eventos adversos endocrinos relacionados con la terapia icpis e un desafo debido a su presentacin clnica inespecfica en un escenario oncolgico y a la dificultades en la evaluacin bioqumica estos eventos adversos endocrinos podran tener consecuencias potencialmente letales pero la disponibilidad de un tratamiento de reemplazo eficaz permite continuar la terapia y junto con un enfoque interdisciplinario generar un impacto positivo en la supervivencia,"Endocrine System Diseases, Humans, Hypophysitis, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms"
33906139,the management of patient with immunerelated adverse event iraes frequently demand a multidisciplinary approach we reviewed the cause and clinical course of medical visit and admission at the instituto alexander fleming due to iraes between september 2015 and july demographic data diagnosis toxicity and it severity requirement of admission treatment mortality and evaluation of the readministration of immunotherapy were collected we found 124 iraes in 89 patient sixtyeight of them received monotherapy and 21 combination of drug cutaneous manifestation were the most frequent cause of iraes followed by general manifestation endocrine dysfunction hypothyroidism the most frequent colitis pneumonitis neurologic disorder and hepatitis in 26 adverse event in 25 patient severity grade wa fifteen were admitted and 6 required icu admission one patient died thirtyfour received glucocorticoid 12 of them by intravenous route one patient received mycophenolate and one ivig in the treatment wa discontinued 8 were reexposed with definitive discontinuation in one patient in this case series we report our experience in the diagnosis and management of adverse reaction related to a family of drug whose use ha grown in recent year el manejo de la reacciones adversas inducidas por los inhibidores del punto de control inmunitario ipci en cncer demanda un trabajo multidisciplinario revisamos la causa y el curso clnico de la consultas e internaciones debidas a reacciones adversas de los ipci entre septiembre de 2015 y julio de 2019 en el instituto alexander fleming se registraron los datos demogrficos diagnstico oncolgico reaccin adversa y su grado requerimiento de internacin tratamiento mortalidad y evaluacin de la reexposicin se registraron 124 reacciones adversas por ipci en 89 pacientes sesenta y ocho reciban monoterapia y 21 terapia combinada la manifestaciones cutneas fueron la m frecuentes seguidas de la generales endocrinas con mayor frecuencia hipotiroidismo colitis neumonitis neurolgicas y hepatitis fueron graf grado 3 26 toxicidades en 25 pacientes se internaron y 6 de ellos requirieron terapia intensiva un caso fue fatal recibieron glucocorticoides 34 12 de ellos por va intravenosa un paciente recibi micofenolato y uno inmunoglobulina endovenosa en 20 se discontinu el tratamiento ocho se reexpusieron y uno de ellos debi suspender definitivamente se presenta en esta serie de casos nuestra experiencia con el diagnstico y tratamiento de la reacciones adversas de una familia de drogas cuya utilizacin ha crecido en los ltimos aos,"Drug-Related Side Effects and Adverse Reactions, Humans, Immune Checkpoint Inhibitors, Immunologic Factors, Immunotherapy, Neoplasms, Nervous System Diseases"
33905962,in egfr mutationpositive nsclc dual egfrvegfr inhibition compared to egfr alone increase antitumor efficacy the phase iii relay trial demonstrated superior pfs for ramucirumab plus erlotinib ram erl over placebo plus erlotinib pbo erl hr 95 ci p egfr mutated nsclc is le prevalent in western versus asian patient this prespecified analysis evaluates efficacy and safety of ram erl in eu and u patient enrolled in relay patient were randomized 11 to erl ram 10 mgkg iv or pbo q2w treatment continued until unacceptable toxicity or progressive disease patient were stratified by geographic region east asia v other euus and canada euus objective included pfs orr dor o pfs safety and biomarker analysis euus subset included patient 58 ram erl 55 pbo erl ram erl improved pfs v month hr 95 ci orr and dcr were similar but median dor wa longer with ram erl v month hr 95 ci o and pfs2 were immature at data cutoff censoring rate and respectively most commonly reported grade 3 teae for ram erl wa hypertension 17 and for pbo erl dermatitis acneiform 5 euus subset analysis showed improved efficacy outcome for ram erl and a safety profile consistent with the overall population ramucirumab is a safe and effective addition to standardofcare egfrtki for egfr mutationpositive metastatic nsclc,"Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Drug Eruptions, ErbB Receptors, Erlotinib Hydrochloride, Europe, Female, Humans, Hypertension, Lung Neoplasms, Male, Middle Aged, Mutation, Placebos, Progression-Free Survival, Response Evaluation Criteria in Solid Tumors, Survival Rate, United States, Young Adult, Ramucirumab"
33904518,some clinical trial have described improved outcome in patient who develop immunerelated adverse event iraes while receiving immune checkpoint inhibitor for advanced melanoma it is unknown if this effect would be seen in a realworld population this is a singlecenter retrospective analysis of all patient receiving singleagent pd1 inhibitor for unresectable stage iii or stage iv melanoma between 2012 and the majority of patient had cutaneous melanoma and were elderly put in median and range totally were braf mutated and had pd1 inhibitor a firstline treatment for metastatic disease also 22 of patient had brain metastasis at presentation of the 87 patient included in this analysis 48 55 developed at least one irae dermatologic toxicity were the most common irae the median time to develop any irae wa 12 week only one patient died of immunerelated toxicity overall survival in the population of patient that had an irae wa significantly greater than those that did not have any toxicity v month p the development of endocrine toxicity had the strongest correlation with survival a did patient with grade 1 nci v5 toxicity the development of multiple toxicity did not correlate with survival in patient with multiple toxicity the type of irae that presented initially did not impact the outcome these finding add to the growing body of literature suggesting an association between iraes and immunecheckpoint inhibitor efficacy while suggesting that this benefit may depend on the type of toxicity and severity,"Aged, Female, Humans, Immune Checkpoint Inhibitors, Male, Melanoma, Skin Neoplasms, Melanoma, Cutaneous Malignant"
33904380,antibodydrug conjugate adcs are targeted therapeutic agent that treat cancer by selective delivery of highly potent cytotoxic drug to tumor cell via cancerspecific antibody however their clinical benefit is limited by offtarget toxicity and narrow therapeutic window to overcome these limitation we have applied reductive alkylation to develop a new type of adc that ha cytotoxic drug conjugated to the nterminal of an antibody through amine bond introduced via reductive alkylation reaction nterm to test whether the ntermconjugated adcs can widen therapeutic window we synthesized three different adcs by conjugating trastuzumab and monomethyl auristatinf using three different method and compared their stability efficacy and toxicity the ntermconjugated adc wa more stable in vitro and in vivo than the thiolconjugated and the lysineconjugated adcs the ntermconjugated adc showed lower toxicity compared to other adcs whereas it efficacy wa comparable to that of the thiolconjugated adc and better than that of the lysineconjugated adc these result suggest that the nterm conjugation method could widen the therapeutic window of adcs by enhancing it stability and reducing toxicity,"Alkylation, Animals, Antineoplastic Agents, Immunological, Breast Neoplasms, Cell Line, Tumor, Drug Compounding, Drug Stability, Female, Immunoconjugates, Oligopeptides, Protein Stability, Rats, Nude, Rats, Sprague-Dawley, Receptor, ErbB-2, Trastuzumab, Tumor Burden, Xenograft Model Antitumor Assays, Rats"
33902379,the current evidence on the role of pembrolizumab for patient with extensive sclc is reviewed in this article particularly preclinical and clinical data from phase iii and iii clinical trial which evaluate the efficacy and toxicity of pembrolizumab for these patient are summarized based on pubmedmedline search and relevant article in addition future perspective on the emerging role of immunotherapy for sclc are highlighted in light of potentially useful biomarkers pembrolizumab show an excellent toxicity profile in recent study and significantly prolonged progressionfree survival pfs but not overall survival o in the phase iii clinical trial kn in contrast to atezolizumab and durvalumab the latter two agent have already been approved and incorporated in the daily clinical practice further research should be conducted so that phase iii clinical trial can validate the potential clinical benefit of this checkpoint inhibitor in combination with other active agent and establish it role in the metastatic setting of sclc,"Antibodies, Monoclonal, Humanized, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Lung Neoplasms, Neoplasm Metastasis, Progression-Free Survival, Small Cell Lung Carcinoma, Survival Rate"
33901868,the atlas trial investigating adjuvant axitinib versus placebo in renal cell carcinoma rcc wa stopped for futility at a preplanned interim analysis we report subgroup outcome analysis by ethnicity time on treatment dose modification and toxicity patient demographic baseline characteristic treatment duration and exposure and safety were analysed for asian versus nonasian patient treated with axitinib versus placebo diseasefree survival dfs wa analysed by ethnicity treatment duration 1 versus 1 year dose modification and adverse event ae grade no dfs benefit wa observed for asian hazard ratio hr 95 confidence interval ci or nonasian hr 95 ci patient treated with axitinib or placebo fewer asian versus nonasian patient were in the highestrisk group in axitinib versus or placebo versus arm highestrisk patient in both subgroup had no dfs benefit with either treatment more axitinibtreated asian versus nonasian patient had dose reduction due to aes versus p asian patient experienced more nasopharyngitis but le fatigue or asthenia than nonasians among asian patient proteinuria hypothyroidism nasopharyngitis and hypertension were more common in japanese patient than korean patient and more common in korean patient than chinese patient patient receiving axitinib 1 year versus 1 year did not have different dfs hr 95 ci p compared with patient on stable axitinib dose dfs wa longer in patient with dose reduction hr 95 ci p whereas dfs wa not different in those with dose escalation hr 95 ci p dfs wa not different in patient experiencing grade 2 versus 2 aes within 6 month of initiating axitinib hr 95 ci p asian versus nonasian subgroup analysis revealed difference in ae experience and drug exposure there were no dfs difference based on ethnicity or treatment duration but axitinib dose reduction led to longer dfs,"Axitinib, Carcinoma, Renal Cell, Disease-Free Survival, Humans, Kidney Neoplasms, Progression-Free Survival"
33901793,l19tnf is a recombinant fusion protein composed of a human antibody fragment and human tumour necrosis factor l19tnf target the edb domain of oncofetal fibronectin highly expressed in tumour vasculature and induces tumour remission in mouse tumour we summarise two phase i trial testing a combination of l19tnf with doxorubicin in patient with solid tumour particularly soft tissue sarcoma sts the first study an openlabel doseescalation and expansion phase i study of l19tnf plus doxorubicin enrolled 27 patient three cohort 17 gkg l19tnf of patient received l19tnf intravenously at day and 5 and doxorubicin 75 mgm then 60 mgm2 on day 1 every 3 week the expansion cohort enrolled patient with sts the second study tried to reescalate the doxorubicin dose to 75 mgm2 with 13 gkg l19tnf among primary objective wa the establishment of a recommended dose rd the combination wa safely applicable doselimiting toxicity occurred either at 17 gkg l19tnf or at 75 mgm2 doxorubicin rd is 13 gkg l19tnf plus 60 mgm2 doxorubicin in 15 sts patient of the extension cohort evaluable for efficacy antitumour activity wa observed with complete remission in partial remission in 1 and minor tumour shrinkage in 7 patient the median overall survival for this heavily pretreated cohort wa month l19tnf can be safely applied in combination with doxorubicin and induces encouraging tumour remission in patient with soft tissue sarcoma,"Adult, Aged, Antibiotics, Antineoplastic, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin, Female, Humans, Male, Middle Aged, Sarcoma, Soft Tissue Neoplasms, Time Factors, Treatment Outcome"
33900450,treatment outcome of relapsedrefractory diffuse large b cell lymphoma rr dlbcl are far from satisfactory certain efficacy of ibrutinib ha been observed in nongcb subtype dlbcl patient this study aimed to investigate the efficacy and safety of ibrutinib plus bcl2 inhibitor venetoclax in rr dlbcl patient with nongcb subtype and bcl2 overexpression combinational therapy ibrutinib 560mgday venetoclax started 1 week later oral dose increased from 100 to 400mgday in 3 week wa conducted and one cycle wa 4 week both drug were stopped when disease progress or serious adverse reaction appear the primary endpoint wa overall response rate orr at two cycle from december 2018 to july a total of 13 patient were treated with the combined therapy among them eleven patient previously received at least two treatment regimen eight patient were cmyc and bcl2 double expression the orr at two cycle wa with 3 patient achieved complete remission cr and 5 patient achieved partial remission pr the orr at four cycle and six cycle wa and respectively the median duration of response wa 11 month range month the median progressionfree survival and overall survival were month range and month range respectively the most common adverse event wa grade neutropenia and nonhematologic toxicity included grade diarrhea and elevated liver enzyme combined therapy of ibrutinib and venetoclax showed promising efficacy and synergistic effect in rr dlbcl patient with nongcb subtype and bcl2 overexpression and the toxicity were welltolerated,"Adenine, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Female, Humans, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Neoplasm Recurrence, Local, Neutropenia, Piperidines, Proto-Oncogene Proteins c-bcl-2, Sulfonamides, Treatment Outcome"
33896016,hcc is a leading cause of cancerrelated death globally with poor outcome and limited therapeutic option although the myelocytomatosis myc oncogene is frequently dysregulated in hcc it is thought to be undruggable thus the current study aimed to identify the critical downstream metabolic network of myc and develop therapy for mycdriven hcc liver cancer wa induced in mouse with hepatocytespecific disruption of myc and control mouse by administration of diethylnitrosamine liquid chromatography coupled with mass spectrometrybased metabolomic analysis revealed that urinary dimethylarginine especially symmetric dimethylarginine sdma wa increased in the hcc mouse model in an mycdependent manner analysis of human sample demonstrated a similar induction of sdma in the urine from patient with hcc mechanistically prmt encoding protein arginine nmethyltransferase which catalyzes sdma formation from arginine wa highly induced in hcc and identified a a direct myc target gene moreover gsk a prmt5 inhibitor suppressed the growth of liver tumor in human mycoverexpressing transgenic mouse that spontaneously develop hcc inhibition of prmt5 exhibited antiproliferative activity through upregulation of the tumor suppressor gene cdkn1bp encoding cyclindependent kinase inhibitor 1b in addition gsk3326595 induced lymphocyte infiltration and major histocompatibility complex class ii expression which might contribute to the enhanced antitumor immune response combination of gsk3326595 with antiprogramed cell death protein 1 pd1 immune checkpoint therapy ict improved therapeutic efficacy in hcc this study reveals that prmt5 is an epigenetic executer of myc leading to repression of the transcriptional regulation of downstream gene that promote hepatocellular carcinogenesis highlight a mechanismbased therapeutic strategy for mycdriven hcc by prmt5 inhibition through synergistically suppressed proliferation and enhanced antitumor immunity and finally provides an opportunity to mitigate the resistance of immunecold tumor to ict,"Adult, Aged, Aged, 80 and over, Alkylating Agents, Animals, Arginine, Carcinogenesis, Carcinoma, Hepatocellular, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27, Diethylnitrosamine, Enzyme Inhibitors, Female, Histocompatibility Antigens Class II, Humans, Immune Checkpoint Inhibitors, Liver Neoplasms, Liver Neoplasms, Experimental, Lymphocytes, Tumor-Infiltrating, Male, Mice, Mice, Transgenic, Middle Aged, Protein-Arginine N-Methyltransferases, Proto-Oncogene Proteins c-myc, Pyrimidines, Quinolines, Up-Regulation, Young Adult"
33895972,ribosome inactivating protein rip a family of anticancer drug recently received much attention due to their interesting anticancer mechanism in spite of small drug rip use the largesize effect lse to prevent the efflux process governed by drug resistance transporter drts which prevents inside of the cell against drug transfection there are many clinical translation obstacle that severely restrict their application especially their delivery approach to the tumor cell a the main goal of this review we will focus on trichosanthin tc and gelonin gel and other type especially scorpion venomderived rip to clarify that they are struggling with what type of biobarriers and these challenge could be solved in cancer therapy science then we will try to highlight recent stateofthearts in delivery of rip for cancer therapy,"Animals, Antineoplastic Agents, Phytogenic, Humans, Neoplasms, Ribosome Inactivating Proteins, Type 1, Scorpion Venoms, Sodium Channel Blockers, Trichosanthin"
